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Preface 
Apoptosis is programmed cell death (PCD). Since its discovery more than a century 
and half ago, apoptosis has been implicated in many processes in living organisms. 
Apoptosis has been shown in a diverse range of healthy as well as stressed and/or 
diseased organisms and probably takes place in all living organisms. For example, a 
chapter in this book reveals the role of PCD in bone resorption under mechanical 
stress.  
Apoptosis has also been shown in senescence in plants. The editor is convinced that 
the process may be involved in plant stress tolerance and sensitivity. 
It is not surprising that apoptosis has been studied extensively in cancer – 
dysfunctional and/or dysregulated cell proliferation - research as PCD and cell 
multiplication maintain a balance – cell homeostasis – in healthy organisms. This book 
provides evidence for the observation. 
Doctor Tobias M. Ntuli, BSc, BScHons, Msc, PhD 
Post-Doctoral (Research) Fellow 
Division of Life Sciences 
Department of Life and Consumer Sciences 
School of Agriculture and Life Sciences 
College of Agriculture and Environmental Sciences 
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1. Introduction 
Apoptosis, as a programmed cell death (PCD) is essential for normal cell mechanism. The 
word “Apoptosis” derives from Greek language “απόπτωσις” and means trees shedding their 
leaves in autumn, which describes the "dropping off" or "falling off" of petals from flowers, or 
leaves from trees. This language imaginarily described the cell death triggered by 
physiological and pathological stimulation. The apoptosis phenomena were first described by 
German Scientist Carl Vogt in 1842 year, while until 1972 year, apoptosis term was first used 
by John Foxton Ross Kerr group. They use apoptosis word to describe the tissue cell death. 
The above is the beginning of apoptosis researches and this period is the apoptosis formation; 
the second period about apoptosis is the biochemical level and apoptosis cell morphological 
changes research. In this age, people know that apoptosis accompany with cell membrane 
wrinkled, DNA fragmentation, cytosol calcium increased and form the apoptosis body which 
contain its own content so on. In this time the electron microscope play a vital role in the 
research. Following the apoptosis research came in the third period in recent years; scientists 
began to research the molecular mechanism of apoptosis and to use this cell death for clinical 
treatment. Some key proteins in the procession of the apoptosis have been found, such as Bcl-2 
family protein, caspase-3, caspase-8, caspase-9, Bid, Bax and so on.  
In the past, the apoptosis was focused on the caspase, a family of cysteine protease. While, 
using the caspase inhibitor to block the apoptosis pathway, the researchers found that the 
apoptosis still happen. So another pathway that is caspase-independent was found. Now, 
apoptosis is classified to type I, Type II, Type III PCD: type I PCD is the classic apoptosis, 
the well know caspase denpendent apoptosis; type II PCD’s morphology characters are the 
appearance of the autophagic and double membrane of vacuole; type III PCD occurs 
without the condensate chromatin and has not been well-known. Type IIand type III PCD 
are the caspase-independent apoptosis. For example, the apoptosis induce factor(AIF), a 
mitochondria intermembrane flavoprotein, that can be released from mitochondria to 
© 2012 Hongmei, licensee InTech. This is a p per distributed under the erms of the C eative Commons
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© 2012 Hongmei, licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Extrinsic and Intrinsic  
Apoptosis Signal Pathway Review 
Zhao Hongmei 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/50129 
1. Introduction 
Apoptosis, as a programmed cell death (PCD) is essential for normal cell mechanism. The 
word “Apoptosis” derives from Greek language “απόπτωσις” and means trees shedding their 
leaves in autumn, which describes the "dropping off" or "falling off" of petals from flowers, or 
leaves from trees. This language imaginarily described the cell death triggered by 
physiological and pathological stimulation. The apoptosis phenomena were first described by 
German Scientist Carl Vogt in 1842 year, while until 1972 year, apoptosis term was first used 
by John Foxton Ross Kerr group. They use apoptosis word to describe the tissue cell death. 
The above is the beginning of apoptosis researches and this period is the apoptosis formation; 
the second period about apoptosis is the biochemical level and apoptosis cell morphological 
changes research. In this age, people know that apoptosis accompany with cell membrane 
wrinkled, DNA fragmentation, cytosol calcium increased and form the apoptosis body which 
contain its own content so on. In this time the electron microscope play a vital role in the 
research. Following the apoptosis research came in the third period in recent years; scientists 
began to research the molecular mechanism of apoptosis and to use this cell death for clinical 
treatment. Some key proteins in the procession of the apoptosis have been found, such as Bcl-2 
family protein, caspase-3, caspase-8, caspase-9, Bid, Bax and so on.  
In the past, the apoptosis was focused on the caspase, a family of cysteine protease. While, 
using the caspase inhibitor to block the apoptosis pathway, the researchers found that the 
apoptosis still happen. So another pathway that is caspase-independent was found. Now, 
apoptosis is classified to type I, Type II, Type III PCD: type I PCD is the classic apoptosis, 
the well know caspase denpendent apoptosis; type II PCD’s morphology characters are the 
appearance of the autophagic and double membrane of vacuole; type III PCD occurs 
without the condensate chromatin and has not been well-known. Type IIand type III PCD 
are the caspase-independent apoptosis. For example, the apoptosis induce factor(AIF), a 
mitochondria intermembrane flavoprotein, that can be released from mitochondria to 
© 2012 Hongmei, licensee InTech. This is a p per distributed under the erms of the C eative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 
Apoptosis and Medicine 4 
translocate into the nuclear and cause many high molecular weight DNA fragmentation and 
chromatin condensation in cells, this type of apoptosis is in the caspase-independent 
manner. [65] No mater the typeI, Type II or type III PCD, the apoptosis will assist the host to 
defense the outer or inner aliens and toxic compounds and help the organism survive.  
In this chapter, we will key on the apoptosis signal pathway and some ligands have the clue 
with apoptosis and mainly on concluded the apoptosis on two aspects, from in vivo and in 
vitro cells, and we can clarify the network of this cell death and give the conclusion of the 
latest research about this.  
2. Apoptosis research time line  
Cell death is essential for body homeostasis, currently years research, cell death can be 
classified as necrosis, apoptosis, pyroptosis. Necrosis is the first to be found, and then in the 
1972 year, the apoptosis term began to be used; several years ago, pyroptosis was been 
known by the symbol of formation hole in cell membrane and released inflammatory 
factors. Apoptosis research started in the nineteen century. According to the past research, 
we collect and analyze the research of apoptosis and give the following summary of history 
and highlights about apoptosis in Table1 
 
Year  Scientist Research  
1842 Carl Vogt First describe the principle of apoptosis  
1885  Walter Flemming Give more precise description of PCD 
1965  John Foxton Ross Kerr 
Distinguish the apoptosis used by electronic 
microscopy 
1972 John Foxton Ross Kerr Initially used the apoptosis term 
2002 
Sydney Brenner, Horvitz and 
John E suston  
Awarded to Nobel prize in medicine 
according they contribute in apoptosis 
research area. 
Table 1. History and highlights about apoptosis research  
In 2002 year, the Nobel Prize in medicine was awarded to the Sydney Brenner, Horvitz and 
John E suston, according they contribute to the apoptosis research. They make a stone 
research work in organ development research and genetic systemic regulation programme 
cell death. Sydney Brenner’s contribution is the construction of nematode of C.elegan 
model. And subsequently, suston found the cell lineage of C.elegan and found the first 
gene(Nuc-1) related with apoptosis. Now the C.elegan is still the classic model to research 
apoptosis and organ development research, Now, apoptosis has been found in the tumor 
development, and it has been clear that alteration of apoptotic pathways is a common 
feature of tumors, enabling cancer cells to survive chemotherapeutic interventions, so 
apoptosis signal pathway molecular become attractive targets in cancer therapy. Beside 
involving in the tumor development, apoptosis have been found in many other diseases, 
such as neurodegenerative diseases, diabetes, stroke and so on. Here, we review the 
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fundamental apoptotic pathways and summarize many ligands that can trigger apoptosis 
and give some insights in the designing some drugs, plus, we also give the opinions that 
changes the dietary arable may be help to improve the people’s healthy.  
3. Apoptosis signal pathway 
Apoptosis is triggered by multi-signal pathways and regulated by multi-complicated 
extrinsic and intrinsic ligands. The process of apoptosis is controlled by diversity cell signals 
pathway and involved in regulation of cell fate death or survival. There are two major 
apoptosis pathways distinguished according to whether caspases are involved or not. The 
mitochondria, as the cross-talk organelles, can connect the different apoptosis pathway.  
3.1. Caspase dependent pathway 
Caspase-dependent apoptosis is the classic programmed cell death pathway, the capase-8, 
caspase-9, caspase-12, caspase-7, caspase-3 cascade usually participate in this type of 
apoptosis pathway, Variety of receptors take part in this type of apoptosis pathway, such as 
the TNF-alpha receptor, FasL receptor, TLR, Death receptor and so on. Some iron channels 
may also be involved in apoptosis pathway. The typical iron channel is the calcium channel, 
Since calcium’s concentration in the cytosol plays an important role in the signal 
transduction regulation and participates in the cell proliferation and cell death, the cell fate 
can be controlled by the calcium channel opening or closing. In this part, we will discuss the 
caspase-dependent apoptosis transduction and review the complex signal crosstalk in the 
cells. 
TNF-alpha induced caspase-8-dependent pathway relies on the TNF-alpha receptor and 
activates the caspase-8 through the death complex, and then the Bcl-2 protein is activated, Bcl-2 
family protein activation may induced the mitochondria membrane changed and stimulates the 
cytochrome c released. Cytochrome c is the proapoptosis signal molecular which can activates 
the caspase cascade reaction and induced the apoptosis in the end. Some radiation UV or X ray 
can make mitochondria depolarization and membrane permeabilization, subsequently, the ROS 
increased; cytochorme c released, and then trigger caspase-9, caspase-3 activation,, In the end, 
the substracts will be cleavaged by the activation caspases and the fate of cells will be apoptosis; 
Some pathogen infection induced the apoptosis may be also have the caspase-8 dependent 
pathway, The alien pathogens can be recognized by FasL receptor and recruit FADD and 
caspase-8, for example, the intracellular pathogen herpervirus infection can induced the 
caspase-8 dependent apoptosis. Beside caspase-8 dependent apoptosis, some pathogens can 
trigger others caspases dependent apoptosis pathway. For example, Mycobacterium 
tuberculosis can induce programmed cell death on macrophage, and this apoptosis pathway is 
the caspase-12 dependent. NO and ROS production, stimulated by ER stress, also take part in 
apoptosis triggered by Mycobacterium tuberculosis; [1] Exclude bacteria, virus also can induce 
the apoptosis. The latest research found that an alternative Kaposi’s sarcoma-associated 
herpesvirus replication can trigger host cell apoptosis in caspase dependent manner. [2]. Apart 
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from the bacteria and virus, we found that many researchers’ data show that RNA fragments 
and DNA can also trigger caspase dependent apoptosis, such as RNA fragment produced by 
mycobacterium tuberculosis which in the early log-phase growth can trigger caspase-8 
dependent apoptosis[3]; In vivo, DNA damage can trigger apoptosis through enhancing ROS 
level and changing the mitochondria membrane permeability; Many proteins or peptides will 
also make cell apoptosis, amyloid β peptide cytotoxicity can induce the intracellular calcium 
disturbance, and then the calpain will be activated by imbalanced calcium storage, While the 
calpain can activate caspase-12 which can located in ER to inactivate the Bcl-Xl, this is a novel 
caspase-12 dependent apoptosis pathway[4]. This way can be used by the mitochondria to 
connect with other cell death pathway.  
Above all, we can give the conclusion that pathogens, RNA or DNA, proteins or peptides, 
some chemical compounds or native compounds can all trigger caspase dependent 
apoptosis. They may have the different receptors and induce cell death through different 
caspase as the transducer to make the downstream signals transduction. The host used this 
way to defense the harmful factors and maintain the healthy physiological state. In the 
figure 1, we summarized the caspase dependent pathway transduction; we clearly known 
that the different ligands and receptors involved in this type of apoptosis, this picture will 
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Figure 1. Summarize the caspase dependent apoptosis pathway  
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In this figure, we can clearly know that mitochondrion and nucleus organelles play the 
pivotal role in this type cell death and these organelles can connect different signals to 
induce the caspase activation, in this process period, ROS; Cytochorme C release; 
mitochondrion membrane potential change; Apart the mitochondrion pathway, some 
ligands can trigger MAPK pathway, such as activate ERK and then activate the caspase 
family which can be confluenced with apoptosis pathway. 
3.2. Caspase independent pathway 
Apoptosis have many mechanisms. It can be triggered by in vitro and in vivo cell ligands, 
and have different signal transduction pathways. Now, Apoptosis pathways are classified 
as caspase dependent pathway and caspase-independent pathway. In the above, we 
describe and conclude the caspase dependent pathway, which is characterized by the 
involvement of caspase in this type cell death process. In this paragraph, we will deep 
research the caspase independent apoptosis pathway. We will know that caspase does not 
participate in this type of process from the literally meaning. Up to now, this type of 
apoptosis has been founded by many researchers, and the research data give much 
information to us, this information can help us to understand the apoptosis complex 
mechanism, beside the mechanisms, the complicated ligands, which can induce this type of 
cell death, can also be found by many researchers. In the following, we will give some 
detailed contents about caspase independent apoptosis. 
In the cell, a lot of ligands can induce mitochondria membrane potential change, the 
mitochondria damage will be the first step of the apoptosis, then ROS production increase, 
and ROS may the mainly factor to induce caspase independent apoptosis. For example, 
Denis Martinvalet found that granzyme A can directly induce the ROS increase and caspase 
independent mitochondria damage. Then the target of granzyme A, ER associated complex 
(SET complex), will translocated to nuclear and contributed to apoptosis [5]; AIF has been 
found the major important caspase-indenpendent pro-apoptosis factor, which can release 
from the mitochondria and translocate in the nuclear to cleavage the DNA, in the end, if the 
DNA damage have not been repaired by cells, the apoptosis will happen. Recently, many 
researchers found some compounds which can accompany with AIF production and induce 
cell death, such as simvastatin, staurosporine, cadmium and so on. These factors triggered 
caspase-independent PCD and fitted for the organism requirement; Beside AIF triggered 
caspase-independent PCD, ROS also participate in this type cell death. ROS can mediate 
poly (ADP-ribose) polymerase-1 (PARP-1) activation, and PARP-1 activation is necessary for 
AIF release from mitochondria. So ROS also involved in this type of cell death 
networks.[6].However, ROS participated in the caspase dependent apoptosis pathway also, 
Consequently, ROS might be the important bridge to connect two types of apoptosis in vivo. 
ROS mainly come from mitochondria, so mitochondria play important role in apoptosis 
pathways crosstalk. And the ligands usually trigger complicated reactions, including that 
AIF nuclear translocation, ROS increase and mitochondrial dysfunctions, these changes can 
cause to the caspase independent apoptosis pathway. For example, Cyclohexyl analogues of 
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Figure 1. Summarize the caspase dependent apoptosis pathway  
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In this figure, we can clearly know that mitochondrion and nucleus organelles play the 
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networks.[6].However, ROS participated in the caspase dependent apoptosis pathway also, 
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Apoptosis and Medicine 8 
Ethylenediamine Dipropanoic Acid, the compound that can induce peripheral blood 
mononuclear cells apoptosis of both healthy controls and leukemic patients through 
stimulating many apoptogenic factors activation(such as: AIF nuclear translocation, ROS 
increase and mitochondrial dysfunction ). [7] Referring the ROS, we propose that the GSH ,  
NO, or other free radical groups may also take part in this type cell death, By this way, the 
GSH or NO modification proteins may also take part in the apoptosis pathway, GSH and 
NO can block some active thiol group and make the protein S-glutathionylation or S-
nitrosylation modification. These types modification may affect the protein’s functions and 
make the cell to apoptosis result. Beside the AIF and ROS, there are many other ligands and 
signal molecular from the vitro or vivo cells as apoptogenic factors involving in caspase 
independent apoptosis pathway, such as lysosomal membrane permeabilization; some 
virus’s protein; drugs; p53 suppression tumor factors or many other unknown compounds. 
Up to now, the caspase independent apoptosis mechanism is still unknown clearly. Although 
some researchers have found AIF; ROS and other ligands can stimulate this type of PCD, the 
signal pathway still stay the phenomena stage and the deep mechanism should be dig out by 
us. No matter either apoptosis form, this type cell death has very important functions and 
deserves to be researched deeply. We collected a variety of information about this cell death 
and found that the caspase independent apoptosis existed in a mount of species and played 
indispensable role in cell growth, proliferation and death. In the figure 2, we give the outline 
about this type apoptosis pathway and the crosstalk manner between the different pathways, 
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Figure 2. Caspase independent apoptosis pathway 
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In this type apoptosis, caspase family members did not involve in this cell death, and can 
not be inhibited by the caspase inhibitor {such as: the z-VAD-FMK; quinolyl valyl-o 
methylaspartyl[-2,6-difluorophenoxy]-methyl ketone(Q-VD-OPH);Ac-DEVD-FMK and so 
on}.  In the cells, some components and events, such as the AIF; ROS; Ca2+; NAD+ and ATP; 
protein misfolding and modification, can trigger the caspase independent apoptosis.  
3.3. Mitochondria dynamics and apoptosis 
Mitochondria, as a semiautonomous organelle in cells, apart from containing their own 
genetic material, play an important role in the energy metabolism. It can produce ATP to 
maintain the cell life activity and be known as an energy company in cells. Beside this major 
role, mitochondria are the places that the lot of biological reaction processes happened, such 
as ROS production, apoptosis, and regulation of aging [8] and so on. Mitochondria’s 
dysfunction has the relation with many diseases (Alzheimer’s disease; Parkinson’s disease, 
cancer, diabetes) [9, 10]. These diseases have been identified to have some relation with the 
apoptosis; ROS produced by mitochondria have been regarded as one of important factors 
for apoptosis. Currently, many researches found the ROS produced increased when some 
pathogen infected, ROS can trigger apoptosis, through apoptosis, the pathogens may lost 
the perfect living environment, the host may defense the pathogen’s diffusion by this 
manner. Due to these roles, mitochondria may be used as a proper therapeutic target to cure 
diseases related with this type cell death [11].  
As a dynamic organelle, mitochondria can change their shape and structure constantly to 
respond to the different stimuli and metabolic demands of cells. According to the latest 
researches about biochemistry and cell biology, the mitochondrial shape changes between 
fusion and fission play a very important role in the regulation of apoptosis [12, 13]. There 
were some debates about the opinion that apoptosis occurred relating with the 
mitochondria fission. These debates focused on which process happened firstly, either 
apoptosis is the result of the mitochondria fission and fragmentation, or reversely, as a 
following up affair, the mitochondria’s fission and fragmentation happened at the 
downstream of apoptosis. While, we can sure that mitochondria shape dynamic changes 
must be connected with apoptosis according to the follow latest researches:  
Calcium irons act as the upstream stimulus which can activate the cellular mitochondrial 
fission, the mitochondrial became fragmentation rapidly depended by the increased 
calcium level in intracellular. If the calcium level increased protractedly, mitochondria’s 
fragmentation will be non-reversible and lead to apoptosis. So Jennifer R. Hom group 
regarded that the calcium involved in mitochondria morphology and participated in the 
apoptosis processing;[14] some mitochondria membrane proteins also have been found to 
control mitochondrial morphology, for example, the Bcl-2 protein resides in the outer 
mitochondrial membrane, and this protein acts as a central regulator of the intrinsic 
apoptotic cascade; while some other toxins or proteins can also regulate the mitochondrial 
fission/fusion, and these variation shapes of mitochondria was found to have relation 
with some diseases, For instance, the PD(Parkinson's disease) have been found with the 
 
Apoptosis and Medicine 8 
Ethylenediamine Dipropanoic Acid, the compound that can induce peripheral blood 
mononuclear cells apoptosis of both healthy controls and leukemic patients through 
stimulating many apoptogenic factors activation(such as: AIF nuclear translocation, ROS 
increase and mitochondrial dysfunction ). [7] Referring the ROS, we propose that the GSH ,  
NO, or other free radical groups may also take part in this type cell death, By this way, the 
GSH or NO modification proteins may also take part in the apoptosis pathway, GSH and 
NO can block some active thiol group and make the protein S-glutathionylation or S-
nitrosylation modification. These types modification may affect the protein’s functions and 
make the cell to apoptosis result. Beside the AIF and ROS, there are many other ligands and 
signal molecular from the vitro or vivo cells as apoptogenic factors involving in caspase 
independent apoptosis pathway, such as lysosomal membrane permeabilization; some 
virus’s protein; drugs; p53 suppression tumor factors or many other unknown compounds. 
Up to now, the caspase independent apoptosis mechanism is still unknown clearly. Although 
some researchers have found AIF; ROS and other ligands can stimulate this type of PCD, the 
signal pathway still stay the phenomena stage and the deep mechanism should be dig out by 
us. No matter either apoptosis form, this type cell death has very important functions and 
deserves to be researched deeply. We collected a variety of information about this cell death 
and found that the caspase independent apoptosis existed in a mount of species and played 
indispensable role in cell growth, proliferation and death. In the figure 2, we give the outline 
about this type apoptosis pathway and the crosstalk manner between the different pathways, 













lysosome Membrane demage andrelease lysosome enzymes 



















Figure 2. Caspase independent apoptosis pathway 
 
Extrinsic and Intrinsic Apoptosis Signal Pathway Review 9 
In this type apoptosis, caspase family members did not involve in this cell death, and can 
not be inhibited by the caspase inhibitor {such as: the z-VAD-FMK; quinolyl valyl-o 
methylaspartyl[-2,6-difluorophenoxy]-methyl ketone(Q-VD-OPH);Ac-DEVD-FMK and so 
on}.  In the cells, some components and events, such as the AIF; ROS; Ca2+; NAD+ and ATP; 
protein misfolding and modification, can trigger the caspase independent apoptosis.  
3.3. Mitochondria dynamics and apoptosis 
Mitochondria, as a semiautonomous organelle in cells, apart from containing their own 
genetic material, play an important role in the energy metabolism. It can produce ATP to 
maintain the cell life activity and be known as an energy company in cells. Beside this major 
role, mitochondria are the places that the lot of biological reaction processes happened, such 
as ROS production, apoptosis, and regulation of aging [8] and so on. Mitochondria’s 
dysfunction has the relation with many diseases (Alzheimer’s disease; Parkinson’s disease, 
cancer, diabetes) [9, 10]. These diseases have been identified to have some relation with the 
apoptosis; ROS produced by mitochondria have been regarded as one of important factors 
for apoptosis. Currently, many researches found the ROS produced increased when some 
pathogen infected, ROS can trigger apoptosis, through apoptosis, the pathogens may lost 
the perfect living environment, the host may defense the pathogen’s diffusion by this 
manner. Due to these roles, mitochondria may be used as a proper therapeutic target to cure 
diseases related with this type cell death [11].  
As a dynamic organelle, mitochondria can change their shape and structure constantly to 
respond to the different stimuli and metabolic demands of cells. According to the latest 
researches about biochemistry and cell biology, the mitochondrial shape changes between 
fusion and fission play a very important role in the regulation of apoptosis [12, 13]. There 
were some debates about the opinion that apoptosis occurred relating with the 
mitochondria fission. These debates focused on which process happened firstly, either 
apoptosis is the result of the mitochondria fission and fragmentation, or reversely, as a 
following up affair, the mitochondria’s fission and fragmentation happened at the 
downstream of apoptosis. While, we can sure that mitochondria shape dynamic changes 
must be connected with apoptosis according to the follow latest researches:  
Calcium irons act as the upstream stimulus which can activate the cellular mitochondrial 
fission, the mitochondrial became fragmentation rapidly depended by the increased 
calcium level in intracellular. If the calcium level increased protractedly, mitochondria’s 
fragmentation will be non-reversible and lead to apoptosis. So Jennifer R. Hom group 
regarded that the calcium involved in mitochondria morphology and participated in the 
apoptosis processing;[14] some mitochondria membrane proteins also have been found to 
control mitochondrial morphology, for example, the Bcl-2 protein resides in the outer 
mitochondrial membrane, and this protein acts as a central regulator of the intrinsic 
apoptotic cascade; while some other toxins or proteins can also regulate the mitochondrial 
fission/fusion, and these variation shapes of mitochondria was found to have relation 
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mitochondrial morphology changes, there were two toxin proteins parkin and PINK1 
which were detected to play a role in maintaining mitochondrial homeostasis through 
targeting the mitochondria and regulating the mitochondrial dynamics[15]; Fusion and 
fission often occur swiftly and are found to have relation with the mitochondria 
membrane potential changes .there are DRP1-dependent division and FZO1-dependent 
fusion reaction in mammalian cells, and division of mitochondria accompany with 
apoptosis., If mitochondrial fission/fusion dynamics losses balance, it will lead to some 
neurodegeneration diseases. So in brief, mitochondria act as the important role to keep 
cell healthy. 
Mitochondrial iron transporter cytochrome C plays an classic role in apoptosis. As a bridge, 
it connect with caspase cascade reaction. When cytochrome C is released to the cytoplasm 
from the mitochondria as a result of response to some intrinsic or extrinsic ligands, it can 
trigger the downstream caspases and induce the intrinsic apoptosis. So mitochondria are not 
only the energy company of cell, but also have the ability to control the intrinsic apoptosis 
pathway through either cytochrome C, calcium, morphology changes(fission/fusion) or 
some membrane proteins expression imbalance(Bcl-2).  
4. Trigger apoptosis ligands and cell environment materials 
Apoptosis, as a major cell death procession for healthy, play an important role in 
homeostasis of whole life. In the period of fetation, apoptosis happened, as the essential 
affair for the finger and toe formation. due the cells between fingers occured apoptosis, we 
can form five fingers per hand. Apoptosis also can enhance embryonic stem cell survival 
during stress by increased expression Bcl-2 protein which significantly weaken the 
apoptosis and help colony formation [16];Apoptosis also take part in some tissues 
regeneration and homeostasis [17,18]; In addition to the function that we have described 
above, apoptosis can still anti-inflammation and hamper pathogens persistence infection, 
especially interfering the intracellular parasites diffusion; In conclusion, apoptosis are good 
for people’s healthy in variety aspects, and apoptosis become research areas hotspots at 
present. Summarizing the currently researcher’s data, we found that many ligands can 
trigger or inhibit apoptosis. We classified these ligands to two parts by its derivation: 1. 
extrinsic signal ligands. 2. Intrinsic ligands. The details about the ligands which can trigger 
the apoptosis will be described below:  
4.1. Extrinsic cell materials 
4.1.1. Cytokines 
TNF-alpha plus z-VAD can trigger cell apoptosis, and this method is well-known in 
creating cell apoptosis model. TNF-alpha can bind to extracellular domain of TNF-alpha 
receptor , and the cytoplasm domain can aggregate FADD and FLICE which can initiated 
the apoptosis; Another famous cytokine, IFN—γ, which can induce the macrophage 
apoptosis, plays a key role in clearance of the mycobacterium tuberculosis by inducing 
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host cell apoptosis depended by the nitric oxide(NO).[19] TGF-β1 acts as a chemo-
attractant and is very important for the immune response, this cytokine also play a 
predominant suppressive role in inhibiting the cell proliferation and stimulating B cells to 
apoptosis. [20] 
Above all, the cytokines are the positive inducer of apoptosis. The investigators also found 
another mechanism of cytokines related apoptosis which is negative induction by loss of 
suppressive signal. Many cells viability required supplying the constant or intermittent 
cytokines or growth factors, Lack of cytokine or growth factors, the cell will go to apoptosis. 
In this circumstance, these cytokines or growth factors act as the suppressors of apoptosis. 
For example, when we culture hematopoietic cells, we should add colony-stimulating 
factors and IL-3; In addition, IL-12 is required to maintain the viability of activated T cells in 
in vitro culture systerm; the neurorophic cells required the nerve growth factor (NGF) for 
survival. Moreover, there are many other cytokines and growth factors as the suppressors of 
apoptosis, such as: epidermal growth factor, platelet-derived growth factor and insulin like 
growth factor-I and so on. They are also act as the survival factors and inhibit the apoptosis, 
while if we block or remove these factors; the related cells will be in the procession of 
apoptosis. So in above all, we have known that cytokines may as inducer or suppressor to 
participate in apoptosis pathway.  
4.1.2. Drugs 
Some cytotoxic drugs (Cispkatin, Gemcitabin, Tooitecan, and paclitaxel) can trigger 
apoptosis; Didymin induce apoptosis by preventing N-Myc protein expression and make 
the cell G2/M arrest, which may be a novel mechanism to anti-neuroblastoma.[21]; apart 
from this anti-neuroblastoma properties, didymin have an anti-no small cell lung cancer 
ability by induced the Fas-mediated apoptosis, it may be a novel new chemotherapeutic 
agent to treat the lung cancer. [22] Gomisin N have anti-hepatotoxic, anti-oxidative and 
anti-inflammation abilities, while it also have anti-cancer activity through triggered the 
TRAIL-induced apoptosis.[23] Andrographolide as an anti-bacteria drug have been found 
having anti-cancer activity adrographolide treated cancer cell can activate the p53 by 
increasing p53 phosphorylation, p53 activation can make DR4 protein expression 
increased and then trigger the TRAIL-induced apoptosis.[24] Ursolic acid can stimulate 
the ROS production and trigger JNK activation, ROS and activated JNK can make the DR 
up expression, and in the end, TRAIL-induced apoptosis happened in p53 independent 
manner.[25] Ciglitazone, as an anti-diabetic drug, has been found by Plissonnier ML 
group that ciglitazone have antineoplastic effectiveness in a lot of cancer cell lines through 
up-regulation of soluble and membrane bound TRAIL, make caspase activation, death 
receptor signal pathway activation and induce Bid to be cleaved as response to TRAIL. 
These data gave the evidence that ciglitazone can down regulate the c-FLIP and surviving 
protein, and then triggered the TRAIL-induced apoptosis to kill the cancer cell.[26] These 
data provided the powerful evidence that triggering apoptosis may be a feasible method 
for clinically cure. 
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4.1.3. Hormone 
Apoptosis occurs in the embryonic development and during the formation of organs, 
Hormones is usually a peptide or steroid, produced by one tissue and conveyed by the 
bloodstream to another place to affect physiological activity, such as growth, proliferation, 
metabolism. Some researchers also found that hormones can regulate the apoptosis, and 
through this way hormone can control the metabolism of tissues or organs. For example, the 
leptin is one hormone produced by adipocytes, and it has been found as a inhibitor of 
apoptosis, leptin can down-regulate cleaved caspase-3 and Bcl-2 associated X protein and 
up-regulate Bcl-2 protein, if this hormone level is normal, there will be no apoptosis, 
however, if the hormone level decreased, the apoptosis will happen[27], this is one 
mechanism by which the hormone act as inhibitor of apoptosis, the other mechanism is that 
hormone act as an inducer of apoptosis. The majority relations between the hormone and 
apoptosis are concluded as below the table 2  
 
Hormones  Apoptosis cell (Target) Reference 
Known inhibitors of apoptosis
Testosterone Prostate 51 
Oestradiol ovarian cells 53,52 
Growth hormone Human monocytes or human promyelocytic 
leukaemia
54 
Leptin myometrial cells 27 
Dihydrotestosterone Prostate 51 
progeterone cardiomyocytes 55 
Act as inducers of apoptosis
Glucocorticoids Human small cell lung cancer 56 
progeterone human endometrial cell 57 
Thyroid hormones Play an important role in Amphibian organ 
remodeling during metamorphosis through 
inducing apoptosis
58 
Estrogen Breast cancer cell 59 
Phytoestrogens Breast cancer cell 60 
Table 2. Involvement of hormones in apoptosis  
4.1.4. Pathogen effectors 
During the fight between host and pathogen, there are many roads that benefit the cell 
survival. There is the proverb “Survival of the fittest”. If failing to defense the pathogen, 
host will be ill, and give the phenomenon of inflammation or cell death (apoptosis, necrosis, 
auto-phage, pyroptosis). In this part, we will give the conclusion about host cell apoptosis 
which can be triggered by some pathogens, If cell occured apoptosis, the pathogen can not 
survival either, so through this way, host cells can clear the pathogen with little bad effects. 
The pathogen effectors, which possess the ability to trigger apoptosis, have been found as 
following below:  
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Mycobacterium can be cleared by macrophage’s apoptosis which was induced by the NO 
and IFN-γ[28]; Chlamydia pneumoniae infection can induce the human T lymphocyte cell 
apoptosis, through this way, Chlamydia pneumonia could induce immunologic tolerance 
and would make pathogen persistence infection and inflammation[29]; Dendritic cells(DC) 
were well known immune cells, as an antigen-process cell, DC can inhibit pathogen 
replication and diffusion by caspase-3 dependent apoptosis in early infection stage, For 
instance, Legionella pneumophila was unable replicated in DC, because DC go to apoptosis 
when Legionella pneumophila infected these cells in the early stage.[30] Beside the bacteria 
infection induced the apoptosis, some virus also be found to involve in the apoptosis. For 
example, transmissible gastroenteritis virus infection can up-regulate the FasL; 
Subsequently, the Bid protein can be cleaved and cytochrome c release; in the end, Caspase-
8 can be activated and the host cell happen apoptosis. [31] Through this way, the pathogens, 
especially the obligate intracellular parasites, will lost the suitable environment for their life 
and will die, however, the host will survival and suffer lowest bad effect. 
From this part, we give the conclusion that apoptosis play the key role in host-pathogen 
confrontation. There are about two mechanisms in this confrontation, one mechanism is that 
pathogen’s target cells can clear the pathogen and inhibit it persistence diffusion by itself 
apoptosis. Another is that pathogens infection didn’t induce the targeted cell apoptosis but 
cause the related immune cells apoptosis. By this way, the host cells will fail to clear the 
pathogen. The loss function of host immune cells will benefit the pathogen’s replication and 
help pathogen’s diffusion persistence. There are always two sides to every thing, the 
apoptosis also have no exception.. 
4.1.5. Native activities compounds 
Although apoptosis is the programmed cell death and can be recognized as the normal cell 
death by the immune system; and apoptosis have many important functions in the tissue 
development. While everything have two sides, in some cases, apoptosis also have the 
damage and negative effect to the life healthy. Recently, food scientists and biologist found 
that some native compounds from the daily life dietary can block or hamper apoptosis, and 
through this way, these native compounds can help to keep the body healthy. 
Vitamin E, another name is tocopherol. As an antioxidant, Vitamin E has an important role 
in redox balance. Recently, apart it’s major role in antioxidant ability, vitamin E can block 
the reduction of the mitochondrial membrane potential and inhibit the activation of caspase-
3, in a brief, vitamin E is conducive to cell viability through blocking the caspase-3 triggered 
apoptosis. [32] Moreover, Purple Sweet Potato Pigments can scavenge ROS and protect the 
murine thymocyte by inhibiting caspase-dependent pathway apoptosis also [33]. Lycopene, 
another name is rhodopurpurin, Lycopene can be taken from the tomatoes, fruits and 
vegetables easily. As an antioxidant, Lycopene was been found that it contribute to body’s 
heath. Nearly, researchers found that lycopene have anti-prostate cancer activity; Apart 
from the anti-tumor properties, it have anti-infection ability. For example, Jang SH’ group 
gave the proof that lycopene can inhibit ROS increased, DNA damage and apoptosis in 
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Act as inducers of apoptosis
Glucocorticoids Human small cell lung cancer 56 
progeterone human endometrial cell 57 
Thyroid hormones Play an important role in Amphibian organ 
remodeling during metamorphosis through 
inducing apoptosis
58 
Estrogen Breast cancer cell 59 
Phytoestrogens Breast cancer cell 60 
Table 2. Involvement of hormones in apoptosis  
4.1.4. Pathogen effectors 
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survival. There is the proverb “Survival of the fittest”. If failing to defense the pathogen, 
host will be ill, and give the phenomenon of inflammation or cell death (apoptosis, necrosis, 
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which can be triggered by some pathogens, If cell occured apoptosis, the pathogen can not 
survival either, so through this way, host cells can clear the pathogen with little bad effects. 
The pathogen effectors, which possess the ability to trigger apoptosis, have been found as 
following below:  
 
Extrinsic and Intrinsic Apoptosis Signal Pathway Review 13 
Mycobacterium can be cleared by macrophage’s apoptosis which was induced by the NO 
and IFN-γ[28]; Chlamydia pneumoniae infection can induce the human T lymphocyte cell 
apoptosis, through this way, Chlamydia pneumonia could induce immunologic tolerance 
and would make pathogen persistence infection and inflammation[29]; Dendritic cells(DC) 
were well known immune cells, as an antigen-process cell, DC can inhibit pathogen 
replication and diffusion by caspase-3 dependent apoptosis in early infection stage, For 
instance, Legionella pneumophila was unable replicated in DC, because DC go to apoptosis 
when Legionella pneumophila infected these cells in the early stage.[30] Beside the bacteria 
infection induced the apoptosis, some virus also be found to involve in the apoptosis. For 
example, transmissible gastroenteritis virus infection can up-regulate the FasL; 
Subsequently, the Bid protein can be cleaved and cytochrome c release; in the end, Caspase-
8 can be activated and the host cell happen apoptosis. [31] Through this way, the pathogens, 
especially the obligate intracellular parasites, will lost the suitable environment for their life 
and will die, however, the host will survival and suffer lowest bad effect. 
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pathogen’s target cells can clear the pathogen and inhibit it persistence diffusion by itself 
apoptosis. Another is that pathogens infection didn’t induce the targeted cell apoptosis but 
cause the related immune cells apoptosis. By this way, the host cells will fail to clear the 
pathogen. The loss function of host immune cells will benefit the pathogen’s replication and 
help pathogen’s diffusion persistence. There are always two sides to every thing, the 
apoptosis also have no exception.. 
4.1.5. Native activities compounds 
Although apoptosis is the programmed cell death and can be recognized as the normal cell 
death by the immune system; and apoptosis have many important functions in the tissue 
development. While everything have two sides, in some cases, apoptosis also have the 
damage and negative effect to the life healthy. Recently, food scientists and biologist found 
that some native compounds from the daily life dietary can block or hamper apoptosis, and 
through this way, these native compounds can help to keep the body healthy. 
Vitamin E, another name is tocopherol. As an antioxidant, Vitamin E has an important role 
in redox balance. Recently, apart it’s major role in antioxidant ability, vitamin E can block 
the reduction of the mitochondrial membrane potential and inhibit the activation of caspase-
3, in a brief, vitamin E is conducive to cell viability through blocking the caspase-3 triggered 
apoptosis. [32] Moreover, Purple Sweet Potato Pigments can scavenge ROS and protect the 
murine thymocyte by inhibiting caspase-dependent pathway apoptosis also [33]. Lycopene, 
another name is rhodopurpurin, Lycopene can be taken from the tomatoes, fruits and 
vegetables easily. As an antioxidant, Lycopene was been found that it contribute to body’s 
heath. Nearly, researchers found that lycopene have anti-prostate cancer activity; Apart 
from the anti-tumor properties, it have anti-infection ability. For example, Jang SH’ group 
gave the proof that lycopene can inhibit ROS increased, DNA damage and apoptosis in 
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gastric epithelial AGS cells induced by helicobactera pylori infection. [34]. Soy isoflavone 
also have been documented as dietary nutrients broadly, it was been classified as “natural 
agents” which play the important role in reducing the incidence of hormone-related cancers 
in Asian countries, and have shown inhibitory effects on cancer’s development and 
progression in vitro and in vivo. [35] Beside this soy isoflavone, in recent years, dietary 
compounds which was from the bounties of nature have been paid any attentions, the latest 
researches data have shown that there are some associations between the consumption of 
some native dietary compounds and the reduced risk of several types of cancers, [36, 37] 
because there are lots of active compounds containing in the food which have some 
associations with the apoptosis, and due by apoptosis, these native compounds will inhibit 
cell abnormal proliferation. 
Apart from these food derived natural compounds, there are many plant components which 
can be used by Chinese traditional medicine (TCM), these plant active components can also 
have trigger apoptosis, such as fisetin, wongonin, emodin and so on. Fisetin is a natural 
flavonoid which can induce several type cancer cells to apoptosis by dose and time 
dependent manner. Fisetin can activate caspase-8/caspase-3 dependent apoptosis pathway, 
and these pathway transducer molecular will be the candidates for cancer therapy; [38] 
Wongonin, as an O-methylated flavonoind, was detected to have anxiolytic activity, and 
also have the ability to trigger some cancer cells apoptosis. For instance, wongonin and 
fisetin can make PARP to be cleaved, then pro-caspase-3 will be activated in HL-60 cells, 
while they can induce the ROS decreased, so it is not the ROS dependent apoptosis 
pathway. Several compounds have the similar structural with flaconoids, including the 
luteolin, nobiletin, wogonin, baicalein, apigenin, myricetin and fisetin, they all have 
biological activities. Up to now, wogonin and fisetin have been found that they have the 
potential ability to trigger apoptosis through caspase-8 dependent manner[40,41]. Rheum 
palmatum is traditional Chinese medicines which have anti-bacteria; anti-inflammation; and 
improving microcirculation, emodin is an active component of Rheum palmatum and have 
apoptosis-inducing activity, Chen YC group found that the emodin can activate caspase-3 
cascade and trigger HL-60 cell apoptosis independent of ROS production also. [41]  
Some researches gave us many inspirations in the apoptosis research. We known that many 
tradition Chinese medicines (TCM) have some active constituents, these active components 
have anti-tumor activity through apoptosis, so combination the molecular biology to dig out 
the mechanism of drug functions will be effective and scientifical, Now, the functions of 
some tradition Chinese medicines are still stay the phenomena, we did not know the real 
mechanism of activity materials. Although TCM have not curative effect faster than western 
medicine, but the TCM have the lowest side effect and help for prognosis, so many patients 
choose TCM to defense the diseases in china. More and more investigators are focusing on 
elucidating the molecular mechanisms of these natural products and identifying its targets. 
Moreover, I think the researches of active components from TCM will be meaningful and 
broadly potential in the future. In the table 3, we summarized some other native compounds 
that can trigger apoptosis, I hope that these informations will guild us to research some 
active components in the drug.  
 
Extrinsic and Intrinsic Apoptosis Signal Pathway Review 15 
Native compound Caspase dependent apoptosis Reference 
luteolin 
Trigger mitochondria- dependent 
apoptosis. And activate Bax, Bcl-xl, Bcl-2, 
Mcl-1, caspase-9, caspase-3, and PARP  
61 
Apigenin  




Leading caspase-8 activation and 
mitochondria-dependent cell death 
63 
β-Lapachone  
Leading ER stress and JNK activation and 
mitochondria mediate apoptosis 
64 
Table 3. Another native compounds which can trigger apoptosis apart from above paragraph’s related  
4.2. Intrinsic cell apoptosis signal materials  
4.2.1. Oxidative stress (ROS; NO; GSH). 
Keratin is a cytoskeleton protein which have some abilities to maintain the cell shape, Guo-
Zhong Tao group found that keratin can modulate the shape of mitochondria and contribute 
to hepatocyte predisposition to apoptosis and oxidative injury [42].Depletion the 
mitochondria GSH in the human B lymphoma cell line by treatment with L-buthionine 
sulfoximine can induce caspase-3 activation and apoptosis, and indicating that GSH may be 
the potential early activator of apoptotic signal [43]. ROS is a type of toxic compound and 
usually detoxified by cells GSH, when the oxidative stress occur, the ROS detoxify will be 
failed, and ROS will participate in apoptosis through redox-sensitive death pathway.  
4.2.2. Cytochrome C 
Cytochrome C, as a proapoptotic protein, plays an important role in triggering programmed 
cell death, The activation of cytochrome C is related with the changes of Bak/Bax ratio. The 
latest researches shown that the interactions of heterotypic mitochondrial membrane will 
change the lipid milieu, in the end, mitochondrial membrane will be permeatable and 
cytochrome c will release. [44]; Apart the changes of lipid milieu, arachidonic acid, 
triiodothyronine (T3), or 6-hydroxdopamine can also effect the permeability of 
mitochondrial membrane and release Ca2+ and cytochrome c. [45] Cytochrome c can thrigger 
caspase activation via oligomerization of APAF1 protein. Caspase activation can catalyze 
the PARP-1, Finally, the apoptosis will happen. In short, cytochrome C is the one of major 
intrinsic cell apoptosis signal molecules. 
4.2.3. Calcium iron  
The concentration of calcium in vivo is the key role in maintain the permeatability of 
mitochondrial membrane. The increased intra-mitochondrial calcium can result in enhanced 
ROS, Furthermore, cytochrome c will be stimulated to release. [46] And calcium also trigger 
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compounds which was from the bounties of nature have been paid any attentions, the latest 
researches data have shown that there are some associations between the consumption of 
some native dietary compounds and the reduced risk of several types of cancers, [36, 37] 
because there are lots of active compounds containing in the food which have some 
associations with the apoptosis, and due by apoptosis, these native compounds will inhibit 
cell abnormal proliferation. 
Apart from these food derived natural compounds, there are many plant components which 
can be used by Chinese traditional medicine (TCM), these plant active components can also 
have trigger apoptosis, such as fisetin, wongonin, emodin and so on. Fisetin is a natural 
flavonoid which can induce several type cancer cells to apoptosis by dose and time 
dependent manner. Fisetin can activate caspase-8/caspase-3 dependent apoptosis pathway, 
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apoptosis-inducing activity, Chen YC group found that the emodin can activate caspase-3 
cascade and trigger HL-60 cell apoptosis independent of ROS production also. [41]  
Some researches gave us many inspirations in the apoptosis research. We known that many 
tradition Chinese medicines (TCM) have some active constituents, these active components 
have anti-tumor activity through apoptosis, so combination the molecular biology to dig out 
the mechanism of drug functions will be effective and scientifical, Now, the functions of 
some tradition Chinese medicines are still stay the phenomena, we did not know the real 
mechanism of activity materials. Although TCM have not curative effect faster than western 
medicine, but the TCM have the lowest side effect and help for prognosis, so many patients 
choose TCM to defense the diseases in china. More and more investigators are focusing on 
elucidating the molecular mechanisms of these natural products and identifying its targets. 
Moreover, I think the researches of active components from TCM will be meaningful and 
broadly potential in the future. In the table 3, we summarized some other native compounds 
that can trigger apoptosis, I hope that these informations will guild us to research some 
active components in the drug.  
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Keratin is a cytoskeleton protein which have some abilities to maintain the cell shape, Guo-
Zhong Tao group found that keratin can modulate the shape of mitochondria and contribute 
to hepatocyte predisposition to apoptosis and oxidative injury [42].Depletion the 
mitochondria GSH in the human B lymphoma cell line by treatment with L-buthionine 
sulfoximine can induce caspase-3 activation and apoptosis, and indicating that GSH may be 
the potential early activator of apoptotic signal [43]. ROS is a type of toxic compound and 
usually detoxified by cells GSH, when the oxidative stress occur, the ROS detoxify will be 
failed, and ROS will participate in apoptosis through redox-sensitive death pathway.  
4.2.2. Cytochrome C 
Cytochrome C, as a proapoptotic protein, plays an important role in triggering programmed 
cell death, The activation of cytochrome C is related with the changes of Bak/Bax ratio. The 
latest researches shown that the interactions of heterotypic mitochondrial membrane will 
change the lipid milieu, in the end, mitochondrial membrane will be permeatable and 
cytochrome c will release. [44]; Apart the changes of lipid milieu, arachidonic acid, 
triiodothyronine (T3), or 6-hydroxdopamine can also effect the permeability of 
mitochondrial membrane and release Ca2+ and cytochrome c. [45] Cytochrome c can thrigger 
caspase activation via oligomerization of APAF1 protein. Caspase activation can catalyze 
the PARP-1, Finally, the apoptosis will happen. In short, cytochrome C is the one of major 
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The concentration of calcium in vivo is the key role in maintain the permeatability of 
mitochondrial membrane. The increased intra-mitochondrial calcium can result in enhanced 
ROS, Furthermore, cytochrome c will be stimulated to release. [46] And calcium also trigger 
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the ER stress, and then activate JNK pathway, afterwards, JNK activation can stimulate Bax 
activation; Moreover, calcuim can regulate the cysteine protease calpain, It’s well known 
that calpain participate in the cell proliferation, cell cycle, and apoptosis. Calpain can cleave 
the N terminal of Bax and generate a proapoptotic fragment, and in the same time, the cells 
will enter the apoptosis. In a brief, calcium can trigger Bcl-2 independent cytochrome c 
release, and through regulating the activity of the calpain, calcium iron can play its roles in 
modulating the apoptosis. [47]. Beside involving in the apoptosis, Cacium iron can take part 
in many other signal pathways by controlling the iron channel’s open or close. 
4.2.4. Endoplasmic reticulum (ER) stress 
As the apoptogenic factor, the permeabilization of lysosomal membrane can induce 
apoptosis by both caspase-dependent and caspase-independent pathway [48]; Tackled with 
the unfolded proteins is the one of the important ER functions, cell can regulate the 
unfolded proteins in ER according to metabolically needed, while if numerous unfolded 
proteins stimulate the ER and make the ER overload stress, the cells which have lots of 
unfolded proteins will apoptosis[49]; Differing from the ER stress, chaperons will protect 
this cell death. For example, the HSP72 protein can hamper the apoptosis through down 
regulating the unfolded protein signal response sensor IRE1alpha. Some neurodegeneration 
diseases usually accompany with unfolded protein accelerated and ER stress. So it is 
meaningful to research the relationship between the ER stress and neurodegenration 
diseases, and by this way, we will well known the function of apoptosis in the some 
neurodegeration diseases.  
The intrinsic components, which can trigger apoptosis pathway, can connect with each other 
by the vivo organelles. By this way, lots of materials in the cells will consisted in the 
network of apoptosis to feedback the vitro stimulus, This type cell death will mostly help for 
the body health. 
5. Apoptosis and diseases 
During the last decade, exceptional for the basic research, the apoptosis have attracted many 
attentions due to its potential application in therapying the various human diseases. In 
order to maintain the function of whole organism, millions of cells will die and proliferate 
every day, cell death like apoptosis is the essential for the regulation of organism growth 
and maintenance the tissue homeostasis. If the cell death and proliferation go to imbalance, 
many diseases will happen. Such as: some acute pathologies (stroke, heart attack, liver 
failure); cancer; neurodegenerative syndromes; diabetes and so on. Due to its no lethal effect 
to the body, Apoptosis play a fundamental role in organism development and tissue 
homeostasis, while if apoptosis was not under controlled, a variety of diseases will occur. 
Some neurodegenerative diseases (Alzheimer's, Parkinson's and Huntington's diseases) 
usually have the phenomena of the ER dyshomeostasis, mitochondrial dysfunction, and 
unfolded protein accelerated. In these diseases, some neural cells occur to apoptosis and 
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brain tissue damage. In the ischemia/reperfusion injury tissue, the intracellular calcium and 
ROS level will increased, these factors all contribute to induce AIF to release and translocate 
to the nucleus, in the end, the caspase-independent apoptosis will happen, if we prevent this 
cell death, the prognosis of ischemia/reperfusion will be favorable. However, if we promote 
this cell death in cancer cells , the cancer cells will form several apoptotic body containing 
the cell content, and did not release the cytosol and will not lead to the fatal inflammation, 
in this way, the patient will have the least bad effect and help them to fight against the 
disease; Apoptosis occur accompanying with inflammation, inflammasome in the cells may 
be related with the caspase family, the tissues or organs may be existed the apoptosis and 
deduct the immune reaction which induced by the inflammation, we proposed that if the 
apoptosis do not happen in this case, the persistent proliferation and serious inflammation 
will be occurred in cancer cells, this is bad for the organism. 
5.1. Drug design 
Apoptosis is the normal cell death in order to maintain the balance of homeostasis. 
Unlikely the necrosis can induce inflammation. apoptosis can give little side effects. So as 
the therapy targets, apoptosis will be the reasonable way to cure some diseases. such as 
obesity [50], cancer,  neuron-degeneration diseases and so on. Due to the genetic changes 
often existed in the human tumor cells and apoptosis have the little side effect in curing 
some diseases, ,it is not surprised that the antitumor drug have direct or indirect to target 
the apoptosis pathway molecular. The identification of the apoptosis signal pathways, 
and together with the increased knowledge about the apoptosis mechanisms, have given 
the great lots of evidences for the discovery of new drugs which can target to the 
apoptosis. 
Above all, from the life beginning and during the whole life, apoptosis always existed to 
make our life healthy. Apoptosis can not release the intracellular content in the end, this cell 
process will not lead to inflammation, and therefore, apoptosis is the injury-limiting mode 
of cell disposal. Above all, it is necessary and meaningful to research the apoptosis 
mechanism, it will give the deep inside to guild the clinical treatment and drug design. 
Beside, in the nutrition research area, there are some native compounds which can be from 
the fruits, vegetables and some marine products can help for healthy through inducing or 
inhibiting apoptosis signal pathway, so knowing the mechanism of apoptosis deeply not 
only good for guiding people to use proper drug or balance dietary in daily life, but also far 
reaching impacts in design some new drugs.  
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1. Introduction 
Biomechanical function is one of primal concern in musculo-skeletal system supporting our 
body as a whole. The functional adaptation of bone to the mechanical environment has been 
most interesting topic in bone mechanics. We have proposed the generalized model of bone 
remodeling simulation considering osteocyte apoptosis and targeted remodeling. These are 
important factors of bone metabolism under physiological and pathological conditions. This 
remodeling model has the capability to speculate the changes in the trabecular bone 
structures under various loading conditions. In this chapter, we describe how the osteocyte 
apoptosis-induced bone resorption has importance in computer simulations for disuse-
meditated trabecular bone remodeling resulting in the osteoporotic bone structure in the 
human femur. 
1.1. Cells activity in bone 
Bone tissue is the component of the skeletal system supporting human body. Bone structure 
is continuously renewed by remodeling, that is, the alternately-repeated events of local bone 
resorption and formation. Three mature cell types of osteoblasts, osteoclasts and osteocytes 
play crucial roles in bone remodeling process. Bone metabolism is regulated by bone cells 
which respond to various environmental signals coming from chemical, magnetic, electrical 
and mechanical stimuli (Klein-Nulend et al., 2005).  
Osteoblast are bone forming cells that synthesize and secrete bone matrix, participate in the 
calcification and formation of bone, and regulate the flux of calcium and phosphate in and 
© 2012 Kwon et al., licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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most interesting topic in bone mechanics. We have proposed the generalized model of bone 
remodeling simulation considering osteocyte apoptosis and targeted remodeling. These are 
important factors of bone metabolism under physiological and pathological conditions. This 
remodeling model has the capability to speculate the changes in the trabecular bone 
structures under various loading conditions. In this chapter, we describe how the osteocyte 
apoptosis-induced bone resorption has importance in computer simulations for disuse-
meditated trabecular bone remodeling resulting in the osteoporotic bone structure in the 
human femur. 
1.1. Cells activity in bone 
Bone tissue is the component of the skeletal system supporting human body. Bone structure 
is continuously renewed by remodeling, that is, the alternately-repeated events of local bone 
resorption and formation. Three mature cell types of osteoblasts, osteoclasts and osteocytes 
play crucial roles in bone remodeling process. Bone metabolism is regulated by bone cells 
which respond to various environmental signals coming from chemical, magnetic, electrical 
and mechanical stimuli (Klein-Nulend et al., 2005).  
Osteoblast are bone forming cells that synthesize and secrete bone matrix, participate in the 
calcification and formation of bone, and regulate the flux of calcium and phosphate in and 
© 2012 Kwon et al., licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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out of bone. Osteoclasts are multinucleated giant cells; their role is to resorb bone. Actively 
resorbing osteoclasts are usually found in cavities on bone surfaces, called resorption 
cavities. Osteocytes are the most abundant cell type in mature bone. During bone formation 
some osteoblasts are left behind in the newly formed osteoid as osteocytes when the bone 
formation moves on. The embedded osteoblast in lacunae differentiate into osteocytes by 
losing much of their organelles but acquiring long, slender processes encased in the lacunar-
canulicular network that allow contact with earlier incorporated osteocytes and with 
osteoblast and bone lining and periosteal cells lining the bone surface and the vasculature. 
The osteocytes are the cells best placed to sense the magnitude and distribution of strains. 
They are strategically placed both to respond to changes in mechanical strain and to 
disseminate fluid flow to transduce information to surface cells of the osteoblastic lineage 
via their network of canalicular processes and communicating gap junctions (Cowin, 2001). 
1.2. Mechanical stimuli in bone 
Mechanical stimuli are one of the important regulation factors of bone remodeling. 
According to recent findings, osteocytes might play a role in the mechanical regulation of 
bone, receiving mechanical input signals and transmitting these stimuli to other cells in 
bone. Osteocyte is believed to comprise a sensory network that monitors mechanical load 
and tissue damage, and triggers appropriate adaptive responses, either formation or 
resorption. Mechanisms by which osteocytes could sense mechanical load have been 
understood by means of fluid movements throughout the lacunar-canalicular system, with 
some combination of shear stress and streaming potentials providing the proximate stimuli. 
The relations between mechanical stimuli and mature bone have been examined by 
experimental studies. There are suggested that higher rates of mechanical loading would 
evoke grater adaptive responses than lower rates of loading in mature bone (LaMonte et al., 
2005). Exercise can substantially alter the physical states of a bone and generate adaptive 
responses. In a randomized controlled clinical trial, Fuchs et al.(2001) showed that, in 
jumpers, jumping significantly increases bone mineral content in femoral neck and lumbar 
skeleton relative to controls. McKay et al. (2000) found that jumping three times weekly for 8 
months significantly augmented a real bone mineral density in the femoral trochanteric 
region. These studies have hypothesized that loading induced stimuli is the main signal-
generating factor and play a key role in mechanobiology. However, disuse uncouples bone 
formation from resorption, leading to increased porosity, decreased bone geometrical 
properties, and decreased bone mineral content which compromises bone mechanical 
properties and increases fracture risk. The removal of routine bone stresses (e.g. from 
immobilization, inactivity, or reduced gravity) has deleterious consequences on bone 
integrity. Reduced skeletal loading causes net bone loss by unbalancing bone formation and 
bone resorption (Takata and Yasui, 2001; Caillot-Augusseau et al., 1998). Rat hindlimb 
immobilization, human spaceflight, and human bedrest can all cause increased bone 
resorption and decreased bone formation (Caillot-Augusseau et al., 1998; Weinreb et al., 
1989; Li et al., 2005; McGee et al., 2008). Therefore, the process of mechanotransduction of 
bone, the conversion of a mechanical stimulus into a biochemical response, is known to 
occur in osteoblast, osteoclast and osteocytes in response to it. 
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1.3. Mechanical stimuli and osteocyte apoptosis 
It is well recognized that the origin of osteocyte is osteoblasts embedded in its own matrix and 
some osteocytes die eventually (apoptosis). Aging, loss of estrogen, loading, and chronic 
glucocorticoid administration is known to increase osteocyte apoptosis and loading decreases 
the proportion of apoptotic osteocyte in cortical bone in rats (Noble et al., 2003; Gu et al., 2005; 
Delgado-Calle et al., 2011; Kennedy et al., 2012). These studies investigated the role of 
osteocytes in the control of loading related remodeling and they exhibited the effects on 
osteocyte viability of mechanical loading applied to the bone. Osteocyte apoptosis triggers 
osteoclast precursor recruitment to initiate bone resorption, whether it is induced by 
weightlessness or fatigue loading and precedes osteoclast resorption. An osteoclast/osteoblast-
dependent process related on the osteocytes population may participate in making the 
decision as to where and when a new remodeling cycle will be initiated. That is, osteocyte 
network could be considered the main sensor of loads. To take these observations into account, 
Frost proposed the concept of mechanostat (Duncan & Turner, 1995; Frost, 2003; Hughes et al., 
2010). According to this concept, the authors have proposed the mathematical model for bone 
remodeling described in the following section. 
2. Bone remodeling simulation 
To develop the computer simulation model of bone remodeling considering bone metabolism 
macroscopically, this section describes the bone remodeling model referring to the strain-
based mechanostat theory submitted by Harold Frost and refined more than 5 decades. 
Physiological, low, and high strain ranges were defined in mechanostat theory, and different 
mechanisms were considered to describe the mechanical surface remodeling of trabecular 
architecture resulting in the structural change (Kwon et al., 2010a).  
The following was assumed as the result of a remodeling turnover for each strain range: 1) in 
the physiological strain range, the occurrence of bone resorption or formation depends on the 
degree of the local stress non-uniformity; 2) in the low strain range, only bone resorption 
occurs owing to osteocyte apoptosis and its frequency increases with decreasing strain; 3) in 
the high strain range, only bone formation occurs by targeted remodeling and its frequency 
increases with strain. Each window is distinguished by threshold values of equivalent strain εc 
in the context of the mechanostat theory, and low, physiological, and high strain range 
correspond to the strain ranges of εc smaller than εdu, between εpl - εpu and larger than εol (Fig 1). 
Trabecular architecture is discretized using voxel finite elements, as schematically shown in 
Fig. 2. The trabecular surface movement by remodeling is expressed by adding and removing 
voxel elements on the surface according to the mechanical stress/strain conditions 
determined by a finite element analysis. Each trabecular element was classified by equivalent 
strain into low, physiological, and high strain range. Bone surface remodeling was assumed 
to occur according to the mathematical models of each window described in the following 
sections in detail. 
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Figure 1. Strain ranges categorized by the equivalent strain and in-between transition ranges. 
 
Figure 2. Discretized trabecular bone. 
2.1. Physiological strain range: Mechanical adaptation by remodeling 
In the physiological strain range (εpl < εc < εpu), the non-uniformity of the stress/strain 
distribution was taken as driving stimuli (Adachi et al., 1997). For the voxel representing a 
point c on bone surface, the magnitude of local stress non-uniformity c was quantified as  
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defining a positive weight for the neighboring point i within the limit of sensing distance lL from 
the point c under consideration. This represents the sensory integration by osteocyte network. 
The probability f(Γc) of bone resorption or formation at the point c is described by  
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where Γu and Γl denote the lower and upper threshold values, respectively. More 
specifically, voxel elements are added around the surface point c when f(Γc) = 1, and the 
voxel c is subtracted when f(Γc)=-1. The case of f(Γc)=0 represents local remodeling 
equilibrium and no change occurs at and around c. Moreover, in the cases of 0 < Γc ≤ Γu and 
Γl ≤ Γc < 0, bone formation and resorption occurs stochastically according to probability f(Γc). 
In this physiological strain range, the activation frequency AFf or AFr, defined as a relative 
rate for bone formation or resorption, is set to unity, i.e., AFf = AFr = 1. 
2.2. Low strain range: Osteocyte apoptosis- induced bone resorption 
In the low strain range (εc < εdu), only osteocyte apoptosis-accelerated bone resorption is 
assumed to occur (Noble et al. 2003; Gu et al., 2005; Li et al. 2005). The probability of bone 
resorption is unity, i.e.,  
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The degree of osteocyte apoptosis increases with the decrease of strain. Thus, the activation 
frequency for bone resorption AFr is also elevated with the decrease of strain and is 



















     

  
   
   
 (7) 
where AFr reaches the maximum AFrmax at εc= εmin. 
2.3. High strain range: Targeted remodeling by over use 
In the high strain range (εol < εc), only bone formation is assumed to occur. The probability of 
bone formation as the result of remodeling turnover is unity, i.e.,  
  1 and 1.HS cP f    (8) 
Bone formation in high strain range undergoes the targeted remodeling mechanism (Burr, 
2002; Da Costa Gómez et al., 2005), and thus the activation frequency for bone formation AFf 
is also elevated with the increase of strain and is described by 
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where AFr reaches the maximum AFrmax at εc= εmin. 
2.3. High strain range: Targeted remodeling by over use 
In the high strain range (εol < εc), only bone formation is assumed to occur. The probability of 
bone formation as the result of remodeling turnover is unity, i.e.,  
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where AFf reaches the maximum AFfmax at εc = εmax. It is noted that the pathological overuse is 
not considered here and the upper limit εmax is enforced for εc in high strain range.  
2.4. Integrated mathematical model and simulation procedures for bone 
remodeling  
The mathematical models of bone remodeling established in low, physiological, and high 
strain ranges were integrated by introducing transition regions. In the transition regions 
between low and physiological range (εdu < εc < εpl) or between physiological and high range 
(εpu < εc < εol), the probabilities of bone resorption or formation in each window were 
combined as a linearly weighed sum as given by Eqs. (10)-(12) resulting the resultant 
probability f* of bone resorption/formation.  
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Using this integrated model, trabecular bone structure was simulated by the following 
procedures. 
1. The initial shape of the trabecular bone is discretized by voxel finite elements and 
Young's modulus and Poisson's ratio are given. 
2. The equivalent stress and strain distributions are determined under a given mechanical 
boundary condition. 
3. The probabilities Pf* and Pr* of bone formation or resorption are calculated for every 
voxel on bone surface by Eqs. (10) - (12). 
4. The activation frequency AFf and AFr of bone formation or resorption are calculated for 
every voxel on bone surface by Eqs. (7) and (9). These are rounded to the nearest integer 
number and truncated by AFfmax or AFrmax. 
5. Bone surface movement (voxel removal or addition) is determined stochastically based 
on Pf* and Pr*. 
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6. For voxels with activation frequency AFr or AFf larger than one, the same surface 
movements in procedure (4) are repeated AFr or AFf times. 
7. Procedures (2)-(6) are repeated until equilibrium is achieved.  
3. Simulation of trabecular bone structures for human proximal femur 
3.1. Voxel FE model of human proximal femur 
The three-dimensional profile of human proximal femur is reconstructed using computed 
tomography (female, 70 years, hip osteoarthritis), the resolution of the images was 0.7 mm 
so that the entire volume could be captured with slice image of 512512 cubic voxels. As the 
random initial trabecular structure in proximal femur, an artificial trabecular structure was 
given by the random-placement of hollow spheres with inside and outside diameters of 
2100 and 4200 μm, respectively (Kwon et al., 2010a). One voxel was transferred to one finite 
element of eight node brick element. The isotropic elastic body with Young's modulus of 
20.0 GPa and Poisson's ratio of 0.3 was assumed for trabecular bone material. The cortical 
outer surface was fixed throughout the remodeling simulation, and the intra-structure, from 
the head to mid-shaft, was remodeled in accordance with the same remodeling procedure. 
The fixed boundary conditions are imposed on the distal end. In the daily loading condition, 
we considered the one-legged stance, abduction, and adduction, which accounted for 50, 25, 
and 25% of this condition as illustrated in Fig. 3. The loading magnitudes and frequencies of 
these three stances were shown in Table 1 (Beaupré et al., 1990; Adachi et al., 1997). The 
extreme ranges of motion of abduction and adduction were assumed. The trabecular 
structure obtained under this daily loading condition was referred to as the normal 
structure and also used for the initial structure for the remodeling simulation under reduced 
weight-bearing conditions (Kwon et al., 2010b). 
 
Figure 3. Standard weight-bearing cases at each stance (daily-loading condition). 
3.2. Healthy trabecular structures in proximal femur 
The simulation results from initial random structure to an equilibrium state are shown in Fig. 
4. In the diaphyseal region, random inner structures disappeared whereas the thickness of 
cortical bone increased with simulation step to the similar level observed in CT image (Fig. 
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Using this integrated model, trabecular bone structure was simulated by the following 
procedures. 
1. The initial shape of the trabecular bone is discretized by voxel finite elements and 
Young's modulus and Poisson's ratio are given. 
2. The equivalent stress and strain distributions are determined under a given mechanical 
boundary condition. 
3. The probabilities Pf* and Pr* of bone formation or resorption are calculated for every 
voxel on bone surface by Eqs. (10) - (12). 
4. The activation frequency AFf and AFr of bone formation or resorption are calculated for 
every voxel on bone surface by Eqs. (7) and (9). These are rounded to the nearest integer 
number and truncated by AFfmax or AFrmax. 
5. Bone surface movement (voxel removal or addition) is determined stochastically based 
on Pf* and Pr*. 
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6. For voxels with activation frequency AFr or AFf larger than one, the same surface 
movements in procedure (4) are repeated AFr or AFf times. 
7. Procedures (2)-(6) are repeated until equilibrium is achieved.  
3. Simulation of trabecular bone structures for human proximal femur 
3.1. Voxel FE model of human proximal femur 
The three-dimensional profile of human proximal femur is reconstructed using computed 
tomography (female, 70 years, hip osteoarthritis), the resolution of the images was 0.7 mm 
so that the entire volume could be captured with slice image of 512512 cubic voxels. As the 
random initial trabecular structure in proximal femur, an artificial trabecular structure was 
given by the random-placement of hollow spheres with inside and outside diameters of 
2100 and 4200 μm, respectively (Kwon et al., 2010a). One voxel was transferred to one finite 
element of eight node brick element. The isotropic elastic body with Young's modulus of 
20.0 GPa and Poisson's ratio of 0.3 was assumed for trabecular bone material. The cortical 
outer surface was fixed throughout the remodeling simulation, and the intra-structure, from 
the head to mid-shaft, was remodeled in accordance with the same remodeling procedure. 
The fixed boundary conditions are imposed on the distal end. In the daily loading condition, 
we considered the one-legged stance, abduction, and adduction, which accounted for 50, 25, 
and 25% of this condition as illustrated in Fig. 3. The loading magnitudes and frequencies of 
these three stances were shown in Table 1 (Beaupré et al., 1990; Adachi et al., 1997). The 
extreme ranges of motion of abduction and adduction were assumed. The trabecular 
structure obtained under this daily loading condition was referred to as the normal 
structure and also used for the initial structure for the remodeling simulation under reduced 
weight-bearing conditions (Kwon et al., 2010b). 
 
Figure 3. Standard weight-bearing cases at each stance (daily-loading condition). 
3.2. Healthy trabecular structures in proximal femur 
The simulation results from initial random structure to an equilibrium state are shown in Fig. 
4. In the diaphyseal region, random inner structures disappeared whereas the thickness of 
cortical bone increased with simulation step to the similar level observed in CT image (Fig. 
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4(g)). On the other hand, trabecular bone in the metaphyseal region, showing an isotropical 
random pattern at the initial (Fig. 4(a)), changed to an anisotropic, non-uniform structure. 
Bone volume was maintained in femoral head region A but decreased in neck region B 








Frequency fn [cycle/day] 6000 2000 2000 
J 24° -15° 56° 
J [N] 2317 1158 1548 
H 28° -8° 35° 
H [N] 703 351 468 
Table 1. Standard magnitude of force and frequency at each stance (daily-loading condition).  
Regions A and B were subdivided to blocks of 10×10×10 voxels to compare local bone 
volume fraction in each block with local bone mineral density(Duchemin et al., 2008) i.e., 
averaged bone mineral density in the corresponding CT voxels referring to the phantoms of 
trabecular bone (B-mas 200). Trabecular bone volume fraction was correlated significantly 
with bone mineral density as shown in Fig. 5.  
 
Figure 4. Simulated trabecular structure in human proximal femur and CT-image (Subject #1). 
3.3. Disuse mediated change in proximal femur 
To estimate the effect of weightlessness-induced osteocyte apoptosis in trabecular bone in 
proximal femur, two reduced weight-bearing conditions were considered here: the infrequent  
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Figure 5. Bone mineral density vs. simulated volume fraction. 
walking and the cane-assisted walking. In the infrequent walking condition, we wedged the 
interval with no loading into the daily loading condition; that is, the infrequent walking 
condition consisted of unloading of zero load and a part of the daily loading conditions. The 
proportion of unloading interval changed from 10 to 70% while the ratio of one-legged 
stance, abduction, and adduction were remained unchanged. In the simulation, the 
parameter of bone resorption and formation were represented with loading frequencies fol, 
fab, fad, and funloading as Eqs. (13) ~ (15). In the cane-assisted walking, we referred to the study on 
relative changes in muscle activity and kinetics during cane-assisted walking (Neumann et 
al., 1998). The cane use reduced the demand on the hip abductors and decreased joint 
compression forces related to muscle contraction in the contralateral side. We calculated 
joint force and hip abductor force at various rates of leaning force when using a cane (Fig. 6). 
That is, in the infrequent walking, the number of loading cycles per day decreased from the 
daily-loading condition (Table 1), while the same loading forces were applied to the femur; 
in the cane-assisted walking, the numbers of loading cycles per day remained unchanged 
but the loading forces were altered from the daily-loading condition (Kwon et al., 2010b).  
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The trabecular structure of the human proximal femur under the infrequent walking 
condition was shown for each rate of unloading interval and the initial, i.e., normal 
trabecular structure was also shown in Fig. 7. In the initial structure of Fig. 7(a), visible are 
all the normal groups of trabecular (Fig. 8), i.e. the compressive and tensile trabecular bones 
cross each other and the upper end of femur is completely occupied by cancellous tissue. 
Even Ward's triangle shows some thin trabecular bone (Singh et al., 1970). 
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Figure 6. Diagram for boundary conditions of cane-assisted walk. 
 
 
Figure 7. Simulated trabecular structure under infrequent walking. 
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Increasing the rate of unloading interval led to the increased bone loss, first in the femoral 
head and the greater trochanter. Ward's triangle was emptier in the case of higher rate of 
unloading frequency. Subsequently, the secondary compressive group disappeared and the 
principal tensile group became thinner with further increasing of the rate of unloading. 
When unloading level increased up to 70%, the principal compressive group little remained 
although the greater trochanter group was still observed clearly.  
Figure 9 shows the trabecular structure changes under cane-assisted walking conditions. 
Using cane decreased joint compression forces related to muscle contraction in the 
contralateral side. Bone loss attracts attention on the greater trochanter group and Ward's 
triangle became clear when reducing hip abductor forces. Subsequent disappearing of the 
secondary compressive group and the thinning of the principal tensile group were observed 
with further increasing. This is similar to those observed for the infrequent walking. 
However, bone loss in the trabecular femoral head differed from that under the infrequent 
walking condition. The hip joint load will be involved in this difference. 
 
Figure 8. Trabecular structure pattern of human femur. 
Clinically, the correlation of bed rest (reducing loading frequency) and muscle activity has 
been reported. The disuse due to bed rest with diseases accompanies with reduced muscle 
activity, and then leads to the cane use for walking. Thus, we simulated the trabecular 
remodeling by combining the two reduced weight-bearing conditions. Figure 10 shows that 
trabecular loss increased with increasing in the rate of unloading interval. Combination of 
reductions of loading frequency and loading forces relatively accentuated the structure of 
principal compressive and principal tensile groups and enhanced the thinning of the 
secondary compressive trabecular bone. Therefore, empty Ward's triangle is clearly 
observed. Further increase in the rate of unloading interval led to a marked reduction of 
tensile trabecular bone and discontinued the principal tensile group. Thus, the tensile 
trabecular bone is observed only in the upper part of the femoral head, where trabeculae are 
still comparable in density to the principal compressive trabeculae. Finally, even the 
principal compressive group became less obvious.  
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Figure 9. Simulated trabecular structures under cane-assisted walking 
 
Figure 10. Simulated trabecular structures under infrequent cane-assisted walking. 
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Trabecular structure of the proximal femur is remodeled differently in response to various 
forms of mechanical stimulation (Wolff, 1986; Carter, 1987). In this study, we investigated 
that the structure changes of human trabecular bone under the reduced weight-bearing 
conditions by a surface remodeling model (Kwon et al., 2010a), in which osteocyte apoptosis 
plays a crucial role below a physiological strain range (Gu et al., 2005). The reduced weight-
bearing conditions were imposed by assuming infrequent and/or cane-assisted walking. 
Depending on the reduced weight-bearing conditions, the trabecular structure reached 
different equilibrium structures even if the same initial structure and model parameters are 
used. In all cases, trabecular bone loss occurred in relation to the mechanical stimuli, 
although there was a regional difference in the pattern of bone loss between the two 
conditions. In the infrequent and cane-assisted walking conditions, significant bone loss 
occurred in the great trochanter and in the femoral head, respectively. 
In the results of imposing the condition combining two reduced weight-bearing conditions, 
we found out the clinically observed trabecular structure in osteoporotic human proximal 
femur. The description for degree of osteoporotic trabecular structure (Singh Index) is 
shown in Table 2. The present stimulations showed that decreasing mechanical stimuli 
enhanced the degree of osteoporosis along with the grade defined by Singh et al. (1970). 
Figure 10 shows trabecular loss at various degrees of unloading. In the initial structure (Fig. 
10 (a)), all groups of trabecular bones are visible, which corresponds to Grade 6 in Singh 
index. The compressive and tensile trabeculae intersect each other and the upper end of the 
femur is completely occupied by cancellous rich structure. Ward's triangle is not clearly 
delineated and there are some thin trabeculae in it. With increasing the proportion of 
unloading, there occurs an apparent accentuation of the structure of the principal 
compressive and principal tensile groups, while the secondary compressive trabeculae 
became thinner (Grade 5, Fig. 10 (b)~(c)). As a result, an empty region appears in Ward's 
triangle. Further increase in the proportion of unloading leads to the marked reduction in 
the tensile trabecular bones (Grade 4, Fig. 10 (d)~(e)); in due course, discontinuity occurs in 
the principal tensile group. At the stages of Fig. 10 (e) and (f), the tensile trabeculae are seen  
 
Grade 6 
All the normal trabecular groups are visible and the upper end of the femur 
seems to be completely occupied by trabecular bone. 
Grade 5 
The structure of principal tensile and principal compressive trabeculae is 
accentuated. Ward's triangle appears prominent. 
Grade 4 
Principal tensile trabeculae are markedly reduced in number but can still be 
observed in lateral cortex to the upper part of the femoral neck. 
Grade 3 
There is a break in the continuity of the principal tensile trabeculae opposite 
the greater trochanter. This grade indicates definite osteoporosis. 
Grade 2 
Only the principal compressive trabeculae stand out prominently; the others 
have been resorbed more or less completely. 
Grade 1 
Even the principal compressive trabeculae are markedly reduced in number 
and are no longer prominent. 
Table 2. Singh Index  
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only in the upper part of the femoral head, where the trabeculae are still comparable in 
density to the principal compressive trabeculae (Grade 3). Finally, even the principal 
compressive group ceases to stand out (Grade 2, Fig. 10 (g)) and decreases markedly in 
number (Grade 1, Fig. 10 (h)). Therefore, the present remodeling model has the competence 
to study the trabecular bone loss in disuse-mediated osteoporosis, where bone resorption-
dominant remodeling due to less mechanical stimuli should be characterized reasonably 
and sufficiently. That is introduced into the present model by considering the effect of 
osteocyte apoptosis under low strain stimuli, and it is essential in predicting the 
osteoporotic change of trabecular bone structure. 
 
Figure 11. Equivalent stress and strain distributions in normal and osteoporotic femurs. 
Finite element analyses were conducted for normal and osteoporotic human femurs obtained 
by remodeling simulation, and trabecular bone stress and strain were examined for a spherical 
volume of interest in the femoral head (Rietbergen et al., 2003). Figure 11 shows the 
distribution of voxel at different stress/strain for the normal femur of Fig. 10(a) and an 
osteoporotic femur of Fig. 10 (b) that is obtained under the disuse loading condition of reduced 
loading frequency and force. Solid and broken blue lines distinguish the stress/strain 
distribution for osteoporotic femur under standard and disuse loading conditions, 
respectively. Trabecular bone stress and strain in the osteoporotic femur were distributed 
more uniformly than those in the normal femur. In the osteoporotic femur, trabecular bones 
orthogonal to the alignment of the principal compressive group (non-principal trabeculae) are 
relatively-scarce because osteocytes in those trabeculae, especially in non-principal group 
originally exposed to relatively small loading, are susceptible to apoptosis when subjected to 
the disuse condition, resulting in scarcely distributed non-principal trabeculae. Consequently, 
trabeculae undergoing relatively-low stress/strain decrease and the peaks of stress and strain 
distributions increased in the osteoporotic femur. Trabeculae in principal compressive group 
are likely to preserve their role of relatively high load-bearing even under the disuse condition.  
3.4. Importance of osteocyte apoptosis-induced bone resorption in remodeling 
simulation 
To evaluate the advantage of including low and high strain ranges, we performed the 
simulation assuming the response model defined for physiological strain range to the entire 
strain range including low and high strain ranges, referred to physiological response-only 
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model hereafter. Results by physiological range-only model were compared with that 
obtained by the present integrated model considering individual response model for low and 
high strain ranges. This physiological response-only model determines the trabecular 
structure only by relative non-uniformity of strain distribution over all the strain range with 
no local acceleration of bone resorption and formation. Figure 12(a) shows the distribution of 
initial equivalent strain. Diaphyseal structure was formed with the loss of trabecular bone 
both integrated and physiological response-only models (Fig. 12(b)). However, bone 
resorption occurred to the higher degree in the integrated model, especially in low strain 
regions as clearly shown in dashed circles of Fig. 12(b). Figure 13 shows the simulation result 
for change of volume fraction in ward’s triangle region at each model. The integrated model 
was reached to equilibrium state, faster than physiological response-only model. Ward’s 
triangle region has a low strain range, as seen in Fig. 12(a). Figure 14 shows the histogram of 
number of trabecular bone elements against initial equivalent strain distribution for both 
simulation models. In the low strain range below 100με, as much as 43, 37, and 46% of 
trabecular bone preserved in the physiological response-only model were resorbed by the 
integrated model in different subjects of #1, #2, and #3, respectively. In low strain regions at 
the initial, the integrated model could reproduce more suitable trabecular structure by taking 
the characteristic response in low strain range into account. Furthermore, the correlation 
between bone volume fraction simulated and bone mineral density by CT image was higher 
in the integrated model than that in the physiological response-only model (Fig. 15).  
 
Figure 12. Initial stress distribution and simulated trabecular structures. 
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for change of volume fraction in ward’s triangle region at each model. The integrated model 
was reached to equilibrium state, faster than physiological response-only model. Ward’s 
triangle region has a low strain range, as seen in Fig. 12(a). Figure 14 shows the histogram of 
number of trabecular bone elements against initial equivalent strain distribution for both 
simulation models. In the low strain range below 100με, as much as 43, 37, and 46% of 
trabecular bone preserved in the physiological response-only model were resorbed by the 
integrated model in different subjects of #1, #2, and #3, respectively. In low strain regions at 
the initial, the integrated model could reproduce more suitable trabecular structure by taking 
the characteristic response in low strain range into account. Furthermore, the correlation 
between bone volume fraction simulated and bone mineral density by CT image was higher 
in the integrated model than that in the physiological response-only model (Fig. 15).  
 
Figure 12. Initial stress distribution and simulated trabecular structures. 
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Figure 13. Volume fraction in Ward’s triangle during remodeling simulation. 
 
Figure 14. Number of trabecular bone elements in simulated proximal femur against initial equivalent 
strain levels before disuse-mediated remodeling. 
Osteocyte Apoptosis-Induced Bone Resorption  
in Mechanical Remodeling Simulation – Computational Model for Trabecular Bone Structure 41 
 
 
Figure 15. Bone mineral density at proximal femur by CT and simulated volume fraction by integrated 
and physiological response-only models. 
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4. Conclusions 
In this chapter, described was the mathematical model of bone remodeling extending the 
established previously (Adachi et al., 1997) based on the mechanostat theory (Duncan & 
Turner, 1995; Frost, 2003; Hughes et al., 2010). Extension was the bone resorption-dominant 
response in low strain range by disuse and formation-dominant response in overuse 
windows. The osteocyte apoptosis in the low strain range due to weightlessness was a key 
aspect in the extended model, and the targeted remodeling was in the high strain range for 
bone formation. Trabecular structure in human proximal femur was simulated using the 
model extended and the reproduced trabecular structure exhibited good agreement with 
that in the actual femur more reasonably by taking the osteocyte apoptosis in low strain 
range and the targeted remodeling in high strain range. Especially, the consideration of 
osteocyte apoptosis was crucial in the mathematical model of bone remodeling model in 
reproducing the healthy normal bone structure and in simulation the disuse-mediated 
osteoporotic bone structure. The former was demonstrated by comparison of simulated 
volume fraction and the X-ray CT bone mineral density. For the latter, disuse-accelerated 
bone loss was examined for infrequent and cane-assisted walking conditions. The 
osteoporotic trabecular structure was examined in terms of Singh Index, a diagnostic 
criterion for the stage of progression of osteoporosis. This competence of the model was 
coming from the effect of osteoporosis due to less mechanical stimulus and its result of bone 
loss acceleration, and the present remodeling model is effective in bone remodeling 
simulation under reduced loading condition. 
In conclusion, the effect of osteocyte apoptosis on bone resorption is inevitable aspect in the 
computer simulation of bone remodeling.  
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1. Introduction 
Autoantibodies are characteristic features of autoimmune diseases (Table 1). In organ or 
tissue-specific autoimmune diseases, autoantibodies against cell-surface molecules are 
usually observed. These antibodies (Abs) stimulate or damage the target cells and cause 
organ- or tissue-specific diseases. In systemic autoimmune diseases, in addition to anti-cell-
surface molecule Abs, Abs against intracellular molecules are frequently observed although 
B cell tolerance to intracellular molecules is strictly enforced in normal subjects. Some 
indicate high disease specificity with a high incidence rate. Therefore, such Abs may be 
closely associated with development of the disease as well as with disease activity. 
However, it is not known how or why Abs against intracellular molecules are generated. 
2. Role of cell death in the generation of anti-intracellular molecule 
antibodies 
Cell death, including apoptosis and necrosis, represents a possible source of exposure of 
intracellular molecules outside the cell. For example, low – intermediate doses (< 35 mJ/cm2) 
of ultraviolet B (UVB) induce apoptosis of keratinocytes, resulting in translocation of native 
DNA, Ku, and Sm to the cytoplasmic membrane, while a high dose (80 mJ/cm2) of UVB 
induces necrosis, resulting in discharge of all of the cell compartments [1]. Intracellular 
molecules are exposed on the surface blebs of apoptotic cells (apoptotic blebs) [2]. Apoptotic 
blebs contain fragmented endoplasmic reticulum (ER), ribosomes, ribonucleoprotein, 
nucleosomal DNA, Ro, La, small nuclear ribonucleoproteins, etc. Autoantigens receive 
various epigenetic modifications (acetylation, methylation, phosphorylation, 
dephosphorylation, ADP-ribosylation, ubiquitination, oxidation, transglutamination, 
citrullination, SUMOylation, etc) during apoptotic cell death [3]. In the case of cytotoxic 
granule-mediated cell death, granzymes plays an important role in cleavage of autoantigens 
[4].  These epigenetic  modifications  may alter preexisting epitopes, expose cryptic epitopes,  
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Anti- Target molecule Disease
1. Organ or tissue-specific autoimmune diseases 
a. Anti-cell-surface molecules 
TSH receptor* TSH receptor Graves’ disease 
NMDA N-methyl-D-aspartate receptor Encephalitis 
GAD glutamic acid decarboxylase Diabetes mellitus type I 
Ach* Acetylcholine Myasthenia gravis 
myelin associated protein myelin Multiple sclerosis 
ganglioside ganglioside Neuropathy 
b. Anti-intracellular molecules 
mitochondria mitochondria PBC 
thyroid microsomal  thyroid microsomal Hashimoto’s thyroiditis 
thyroid peroxidase thyroid peroxidase Hashimoto’s thyroiditis 
thyroglobulin thyroglobulin Hashimoto’s thyroiditis 
2. Systemic autoimmune diseases 
a. Anti-cell-surface molecules 
PDGF receptor PDGF receptor Systemic sclerosis 
phospholipid* phospholipid APS 
b. Anti-intracellular molecules 
 dsDNA* dsDNA SLE 
 Sm Smith SLE 
 SS-B La/SS-B Sjögren’s syndrome 
 centromere centromere Systemic sclerosis 
 topoisomerase-I topoisomerase-I Systemic sclerosis 
 Jo-1 histidyl-tRNA synthetase DM 
 PR3-ANCA* proteinase 3 WG 
 MPO-ANCA* myeloperoxidase MPA, AGA 
TSH: thyroid stimulating hormone; PBC: Primary biliary cirrhosis; PDGF: Platelet-derived growth factor; APS: Anti-
phospholipid syndrome; dsDNA: double-stranded DNA; SLE: systemic lupus erythematosus; DM: dermatomyositis; 
WG: Wegener's granulomatosis; MPA: microscopic polyarteritis; AGA: allergic granulomatous angiitis (Churg–Strauss 
syndrome). 
*: The titer of the Ab is correlated with the disease activity in a proportion of patients. 
Table 1. Examples of autoantibodies. 
or form novel epitopes, and may contribute to bypassing tolerance to autoantigens [5]. 
Normally, apoptotic cells are quickly eliminated by professional phagocytes. Delay of 
apoptotic cell clearance not only increases the time of exposure of intracellular molecules to 
the immune system but also changes the degree of modification of these molecules, which 
alters their antigenicity. When clearance fails, apoptotic cells enter the stage of secondary 
necrosis. The ability to cause inflammation depends on the stage of cell death [6]. Damage-
associated molecular patterns (DAMPs), such as HMGB1, SAP130, etc., are released from 
late apoptotic/necrotic cells into the extracellular space [7-9]. DAMPs activate Toll-like 
receptors and act as intrinsic adjuvants, resulting in inflammation and initiation of the host 
immune system. Thus, delay of apoptotic cell clearance increases the risk of an autoimmune 
response. 
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3. Abnormalities related to apoptosis in SLE 
There are many lupus autoantibodies that bind to autoantigens of apoptotic cells [10]. In 
SLE, defective clearance of apoptotic cells has been reported. As a result, high levels of 
circulating early apoptotic cells are found in SLE [11]. T-lymphocytes [12], 
macrophages/monocytes [13,14], neutrophils [15], and endothelial cells [16] are included 
among the increased numbers of apoptotic cells. Monocytes and granulocytes, which take 
up autoantibody remnants of secondary necrotic cell complex, secrete inflammatory 
cytokines in SLE [17]. These phenomena threaten self-tolerance and are likely involved in 
the production of lupus autoantibodies [18,19]. The reason for defective apoptotic cell 
clearance in SLE has yet to be elucidated. It has been suggested that the efficacy of clearance 
is affected by the cell death trigger, but there have been no reports related to SLE from this 
viewpoint [20]. Anti-class A scavenger receptor autoantibodies from patients with SLE 
impair the clearance of apoptotic debris by macrophages [21]. However, the mechanism of 
autoantibody production is not yet known. 
In SLE, the response to early apoptotic cells is also abnormal. Under normal conditions, 
macrophages secrete antiinflammatory cytokines (IL-10, TGF-, PGE2, etc.) to send “tolerate 
me” signals after ingestion of apoptotic cells [22]. Monocytes from healthy controls showed 
prominent TGF- secretion and minimal TNF- production, but monocytes from SLE patients 
show prominent TNF- production and diminished TGF- secretion [23]. The authors 
speculated that this abnormal response may be an intrinsic property of lupus monocytes. 
Recent studies have highlighted the role of neutrophils in the pathogenesis and manifestations 
of SLE [24]. NETosis is a process characterized by the formation of neutrophil extracellular 
traps (NETs) [25]. NETs become not only a source of intracellular molecules but also 
immunogens for lupus autoantibodies [26]. Low-density granulocytes (LDGs), an abnormal 
subset of neutrophils, were identified among the PBMCs derived from patients with SLE [27]. 
LDGs secrete type I interferons (INFs), have endothelial cytotoxicity, and have higher capacity 
to form NETs [28]. Degradation of NETs is impaired in patients with SLE [29]. NETs activate 
complement and deposited C1q inhibits NET degradation [30]. These phenomena increase 
NETs and may contribute to the production of autoantibodies, including anti-DNA Abs. 
It has recently been demonstrated that the source of intracellular molecules is microparticles 
(MPs), which are small membrane-bound vesicles [31]. MPs, which emerge from the cell 
membrane during cell activation and apoptosis, contain a variety of cellular components, 
including nucleic acids [32]. MPs become antigenic targets of anti-DNA Abs, form huge immune 
complexes in the plasma of patients with SLE, and induce complement activation [33,34]. 
4. Anti-dsDNA Abs 
4.1. Brief historical aspects of anti-dsDNA Abs 
SLE is characterized by the production of a variety of autoantibodies. Especially, anti-
dsDNA Abs are the most characteristic of SLE and contribute to the pathogenesis of lupus 
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nephritis. In general, anti-dsDNA Abs are specific for SLE and the anti-dsDNA Abs titer is 
closely correlated to the activity of lupus nephritis [35]. A proportion of anti-dsDNA Abs are 
directly involved in immune complex-mediated glomerulonephritis [36]. Thus, the trigger of 
anti-DNA response may be closely related to the pathogenesis of SLE. However, 
mammalian native dsDNA is not immunogenic, suggesting that DNA itself does not act as a 
triggering or driving antigen [37]. The origin of anti-DNA Abs is a long-standing enigma. 
Anti-dsDNA responses can be evoked by dsDNA with the aid of a carrier, such as the 27-
amino acid nucleic acid-binding Fus1 peptide [38], polyoma BK virus large T Ag [39], or 
DNaseI-dsDNA complex [40] which have been shown to induce production of anti-dsDNA 
Abs in mice, suggesting a possible role of excess amounts of DNA – protein complex in 
disruption of tolerance to DNA. Nucleosomes have been suggested as possible Ags 
responsible for triggering of anti-dsDNA Abs [41,42]. Crude nucleosomes or crude histones 
[41] have been shown to induce production of anti-dsDNA Abs in mice. Mononucleosome-
reactive Th clones augment the production of IgG autoantibodies to dsDNA, histones, and 
histone – DNA complex. However, immunization of SNF1 mice with pure 
mononucleosomes did not elicit production of IgG anti-dsDNA Abs [43]. HMGB1 – 
nucleosome complexes derived from apoptotic cells, but not HMGB1-free nucleosomes, 
elicited IgG anti-dsDNA Abs in BALB/c mice although their titer was not high, suggesting 
that adjuvants such as HMGB1 are necessary to break tolerance to dsDNA in non-
autoimmune mice [44]. 
Another possible mechanism is molecular mimicry. Some mouse or human monoclonal 
anti-DNA Abs have been shown to cross-react with non-nucleic acid self-Ags, such as 
extracellular matrix protein HP8 [45], heterogeneous nuclear ribonucleoprotein A2 [46], NR2 
glutamate receptor [47], -actinin [48,49], ribosomal protein S1 [50], and phospholipids, 
including cardiolipin [51]. However, it is not yet known whether these molecules can elicit 
anti-DNA responses. 
The peptide, DWEYSVWLSN, is recognized by the R4A mouse monoclonal anti-dsDNA Ab 
[52]. Immunization with this peptide elicited anti-dsDNA Ab production and caused 
deposition of IgG in glomeruli in normal mice [53]. These observations indicate that a non-
nucleic acid Ag can elicit production of anti-DNA Abs and cause renal disorder in normal 
animals. However, no proteins containing this peptide sequence have been reported to date. 
It should be noted that immunization with recombinant EBNA-1 protein elicited anti-
EBNA-1 Abs that cross-react with dsDNA, suggesting molecular mimicry between the viral 
antigen and dsDNA [54]. However, nephritogenicity of the anti-EBNA-1/dsDNA Abs has 
not been reported. 
4.2. Cross-reactive antigen of the O-81 human nephritogenic anti-DNA mAb 
We prepared human monoclonal anti-DNA Ab, O-81, which binds strongly to single-
stranded DNA (ssDNA) and moderately to dsDNA, and demonstrated that the O-81 
idiotype (Id) is distributed among IgG anti-DNA Abs of circulating immune complexes as 
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well as lupus glomerular deposits [55-58]. The intravenous infusion of IgG isotype anti-
DNA Abs expressing O-81 Id also caused glomerular IgG deposition in SCID mice [59]. The 
VH region of O-81 Ab contains many somatic mutations [60]. Similarly, the VH regions of 
O-81 Id-positive B cells in patients with SLE were shown to already contain somatic 
mutations [61]. These observations prompted us to explore the triggering Ags for human 
nephritogenic anti-DNA Abs using the O-81 Ab. 
 
Figure 1. The expression of Herp in peripheral blood mononuclear cells (PBMCs) or the cells in a 
cervical lymph node (LN) from a patient who developed SLE and had yet to receive treatment. 
[Methods] The cells were fixed in 50% acetone/50% methanol for 20 min at –20°C and 
blocked with 5% normal goat serum and 3% BSA in PBS overnight at 4°C. The cells were 
then incubated with HT2 mouse monoclonal IgG1 anti-Herp Ab or mouse IgG1 as an isotype 
control for 1 h at room temperature followed by incubation with FITC-conjugated goat 
F(ab') 2 anti-mouse IgG Ab (KPL, Gaithersburg, MD) for 1 h at room temperature [63]. 
We found that the O-81 Ab specifically cross-reacts with human homocysteine-induced 
endoplasmic reticulum protein (Herp) [62]. Anti-dsDNA Abs purified from the sera of SLE 
patients bound to Herp, and anti-Herp Abs purified from the sera of SLE bound to dsDNA 
[62]. The production of Herp is induced by endoplasmic reticulum (ER) stress. The PBLs 
from subjects in active SLE, especially at the time of onset or flare-up of the disease, tended 
to show Herp expression [62]. The expression of Herp was also observed in the lymph node 
of an untreated patient with active SLE, indicating that Herp can be exposed to the immune 
system in lymph nodes where Ag recognition occurs (Figure 1). 
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Excessive ER stress is known to induce apoptosis [64,65]. Herp can be exposed on apoptotic 
blebs of ER stress-induced apoptotic cells [62]. Many apoptotic cells expressing Herp were 
observed in the peripheral blood mononuclear cells (PBMCs) of patients with active SLE, 
but not normal control subjects [62]. This observation is compatible with those reported 
previously [11]. These results suggest that Abs against Herp on ER stress-induced apoptotic 
cells may become anti-Herp/dsDNA cross-reactive Abs, i.e., initial anti-dsDNA Abs. 
4.3. Antigenicity of Herp for anti-dsDNA Ab production in mice 
Immunization of normal BALB/c mice with Herp elicited anti-dsDNA Abs and caused 
glomerular IgG deposition [62]. However, urinary protein level did not increase and overt 
nephritis did not develop. The pathological changes in the kidneys in Herp-immunized 
BALB/c mice went no further than silent lupus nephritis. 
Nucleosomes, which are major autoantigens in SLE, are exposed at the apoptotic cell surface 
[66,67]. Anti-nucleosome Abs are present in SLE at a rate of more than 50% and they have 
been linked to lupus nephritis [68]. Nucleosomes and histones are present in glomerular 
deposits [69]. Nucleosomes bind to glomerular endothelial cells and serve as targets for anti-
nucleosome Abs [70]. Therefore, a portion of anti-nucleosome Abs may be involved in lupus 
nephritis [71]. However, even oligonucleosomes are much less effective than Herp in 
inducing anti-nucleosome Abs as well as anti-dsDNA Abs [62]. Therefore, to reproduce 
overt lupus nephritis, BALB/c mice were immunized with Herp followed by immunization 
with oligonucleosomes. In this procedure, both anti-dsDNA Ab and anti-nucleosome Ab-
producing clones induced by Herp may be able to recognize oligonucleosomes easily. The 
production of anti-dsDNA Abs and glomerular IgG deposition were observed in all mice. In 
addition, overt nephritis with significant proteinuria occurred in one mouse (Figure 2). 
Although further investigations are in progress to define the mechanisms, it was speculated 
that (i) the Herp-induced anti-dsDNA Abs efficiently bound to nucleosomes and formed 
pathogenic immune complexes, and (ii) affinity maturation and epitope spreading of Herp-




Figure 2. Overt nephritis in a BALB/c mouse immunized with Herp followed by immunization with 
oligonucleosomes. Left: Periodic acid Schiff (PAS) staining. Right: Immunofluorescence staining with 
fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG Ab. 
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[Methods] Five 6-week-old female BALB/c mice were immunized intraperitoneally with 100 
g of Herp on days 0 and 10 and 50 g of Herp on day 20, followed by immunization with 
10 g of oligonucleosomes on days 30, 40, and 50. Preparation of Herp and 
oligonucleosomes was described previously [62]. Fresh-frozen tissue sections 4 m thick 
were fixed in 100% acetone for 10 min at 4°C and blocked with 5% normal goat serum and 
3% BSA in PBS overnight at 4°C. Sections were stained with FITC-conjugated goat F(ab')2 
anti-mouse IgG Ab (KPL) for 1 h at room temperature. 
4.4. Antigenicity of Herp for anti-dsDNA Ab production in humans 
To examine whether Herp can be an antigen for anti-dsDNA Ab production in humans, 
ELISPOT was performed using PBMCs (representative cases are shown in Figure 3). The 
number of spots increased when the PBMCs were incubated with Herp, but not with 
dsDNA, in 4 of 6 untreated active SLE patients (Figure 3A); in 2 of these 4 positive cases, a 
few spots were observed even in wells without stimulation (Figure 3B). The remaining two 
cases showed no spots (Figure 3C). On the other hand, no spots were detected in the PBMCs 
from nine treated active SLE patients, eight inactive SLE patients, and five normal control 
subjects (data not shown). These results suggest that Herp can stimulate anti-dsDNA 
antibody-producing clones but this stimulation is cancelled by immunosuppressive therapy. 
[Methods] Approximately 1106 PBMCs in 20% fetal calf serum (FCS)-supplemented RPMI 
1640 (20% FCS-RPMI 1640) were cultured for 5 days with or without 2 g/mL Herp, or 10 
g/mL dsDNA. For preparation of dsDNA, calf thymus DNA (Invitrogen, Carlsbad, CA) 
was pretreated with S1 nuclease (Takara Bio, Otsu, Japan) to remove single-stranded DNA 
(ssDNA) according to the manufacturer’s instructions. Multiscreen 96-well filtration plates 
(Millipore, Billerica, MA) were coated with 10 mg/mL protamine overnight at 4°C, and 
washed with PBS followed by coating with 10 g/mL dsDNA in PBS for 2 h at room 
temperature. Following blocking with 20% FCS-RPMI 1640, the cultured PBMCs in 20% 
FCS-RPMI were plated at 1×105 cells/well and cultured for 24 h. After washing the cells with 
PBS, goat alkaline phosphatase-conjugated anti-human IgG antibodies (diluted 1:10000; 
Sigma-Aldrich, St. Louis, MO) were added and the wells were incubated for 1 h at room 
temperature. Following a further wash, the spots were visualized using NBT-5-bromo-4-
chloro-3-indolyl phosphate substrate (Sigma-Aldrich).  
5. Anti-single-stranded DNA (ssDNA) Abs 
The mechanism involved in the production of anti-ssDNA Abs has yet to be elucidated. As 
ssDNA can have multiple conformational epitopes and all Abs that bind to ssDNA are 
called anti-ssDNA Abs, these Abs are highly heterogeneous and display low disease 
specificity. However, the susceptibility of lupus-inducing drugs to anti-ssDNA Ab 
production is very high. In such cases, there may be a unique mechanism of anti-ssDNA Ab 
production, as the chemical structures and pharmacological actions of lupus-inducing drugs 
are known to be highly diverse [72,73]. As higher risk drugs include procainamide and 
hydralazine, which inhibit DNA methylation, hypomethylation may be one of the causes of 
anti-ssDNA Ab production, but its precise mechanism remains unknown [74-76]. 
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Excessive ER stress is known to induce apoptosis [64,65]. Herp can be exposed on apoptotic 
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Figure 2. Overt nephritis in a BALB/c mouse immunized with Herp followed by immunization with 
oligonucleosomes. Left: Periodic acid Schiff (PAS) staining. Right: Immunofluorescence staining with 
fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG Ab. 
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[Methods] Five 6-week-old female BALB/c mice were immunized intraperitoneally with 100 
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3% BSA in PBS overnight at 4°C. Sections were stained with FITC-conjugated goat F(ab')2 
anti-mouse IgG Ab (KPL) for 1 h at room temperature. 
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Figure 3. Herp can stimulate anti-dsDNA Ab-producing B cells in untreated patients with active SLE. 
The PBMCs were stimulated with Herp or dsDNA. Anti-dsDNA Ab-producing PBMCs were detected 
with ELISPOT. Three representative cases (A, Case M. S.; B, Case S. S.; C, Case R. S.) are shown. The 
lowest row is the positive control (P. C.: human serum with anti-dsDNA Abs, diluted 1:200) and 
negative control (N. C.; second antibody only). 
Immunization with Herp elicits production of not only anti-dsDNA antibodies but also anti-
ssDNA antibodies in BALB/c mice. Among several anti-Herp mAbs established in our 
laboratory, the HT4 anti-Herp mAb cross-reacts specifically with ssDNA [77]. The epitope of 
the HT4 mAb on Herp, EPAGSNR, was identified by screening a synthetic peptide library. 
The binding of HT4 mAb to the peptide was competitively inhibited by ssDNA. 
Immunization of the epitope peptide elicited anti-ssDNA Abs in BALB/c mice. Treatment 
with chlorpromazine, procainamide, and hydralazine induced Herp expression and 
apoptosis in HeLa cells. These findings suggest that (i) ER stress and apoptosis by drugs and 
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(ii) molecular mimicry between Herp and ssDNA are involved in anti-ssDNA antibody 
production in drug-induced lupus. 
6. Postulated mechanism of anti-DNA Ab generation 
Autoimmunity is associated with both genetic predisposition and environmental factors 
[78]. The monozygotic disease concordance rate ranges from 24% to 57% (and not 100%) for 
SLE [79]. Most patients with SLE are non-familial sporadic cases. That is, environmental 
etiologies of SLE may be common. It is well known that environmental factors such as viral 
infection, UV exposure, chemicals, etc., can trigger clinical onset or flare of SLE [80,81]. 
However, little is known regarding how those factors elicit anti-DNA antibody production 
in vivo. These factors, i.e., cell stressors, affect the expression patterns of cellular proteins, 
resulting in ER stress in some cases. 
What is a practical model of this hypothesis? Natural infection with viruses can cause ER 
stress on a large scale in vivo [80]. ER stress has been shown to increase when viral proteins 
are produced at high levels, e.g., in virion formation during the active lytic cycle of infection. 
Epstein–Barr virus (EBV) infection has been suggested to have a causative role in SLE 
[82,83]. The titers of anti-EBV Abs in SLE patients are higher than those of healthy controls 
[84]. Kang et al. reported that: (i) patients with SLE had an approximately 40-fold increase in 
EBV viral load compared with controls; (ii) the frequency of EBV-specific CD69+ CD8+ T 
cells producing IFN- was higher in patients with SLE than in controls, but the frequency of 
EBV-specific CD69+ CD4+ T cells producing IFN- was lower in patients with SLE than in 
controls; and (iii) the EBV viral loads were positively correlated with the frequency of EBV-
specific CD69+ CD8+ T cells but inversely correlated with the frequency of EBV-specific 
CD69+ CD4+ T cells [85]. Larsen et al. reported that EBV-specific CD8+ T cell responses in 
patients with SLE are functionally impaired [86]. The defective control of latent EBV 
infection in patients with SLE may result in recurrent reactivation of EBV. In fact, aberrant 
expression of BZLF1, which is a hallmark of EBV lytic infection, has been detected in the 
PBMCs of SLE patients [87]. In primary EBV infection, EBV infects tonsillar B cells in which 
lytic replication occurs, and differentiation of latently EBV-infected B cells to plasma cells in 
lymphoid tissues is associated with induction of the EBV lytic cycle [88]. Herp is expressed 
in BZLF1-positive EBV-infected B cells (Figure 4). 
[Methods] EBV-transformed B cells were fixed in 50% acetone/50% methanol for 20 min at –
20°C and blocked with 5% normal goat serum and 3% BSA in PBS overnight at 4°C. The 
cells were stained with DAPI. The cells were then co-stained with HT4 mouse IgG2a anti-
human Herp mAb and mouse IgG1 anti-BZLF1 mAb (Dako, Glostrup, Denmark) for 1 h at 
room temperature followed by co-staining with rhodamine-conjugated goat anti-mouse 
IgG2a Ab (Santa Cruz Biotechnology, Santa Cruz, CA) and FITC-conjugated goat anti-
mouse IgG1 Ab (Santa Cruz Biotechnology) for 1 h at room temperature. 
ER stress, which is induced by the production of viral proteins, causes EBV lytic replication, 
resulting in the release of virions and intracellular molecules [89]. The Herp produced in 
cells entering the lytic phase of EBV infection can be recognized by the immune system in  
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(ii) molecular mimicry between Herp and ssDNA are involved in anti-ssDNA antibody 
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[78]. The monozygotic disease concordance rate ranges from 24% to 57% (and not 100%) for 
SLE [79]. Most patients with SLE are non-familial sporadic cases. That is, environmental 
etiologies of SLE may be common. It is well known that environmental factors such as viral 
infection, UV exposure, chemicals, etc., can trigger clinical onset or flare of SLE [80,81]. 
However, little is known regarding how those factors elicit anti-DNA antibody production 
in vivo. These factors, i.e., cell stressors, affect the expression patterns of cellular proteins, 
resulting in ER stress in some cases. 
What is a practical model of this hypothesis? Natural infection with viruses can cause ER 
stress on a large scale in vivo [80]. ER stress has been shown to increase when viral proteins 
are produced at high levels, e.g., in virion formation during the active lytic cycle of infection. 
Epstein–Barr virus (EBV) infection has been suggested to have a causative role in SLE 
[82,83]. The titers of anti-EBV Abs in SLE patients are higher than those of healthy controls 
[84]. Kang et al. reported that: (i) patients with SLE had an approximately 40-fold increase in 
EBV viral load compared with controls; (ii) the frequency of EBV-specific CD69+ CD8+ T 
cells producing IFN- was higher in patients with SLE than in controls, but the frequency of 
EBV-specific CD69+ CD4+ T cells producing IFN- was lower in patients with SLE than in 
controls; and (iii) the EBV viral loads were positively correlated with the frequency of EBV-
specific CD69+ CD8+ T cells but inversely correlated with the frequency of EBV-specific 
CD69+ CD4+ T cells [85]. Larsen et al. reported that EBV-specific CD8+ T cell responses in 
patients with SLE are functionally impaired [86]. The defective control of latent EBV 
infection in patients with SLE may result in recurrent reactivation of EBV. In fact, aberrant 
expression of BZLF1, which is a hallmark of EBV lytic infection, has been detected in the 
PBMCs of SLE patients [87]. In primary EBV infection, EBV infects tonsillar B cells in which 
lytic replication occurs, and differentiation of latently EBV-infected B cells to plasma cells in 
lymphoid tissues is associated with induction of the EBV lytic cycle [88]. Herp is expressed 
in BZLF1-positive EBV-infected B cells (Figure 4). 
[Methods] EBV-transformed B cells were fixed in 50% acetone/50% methanol for 20 min at –
20°C and blocked with 5% normal goat serum and 3% BSA in PBS overnight at 4°C. The 
cells were stained with DAPI. The cells were then co-stained with HT4 mouse IgG2a anti-
human Herp mAb and mouse IgG1 anti-BZLF1 mAb (Dako, Glostrup, Denmark) for 1 h at 
room temperature followed by co-staining with rhodamine-conjugated goat anti-mouse 
IgG2a Ab (Santa Cruz Biotechnology, Santa Cruz, CA) and FITC-conjugated goat anti-
mouse IgG1 Ab (Santa Cruz Biotechnology) for 1 h at room temperature. 
ER stress, which is induced by the production of viral proteins, causes EBV lytic replication, 
resulting in the release of virions and intracellular molecules [89]. The Herp produced in 
cells entering the lytic phase of EBV infection can be recognized by the immune system in  
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Figure 4. Herp protein is expressed in BZLF1 positive EBV infected B cells. 
lymphoid tissues. In addition, EBV-encoded latent membrane protein 2A (LMP2A) induces 
hypersensitivity to TLR stimulation, leading to activation of autoreactive B cells through the 
BCR/TLR pathway [90]. Immunization with the membrane fraction of EBV-transformed B 
cells elicited anti-dsDNA Abs as well as anti-Herp Abs and causes glomerular IgG 
deposition in BALB/c mice [62]. These observations support the hypothesis that EBV 
infection may be a trigger of SLE. 
 
Figure 5. Hypothetical mechanism of anti-dsDNA Ab induction. 
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The results of the present study led to the following hypothesis in which cell stress triggers 
an anti-DNA response via Herp in normal individuals: ER stress by environmental factors 
 Herp expression  recognition by the immune system of minor epitope(s) mimicking 
ssDNA|or dsDNA  anti-Herp/ssDNA or dsDNA cross-reactive Abs (initial anti-ssDNA or 
anti-dsDNA Abs)  anti-DNA Ab – DNA complex, anti-DNA Ab – nucleosome complex  
? tissue injury (Figure 5). After the initial production of anti-Herp/DNA Abs, the 
production of the Abs is stimulated whenever ER stress-induced apoptosis occurs, and the 
cause of ER stress is not restricted. Repeated cell stress during daily life may strengthen this 
pathway. Herp is a good candidate as a link between common environmental factors and 
the etiology of SLE. 
7. Conclusions 
As dead cells are not only a source of intracellular antigens but also a source of 
proinflammatory molecules, it is likely that they play an important role in the generation of 
nephritogenic anti-dsDNA Abs. Herp was identified as a molecule directly involved in cell 
stress/death as the cause of anti-dsDNA Ab production. Further investigations are therefore 
needed to clarify the relationship between cell stress/death and the etiology of SLE. 
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1. Introduction 
1.1. History, definition and classification 
Life and death are essential parts of the natural cycle of all multicellular organisms. In 
metazoans, somatic cells divide normally during the process known as mitosis. Cell 
proliferation is tightly controlled, according to the organism needs. An increase in the 
number of cells takes place during growth and when one of these cells finishes its 
physiological function or detects DNA or cell damage, it undergoes a physiological process 
known as apoptosis that induces its own death. In humans about a hundred thousand cells 
are formed every second through mitosis, while a similar number is destroyed by apoptosis 
[1]. This dynamic balance between proliferation and cell death is known as homeostasis. If 
altered, different pathologic processes such as carcinogenesis can take place. Besides its role 
in embryonic development, homeostasis maintenance and aging, apoptosis is also a defence 
mechanism by which infected, injured or mutated cells as a result of irradiation or 
chemotherapeutic drugs are eliminated. This type of cell death involves the activation of an 
evolutionary conserved and tightly regulated intracellular machinery that requires energy 
consumption [2]. An important feature of apoptosis is that the cell is eliminated without 
triggering an immune response, avoiding thus tissue damage [3]. 
The term apoptosis to describe cell death was introduced by Kerr and colleagues in 1972 [4], 
from the Greek term “appo-teo-sis” which means “falling off” (as in leaves from a tree or 
petals from a flower). Apoptosis has been used as a synonym of programmed cell death and 
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refers to a suicidal type of death. However, as more mechanisms of programmed cell death 
are being elucidated, the Nomenclature Committee on Cell Death (NCCD) recommends 
caution when using the term apoptosis [5]. Historically, the classical methods to define cell 
death rely on morphological criteria. Thus, apoptosis was termed programmed cell death 
type I, autophagy named as programmed cell death type II and necrosis as a type of death 
lacking characteristics of both type I and type II. As more biochemical methods become 
available over the last decades, a more definite and concise classification of types of cell 
death has become necessary. Therefore, cell death types can be classified according to 
morphological appearance, biochemical features, functional criteria or immunological 
aspects. In the following figure (Figure 1) the classification of different types of cell death, in 
accordance with to the NCCD are described: 
 
Figure 1. Classification of different types of cell death according to the NCCD (modified from Galluzzi 
et al. 2012) 
It is important to mention that a single stimulus can trigger more than one mechanism of 
cell death simultaneously within a cell. However, only the most efficacious mechanism will 
be prevalent. 
2. Apoptosis 
2.1. Morphological and biochemical features 
Morphological features that share both caspase-dependent and independent apoptotic 
pathways are: a) loss of plasma membrane symmetry and loss of cell-to-cell contact and cell 
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round-up, b) chromatin condensation (picnosis) and fragmentation and nuclear breakdown, 
c) overall cell shrinkage and cytoskeleton alterations although the majority of the cell 
organelles remain intact, d) membrane blebbing and formation of the membrane-enclosed 
particles called apoptotic bodies that contain nuclear or cytoplasmic material and will be 
engulfed by phagocytes or neighbouring cells [6]. 
Because apoptotic cells are eaten so quickly, there are few dead cells left on tissue sections. 
This is the reason why apoptosis was neglected by pathologists for a long time, even though 
apoptosis is the main mechanism for discarding of harmful or unwanted cells in 
multicellular organisms. 
Along with the morphological transformation described, there are several biochemical 
alterations that take place. For instance, activation of endonucleases, some of them 
dependent on Ca2+ and Mg2+ channels, that cleaves genomic DNA. In the apoptotic 
process, this event gives rise to internucleosomal DNA double-strand breaks with 
fragments of multiples of 180 bp, resulting in the typical pattern of DNA ladder that can be 
detected by electrophoresis on agarose gels. Other changes include loss of the inner 
mitochondrial transmembrane potential [7] and exposure of the phospholipid 
phosphatidylserine to the outer cell membrane, which allows phagocytes to detect and 
engulf these apoptotic cells [8]. 
 
Figure 2. Features of Apoptosis, Oncosis and Necrosis (taken from Hail et al., 2006) 
The most distinguishable feature of apoptosis is the formation of apoptotic bodies. On the 
other hand, oncosis is characterized by cytoplasmic swelling, dilation of organelles and 
vacuolization and plasma membrane blebbing. The cell will finally die by cytolysis, which is 
a typical hallmark of necrosis [9]. Apoptotic cells can also lose their plasma membrane and 
eventually undergo a secondary necrosis. However, this phenomenon has only been 
observed in vitro. According to Majno and Joris, necrosis is not a type of cell death, but 
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rather, it refers to changes subsequent to any type of death. They prefer to use the term 
oncosis to describe a nonprogrammed or accidental type of cell death characterized by 
swelling [10]. Moreover, a new modality of cell death has recently emerged, termed 
necroptosis to indicate a regulated form of necrosis [11]. 
Apoptosis can be divided into three stages: initiation, integration/decision and 
execution/degradation [12]. The initiation phase mainly depends upon cell type and 
apoptotic stimulus. The integration/decision phase consists of the activation of proteases, 
nucleases and other effector molecules. The execution/degradation phase involves 
morphological and biochemical changes that are common to all apoptotic mechanisms, 
regardless of the stimulus that initiated the process. The classical apoptosis is defined as a 
type of programmed cell death characterized by the activation of zymogens known as 
caspases, which are cystein-dependent aspartate-directed proteases. Both caspase-
dependent and caspase-independent cell death mechanisms share multiple characteristics, 
such as mitochondrial membrane permeabilization (MMP), DNA fragmentation, etc. Hence, 
(MMP) can commit cells to die even in the absence of caspase activation, by releasing factors 
such as apoptosis inducing-factor (AIF) or endonuclease G (endo G). 
3. Caspases: Executioners of the apoptotic process 
Caspases are the effector molecules of apoptosis in mammals. They were first discovered 
mediating programmed cell death during development in the nematode Caenorhabditis 
elegans [13]. The caspase family is characterized by their specificity for cleaving substrates 
after aspartic acid residues and for containing cystein in their active centre [14]. There are 
about fourteen caspases that used to be classified into two families: one involved in 
inflammation processes and the other taking part in apoptosis. However, some of the non-
apoptotic caspases have some apoptotic roles, and conversely, some non-apoptotic caspases 
can induce pyroptosis [15]. They are synthesized as inactive precursors or zymogens (pro-
caspases) that need to be proteolytically processed to become active. Once a caspase is 
activated, it can cleave another caspase creating thus an expansive hierarchical activating 
cascade that serves to amplify the apoptotic signal. Caspase activation is a complex and 
tightly regulated process. Within the apoptotic group, there are two types of caspases: 
upstream initiator or apical caspases and downstream effector or executioner caspases. The 
initiator group consists of caspases -2, -8, -9 and -10 and the effector group consists of -3, -6 
and -7 caspases. Apical but not executioner caspases have long prodomains. Caspase-9 is 
considered the initiator of the mitochondrial pathway and caspase-8 is regarded as the 
originator of the dead receptor-mediated apoptotic pathway. Effector caspases carry out 
apoptotic programmes through direct processing of a variety of cellular substrates. The 
proteolytic cleavage of such substrates brings about a whole plethora of effects within the 
cell: disassembling of cytoskeleton, cytoplasm scaffolding, nuclear fragmentation as a 
consequence of laminin degradation, activation of endonucleases that cleave chromatin, 
inactivation of DNA damage repair proteins (PARP1, Rad9, etc.), phagocyte signalling, loss 
of cell-to-cell contact, etc. [16-18] 
 




PARP, DSBs, Rad51 and Rad9, DNA-
PKCs and ATM 
DNA damage repair  
C1, C2 and U170 mRNA processing 
Actin, Gas2, FAK, PAK2, Fodrin and 
Gelsolin 
Cellular structure 
PKC and Akt Apoptosis and cell cycle 
Phosphatase 2A, Raf1 and Rb Cell cycle 
Bid, Bcl-2, Bcl-xL and XIAP Apoptosis regulation 
Pro-IL-1β Cytokine 
D4-GDP Inhibitor Rho GTPases regulator 
Laminin A/C and B and NuMA Nuclear shape maintenance 
ACINUS Regulation of chromatin condensation 
ICAD DNA fragmentation 
Huntingtin Huntington disease 
SREBP-1 and SREBP-2 Sterol regulatory element binding proteins 
MDM2 Transcription factor 
Table 1. Proteins substrates of caspases (Blank and Shiloh 2007; Cohen et al 1997) 
Caspase activity can be regulated both in a positive and in a negative manner. Negative 
caspase regulators are called Inhibitors of Apoptosis Proteins (IAPs) that bind to the 
catalytic site of caspases neutralizing its activity [19], or targeting them to degradation by 
ubiquinitation [20,21]. Some examples of IAPs are: XIAP, c-IAP1, c-IAP2, NAIP and 
survivin. On the other hand, Smac/DIABLO and Omi/HtrA2 act as positive regulators by 
inactivating IAPs [22]. 
4. Extrinsic and intrinsic apoptotic pathways 
There are at least two main well characterized apoptotic routes: the death receptor or 
extrinsic pathway and the mitochondrial or intrinsic pathway. The extrinsic pathway plays a 
major role in tissue homeostasis and responds to external cues, coming especially from the 
immune system, whereas the intrinsic pathway is triggered as a response to various internal 
insults such as DNA damage, cytosolic calcium overload, starvation, oxidative stress, 
radiation, cytotoxic agents, etc., and involves mitochondrial destabilization [23,24]. 
The death receptor pathway is initiated by extracellular stimuli that are recognized by a 
subgroup of the tumour necrosis factor receptor (TNF-R) family named dead receptors 
(Fas/CD95/APO-1, TNFR1, TRAIL R1/DR4 and TRAIL R2/DR5). Upon binding of their 
ligands (FAS, TNFα and TRAIL) these receptors become activated and interact via their 
death domain with the protein motif Fas-associated death domain (FADD) in adapter 
proteins, forming the Death inducing signalling complex (DISC), which binds to the 
prodomain of the initiator caspase-8 [25]. Thus, caspase-8 is activated by dimerization, 
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which leads to autocatalyisis and consequently activation of executioner caspases -3, -6 and -
7 [26].  
The intrinsic mitochondrial pathway is characterized by the action of B-cell lymphoma (Bcl-
2) proteins. This family consists of proapoptotic and antiapoptotic proteins. The 
proapoptotic members promote mitochondrial outer membrane permeabilization (MOMP) 
and the antiapoptotic members counteract this action, so that the balance between these two 
groups of proteins determines the final outcome [27,28]. If the balance is in favour of the 
proapoptotic members, the outer mitochondrial membrane is permeabilized through pore 
formation and cytchrome c and other proteins such as Smac/DIABLO and Omi/HtrA2 are 
released to the cytosol. Then, cytochrome c binds to the adaptor protein Apaf-1 and dATP, 
forming the apoptosome, a catalytic complex that activates caspase-9 which in turn activates 
the executioner caspases. 
The extrinsic and intrinsic pathways are interconnected through Bid. In some cases, when 
DISC formation is low, caspase-8 activation can induce MOMP through Bid cleavage, which 
translocates to the mitochondria and induces cytchrome c release, apoptosome formation 
and engagement of the caspase cascade [29]. 
 
Figure 3. The extrinsic and intrinsic apoptotic pathways. 
5. Death receptors 
Death receptors belong to the TNF-R superfamily of receptors. They participate in 
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fact, TNF-R1 and Fas (CD95/APO-1) are involved in apoptotic processes [30]. Death 
receptors are stimulated by death ligands: TNF; Fas ligand (FasL) and TNF-related 
apoptosis-inducing ligand (TRAIL). Death receptors contain an intracellular globular 
interaction domain called death domain (DD). Upon ligand binding, death receptors 
aggregate forming trimers. As a consequence of this aggregation, they recruit adaptors such 
as FADD, which interacts with caspase-8 by virtue of its death effector domain (DED), 
forming the multi-protein complex known as DISC. However, in some instances, death 
receptors can oligomerize in the abscence of ligand binding. For example, they can be 
activated by UV radiation [31]. Fas and TNF-R1 can also recruit RIP (receptor-interacting 
protein) -associated Ich-1/CED homologous [ICE (interleukin-1β-converting enzyme)/CED-3 
(cell-death determining 3) homologue 1] protein with death domain (RAIDD) which 
activates caspase-2 through a caspase activation and recruitment domain (CARD). In 
addition, death receptors can participate in caspase-independent mechanisms. For instance, 
TNF-R1 can activate Extracellular signal-regulated kinase 2 (Erk2) through the mitogen-
activated kinase activating death domain (MADD) protein [32]. Fas can bind Death-domain 
associated protein (Daxx) and activate c-Jun amino-terminal kinase (JNK) [33]. TNF-receptor 
associated death domain (TRADD) and RIP can activate Nuclear factor kappa-light-chain-
enhancer of activated B cells (NFkB), triggering a form of regulated necrosis named 
necroptosis [34]. 
6. Role of mitochondria in cell death 
MMP, a crucial event of the intrinsic mitochondrial apoptotic pathway, is considered a 
“point of no return” in the sequence of events leading to apoptosis. This phenomenon is 
associated with mitochondrial membrane potential loss (∆Ψm) that occurs as a result of 
assymetrical distribution of protons on both sides of the inner mitochondrial membrane. 
This irreversible process can take place before, during or after MOMP. The pore formation 
caused by Bcl-2 proteins induces MOMP, which leads to ∆Ψm dissipation, inhibition of ATP 
synthesis and ∆Ψm-dependent transport activities. Consequently, the respiratory change 
ceases, causing reactive oxygen species (ROS) generation and release of proteins confined 
within the inner mitochondrial space [35]. The contribution of the inner mitochondrial 
permeabilization, however, is controversial. MOMP can also result from the phenomenon 
called mitochondrial permeability transition that implies the opening of a non-selective pore 
in the inner mitochondrial membrane known as the mitochondrial permeability transition 
pore complex [12]. 
6.1. Mechanisms of MOMP 
Bax/Bak pore formation. The first proposed mechanism of MOMP is mediated by the Bcl-2 
family of proteins that directly act on the outer mitochondrial membrane. This family 
consists of about 17 members, some of which are proapoptotic and others antiapoptotic. The 
antiapoptotic members (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, A1, Bcl-B, etc.) contain 3-4 BH domains 
(Bcl-2 homology regions: BH-1, BH-2, BH-3 and BH-4) and are named “Bcl-2 like” proteins. 
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which leads to autocatalyisis and consequently activation of executioner caspases -3, -6 and -
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Among the proapoptotic members, some contain 2-3 BH domains (Bax, Bak, Bok, etc.) and 
the “BH3-only” proteins (Bid, Bad, Bim, Bik, Bmf, Hrk, Bnip3, Noxa, Puma, Spike, etc.) have 
the biggest proapoptotic potential. BH-3 only proteins exert their effects either by inhibiting 
antiapoptotic Bcl-2 like members or by directly activating Bak and Bax. In the first 
mechanism, “facilitators” such as Bad interact with antiapoptotic Bcl-2 like proteins, 
dissociating them and creating MMP. In the second mechanism, however, “activators” such 
as truncated Bid (tBid) activate proapoptotic proteins by stimulating translocation of Bax to 
the mitochondrial membrane or by activating Bak [36].  
The interplay between antiapoptotic and proapoptotic proteins decides the final fate of the 
damaged cell. Antiapoptotic proteins can be found in the outer mitochondrial membrane, in 
the cytoplasm or in the Endoplasmic Reticulum (ER). Some propapoptotic members such as 
Bax or Bid reside in the cytosol, but translocate to the outer membrane upon triggering of a 
death stimulus, where they oligomerize to form a channel, either with themselves or with 
membrane anchored-Bak or tBid. The importance of the interactions between proteins and 
lipids is becoming more evident. In fact, it is now thought that Bak or Bax destabilize lipid 
bilayers instead of forming pores. BH3-only proteins activity is transcriptionally and 
posttranslationally regulated. Bid, for instance, is regulated by caspase-8, cathepsins, 
granzyme B or calpain [37-39]. The proapototic protein Bad in inhibited through 
phosphorylation by Akt and activated through dephosphorylation by calcineurin [40].  
 
Figure 4. Proposed model of mitochondria membrane permeabilization. Bax/Bak pore formation. Bcl-2 
family members regulation. 
Permeability transition pore complex. The second proposed mechanism of MOMP is based on 
the formation of the permeability transition pore (PTP) complex, a high conductance 
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channel which allows the influx of water and small solutes. PTP is a multiprotein complex 
located in the mitochondrial membrane that spans contact sites between the inner and the 
outer mitochondrial membranes. It is composed of three proteins: the voltage-dependent 
anion channel (VDAC), which is the most abundant protein of the outer membrane, the 
soluble matrix protein cyclophilin D (CypD), and the adenine nuclease translocase (ANT) 
located in the inner membrane. Other proposed PTP components are: hexokinase, creatine 
kinase and peripheral benzodiazepine receptor. The requirement of ANT is controversial. 
Distinct VDAC isoforms may interact with Bcl-2 members in a different manner. PTP 
opening leads to ∆Ψm dissipation, uncoupling of oxidative phosphorylation, water and ions 
influx, matrix swelling, outer membrane rupture and release of intermembrane space 
proteins, such as cytochrome c. Ca2+ favours PTP opening and permeability transitions are 
regulated by ∆Ψm, pH of mitochondrial matrix, redox potential, adenine nucleotides and 
bivalent metallic ions. PTP regulation by Bcl-2 proteins is still a matter of debate. It has been 
proposed that proapototic members promote pore opening, whereas antiapoptotic proteins 
favour pore closure [41]. Bcl-2 members can indirectly regulate PTP opening through Ca2+ 
efflux from the ER. In healthy cells, Bcl-2 or Bcl-XL can be located not only inserted in the 
mitochondrial outer membrane but also in the ER. Calcium ions exit the ER through inositol 
phosphate 3 receptors (IP3R), which can be blocked upon Bcl-2 binding. The proapoptotic 
members Bax and Bak induce Ca2+ movement from the ER to the mitochondrion [42]. 
However, Ca2+ interchange through PTP can be regulated by proapoptotic tBid [43,44].  
 
Figure 5. Proposed model of mitochondrial membrane permeabilization. Permeability transition pore 
complex. OM: outer membrane. IMS: intermembrane space. IM: inner membrane. VDAC: voltage-
dependent anion channel. HK: hexokinase. PBR: peripheral benzodiazepine receptor. CK: creatine 
kinase. ANT: adenine nuclease translocase. CypD: cyclophilin D (modified from Kroemer et al. 2007). 
The rise of mitochondrial matrix Ca2+ induces oxidative metabolism. However, upon 
apoptotic stimulus, Ca2+ can cause PTP opening, which can be transient and provide a fast 
calcium release mechanism, or persistent, giving rise to outer membrane rupture and release 
of apoptotic factors. Additionally, a different channel has been identified in the 
mitochondrion, composed of ceramide, a lipid that can form hydrogen bonds giving rise to 
ceramide structures that form channels which allow the efflux of proteins up to 60 kDa [42].  
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6.2. Cell death effectors released from mitochondria 
The release of proteins from the intermembrane space and the loss of membrane-associated 
mitochondrial functions lead to cell death. Albeit is not clear the mechanism, mitochondrial 
destabilization provokes release of factors that mediate in caspase-dependent and 
independent pathways. 
Cytochrome c is a protein localized in the intermembrane mitochondrial space where it 
participates in the electron transport between complex III and IV of the mitochondrial 
respiratory chain. As already mentioned, cytochrome c is involved in the apoptosome 
formation and caspase cascade activation [45]. Cytochrome c release is a crucial step in the 
intrinsic apoptotic pathway. 
Smac/DIABLO means Second mitochondrial activator of caspases or Direct IAP Binding 
protein with LOw pI. This 29 kDa protein is also localized in the intermembrane space and 
is released to the cytosol upon activation by certain apoptotic stimuli, where it binds IAPs, 
preventing their function and favouring caspase activation. 
Omi/HtrA2 functions in a similar way to Smac/Diablo. This 36 kDa protein belongs to a 
highly conserved protein family. In healthy cells, Omi/HtraA2 is located in the 
intermembrane space. Upon apoptotic triggering (TRAIL, UV radiation, staurosporine, etc.) 
is released to the cytosol where it binds and inactivates IAPS promoting caspase activation. 
In addition, to the caspase-dependent effectors already mentioned, other caspase-
independent proteins can be activated: 
AIF stands for Apoptosis Inducing Factor. AIF is a 57 kDa flavoprotein localized in the 
intermembrane space whose aminoacid sequence resembles ferrodoxin. AIF is expressed as 
a 67 kDa precursor that possesses two mitochondrial localization sequences in its amino-
terminal end. Once in the mitochondria, AIF precursor is cleaved giving rise to the mature 
protein that is believed to have an oxidoreductase function based on its FAD domain, 
playing an important physiological role in oxidative phosphorylation. AIF translocates to 
the nucleus in response to apoptotic stimuli where it induces chromatin condensation and 
large-scale (50 Kbp) DNA fragmentation by an unknown mechanism, leading to apoptosis 
in a caspase-independent fashion. It has been recently suggested that Steroid receptor 
coactivator-interactive protein prevents AIF release from the mitochondria [46]. Conversely, 
calcium-activated calpain promotes AIF release from the mitochondria [47] and poly-ADP-
ribose-plymerase 1 (PARP-1) activity is necessary for AIF translocation to the nucleus [48]. 
Endo G or Endonuclease G also participates in caspase-independent cell demise 
mechanisms. It belongs to a family of Mg2+-dependent endonucleases. Endo G is a 30 kDa 
mitochondrial protein that, like AIF, is synthesized as a precursor form and its 
mitochondrial localization sequence is cleaved when the protein reaches the intermembrane 
space. Endo G is released from the mitochondria upon certain apoptotic stimuli such as UV 
radiation or anti-Fas antibodies, and it translocates to the nucleus, where it cleaves 
chromatin DNA into nucleosomal fragments. Endo G cooperates with exonucleases and 
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DNase I in order to facilitate DNA processing. Endo G nuclease activity has been observed 
even in the presence of caspase inhibitors. Therefore, similarly to AIF, Endo G participates 
in caspase-independent cell death mechanisms. The physiological role of Endo G, however, 
needs to be established. 
Besides its function as IAP inhibitor, Omi/HtrA2 has been implicated in caspase-
independent cell death mechanisms by virtue of its serine protease activity. This effector 
molecule cleaves proteins such as ped/pea-15 [49], HAX-1 [50], or RIP-1 [51]. However, the 
exact mechanism as to how this occurs is still unknown. 
AIF and Endo G activity together with Omi/HtrA2 serine protease activity are considered 
responsible for the recently called caspase-independent intrinsic apoptosis [11]. 
6.3. Afferent signals from other organelles 
Mitochondria play a central role in programmed cell death pathways and integrate different 
signals coming from other organelles, being MMP, a point of no return, as already 
mentioned. 
6.3.1. Nuclear DNA damage 
The tumour suppressor p53 mediates DNA damage response, either by stimulating DNA 
damage response or by inducing apoptosis. As a transcription factor, p53 transactivates Bcl-
2 proteins (Bad, Bid, Puma and Noxa) [52], which induce MMP and release of proteins from 
the intermembrane space [12]. After DNA damage, p53 can also induce the expression of 
p53-induced protein with a death domain (PIDD), which activates nuclear caspase-2. PIDD 
associates with RAIDD, forming a signalling platform known as the PIDDosome [53]. The 
PIDDosome can activate caspase-2 and the transcription factor NFkB in response to DNA 
damage [54]. Caspase-2 acts upstream of the mitochondria by inducing Bid cleavage, Bax 
translocation and cytochrome c release. The role of caspase-2 in apoptosis, however, is 
controversial. It is now thought that caspase-2 functions as a tumour suppressor gene 
regulating the cell cycle machinery [55]. p53 may also induce apoptosis by transcription-
independent mechanisms, for instance, by directly interacting with Bak, Bax, Bcl-2 and Bcl-
XL at the outer mitochondrial membrane [56]. The activity of p53 can be promoted by 
glycogen synthase kinase 3β (GSK3β) binding both in the nucleus and in the mitochondria, 
which in turns promotes cytochrome c release and caspase-3 activation [57].  
6.3.2. Endoplasmic reticulum: Unfolded protein response 
The ER has primordial roles in normal physiological and survival processes. These include 
intracellular calcium homeostasis, protein secretion and lipid biosynthesis [58]. Apoptosis 
can be initiated as a consequence of stress in the ER. This stress condition can be caused by 
calcium homeostasis alteration, glucose deprivation, hypoxia, low redox potential, excessive 
protein synthesis or defective protein secretion. These insults can cause accumulation of 
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unfolded proteins in the lumen of the ER, triggering an evolutionary conserved signalling 
pathway known as the Unfolded Protein Response (UPR) which can culminate in cell death. 
UPR consists of global protein synthesis reduction, synthesis induction of chaperones and 
other proteins related to protein folding and retro-translocation of misfolded or unfolded 
proteins from the ER to the cytosol, where they will be degraded by the proteasome [59]. 
When the ER stress is sustained and ER function cannot be restored, UPR activates a specific 
apoptotic pathway. Caspase-12, which is localized in the ER, is activated by calcium-
dependent proteases known as calpains [60]. Once activated, caspase-12 activates caspase-9 
without apoptosome intervention [61,62]. It has been postulated that ER stress can also 
activate caspase-8, which induces cytochrome c release through Bid processing [29,63]. In 
addition, ER stress can also initiate autophagy, a different type of cell death. 
6.3.3. Lysosomes 
Lysosomes are organelles that contain acidic hydrolases such as cathepsins. Rupture of 
lysosomes release cathepsins to the cytosol, where they can trigger apoptosis or necrosis. 
Cystatins, on the other hand, are cytosolic proteins that act as negative regulators of 
cathepsins when they are translocated from lysosomes to the cytosol. Apoptosis initiated in 
lysosomes follows a mitochondrion-dependent pathway associated to caspase activation. 
However, it has been shown that cathepsin D activates Bax and AIF release, triggering a 
caspase-independent apoptotic pathway [37]. Furthermore, some cathepsins induce Bid 
cleavage [38], interaction with Bcl-2 proteins and permeabilization of the mitochondrial 
membrane [64]. In addition, cathepsins can alter mitochondria functions by cleaving 
subunits of the oxidative phosphorylation complexes, inducing ROS generation [12]. 
Lysosomes are essentially involved in autophagic cell death mechanisms. 
6.3.4. Cytosol 
Several signals coming from the cytosol can induce MMP. These include: metabolites such 
as glucose 6-phospate and palmitate, ROS and activation of certain kinases: GSK3β, protein 
kinase C (PKC) δ, [65] and members of the JNK signalling pathway [38,66]. On the other 
hand, other molecules inactivate PTP and protect mitochondrial membrane from 
permeabilization, inhibiting apoptosis. These include: metabolites (ATP, glucose, NADH, 
UTP, etc.), antiapoptotic Bcl-2 family members, antioxidant enzymes such as glutathiones S 
transferase and prosurvival kinases such as Akt. In this sense, Akt can inhibit apoptosis by 
several mechanisms: activation of NFkB [67], inactivation of GSK3β and caspases and 
through hexokinase II-dependent mechanisms [12]. 
6.3.5. Cytoskeleton 
The cytoskeleton is composed of microtubules, microfilaments and intermediate filaments 
that play important roles in cell motility, polarity, attachment, shape maintenance, etc. 
Adherent cells can undergo a specific type of caspase-dependent cell death called anoikis 
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when they become detached from the extracellular matrix or neighbouring cells [68,69]. 
Besides its well-established role in mitosis, cytoskeleton components can modulate 
mitochondria. For example, microtubules sequester BH3-only proteins Bim and Bmf, which 
interact with dynein [70]. Gelsolin has anti-apoptotic effect by closing the VDAC channel 
[71]. Actin can also modulate VDAC closure [69,72]. 
7. Parp proteolysis as an indicator of cell death 
Poly-ADP-Ribose Polymerase (PARP) is a family of 16 nuclear enzymes, among which, the 
best characterized is PARP-1. PARPs have several functions in cell proliferation, cell death, 
DNA recombination and DNA repair. PARP-1 is a 116 kDa nuclear protein involved in 
DNA repair mechanisms. PARP synthesis is activated when DNA is fragmented in the 
presence of nuclear poly-ADP ribosylated proteins. In an early apoptotic stage, caspases 
cleave PARP resulting in an 89 kDa and a 24 kDa fragments [73]. The smaller fragment 
irreversibly binds DNA fragment ends, impeding the access of DNA repair enzymes. Hence, 
PARP proteolysis facilitates nuclear disorganization and ensures irreversibility of the 
apoptotic process [74]. PARP cleaves also takes place during necrosis. However, the 
fragments obtained are of different size [75]. A role of PARP cleavage in autophagy induced 
by DNA damage has been recently suggested [76]. Parthanatos is a particular case of 
regulated necrosis in which PARP activation plays an important role. PAR polymer, the 
product of PARP-1 activation, translocates to the mitochondria and induces AIF release. 
Subsequently, AIF translocates to the nucleus and provokes chromatin condensation and 
DNA fragmentation [77]. Necroptosis or regulated necrosis also involves PARP activation 
[78]. Therefore, PARP can participate in different types of cell death and it is not exclusive of 
apoptosis, as previously thought. 
8. Autophagy 
Autophagy is a self-digestive physiological process that occurs in all eukaryotic cells, during 
which long-lived proteins and organelles are degraded by lysosomes to maintain cellular 
homeostasis [79]. To date, at least three types of autophagic pathways have been described: 
macroautophagy (simply called ‘‘autophagy’’), microautophagy and Chaperone-Mediated 
Autophagy (CMA). These forms differ in the mode the cargo is delivered to the lysosome. 
Macroautophagy is a dynamic process in which portions of the cellular cytoplasm and 
organelles are sequestered in a double-membrane bound vesicle called autophagosome, 
which then fuses with the lysosome [80,81]. Microautophagy involves the sequestering by 
the lysosome itself of part of the cytoplasm. During microautophagy, the membrane of the 
lysosome invaginates, and then pinches off to form an internal vacuole that contains 
material derived from the cytoplasm [82]. The notable difference between macroautophagy 
and microautophagy is that in the latter, part of the cytoplasm is directly taken up into the 
lysosome. Both macroautophagy and microautophagy are basically nonselective 
degradation pathways in which bulk cytoplasm is randomly sequestered. However, in some 
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unfolded proteins in the lumen of the ER, triggering an evolutionary conserved signalling 
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cases, autophagy can selectively eliminate some organelles, such as damaged peroxisomes, 
mitochondria or ER. In contrast, CMA does not involve vesicular traffic and is specific for 
the degradation of proteins. During this process, proteins are delivered to lysosomes with 
the help of molecular chaperones and a lysosomal receptor. Cytosolic proteins with a 
specific peptide sequence motif (‘‘KFERQ’’ motif) are recognized by a complex of molecular 
chaperones (Hsc70) and then bind to a lysosomal receptor called lysosome associated 
membrane protein (LAMP) type 2a [83].  
Macroautophagy (hereafter referred to as autophagy) is the most studied and prevalent 
form of autophagy in cells. This process begins with the formation of a “C” shaped double-
membrane structure in the cytosol, called “omegasome”, which is formed from the ER 
(Initiation phase). Following this, the omegasome grows to form the “isolation membrane”, 
which elongates to engulf cytoplasmic components (Elongation phase). Then, the “isolation 
membrane” curves and closes to form a vacuole called the autophagosome (Maturation 
phase). As a result, portions of the cell cytoplasm and some organelles are sequestered in 
this vacuole. Finally, the outer membrane of the autophagosome fuses with the lysosomal 
membrane and the inner membrane (the autophagic body) carrying the cytosolic 
constituents enters the lysosome. The autophagic body is degraded in the lysosome by 
hydrolases and the resulting free amino acids and macromolecules are transported back into 
the cytosol for reuse [84]. In this way, autophagy contributes to the maintenance of the 
cellular energy homeostasis, to the clearance of damaged organelles and to adaptation to 
environmental stresses [85]. Accordingly, autophagy defects have been linked to a wide 
range of human pathologies, including cancer. 
 
Figure 6. Autophagy. Three different forms of autophagy are depicted: Macroautophagy, 
Microautophagy and Chaperone-mediated autophagy (CMA) (taken from Yen and Klionsky, 2008). 
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9. Mitotic catastrophe 
The cell death process that takes place when mitosis cannot be completed is called mitotic 
catastrophe. This phenomenon is triggered as a consequence of perturbations of the mitotic 
machinery that governs appropriate chromosome segregation. The main hallmark of mitotic 
catastrophe is the enlarged cell size accompanied by multinucleation [5]. Other features are 
chromatin condensation, DNA degradation, MMP, cyrochrome c release from the 
mitochondria and caspase activation [86]. Some types of mitotic catastrophe, however, take 
place without intervention of caspases, what has been named caspase-independent mitotic 
death [87]. Mitotic catastrophe results form the combination of deficient checkpoints (DNA 
and mitotic spindle) and DNA damage. Cells that evade the mitotic checkpoint and do not 
undergo apoptosis are prone to generate aneuploidy. Therefore, mitotic catastrophe is 
conceived as a device to avoid genomic instability. The players that take part in mitotic 
catastrophe are: cell cycle-dependent kinases (Cdk1, Aurora, Plk), cell cycle-check points 
proteins (Chk2, p53, p73), survivin, MCl-2, Blc-2 proteins, caspase-2, etc. [86]. Mitotic 
catastrophe is a poorly defined molecular signalling pathway that precedes apoptosis, 
necrosis or senescence [88].  
 
Figure 7. Mitotic catastrophe. a) In the absence of perturbations cells progress normally. A mitotic 
defect is detected and: b) cells die without exiting mitosis, c) cells undergo mitotic arrest, exit mitosis 
(mitotic slippage), reach the subsequent G1 and die or d) undergo senescence (taken from Galluzzi et al. 
2012). 
10. Necroptosis 
Necrosis is characterized by plasma membrane permeabilization, swelling and rupture. 
Necrosis can be accompanied in many instances by release of lysosomal hydrolases. 
Recently, a novel form of regulated necrosis has emerged and has been named necroptosis 
[78]. This cell death modality presents morphological features of necrosis but is regulated by 
signalling pathways and catabolic mechanisms. The most studied necroptotic pathway is 
mediated by the death receptor TNFR1 and inhibited by necrostatin-1. Upon TNF binding, 
TNFR1 undergoes a conformational change and recruits TRADD, TRARF2, cIAP1, cIAP2 
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TNFR1 undergoes a conformational change and recruits TRADD, TRARF2, cIAP1, cIAP2 
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and RIP1 to form complex I. RIP1 is polyubiquinated by cIPA1 and cIAP2 and activates the I 
Kappa B kinase (IKK) complex, triggering NFkB activation. RIP1 can be deubiquitinated by 
cylindromatosis D (CYLD) and together with RIP3 forms the complex II which also contains 
TRADD, FADD, and caspase-8. Subsequently, caspase-8 cleavage will induce apoptosis, 
whereas caspase-8 inhibition by caspase inhibitors (zVAD-fmk) for example, will favour 
necroptosis [89]. A novel death regulation platform named ripoptosome has recently been 
described. Unlike complex II, the ripoptosome  forms independently of death receptors, is 
activated by genotoxic stress or IAP antagonists and is tightly regulated by IAPs (ciAP1, 
cIAP2, xIAP) or cellular FLICE-like inhibitory protein (FLIP), a catalytically inactive 
homologue of caspase-8 [78,90,91]. The executioner mechanisms of necroptosis are unclear. 
However, in some cases the necroptotic process involves ROS generation, lysosomal 
membrane permeabilization, AIF release from the mitochondria and PARP activation. When 
caspase activation is not involved, necroptosis is associated with formation of autophagic 
vesicles [92,93]. 
 
Figure 8. TNFR1-mediated apoptosis and necroptosis (taken from Long and Ryan 2012). 
11. Apoptosis, chemoresistance and cancer 
So far, we have reviewed generalities of different modalities of cell death that can take place 
after various pathologies: inflammation, stroke, ischemic injury, neurodegenerative 
disorders, viral infection, neoplasia, etc. The implication of apoptosis in cancer was initially 
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observed as the type of cell death occurring in untreated tumours and in tumour regression 
after radiotherapy [4]. The oncogenic process requires accumulation of diverse alterations 
within a cell that disrupt its normal homeostasis of cell death and growth. It is well 
established that excessive proliferation is not only due to oncogene activation but also to 
failure of the pathways controlling programmed cell death mechanisms [94]. A malignant 
cell can be protected from cell demise though expression and/or activation of antiapoptotic 
factors (acting as oncogenes) or through inactivation of antiapoptotic factors (acting as 
tumour suppressor genes). Evasion of apoptosis is a hallmark of cancer [95]. Dysregulation 
of apoptotic pathways renders cells resistant to antitumour strategies since the final 
outcome of radio and chemotherapy is frequently apoptosis of cancer cells. Therefore, 
resistance to cell death- in particular apoptotic cell death- is an important aspect of 
carcinogenesis, as it confers resistance to anticancer agents [96]. In many tumours, 
chemoresistance acquisition is due to upregulation or modification of key elements of 
apoptosis control, such as Bcl-2, Bcl-XL and IAP family members [36]. Other mechanisms are 
characterized by inactivating mutations in proapoptotic proteins, such as p53. 
Bcl-2. The first apoptotic gene related to neoplasia was the apoptotic inhibitor bcl-2. 
Therefore, Bcl-2 overexpression can contribute to tumour cell survival. Indeed, it was 
discovered at the breakpoint of the t(14;18) chromosomal translocation occurring in 
follicular lymphomas and leukemias [97,98]. Bcl-2 is the first oncogene that acts by 
inhibiting cell death instead of stimulating cell proliferation. In this respect, it was shown to 
cooperate with myc in immortalization of lymphoid cells [99] and in lymphomagenesis in 
transgenic mice [100]. Furthermore, it has been shown that Bcl-2 overexpression can confer 
multidrug resistance (MDR) phenotype and evasion of apoptosis to tumour cells exposed to 
serum deprivation, certain toxins or chemotherapeutic agents [101]. Mcl-1 and Bcl-XL have 
been shown to play important roles in tumourigenesis as well. Bcl-2 overexpression can also 
be the result of gene amplification or reduced expression of  micro RNAs (miRNAs) in 
cancer cells [102].  
BH3-only proteins. Loss or suppression of proaptotic proteins is frequent in cancer. Bax 
frameshift mutations appear in 50 % of colon carcinomas with DNA mismatch repair defects 
[103]. In addition, 17% of mantel cell lymphoma has homozygous Bim deletions [104], Bok 
and Puma suffer allelic deletions [105], and Bim and Puma are silenced by 
hypermethylationin Burkitt lymphoma [106,107]. Bim expression can also by silenced by 
miRNAs in several types of cancers [102]. Some BH-3 only proteins (Bim, Puma and Bmf) 
are necessary to initiate apoptosis in response to certain antineoplasic drugs [101].  
XIAP. The X-linked inhibitor factor of apoptosis (XIAP) belongs to the IAP protein family. 
XIAP can render chemoresistance to cancer cells by inactivating caspases. XIAP 
overexpression is frequent in several tumour types [108]. Since XIAP is the only protein 
capable of inactivating both initiator and executioner caspases, it has become a putative 
biomarker of chemoresistance. It is the only IAP member capable of blocking active caspases 
[109]. However, XIAP has other roles in malignant transformation apart from preventing 
apoptosis. XIAP is involved in NFkB, MAPK and ubiquitin-proteasome pathways [108]. 
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Survivin. This protein is a member of the IAP family that inhibits apoptosis by inactivating 
caspases [110] and stimulates DNA repair upon binding to DNA-PK in glioblastoma cell 
lines [111]. In addition, survivin plays a role in regulation of the mitotic checkpoint. Survivin 
expression is deregulated in cancer through several mechanisms: amplification of the locus 
on chromosome 17q25 [112], exon demethylation [113], or increased promoter activity [114]. 
Overall, survivin overexpression is an unfavourable prognostic marker and correlates with 
poor prognosis [110]. It is also involved in angiogenesis [115], tumour progression and 
chemoresistance. It has been shown that survivin inhibition sensitizes tumour cells to 
paclitaxel, cisplatin, etoposide, gamma radiation and immunotherapy [116]. 
p53. Inactivating mutations in the tumour suppressor p53 account for about 50% of human 
tumours and are associated with poor prognosis. One role of p53 is the regulation of cell 
cycle through the DNA damage response. Many chemotherapeutic agents cause DNA 
damage and activate p53. As a result, the cdk inhibitor p21 can be transcriptionally activated 
causing cell cycle arrest or Bax can be activated by translocation to the mitochondria 
inducing apoptosis [56]. When p53 is not mutated, cells showing DNA damage induced by 
genotoxic stress that cannot be repaired during cell cycle arrest, are induced to apoptosis 
through p53 activation of the mitochondrial pathway, mostly increasing transcription of the 
BH-3-only proteins, Bid, Noxa and Puma [52]. In addition, p53 can activate genes of the 
extrinsic pathway: TRAIL-R2 (DR5) and Fas (CD95/Apo-1) [117]. 
 
Figure 9. Transcription-dependent and independent effects of p53 activation  
11.1. Defective checkpoints 
p53 and the DNA damage response. DNA damaging agents can induce different types of 
lesions that culminate in cell death. DNA damage is detected by sensors within the cell that 
relay a signal causing cell cycle arrest and DNA repair or apoptosis. These networks of 
genome surveillance are known as replication checkpoints. When DNA damage is low the 
lesions can be repaired by several mechanisms. On the other hand, when the DNA damage 
is high or persistent, the cell undergoes apoptosis [118]. For example, as a response to 
genotoxic insults, p53 is phosphorylated by Checkpoint kinase 1 (Chk1) and Checkpoint 
kinase 2 (Chk2) and cannot be ubiquinated by mdm2 and becomes stabilized. Consequently, 
p21 is activated and cells are arrested either in the G1 or the G2 phase of the cell cycle. 
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balance between cell cycle arrest and apoptosis. The frequent loss of p53 in cancer 
enhances its ability to survive after DNA damage and evade apoptosis. When p53 is 
mutated, the response to DNA damage depends on mechanisms regulated by Ataxia 
telangiectasia mutated (ATM) and Ataxia telangiectasia and Rad3 related (ATR) 
independent of p53, which regulate Chk1 or Chk2 [119]. These kinases in turn activate 
NFkB, Akt and survivin [120].  
Cell cycle checkpoints. Checkpoints are mechanisms that respond to internal or external stress 
by activating machineries that arrest the cell cycle at particular points (G1/S, intra-S-phase, 
G2/M, or mitotic spindle). Many tumour suppressor genes are components of DNA damage 
or cell cycle checkpoints: p53, Retinoblastoma (Rb), ATM, p16, BRCA1/2, etc. The frequency 
of tumour suppressor loss in cancer cells provides an advantage to their growth. The G1 
checkpoint is controlled by Rb, which in turn, is phosphorylated by cdk’s. One cdk inhibitor 
is p16. Both Rb and p16 are frequently mutated in diverse types of cancer. The mitotic 
checkpoint utilizes genes (Mad, Bub, Aurora kinases) to detect spindle defects. When the 
cell is not able to surpass the damage, it undergoes mitotic catastrophe. In addition, loss of 
checkpoint controls increases genomic stability, providing cancer cells with adaptive or 
evolutionary advantages [121].  
 
Figure 10. DNA damage and cell cycle checkpoints 
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Figure 9. Transcription-dependent and independent effects of p53 activation  
11.1. Defective checkpoints 
p53 and the DNA damage response. DNA damaging agents can induce different types of 
lesions that culminate in cell death. DNA damage is detected by sensors within the cell that 
relay a signal causing cell cycle arrest and DNA repair or apoptosis. These networks of 
genome surveillance are known as replication checkpoints. When DNA damage is low the 
lesions can be repaired by several mechanisms. On the other hand, when the DNA damage 
is high or persistent, the cell undergoes apoptosis [118]. For example, as a response to 
genotoxic insults, p53 is phosphorylated by Checkpoint kinase 1 (Chk1) and Checkpoint 
kinase 2 (Chk2) and cannot be ubiquinated by mdm2 and becomes stabilized. Consequently, 
p21 is activated and cells are arrested either in the G1 or the G2 phase of the cell cycle. 
















Cell Death and Cancer, Novel Therapeutic Strategies 
 
85 
balance between cell cycle arrest and apoptosis. The frequent loss of p53 in cancer 
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is p16. Both Rb and p16 are frequently mutated in diverse types of cancer. The mitotic 
checkpoint utilizes genes (Mad, Bub, Aurora kinases) to detect spindle defects. When the 
cell is not able to surpass the damage, it undergoes mitotic catastrophe. In addition, loss of 
checkpoint controls increases genomic stability, providing cancer cells with adaptive or 
evolutionary advantages [121].  
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Figure 11. Akt signalling pathway 
Akt. Classically, the phosphoinositide-3-kinase (PI3K)-Akt-mTOR pathway is described as a 
key signal transduction cascade that integrates signals from growth factors and nutrients to 
regulate cell growth and proliferation [122]. Following growth factor binding to cell surface 
receptors, PI3K is activated and phosphorylates phosphatidylinositol-4,5-biphosphate (PIP2) 
to generate the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3). This 
process can be inhibited by the tumour suppressor protein phosphatase and tensin homolog 
(PTEN), which dephosphorylates PIP3 and terminates PI3K signalling. Then, the 
accumulated PIP3 recruits PDK1 and Akt through their Pleckstrin homology domains, and 
Akt is activated [123]. Akt recognizes and phosphorylates a consensus sequence that is 
present in many proteins. These substrates control key cellular processes such as apoptosis, 
cell cycle progression, transcription, and translation, all of which are critical events in cancer 
[124]. The Akt signal transduction pathway is probably the best survival pathway 
characterized. Moreover, Akt is constitutively activated in several malignant tumours, such 
as prostate, breast, ovary, lung and liver carcinomas [125]. Akt suppresses apoptosis 
through different mechanisms, including phosphorylation of forkhead transcription factors, 
which regulate proapoptotic proteins such as Bim and Fas ligand. The phosphorylated 
forkhead proteins are trapped in the cytosol and cannot enter the nucleus. Akt also 
phosphorylates and inactivates several proapoptotic proteins like Bad and caspase-9. 
Importantly, it activates IKK inducing the transcription factor NF-κB, leading to 
transcription of several antiapoptotic proteins such as Bcl-xL, and XIAP [96,126]. Akt also 
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prevents the nuclear localization of p53 upon binding and phosphorylation of mdm2 [120]. 
Therefore, deregulation of the PI3K-Akt pathway can be considered as a cause of 
chemoresistance [127]. 
11.2. Immunogenecity of cancer cell death 
It is becoming more evident that the immune response facilitates the effects of 
chemotherapy. Physiological death avoids autoimmunity. However cancer cell death 
triggered by radiotherapy or some chemotherapeutic agents such as anthracyclines can be 
immunogenic [128]. Immunogenic death involves changes in the composition of the cell 
membrane and the release of molecules called Damage Associated Molecular Patterns or 
alarmins. In particular, calreticulin has been shown to be crucial for immunogenic cancer 
cell death [129]. The immune system determines the long-term success of antitumor 
therapies. It seems that mitochondrial events as well as the ER response in conjunction with 
autophagy can establish whether cancer cells die in response to chemotherapy [130]. It has 
been found that calreticulin is the dominant pro-phagocytic signal on several cancers 
including neuroblastoma, non Hodgkin’s lymphoma and bladder cancer. However, 
calreticulin is counterbalanced by the “don´t eat me” signal CD47, which prevents cancer 
cell phagocytosis and is also highly expressed in these tumours [131]. Moreover, since CD47 
is expressed on the surface of all human cancer cells but not in normal cells, blocking CD47 
function with antibodies is emerging as a novel potential cancer strategy [132]. 
12. Senescence and cancer 
We have already mentioned that strong p53 activation induces apoptosis. However, 
Leontieva and colleagues have shown that a weak and sustained p53 activation during cell 
cycle arrest can promote a different type of cell demise known as senescence [133]. Cellular 
senescence, induced after an irreversible cell cycle arrest, is a protective mechanism that 
limits proliferation of cells exposed to endogenous or exogenous insults. This cell death type 
can take part in processes of tumour suppression, tumour promotion, aging, and tissue 
repair [134]. Senescent cells become flattened and enriched with vacuoles. Some of the 
biochemical changes characteristic of senescence include elevation in β-galactosidase 
activity at an acidic pH, increase in senescence markers (p16, p15, p21, p53, ARF, etc.), 
heterochromatinization and, similarly to autophagy, formation of autolysosomes. It has 
been recently shown that chemotherapeutic agents may cause a form of “premature 
senescence” that can be considered as a tumour suppressor mechanism. Therefore, the 
induction of premature senescence as a drug-inducible arrest program has therapeutic 
potential for cancer treatment, but requires further investigation [135]. 
13. Autophagy and cancer 
Regarding the role played by autophagy in cancer, mounting evidences suggest that 
autophagic cell death functions as a tumour suppressor mechanism. Several tumour 
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suppressor proteins have been shown to induce autophagy. Supporting this idea, there are 
also several works showing that certain oncogenic proteins inhibit autophagy. Most of this 
oncogene products form part of the classic PI3K-Akt-mTOR pathway. In the following 
section, we summarize the literature on the role played by key tumour suppressors and 
oncogene products in the regulation of autophagy and the involvement of autophagic genes 
in cancer. 
13.1. Tumour suppressor genes that regulate autophagy 
To date, several tumour suppressor proteins that regulate autophagy have been described. 
These include: Beclin 1, UV irradiation-resistance-associated gene (UVRAG), PTEN, Bcl-2, 
and p53. The majority of them act as autophagy inducers with the exception of p53 that is 
able to activate or inhibit autophagy.  
Role of Beclin 1 in autophagy: Beclin1 is a key regulator of autophagy. It regulates the 
autophagic process at different levels by combining with the enzyme class III PI3K (PI3KC3) 
and specific group of proteins forming unique class III PI3K-Beclin complexes. This PI3KC3-
Beclin complex functions as a core complex during autophagy [136,137] by phosphorylating 
phosphatidylinositol to produce phosphatidylinositol 3-monophosphate, which presumably 
allows the recruitment of essential autophagy related (Atg) proteins to the membrane. In 
mammals, at least three types of class III PI3-kinase-Beclin complexes contribute to 
autophagy [84,138,139]. 
Role of Beclin 1 in tumour suppression vs. autophagy: The first link between autophagy and 
cancer was established in 1999, when Liang and colleagues discovered that the autophagic 
protein Beclin 1 was able to inhibit tumourigenesis [140]. Beclin 1 is a tumour suppressor 
gene [141,142] monoallelically deleted in many types of cancers, including ovary (75%), 
breast (50%) and prostate (40%). Several studies suggest that the activation of autophagy by 
Beclin 1 is tightly associated with its tumour suppression function. For example, 
overexpression of Beclin-1 in the human MCF-7 breast carcinoma cell line is associated with 
inhibition of cell proliferation and induces autophagy [140]. In contrast, studies in vivo 
demonstrate that the monoallelic disruption of Beclin 1 gene promotes cellular proliferation 
and reduces autophagy [142]. Furthermore, genetically engineered mouse models with 
heterozygous disruption of Beclin 1 have decreased autophagy and are more prone to 
develop tumours, including lung carcinomas, hepatocellular carcinomas, lymphomas and 
mammary precancerous lesions [141,143]. Taken together, these studies firmly support the 
notion that autophagy induction and tumour inhibition function of Beclin 1 are closely 
interconnected. 
UVRAG is another tumour suppressor protein that is able to activate autophagy. UVRAG is 
a positive regulator of Beclin 1, as it promotes its binding to PI3KC3 to form the complex 
and enhance Beclin 1 activity. Through mediating Beclin 1-PI3KC3 complex, UVRAG can 
promote autophagy, thus inhibiting carcinogenesis of human colon cancer cells. It has also 
been proposed that UVRAG is involved in causing membrane curving [144]. Furthermore, 
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the monoallelic deletion or mutation of UVRAG has been observed in several human 
cancers such as colon, gastric and breast cancer [145-147]. 
Bif-1 is also a tumour suppressor that promotes autophagy. Similar to UVRAG, Bif-1 is a 
positive regulator of Beclin 1, as it enhances its interaction with PI3KC3, thus increasing 
autophagy. Consistently, it has been shown that loss of Bif-1 prevented the formation of 
autophagosomes and induced the development of spontaneous tumours in mice [144]. 
Furthermore, expression of Bif-1 is significantly reduced in prostate, colon, urinary bladder 
and gastric tumours [146,148,149]. The precise mechanism of Bif-1 in suppressing 
tumourigenesis has not been fully clarified, but it is reasonable to presume that its tumour 
inhibitory activity is associated with its role in inducing autophagy. Some groups have also 
suggested that Bif-1 suppresses tumour growth through its interaction with proapoptotic 
Bax [150]. 
13.2. Oncogenic genes that regulate autophagy 
Most of the oncogenic genes that regulate autophagy described to date are key proteins of 
the PI3K-Akt-mTOR pathway. These proteins inhibit autophagy and promote 
carcinogenesis.  
mTOR: the best-studied downstream substrate of Akt is the serine/threonine kinase 
mammalian target of rapamycin (mTOR). In mammals, mTOR exists in two different 
complexes, known as mTORC1 and mTORC2. In the mTORC1 complex, mTOR is bound to 
a protein called Raptor, and in the mTORC2 complex, mTOR is bound to Rictor. mTORC1 is 
best known for its role in regulating protein synthesis through two of its substrates, 4E-BP1 
and p70S6K [151]. Akt can directly phosphorylate and activate mTOR, or activate it 
indirectly by phosphorylation and inactivation of TSC2. When TSC2 is inactivated by 
phosphorylation, it can no longer associate with TSC1, thus abolishing the inhibitory effect 
of TSC1-TSC2 complex on mTORC1. As a result, mTOR is activated and signals to its 
downstream targets p70S6 kinase, ribosomal protein S6 and 4EBP-1/eIF-4E to control protein 
translation and proliferation [152]. mTORC1 is not only a key regulator of proliferation and 
survival, but also a master inhibitor of autophagy. Under nutrient-rich conditions, mTORC1 
is activated and phosphorylates ULK1, ULK2 and mAtg13, inhibiting the initiation of 
autophagy. In contrast, in nutrient starvation conditions mTORC1 is inactivated and 
dissociates, resulting in activation of ULK1 and ULK2, which initiates the autophagy 
cascade [151]. The PI3K-Akt-mTOR pathway is probably the most commonly activated 
signalling pathway in human cancers [124]. This route is activated aberrantly in many types 
of tumours, and hence, inhibited autophagy and increased proliferation and protein 
synthesis are often observed. For example, many human cancers are characterized by 
activating mutations in specific components of the signalling pathway that connect Receptor 
tyrosine kinases to mTOR, including Ras, PI3K and Akt. Somatic mutations in PIK3CA gene 
encoding the catalytic subunit of class I PI3K frequently occur in cancers of colon, breast, 
brain and lung [153]. PTEN, another regulator of PI3KI-Akt pathway, is a tumour 
suppressor that is found to be mutated in many types of cancer.  
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Bcl-2 forms part of the Bcl-2 family proteins. For almost two decades, Bcl-2 has been 
regarded to function as an antiapoptotic protein that contributes to tumourigenesis. The role 
of Bcl-2 in autophagy was realized in 1998 when Liang identified Beclin 1 as Bcl-2 
interacting protein [140]. Bcl-2 acts as a negative regulator of autophagy by inhibiting Beclin 
1. It binds constitutively to Beclin 1, blocking the interaction between Beclin 1 and PI3KC3 
[154-156]. As a result, PI3KC3 activity is decreased and autophagy is downregulated [155]. 
The binding of Bcl-2 with Beclin 1 seems to be constitutive, and its detachment from Beclin 1 
is speculated to be essential in autophagy. 
13.3. How does autophagy suppress tumourigenesis? 
The combined data presented above strongly support the idea that autophagy functions as a 
tumour suppressor process. Consistent with this, oncogenes that have a role in autophagy 
are potent inhibitors of this process. Although the molecular mechanisms by which 
autophagy functions in tumour suppression are poorly defined, at least two mechanisms 
have been described: 
a. Autophagy maintains the integrity of the genome 
The first hypothesis is that autophagy may function as a housekeeping pathway to exert the 
quality control of organelles, proteins and DNA. Mathews and colleague observed that in 
autophagy deficient tumour cells, metabolic stress promotes the accumulation of p62, 
damaged mitochondria and ROS generation, promoting genomic instability and leading to 
oncogene activation and tumour progression [157,158]. Furthermore, immortalized mouse 
epithelial cells with a defect in ATG genes (loss of Beclin 1 or Atg 5) display increased DNA 
damage, centrosome abnormalities, numerical and structural chromosomal abnormalities 
and gene amplification, especially after ischemic stress.  
However, the mechanisms through which autophagy preserves the integrity of the genome 
remains elusive. One possibility could be that autophagy may contribute to cell cycle 
regulation, for example by degrading organelles and/or proteins involved in the cell cycle 
checkpoints [159]. Another possibility is that autophagy might simply function at a more 
general level to ensure the minimal amount of ATP and other metabolites required for DNA 
repair. Finally, autophagy may act by removing old and/or damaged organelles (for 
example, uncoupled mitochondria) which may act as a source of genotoxic chemical species 
such as ROS. 
b. Autophagy limits necrosis-mediated inflammation 
Necrosis normally results from physical injury in which the cell lyses and releases its 
intracellular contents, which activate the innate immune system and a wound-healing 
response [160]. As a result, inflammatory cells are recruited and cytokines are released to 
promote cell growth to replace the damaged tissue [161,162].  
In contrast, apoptosis may be the preferred means of cell demise for cells upon metabolic 
stress, as cells are eliminated without inflammation. However, in cancer cells with a defect 
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in apoptosis, autophagy is induced for cell survival. Through autophagy, cells eliminate 
damaged organelles and may maintain their normal cellular function under adverse 
conditions of fluctuating oxygen and nutrient supply. However, this beneficial effect of 
autophagy functions during short term interruptions in nutrient availability, as in the long 
term (excess of autophagy) it can possibly lead to cell death.  
A high proportion of tumours have been seen to present a defect both in autophagy and 
apoptosis. Degenhardt and colleagues have shown that the inhibition of both processes 
under conditions of metabolic stress generates a necrotic cell-death, suggesting that 
apoptosis and autophagy function to limit necrosis [163]. In these necrotic tumours a 
persistent inflammatory infiltration and cytokine production exists, which is thought to 
promote tumour growth and thus, is associated with poor prognosis.  
13.4. Role of autophagy in tumour survival 
The data presented above strongly supports the idea that autophagy functions as a tumour 
suppressor process and that inhibition of autophagy leads to carcinogenesis. However, there 
are some circumstances where autophagy contributes to tumour survival promoting 
carcinogenesis: 
a. Autophagy is induced by nutrient starvation  
The survival role of autophagy during nutrient limitation is well established. When cells 
encounter environmental stresses such as nutrient starvation, autophagy can be activated 
and protects cells by preventing them from undergoing apoptosis. Through autophagy, 
starving cells degrade cytoplasmic material to generate both nutrients and energy [85]. 
Consistent with this, during nutrient starvation, inhibition of autophagy promotes apoptosis 
[164]. 
b. Autophagy is induced by hypoxia 
Hypoxia in tumours results from inadequate tumour vasculature and is associated with a 
more malignant phenotype, higher predisposition for metastasis, and poor prognosis. 
Hypoxic stress selects for cells that are resistant to apoptosis as well as poses a major barrier 
to chemotherapy and radiotherapy. 
White and colleagues first showed that autophagy is induced specifically in the hypoxic 
core of tumours, where it promotes survival [163]. Further studies have unveiled the 
molecular connections between hypoxia and the activation of autophagy. For example, it 
has been reported that when oxygen concentration falls below 5% hypoxia inducible 
factor 1 (HIF1) is activated and this transcription factor activates key autophagy inducers 
(BNIP3), which in turn activate the key autophagy complex formed by PI3K III [165,166]. 
Further mechanistic studies have revealed that induction of BNIP3 and BNIP3L in 
hypoxic cells disrupts the Becn1-Bcl-2 complex, thereby releasing Becn1 to induce 
autophagy [167].  
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in apoptosis, autophagy is induced for cell survival. Through autophagy, cells eliminate 
damaged organelles and may maintain their normal cellular function under adverse 
conditions of fluctuating oxygen and nutrient supply. However, this beneficial effect of 
autophagy functions during short term interruptions in nutrient availability, as in the long 
term (excess of autophagy) it can possibly lead to cell death.  
A high proportion of tumours have been seen to present a defect both in autophagy and 
apoptosis. Degenhardt and colleagues have shown that the inhibition of both processes 
under conditions of metabolic stress generates a necrotic cell-death, suggesting that 
apoptosis and autophagy function to limit necrosis [163]. In these necrotic tumours a 
persistent inflammatory infiltration and cytokine production exists, which is thought to 
promote tumour growth and thus, is associated with poor prognosis.  
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carcinogenesis: 
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and protects cells by preventing them from undergoing apoptosis. Through autophagy, 
starving cells degrade cytoplasmic material to generate both nutrients and energy [85]. 
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[164]. 
b. Autophagy is induced by hypoxia 
Hypoxia in tumours results from inadequate tumour vasculature and is associated with a 
more malignant phenotype, higher predisposition for metastasis, and poor prognosis. 
Hypoxic stress selects for cells that are resistant to apoptosis as well as poses a major barrier 
to chemotherapy and radiotherapy. 
White and colleagues first showed that autophagy is induced specifically in the hypoxic 
core of tumours, where it promotes survival [163]. Further studies have unveiled the 
molecular connections between hypoxia and the activation of autophagy. For example, it 
has been reported that when oxygen concentration falls below 5% hypoxia inducible 
factor 1 (HIF1) is activated and this transcription factor activates key autophagy inducers 
(BNIP3), which in turn activate the key autophagy complex formed by PI3K III [165,166]. 
Further mechanistic studies have revealed that induction of BNIP3 and BNIP3L in 
hypoxic cells disrupts the Becn1-Bcl-2 complex, thereby releasing Becn1 to induce 
autophagy [167].  
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The role of autophagy as a key mediator of survival of hypoxic cells is emerging so that the 
exact mechanisms underlying this phenotype remain unclear. Because chronic hypoxia 
leads to major metabolic perturbations in tumour tissues, one can postulate that by recycling 
basic cellular components, autophagy helps stressed cells cope with the increased metabolic 
demand [168]. However, further studies are needed to validate this hypothesis.  
c. Autophagy is induced in metastatic cells 
Epithelial cells critically depend on cell adhesion to extracellular matrix (ECM) for proper 
growth and survival. Upon detachment of cells from the ECM, cells undergo anoikis, a type 
of apoptotic cell death that serves the homeostatic function of killing cells that have lost 
contact with the basement membrane [68]. It has been shown that autophagy is induced in 
oncogene-transformed cells following matrix detachment [169]. Similarly, in three 
dimensional (3D) epithelial cell culture models, autophagy is significantly increased in the 
detached luminal cells. Furthermore, when autophagy is inhibited accelerated luminal 
clearance occurs [158,169]. Altogether, these results suggest that autophagy is fundamental 
in anoikis resistance, a process exploited by tumour cells to survive after detachment from 
the primary site, as well as while migrating to distant metastatic sites [170].  
Debnath and colleagues have shown that detachment induces autophagy in both 
nontumourigenic epithelial cell lines and in primary epithelial cells. Autophagy inhibition 
through siRNA for ATG genes inhibits detachment-induced autophagy and increases 
apoptosis. Remarkably, even when apoptosis is inhibited matrix-detached cells still exhibit 
autophagy. Moreover, inhibition of autophagy in MCF-10 acini enhances luminal apoptosis 
during morphogenesis and fails to elicit long-term luminal filling [171]. Altogether, these 
results indicate that autophagy promotes epithelial cell survival during anoikis, including in 
detached cells harbouring antiapoptotic lesions. 
14. Current therapeutic advances 
In addition to inactivation of proliferative and prosurvival oncogenic pathways, current 
anticancer strategies deal with reactivation of cancer death cell signalling routes in order to 
induce tumour regression. The most promising cancer therapies that specifically target 
apoptosis, necrosis/necroptosis and autophagy are described in the following section. 
14.1. Extrinsic apoptotic pathway 
TRAIL: This member of the TNF family stimulates the extrinsic apoptotic pathway in a wide 
variety of cancers upon binding to death receptors, while having no effect on normal cells. 
Therefore, the use of recombinant TRAIL or agonistic TRAIL-receptor antibodies constitutes 
a novel therapeutic strategy [172]. TRAIL has been found to bind five receptors in human 
cells: TRAIL-R1, TRAIL-R2, TRAIL-R3 (DcR1), TRAIL-R4 (DcR2) and the soluble receptor 
osteoprogeterin. However, DcR1 and DcR2 are unable to transduce a death signal and are 
considered “decoy receptors”. Ashkenazi and colleagues have proposed that the specificity 
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of TRAIL for cancer cells is due to the fact that normal cells express more frequently these 
decoy receptors [173]. Moreover, TRAIL only weakly induces the prosurvival NFkB 
pathway [78]. Unfortunately, many primary tumour cell lines have shown resistance to 
TRAIL [174]. It has been shown that in preclinical studies, the combination of recombinant 
human TRAIL (rhTRAIL, AMG951, Dulanermin) or agonistic antibodies with irradiation, 
several chemotherapeutic agents, Akt or proteosome inhibitors induced cell death in 
tumours resistant to TRAIL [175-177]. Therefore, the efficacy of rhTRAIL or anti-TRAIL-R1/2 
antibodies is being examined in different phase I and phase II clinical trails alone or in 
combination with other chemotherapeutic agents [172,178,179]. 
Fas activating compounds: Fas, also called CD95 or APO-1 is a member of the TNF family of 
death receptors involved in the extrinsic apoptotic pathway. Fas plays an important role in 
regulation of the immune system. This receptor belongs to a subgroup within the TNFR 
family which includes TNFR1, DR3, TRAIL-R4 and TRAIL-R5 [180]. Fas has been recently 
implicated in the activation of RIP1, resulting in necroptosis when caspase-8 is inactive 
[181,182]. In addition, Tschopp and colleagues have demonstrated that Fas can activate 
other signalling pathways involved in proliferation or differentiation [109]. Fas agonists, 
such as highly aggregated FasL or anti-Fas antibodies are not suitable for cancer therapy 
owing to their profound liver toxicity. However, weaker Fas agonists may be useful. In this 
respect, APO010 is undergoing clinical trials for solid tumours [109].  
14.2. Intrinsic apoptotic pathway 
Bcl-s inhibitors/BH3 mimetics: Many efforts in cancer therapeutics are directed towards 
inhibition of antiapoptotic Bcl-2 like proteins. The first class of drugs being developed was 
antisense nucleotides. Oblimersen has been tested in clinical trials in different types of 
cancers. Even though some clinical trials shows efficacy of oblimersen combined with 
chemotherapy in treating melanoma [183], other studies show that this Bcl-2 inhibitor does 
not confer significant benefit to cancer patients [178]. Small molecule Bcl-2 inhibitors are also 
called “BH3 mimetics”, as they imitate the function of BH3-only proteins: Gossypol (AT-
101) binds Bcl-2, Bcl-XL and MCl-1, inhibiting their binding to Bax and Bak. In combination 
with other chemotherapeutic agents it promotes apoptosis in preclinical studies and has 
shown efficacy in at least one clinical trial [178]. Obotoclax is a pan Bcl-2 inhibitor that 
induces apoptosis in leukemia cells. However, recent studies have shown that its activity is 
partially mediated by autophagy [184,185]. Therefore, caution should be taken when using 
these kinds of drugs. ABT-737 and its orally available derivative, ABT-263 (navitoclax), have 
shown promising results in preclinical studies. They bind Bcl-2, Bcl-XL and Bcl-w [186], but 
mildly inhibit Mcl-1 [187] or A1 [101]. ABT-727 synergizes with standard chemotherapeutic 
agents, radiation and tyrosine kinase inhibitors in cancer cells and is effective as a single 
agent promoting tumour regression in mice. ABT-263 is currently in phase I and II clinical 
trails as a single agent [78,188]. However, its use is limited because it causes 
trombocytophenia owing to Bcl-XL inhibition [189]. A new BH-3 mimetic agent, GDC-0199 
has been developed and entered clinical trails for lymphomas [101]. 
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IAP inhibitors and Smac mimetics: Moreover, the role of IAPs in regulating apoptosis and/or 
necroptosis has led to the development of small molecules that antagonize IAP, or mimic the 
function of Smac/DIABLO. In fact, IAPs have been found to be overexpressed in many 
cancers and to be associated with poor prognosis and chemoresistance [102], making them 
putative targets for cancer therapeutics. Smac mimetics can sensitize chemoresistant cancer 
cells to cisplatin, doxorubicin or TRAIL [190], either as single agents or in combination with 
other drugs [109]. Therefore, some of these agents (AT-406, LCL-161, HGS-1029, TL32711, 
GDC-0917) [73] have recently entered clinical trials [191] for the treatment of solid tumours 
and lymphomas [192]. However, the potential of Smac mimetics as antitumour agents has 
been questioned, since the inhibition of cIAP1 and cIAP2 can stabilize IKK and activate the 
proinflammatory NFkB pathway [102].  
Other IAP-targeted therapies such as XIAP and survivin antisense oligonucleotides have 
been developed [102]. Antisense oligonucleotides against survivin synergize with etoposide 
in non small lung cancer cells [117]. LY2181308 is a second generation antisense 
oligonucleotide being evaluated in clinical trials. In addition, a small molecule inhibitor of 
survivin, YM155, has shown potency in preclinical models and has entered phase II clinical 
trails [110].  
14.3. DNA damage and cell cycle 
p53 inhibitors: Since p53 is frequently mutated in tumours, therapeutic approaches have been 
made to restore p53 function. Since p53 is targeted to degradation through interaction with 
mdm2, some drugs such as RITA, Nutlin-3 or HLI198 have been designed to disrupt p53-
mdm2 interaction. These compounds bind to the p53 binding site on mdm2 or inhibit mdm2 
ubiquitin ligase activity. This approach is valid in cancers with wild type p53, such as 
haematological malignancies [56]. A second approach is to rescue wild-type 53 function in 
p53-mutated tumours. PRIMA-1 restores sequence-specific DNA binding and active 
conformation of mutant p53 proteins. PRIMA-1 can synergize with conventional 
chemotherapeutic drugs and inhibit tumour growth in mice with no apparent toxicity and 
has recently entered clinical trials [78]. 
Chk1/2 inhibitors: The concept of “synthetic lethality” coined by Kaelin, by which two 
molecular lesions combine to have a lethal effect on the cell, although neither of them is 
harmful individually, has recently gained interest [193,194]. In this context, Chk inhibitors 
may have a therapeutic potential in p53-mutated tumours. UCN-01, the first Chk inhibitor 
evaluated in humans, has limited clinical value due to its toxicity. Other Chk inhibitors 
functioning as checkpoint abrogators that are being evaluated in clinical trials are: AZD7762, 
LY26303618, CBT501, PF-00477736, SCH 900776, XL844, and the wee-1 inhibitor MK-1775 
[195,196]. 
PARP inhibitors: Other example of synthetic lethality is BRCA mutant breast cancer. BRCA1 
and BRCA2 play a role in homologous recombination, an important repair pathway for 
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DNA double strand breaks. The current hypothesis is that since PARP is involved in repairs 
in DNA single strands breaks, inhibition of PARP leads to accumulation of single strand 
unrepaired breaks and becomes synthetically lethal in BRCA-mutated cancers [197]. Several 
PARP inhibitors are being evaluated in clinical trials: AG014699, AZD2281 (olaparib), 
ABT888 (veliparib), BSI-201 (iniparib), INO-1001, GP121016, CEP-9722 and MKI4827 
[197,198]. PARP inhibitors may be useful in tumours bearing other types of genomic or 
functional defects in DNA damage response pathways. 
14.4. Necroptosis 
cFLIP: This antiapoptotic regulator is expressed as long (c-FLIPL) short (c-FLIPS) or c-FLIPR 
variants in human cells. In the absence of cFLIP, the ripoptosome triggers apoptotic cell 
death. On the contrary, expression of cFLIPL, which binds caspase-8, neutralizes its ability to 
engage the apoptotic machinery, but inhibits necroptosis by preventing RIP1-RIP3 
association. On the other hand, c-FLIPS, although is able to bind caspase-8, does not form an 
active heteromer and necroptosis can develop [78,199]. Increased expression of c-FLIP has 
been found in several human cancers and is associated with poor prognosis [102]. 
Downregulation of FLIP seems to be a promising therapeutic strategy. Research efforts are 
being focused on the development of small interference RNA (siRNA) targeted against c-
FLIP. In addition, several antitumour agents can downregulate c-FLIP at the transcriptional 
or posttranscriptional level [200].  
14.5. Autophagy 
a. Autophagy as a protective mechanism  
A large series of anticancer drugs (both clinically approved and experimental) are able to 
induce a significant accumulation of autophagosomes in tumour cells both in vitro and in 
vivo [201]. For many years, it was thought that these therapies may kill tumours through 
autophagy and this massive vacuolization of the cytoplasm has been considered a 
manifestation of autophagic cell death. According to this notion, autophagy would 
represent another mechanism of cell death and the inhibition of autophagy would protect 
the cell from dying. However, this perspective is nowadays rather discredited, as the 
majority of the literature has reported that specific inhibition of autophagy (through siRNA) 
contributes to cell death during cancer treatment [202-204]. Besides, it is now well accepted 
that acquired resistant to chemotherapeutic drugs is, in part, due to the adaptive prosurvival 
response conferred by autophagy. Also, several studies have shown that inhibition of 
autophagy by pharmacological inhibitors such as Bafilomycin A1, cloroquine, or 3-
methyladenine can enhance and accelerate cytotoxic cancer therapy in several tumours [205-
207]. In particular, some reports show that chloroquine as a single agent is sufficient to 
promote tumour regression in transplanted cancer models [208,209]. Moreover, chloroquine is 
a well-tolerated nontoxic drug that has entered a clinical trail as monotherapy for pancreatic 
cancer treatment [78]. This clearly indicates that the induction of autophagy represents an 
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attempt of the cells to cope with the stress induced by cytotoxic drugs and suggests that the 
inhibition of the autophagic process might be beneficial in cancer treatment. 
b. Autophagy as a death mechanism  
Although there is robust evidence indicating that autophagy has a protective role in cancer 
therapeutics, in certain cancer treatments, autophagy can kill cells by inducing autophagic 
cell death. For example, Abe and colleagues have demonstrated that harmol, a β-carboline 
alkaloid, triggered autophagic cell death in human lung carcinoma A549 cells without 
activation of caspase-3, caspase-8, or caspase-9 or PARP cleavage. Autophagy, but not 
apoptosis, was detected by electron microscopy in these cancer cells. Furthermore, 
pretreatment of A549 cells with the autophagy inhibitor 3-methyladenine or siRNA-
mediated knockdown of LC3 suppressed harmol-induced cell death [210]. Another study 
shows that L929 fibrosarcoma cells die in a caspase-independent manner involving 
autophagy and that ATG genes are required for this cell death process [211]. In this model, 
caspase inhibition induces the selective autophagic degradation of catalase, a major ROS 
scavenger, and the resulting ROS accumulation promotes autophagic cell death [212].  
14.6. What determines if autophagy is cytoprotective or cytotoxic? 
Autophagy is a process that allows cells to escape death or paradoxically leads to cell death. 
It is not yet understood what factors determine whether autophagy is cytoprotective or 
cytotoxic. It has been suggested that autophagy induced under pathological conditions 
functions as an adaptive cell response, allowing the cell to survive bioenergetic stress. 
However, autophagy is a process that destroys cellular content and organelles. In this 
way, it has been suggested that deregulated, excessive or persistent autophagy may lead 
to autophagic cell death. That is, the destruction of proteins and organelles may pass a 
threshold, leading to cell death. However, the point at which autophagy becomes 
autophagic cell death remains unclear. In this perspective, the dissection of the transition 
from autophagy to autophagic cell death and the cross-talking between apoptosis and 
autophagy may help to understand this process, leading to more efficacious treatments in 
cancer. In contrast, a different study has reported that when cells are subjected to 
prolonged growth factor deprivation or shortage of glucose and oxygen they can lose the 
majority of their mass via autophagy. However, when these cells are placed in optimal 
culture conditions, they are able to fully recover [163,213]. This result suggests that cell 
death via autophagy may not be simply a matter of crossing a quantitative threshold of 
self-digestion. 
14.7. Interplay among apoptosis, necrosis/necroptosis and autophagy 
Cell death process in vivo involves a complex interaction among apoptosis, 
necrosis/necroptosis and autophagy [78]. In some situations, a specific stimulus triggers 
only one mechanism, but in other cases, the same stimulus can evoke more than one cell 
demise machinery. Therefore, several mechanisms can coexist within a cell, but only one 
will predominate over the others. The decision to undergo apoptosis, necrosis/necroptosis or 
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autophagy depends on various factors: energy/ATP availability, extent of the stress and the 
damage and presence of inhibitors of particular pathways (e. g. caspases inhibitors) [214]. 
ATP depletion activates autophagy, but if autophagy fails to maintain energy levels, 
necrosis/necroptosis results [215]. Apoptosis is usually triggered with sufficient ATP levels 
to trigger caspases. If the damage is severe necrosis prevails over apoptosis [216,217]. Hence, 
apoptosis is the first choice in most circumstances and necroptosis is triggered only as a 
backup alternative to guarantee that cell death takes place. However, in some cases (e.g. 
viral infection) TNF-mediated necroptosis predominate [218]. Apoptosis can inhibit 
autophagy through Bcl-2-mediated sequestration [155,156] or caspase-dependent cleavage 
of Beclin 1 [219,220,220], and conversely, autophagy can inhibit apoptosis by caspase-8 
degradation [221]. 
15. Concluding remarks 
Programmed cell death mechanisms are intricate and usually interconnected processes. 
Evasion of cell death is a common feature of cancer cells leading to chemoresistance. 
Apoptosis, necrosis/necroptosis and autophagy are the main explored pathways that had 
gained interest among cancer biologists, as means to develop novel cancer therapeutics. 
Deeping our knowledge on the nexus between cell death and cancer will enable us to 
predict in a more refined manner the carcinogenic process and therefore, pave the way for a 
personalized approach to the disease. 
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attempt of the cells to cope with the stress induced by cytotoxic drugs and suggests that the 
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self-digestion. 
14.7. Interplay among apoptosis, necrosis/necroptosis and autophagy 
Cell death process in vivo involves a complex interaction among apoptosis, 
necrosis/necroptosis and autophagy [78]. In some situations, a specific stimulus triggers 
only one mechanism, but in other cases, the same stimulus can evoke more than one cell 
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will predominate over the others. The decision to undergo apoptosis, necrosis/necroptosis or 
 
Cell Death and Cancer, Novel Therapeutic Strategies 
 
97 
autophagy depends on various factors: energy/ATP availability, extent of the stress and the 
damage and presence of inhibitors of particular pathways (e. g. caspases inhibitors) [214]. 
ATP depletion activates autophagy, but if autophagy fails to maintain energy levels, 
necrosis/necroptosis results [215]. Apoptosis is usually triggered with sufficient ATP levels 
to trigger caspases. If the damage is severe necrosis prevails over apoptosis [216,217]. Hence, 
apoptosis is the first choice in most circumstances and necroptosis is triggered only as a 
backup alternative to guarantee that cell death takes place. However, in some cases (e.g. 
viral infection) TNF-mediated necroptosis predominate [218]. Apoptosis can inhibit 
autophagy through Bcl-2-mediated sequestration [155,156] or caspase-dependent cleavage 
of Beclin 1 [219,220,220], and conversely, autophagy can inhibit apoptosis by caspase-8 
degradation [221]. 
15. Concluding remarks 
Programmed cell death mechanisms are intricate and usually interconnected processes. 
Evasion of cell death is a common feature of cancer cells leading to chemoresistance. 
Apoptosis, necrosis/necroptosis and autophagy are the main explored pathways that had 
gained interest among cancer biologists, as means to develop novel cancer therapeutics. 
Deeping our knowledge on the nexus between cell death and cancer will enable us to 
predict in a more refined manner the carcinogenic process and therefore, pave the way for a 
personalized approach to the disease. 
Author details 
Silvina Grasso, Estefanía Carrasco-García, Lourdes Rocamora-Reverte,  
Ángeles Gómez-Martínez and José A. Ferragut 
Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Elche (Alicante), Spain 
M. Piedad Menéndez-Gutiérrez 
Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Elche (Alicante), Spain 
Centro Nacional de Investigaciones Cardiovasculares, Departamento de Desarrollo y Reparación 
Cardiovascular, Madrid, Spain 
Leticia Mayor-López, Elena Tristante, Isabel Martínez-Lacaci* 
Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Elche (Alicante), Spain 
Unidad AECC de Investigación Traslacional en Cáncer, Hospital Universitario Virgen de la 
Arrixaca, Instituto Murciano de Investigación Biosanitaria, Murcia, Spain 
Pilar García-Morales and Miguel Saceda 
Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Elche (Alicante), Spain 
Unidad de Investigación, Hospital General Universitario de Elche, Elche (Alicante), Spain 
                                                                 
* Corresponding Author 
 




[1] Vaux DL, Korsmeyer SJ (1999) Cell death in development. Cell ;96: 245-254. 
[2] Vermeulen K, Van Bockstaele DR, Berneman ZN (2005) Apoptosis: mechanisms and 
relevance in cancer. Ann.Hematol.84: 627-639. 
[3] deCathelineau AM, Henson PM (2003) The final step in programmed cell death: 
phagocytes carry apoptotic cells to the grave. Essays Biochem.39: 105-117. 
[4] Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with 
wide-ranging implications in tissue kinetics. Br.J.Cancer ;26: 239-257. 
[5] Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. 
(2009) Classification of cell death: recommendations of the Nomenclature Committee on 
Cell Death 2009. Cell Death.Differ.16: 3-11. 
[6] Wyllie AH, Kerr JF, Currie AR (1980) Cell death: the significance of apoptosis. 
Int.Rev.Cytol.68: 251-306. 
[7] Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssiere JL, Petit PX, et al. (1995) 
Reduction in mitochondrial potential constitutes an early irreversible step of 
programmed lymphocyte death in vivo. J.Exp.Med.181: 1661-1672. 
[8] Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, et 
al. (1995) Early redistribution of plasma membrane phosphatidylserine is a general 
feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression 
of Bcl-2 and Abl. J.Exp.Med.182: 1545-1556. 
[9] Majno G, Joris I (1995) Apoptosis, oncosis, and necrosis. An overview of cell death. 
Am.J.Pathol.146: 3-15. 
[10] Hail N, Jr., Carter BZ, Konopleva M, Andreeff M (2006) Apoptosis effector mechanisms: 
a requiem performed in different keys. Apoptosis.11: 889-904. 
[11] Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. 
(2012) Molecular definitions of cell death subroutines: recommendations of the 
Nomenclature Committee on Cell Death 2012. Cell Death.Differ.19: 107-120. 
[12] Kroemer G, Galluzzi L, Brenner C (2007) Mitochondrial membrane permeabilization in 
cell death. Physiol Rev.87: 99-163. 
[13] Ellis HM, Horvitz HR (1986) Genetic control of programmed cell death in the nematode 
C. elegans. Cell ;44: 817-829. 
[14] Thornberry NA, Lazebnik Y (1998) Caspases: enemies within. Science ;281: 1312-1316. 
[15] Pop C, Salvesen GS (2009) Human caspases: activation, specificity, and regulation. 
J.Biol.Chem.284: 21777-21781. 
[16] Kumar S (2007) Caspase function in programmed cell death. Cell Death.Differ.14: 32-43. 
[17] Blank M, Shiloh Y (2007) Programs for cell death: apoptosis is only one way to go. Cell 
Cycle ;6: 686-695. 
[18] Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem.J.326 ( Pt 1): 1-16. 
[19] Tenev T, Zachariou A, Wilson R, Ditzel M, Meier P (2005) IAPs are functionally non-
equivalent and regulate effector caspases through distinct mechanisms. Nat.Cell Biol.7: 
70-77. 
 
Cell Death and Cancer, Novel Therapeutic Strategies 
 
99 
[20] Huang H, Joazeiro CA, Bonfoco E, Kamada S, Leverson JD, Hunter T (2000) The 
inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in 
vitro monoubiquitination of caspases 3 and 7. J.Biol.Chem.275: 26661-26664. 
[21] Suzuki Y, Nakabayashi Y, Takahashi R (2001) Ubiquitin-protein ligase activity of X-
linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 
and enhances its anti-apoptotic effect in Fas-induced cell death. 
Proc.Natl.Acad.Sci.U.S.A ;98: 8662-8667. 
[22] Yang QH, Church-Hajduk R, Ren J, Newton ML, Du C (2003) Omi/HtrA2 catalytic 
cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates 
caspase activity in apoptosis. Genes Dev.17: 1487-1496. 
[23] Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell ;116: 205-219. 
[24] Meier P, Vousden KH (2007) Lucifer's labyrinth--ten years of path finding in cell death. 
Mol.Cell ;28: 746-754. 
[25] Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, et al. (2007) The 
CD95 receptor: apoptosis revisited. Cell ;129: 447-450. 
[26] Lavrik I, Golks A, Krammer PH (2005) Death receptor signaling. J.Cell Sci.118: 265-267. 
[27] Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 
;305: 626-629. 
[28] Tait SW, Green DR (2010) Mitochondria and cell death: outer membrane 
permeabilization and beyond. Nat.Rev.Mol.Cell Biol.11: 621-632. 
[29] Luo X, Budihardjo I, Zou H, Slaughter C, Wang X (1998) Bid, a Bcl2 interacting protein, 
mediates cytochrome c release from mitochondria in response to activation of cell 
surface death receptors. Cell ;94: 481-490. 
[30] Chinnaiyan AM, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S, et al. 
(1996) FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis 
factor receptor-induced apoptosis. J.Biol.Chem.271: 4961-4965. 
[31] Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-
induced serum factor that causes necrosis of tumors. Proc.Natl.Acad.Sci.U.S.A ;72: 3666-
3670. 
[32] Schievella AR, Chen JH, Graham JR, Lin LL (1997) MADD, a novel death domain 
protein that interacts with the type 1 tumor necrosis factor receptor and activates 
mitogen-activated protein kinase. J.Biol.Chem.272: 12069-12075. 
[33] Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, et al. (1997) Prevention of apoptosis 
by Bcl-2: release of cytochrome c from mitochondria blocked. Science ;275: 1129-1132. 
[34] Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G (2010) Molecular 
mechanisms of necroptosis: an ordered cellular explosion. Nat.Rev.Mol.Cell Biol.11: 
700-714. 
[35] Galluzzi L, Zamzami N, de La Motte RT, Lemaire C, Brenner C, Kroemer G (2007) 
Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. 
Apoptosis.12: 803-813. 
[36] Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and 
therapy. Oncogene ;26: 1324-1337. 
 




[1] Vaux DL, Korsmeyer SJ (1999) Cell death in development. Cell ;96: 245-254. 
[2] Vermeulen K, Van Bockstaele DR, Berneman ZN (2005) Apoptosis: mechanisms and 
relevance in cancer. Ann.Hematol.84: 627-639. 
[3] deCathelineau AM, Henson PM (2003) The final step in programmed cell death: 
phagocytes carry apoptotic cells to the grave. Essays Biochem.39: 105-117. 
[4] Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with 
wide-ranging implications in tissue kinetics. Br.J.Cancer ;26: 239-257. 
[5] Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. 
(2009) Classification of cell death: recommendations of the Nomenclature Committee on 
Cell Death 2009. Cell Death.Differ.16: 3-11. 
[6] Wyllie AH, Kerr JF, Currie AR (1980) Cell death: the significance of apoptosis. 
Int.Rev.Cytol.68: 251-306. 
[7] Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssiere JL, Petit PX, et al. (1995) 
Reduction in mitochondrial potential constitutes an early irreversible step of 
programmed lymphocyte death in vivo. J.Exp.Med.181: 1661-1672. 
[8] Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, et 
al. (1995) Early redistribution of plasma membrane phosphatidylserine is a general 
feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression 
of Bcl-2 and Abl. J.Exp.Med.182: 1545-1556. 
[9] Majno G, Joris I (1995) Apoptosis, oncosis, and necrosis. An overview of cell death. 
Am.J.Pathol.146: 3-15. 
[10] Hail N, Jr., Carter BZ, Konopleva M, Andreeff M (2006) Apoptosis effector mechanisms: 
a requiem performed in different keys. Apoptosis.11: 889-904. 
[11] Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. 
(2012) Molecular definitions of cell death subroutines: recommendations of the 
Nomenclature Committee on Cell Death 2012. Cell Death.Differ.19: 107-120. 
[12] Kroemer G, Galluzzi L, Brenner C (2007) Mitochondrial membrane permeabilization in 
cell death. Physiol Rev.87: 99-163. 
[13] Ellis HM, Horvitz HR (1986) Genetic control of programmed cell death in the nematode 
C. elegans. Cell ;44: 817-829. 
[14] Thornberry NA, Lazebnik Y (1998) Caspases: enemies within. Science ;281: 1312-1316. 
[15] Pop C, Salvesen GS (2009) Human caspases: activation, specificity, and regulation. 
J.Biol.Chem.284: 21777-21781. 
[16] Kumar S (2007) Caspase function in programmed cell death. Cell Death.Differ.14: 32-43. 
[17] Blank M, Shiloh Y (2007) Programs for cell death: apoptosis is only one way to go. Cell 
Cycle ;6: 686-695. 
[18] Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem.J.326 ( Pt 1): 1-16. 
[19] Tenev T, Zachariou A, Wilson R, Ditzel M, Meier P (2005) IAPs are functionally non-
equivalent and regulate effector caspases through distinct mechanisms. Nat.Cell Biol.7: 
70-77. 
 
Cell Death and Cancer, Novel Therapeutic Strategies 
 
99 
[20] Huang H, Joazeiro CA, Bonfoco E, Kamada S, Leverson JD, Hunter T (2000) The 
inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in 
vitro monoubiquitination of caspases 3 and 7. J.Biol.Chem.275: 26661-26664. 
[21] Suzuki Y, Nakabayashi Y, Takahashi R (2001) Ubiquitin-protein ligase activity of X-
linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 
and enhances its anti-apoptotic effect in Fas-induced cell death. 
Proc.Natl.Acad.Sci.U.S.A ;98: 8662-8667. 
[22] Yang QH, Church-Hajduk R, Ren J, Newton ML, Du C (2003) Omi/HtrA2 catalytic 
cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates 
caspase activity in apoptosis. Genes Dev.17: 1487-1496. 
[23] Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell ;116: 205-219. 
[24] Meier P, Vousden KH (2007) Lucifer's labyrinth--ten years of path finding in cell death. 
Mol.Cell ;28: 746-754. 
[25] Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, et al. (2007) The 
CD95 receptor: apoptosis revisited. Cell ;129: 447-450. 
[26] Lavrik I, Golks A, Krammer PH (2005) Death receptor signaling. J.Cell Sci.118: 265-267. 
[27] Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 
;305: 626-629. 
[28] Tait SW, Green DR (2010) Mitochondria and cell death: outer membrane 
permeabilization and beyond. Nat.Rev.Mol.Cell Biol.11: 621-632. 
[29] Luo X, Budihardjo I, Zou H, Slaughter C, Wang X (1998) Bid, a Bcl2 interacting protein, 
mediates cytochrome c release from mitochondria in response to activation of cell 
surface death receptors. Cell ;94: 481-490. 
[30] Chinnaiyan AM, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S, et al. 
(1996) FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis 
factor receptor-induced apoptosis. J.Biol.Chem.271: 4961-4965. 
[31] Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-
induced serum factor that causes necrosis of tumors. Proc.Natl.Acad.Sci.U.S.A ;72: 3666-
3670. 
[32] Schievella AR, Chen JH, Graham JR, Lin LL (1997) MADD, a novel death domain 
protein that interacts with the type 1 tumor necrosis factor receptor and activates 
mitogen-activated protein kinase. J.Biol.Chem.272: 12069-12075. 
[33] Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, et al. (1997) Prevention of apoptosis 
by Bcl-2: release of cytochrome c from mitochondria blocked. Science ;275: 1129-1132. 
[34] Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G (2010) Molecular 
mechanisms of necroptosis: an ordered cellular explosion. Nat.Rev.Mol.Cell Biol.11: 
700-714. 
[35] Galluzzi L, Zamzami N, de La Motte RT, Lemaire C, Brenner C, Kroemer G (2007) 
Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. 
Apoptosis.12: 803-813. 
[36] Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and 
therapy. Oncogene ;26: 1324-1337. 
 
Apoptosis and Medicine 
 
100 
[37] Bidere N, Lorenzo HK, Carmona S, Laforge M, Harper F, Dumont C, et al. (2003) 
Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor 
(AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. 
J.Biol.Chem.278: 31401-31411. 
[38] Cirman T, Oresic K, Mazovec GD, Turk V, Reed JC, Myers RM, et al. (2004) Selective 
disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by 
multiple papain-like lysosomal cathepsins. J.Biol.Chem.279: 3578-3587. 
[39] Thomas DA, Scorrano L, Putcha GV, Korsmeyer SJ, Ley TJ (2001) Granzyme B can cause 
mitochondrial depolarization and cell death in the absence of BID, BAX, and BAK. 
Proc.Natl.Acad.Sci.U.S.A ;98: 14985-14990. 
[40] Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. (1997) Akt phosphorylation 
of BAD couples survival signals to the cell-intrinsic death machinery. Cell ;91: 231-241. 
[41] Donovan M, Cotter TG (2004) Control of mitochondrial integrity by Bcl-2 family 
members and caspase-independent cell death. Biochim.Biophys.Acta ;1644: 133-147. 
[42] Belizario JE, Alves J, Occhiucci JM, Garay-Malpartida M, Sesso A (2007) A mechanistic 
view of mitochondrial death decision pores. Braz.J.Med.Biol.Res.40: 1011-1024. 
[43] Szabadkai G, Rizzuto R (2004) Participation of endoplasmic reticulum and 
mitochondrial calcium handling in apoptosis: more than just neighborhood? FEBS 
Lett.567: 111-115. 
[44] Thomenius MJ, Wang NS, Reineks EZ, Wang Z, Distelhorst CW (2003) Bcl-2 on the 
endoplasmic reticulum regulates Bax activity by binding to BH3-only proteins. 
J.Biol.Chem.278: 6243-6250. 
[45] Liu X, Kim CN, Yang J, Jemmerson R, Wang X (1996) Induction of apoptotic program in 
cell-free extracts: requirement for dATP and cytochrome c. Cell ;86: 147-157. 
[46] Wang D, Liang J, Zhang Y, Gui B, Wang F, Yi X, et al. (2012) Steroid Receptor 
Coactivator-interacting Protein (SIP) Inhibits Caspase-independent Apoptosis by 
Preventing Apoptosis-inducing Factor (AIF) from Being Released from Mitochondria. 
J.Biol.Chem.287: 12612-12621. 
[47] Norberg E, Gogvadze V, Ott M, Horn M, Uhlen P, Orrenius S, et al. (2008) An increase 
in intracellular Ca2+ is required for the activation of mitochondrial calpain to release 
AIF during cell death. Cell Death.Differ.15: 1857-1864. 
[48] Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, et al. (2002) 
Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-
inducing factor. Science ;297: 259-263. 
[49] Trencia A, Fiory F, Maitan MA, Vito P, Barbagallo AP, Perfetti A, et al. (2004) 
Omi/HtrA2 promotes cell death by binding and degrading the anti-apoptotic protein 
ped/pea-15. J.Biol.Chem.279: 46566-46572. 
[50] Cilenti L, Soundarapandian MM, Kyriazis GA, Stratico V, Singh S, Gupta S, et al. (2004) 
Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death. 
J.Biol.Chem.279: 50295-50301. 
[51] Vande WL, Wirawan E, Lamkanfi M, Festjens N, Verspurten J, Saelens X, et al. (2010) 
The mitochondrial serine protease HtrA2/Omi cleaves RIP1 during apoptosis of Ba/F3 
cells induced by growth factor withdrawal. Cell Res.20: 421-433. 
 
Cell Death and Cancer, Novel Therapeutic Strategies 
 
101 
[52] Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat.Rev.Cancer ;2: 
594-604. 
[53] Berube C, Boucher LM, Ma W, Wakeham A, Salmena L, Hakem R, et al. (2005) 
Apoptosis caused by p53-induced protein with death domain (PIDD) depends on the 
death adapter protein RAIDD. Proc.Natl.Acad.Sci.U.S.A ;102: 14314-14320. 
[54] Janssens S, Tinel A (2012) The PIDDosome, DNA-damage-induced apoptosis and 
beyond. Cell Death.Differ.19: 13-20. 
[55] Bouchier-Hayes L, Lartigue L, Newmeyer DD (2005) Mitochondria: pharmacological 
manipulation of cell death. J.Clin.Invest ;115: 2640-2647. 
[56] Yu Q (2006) Restoring p53-mediated apoptosis in cancer cells: new opportunities for 
cancer therapy. Drug Resist.Updat.9: 19-25. 
[57] Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, Jope RS (2003) Glycogen synthase 
kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J.Biol.Chem.278: 
48872-48879. 
[58] Kim I, Xu W, Reed JC (2008) Cell death and endoplasmic reticulum stress: disease 
relevance and therapeutic opportunities. Nat.Rev.Drug Discov.7: 1013-1030. 
[59] Hoyer-Hansen M, Jaattela M (2007) Connecting endoplasmic reticulum stress to 
autophagy by unfolded protein response and calcium. Cell Death.Differ.14: 1576-1582. 
[60] Nakagawa T, Yuan J (2000) Cross-talk between two cysteine protease families. 
Activation of caspase-12 by calpain in apoptosis. J.Cell Biol.150: 887-894. 
[61] Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y (2002) An 
endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-
independent activation of caspase-9 by caspase-12. J.Biol.Chem.277: 34287-34294. 
[62] Rao RV, Castro-Obregon S, Frankowski H, Schuler M, Stoka V, del RG, et al. (2002) 
Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-
independent intrinsic pathway. J.Biol.Chem.277: 21836-21842. 
[63] Jimbo A, Fujita E, Kouroku Y, Ohnishi J, Inohara N, Kuida K, et al. (2003) ER stress 
induces caspase-8 activation, stimulating cytochrome c release and caspase-9 activation. 
Exp.Cell Res.283: 156-166. 
[64] Fehrenbacher N, Jaattela M (2005) Lysosomes as targets for cancer therapy. Cancer 
Res.65: 2993-2995. 
[65] Deacon EM, Pongracz J, Griffiths G, Lord JM (1997) Isoenzymes of protein kinase C: 
differential involvement in apoptosis and pathogenesis. Mol.Pathol.50: 124-131. 
[66] Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q, et al. (2000) 
Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response 
to DNA damage. J.Biol.Chem.275: 322-327. 
[67] Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB (1999) NF-kappaB 
activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 
;401: 82-85. 
[68] Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces 
apoptosis. J.Cell Biol.124: 619-626. 
[69] Gourlay CW, Ayscough KR (2005) The actin cytoskeleton: a key regulator of apoptosis 
and ageing? Nat.Rev.Mol.Cell Biol.6: 583-589. 
 
Apoptosis and Medicine 
 
100 
[37] Bidere N, Lorenzo HK, Carmona S, Laforge M, Harper F, Dumont C, et al. (2003) 
Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor 
(AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. 
J.Biol.Chem.278: 31401-31411. 
[38] Cirman T, Oresic K, Mazovec GD, Turk V, Reed JC, Myers RM, et al. (2004) Selective 
disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by 
multiple papain-like lysosomal cathepsins. J.Biol.Chem.279: 3578-3587. 
[39] Thomas DA, Scorrano L, Putcha GV, Korsmeyer SJ, Ley TJ (2001) Granzyme B can cause 
mitochondrial depolarization and cell death in the absence of BID, BAX, and BAK. 
Proc.Natl.Acad.Sci.U.S.A ;98: 14985-14990. 
[40] Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. (1997) Akt phosphorylation 
of BAD couples survival signals to the cell-intrinsic death machinery. Cell ;91: 231-241. 
[41] Donovan M, Cotter TG (2004) Control of mitochondrial integrity by Bcl-2 family 
members and caspase-independent cell death. Biochim.Biophys.Acta ;1644: 133-147. 
[42] Belizario JE, Alves J, Occhiucci JM, Garay-Malpartida M, Sesso A (2007) A mechanistic 
view of mitochondrial death decision pores. Braz.J.Med.Biol.Res.40: 1011-1024. 
[43] Szabadkai G, Rizzuto R (2004) Participation of endoplasmic reticulum and 
mitochondrial calcium handling in apoptosis: more than just neighborhood? FEBS 
Lett.567: 111-115. 
[44] Thomenius MJ, Wang NS, Reineks EZ, Wang Z, Distelhorst CW (2003) Bcl-2 on the 
endoplasmic reticulum regulates Bax activity by binding to BH3-only proteins. 
J.Biol.Chem.278: 6243-6250. 
[45] Liu X, Kim CN, Yang J, Jemmerson R, Wang X (1996) Induction of apoptotic program in 
cell-free extracts: requirement for dATP and cytochrome c. Cell ;86: 147-157. 
[46] Wang D, Liang J, Zhang Y, Gui B, Wang F, Yi X, et al. (2012) Steroid Receptor 
Coactivator-interacting Protein (SIP) Inhibits Caspase-independent Apoptosis by 
Preventing Apoptosis-inducing Factor (AIF) from Being Released from Mitochondria. 
J.Biol.Chem.287: 12612-12621. 
[47] Norberg E, Gogvadze V, Ott M, Horn M, Uhlen P, Orrenius S, et al. (2008) An increase 
in intracellular Ca2+ is required for the activation of mitochondrial calpain to release 
AIF during cell death. Cell Death.Differ.15: 1857-1864. 
[48] Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, et al. (2002) 
Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-
inducing factor. Science ;297: 259-263. 
[49] Trencia A, Fiory F, Maitan MA, Vito P, Barbagallo AP, Perfetti A, et al. (2004) 
Omi/HtrA2 promotes cell death by binding and degrading the anti-apoptotic protein 
ped/pea-15. J.Biol.Chem.279: 46566-46572. 
[50] Cilenti L, Soundarapandian MM, Kyriazis GA, Stratico V, Singh S, Gupta S, et al. (2004) 
Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death. 
J.Biol.Chem.279: 50295-50301. 
[51] Vande WL, Wirawan E, Lamkanfi M, Festjens N, Verspurten J, Saelens X, et al. (2010) 
The mitochondrial serine protease HtrA2/Omi cleaves RIP1 during apoptosis of Ba/F3 
cells induced by growth factor withdrawal. Cell Res.20: 421-433. 
 
Cell Death and Cancer, Novel Therapeutic Strategies 
 
101 
[52] Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat.Rev.Cancer ;2: 
594-604. 
[53] Berube C, Boucher LM, Ma W, Wakeham A, Salmena L, Hakem R, et al. (2005) 
Apoptosis caused by p53-induced protein with death domain (PIDD) depends on the 
death adapter protein RAIDD. Proc.Natl.Acad.Sci.U.S.A ;102: 14314-14320. 
[54] Janssens S, Tinel A (2012) The PIDDosome, DNA-damage-induced apoptosis and 
beyond. Cell Death.Differ.19: 13-20. 
[55] Bouchier-Hayes L, Lartigue L, Newmeyer DD (2005) Mitochondria: pharmacological 
manipulation of cell death. J.Clin.Invest ;115: 2640-2647. 
[56] Yu Q (2006) Restoring p53-mediated apoptosis in cancer cells: new opportunities for 
cancer therapy. Drug Resist.Updat.9: 19-25. 
[57] Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, Jope RS (2003) Glycogen synthase 
kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J.Biol.Chem.278: 
48872-48879. 
[58] Kim I, Xu W, Reed JC (2008) Cell death and endoplasmic reticulum stress: disease 
relevance and therapeutic opportunities. Nat.Rev.Drug Discov.7: 1013-1030. 
[59] Hoyer-Hansen M, Jaattela M (2007) Connecting endoplasmic reticulum stress to 
autophagy by unfolded protein response and calcium. Cell Death.Differ.14: 1576-1582. 
[60] Nakagawa T, Yuan J (2000) Cross-talk between two cysteine protease families. 
Activation of caspase-12 by calpain in apoptosis. J.Cell Biol.150: 887-894. 
[61] Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y (2002) An 
endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-
independent activation of caspase-9 by caspase-12. J.Biol.Chem.277: 34287-34294. 
[62] Rao RV, Castro-Obregon S, Frankowski H, Schuler M, Stoka V, del RG, et al. (2002) 
Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-
independent intrinsic pathway. J.Biol.Chem.277: 21836-21842. 
[63] Jimbo A, Fujita E, Kouroku Y, Ohnishi J, Inohara N, Kuida K, et al. (2003) ER stress 
induces caspase-8 activation, stimulating cytochrome c release and caspase-9 activation. 
Exp.Cell Res.283: 156-166. 
[64] Fehrenbacher N, Jaattela M (2005) Lysosomes as targets for cancer therapy. Cancer 
Res.65: 2993-2995. 
[65] Deacon EM, Pongracz J, Griffiths G, Lord JM (1997) Isoenzymes of protein kinase C: 
differential involvement in apoptosis and pathogenesis. Mol.Pathol.50: 124-131. 
[66] Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q, et al. (2000) 
Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response 
to DNA damage. J.Biol.Chem.275: 322-327. 
[67] Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB (1999) NF-kappaB 
activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 
;401: 82-85. 
[68] Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces 
apoptosis. J.Cell Biol.124: 619-626. 
[69] Gourlay CW, Ayscough KR (2005) The actin cytoskeleton: a key regulator of apoptosis 
and ageing? Nat.Rev.Mol.Cell Biol.6: 583-589. 
 
Apoptosis and Medicine 
 
102 
[70] Day CL, Puthalakath H, Skea G, Strasser A, Barsukov I, Lian LY, et al. (2004) 
Localization of dynein light chains 1 and 2 and their pro-apoptotic ligands. 
Biochem.J.377: 597-605. 
[71] Kusano H, Shimizu S, Koya RC, Fujita H, Kamada S, Kuzumaki N, et al. (2000) Human 
gelsolin prevents apoptosis by inhibiting apoptotic mitochondrial changes via closing 
VDAC. Oncogene ;19: 4807-4814. 
[72] Tang HL, Le AH, Lung HL (2006) The increase in mitochondrial association with actin 
precedes Bax translocation in apoptosis. Biochem.J.396: 1-5. 
[73] Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG (1993) Specific 
proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of 
chemotherapy-induced apoptosis. Cancer Res.53: 3976-3985. 
[74] Oliver FJ, Menissier-de MJ, de MG (1999) Poly(ADP-ribose) polymerase in the cellular 
response to DNA damage, apoptosis, and disease. Am.J.Hum.Genet.64: 1282-1288. 
[75] Guillouf C, Wang TS, Liu J, Walsh CE, Poirier GG, Moustacchi E, et al. (1999) Fanconi 
anemia C protein acts at a switch between apoptosis and necrosis in mitomycin C-
induced cell death. Exp.Cell Res.246: 384-394. 
[76] Munoz-Gamez JA, Rodriguez-Vargas JM, Quiles-Perez R, Aguilar-Quesada R, Martin-
Oliva D, de MG, et al. (2009) PARP-1 is involved in autophagy induced by DNA 
damage. Autophagy.5: 61-74. 
[77] Wang Y, Dawson VL, Dawson TM (2009) Poly(ADP-ribose) signals to mitochondrial 
AIF: a key event in parthanatos. Exp.Neurol.218: 193-202. 
[78] Long JS, Ryan KM (2012) New frontiers in promoting tumour cell death: targeting 
apoptosis, necroptosis and autophagy. Oncogene . 
[79] Klionsky DJ (2007) Autophagy: from phenomenology to molecular understanding in 
less than a decade. Nat.Rev.Mol.Cell Biol.8: 931-937. 
[80] Nakatogawa H, Suzuki K, Kamada Y, Ohsumi Y (2009) Dynamics and diversity in 
autophagy mechanisms: lessons from yeast. Nat.Rev.Mol.Cell Biol.10: 458-467. 
[81] Tanida I, Ueno T, Kominami E (2004) LC3 conjugation system in mammalian 
autophagy. Int.J.Biochem.Cell Biol.36: 2503-2518. 
[82] Mijaljica D, Prescott M, Devenish RJ (2011) Microautophagy in mammalian cells: 
revisiting a 40-year-old conundrum. Autophagy.7: 673-682. 
[83] Majeski AE, Dice JF (2004) Mechanisms of chaperone-mediated autophagy. 
Int.J.Biochem.Cell Biol.36: 2435-2444. 
[84] Tanida I (2011) Autophagosome formation and molecular mechanism of autophagy. 
Antioxid.Redox.Signal.14: 2201-2214. 
[85] Yen WL, Klionsky DJ (2008) How to live long and prosper: autophagy, mitochondria, 
and aging. Physiology.(Bethesda.) ;23: 248-262. 
[86] Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G (2004) Cell 
death by mitotic catastrophe: a molecular definition. Oncogene ;23: 2825-2837. 
[87] Niikura Y, Dixit A, Scott R, Perkins G, Kitagawa K (2007) BUB1 mediation of caspase-
independent mitotic death determines cell fate. J.Cell Biol.178: 283-296. 
[88] Vitale I, Galluzzi L, Castedo M, Kroemer G (2011) Mitotic catastrophe: a mechanism for 
avoiding genomic instability. Nat.Rev.Mol.Cell Biol.12: 385-392. 
 
Cell Death and Cancer, Novel Therapeutic Strategies 
 
103 
[89] Vanlangenakker N, Vanden Berghe T, Vandenabeele P (2012) Many stimuli pull the 
necrotic trigger, an overview. Cell Death.Differ.19: 75-86. 
[90] Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, et al. (2011) 
cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell 
death complex differentially regulated by cFLIP isoforms. Mol.Cell ;43: 449-463. 
[91] Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, et al. (2011) The 
Ripoptosome, a signaling platform that assembles in response to genotoxic stress and 
loss of IAPs. Mol.Cell ;43: 432-448. 
[92] Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, et al. (2009) 
Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed 
necrosis and virus-induced inflammation. Cell ;137: 1112-1123. 
[93] Dunai Z, Bauer PI, Mihalik R (2011) Necroptosis: biochemical, physiological and 
pathological aspects. Pathol.Oncol.Res.17: 791-800. 
[94] Martinez-Lacaci I, Garcia MP, Soto JL, Saceda M (2007) Tumour cells resistance in 
cancer therapy. Clin.Transl.Oncol.9: 13-20. 
[95] Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell ;100: 57-70. 
[96] Hersey P, Zhang XD (2003) Overcoming resistance of cancer cells to apoptosis. J.Cell 
Physiol ;196: 9-18. 
[97] Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an 
inner mitochondrial membrane protein that blocks programmed cell death. Nature ;348: 
334-336. 
[98] Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM (1984) Cloning of the 
chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome 
translocation. Science ;226: 1097-1099. 
[99] Vaux DL, Cory S, Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival and 
cooperates with c-myc to immortalize pre-B cells. Nature ;335: 440-442. 
[100] Strasser A, Harris AW, Bath ML, Cory S (1990) Novel primitive lymphoid tumours 
induced in transgenic mice by cooperation between myc and bcl-2. Nature ;348: 331-333. 
[101] Strasser A, Cory S, Adams JM (2011) Deciphering the rules of programmed cell death 
to improve therapy of cancer and other diseases. EMBO J.30: 3667-3683. 
[102] Plati J, Bucur O, Khosravi-Far R (2011) Apoptotic cell signaling in cancer progression 
and therapy. Integr.Biol.(Camb.) ;3: 279-296. 
[103] Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. (1997) Somatic 
frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator 
phenotype. Science ;275: 967-969. 
[104] Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A, et al. (2005) Genome-wide 
array-based CGH for mantle cell lymphoma: identification of homozygous deletions of 
the proapoptotic gene BIM. Oncogene ;24: 1348-1358. 
[105] Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. (2010) 
The landscape of somatic copy-number alteration across human cancers. Nature ;463: 
899-905. 
 
Apoptosis and Medicine 
 
102 
[70] Day CL, Puthalakath H, Skea G, Strasser A, Barsukov I, Lian LY, et al. (2004) 
Localization of dynein light chains 1 and 2 and their pro-apoptotic ligands. 
Biochem.J.377: 597-605. 
[71] Kusano H, Shimizu S, Koya RC, Fujita H, Kamada S, Kuzumaki N, et al. (2000) Human 
gelsolin prevents apoptosis by inhibiting apoptotic mitochondrial changes via closing 
VDAC. Oncogene ;19: 4807-4814. 
[72] Tang HL, Le AH, Lung HL (2006) The increase in mitochondrial association with actin 
precedes Bax translocation in apoptosis. Biochem.J.396: 1-5. 
[73] Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG (1993) Specific 
proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of 
chemotherapy-induced apoptosis. Cancer Res.53: 3976-3985. 
[74] Oliver FJ, Menissier-de MJ, de MG (1999) Poly(ADP-ribose) polymerase in the cellular 
response to DNA damage, apoptosis, and disease. Am.J.Hum.Genet.64: 1282-1288. 
[75] Guillouf C, Wang TS, Liu J, Walsh CE, Poirier GG, Moustacchi E, et al. (1999) Fanconi 
anemia C protein acts at a switch between apoptosis and necrosis in mitomycin C-
induced cell death. Exp.Cell Res.246: 384-394. 
[76] Munoz-Gamez JA, Rodriguez-Vargas JM, Quiles-Perez R, Aguilar-Quesada R, Martin-
Oliva D, de MG, et al. (2009) PARP-1 is involved in autophagy induced by DNA 
damage. Autophagy.5: 61-74. 
[77] Wang Y, Dawson VL, Dawson TM (2009) Poly(ADP-ribose) signals to mitochondrial 
AIF: a key event in parthanatos. Exp.Neurol.218: 193-202. 
[78] Long JS, Ryan KM (2012) New frontiers in promoting tumour cell death: targeting 
apoptosis, necroptosis and autophagy. Oncogene . 
[79] Klionsky DJ (2007) Autophagy: from phenomenology to molecular understanding in 
less than a decade. Nat.Rev.Mol.Cell Biol.8: 931-937. 
[80] Nakatogawa H, Suzuki K, Kamada Y, Ohsumi Y (2009) Dynamics and diversity in 
autophagy mechanisms: lessons from yeast. Nat.Rev.Mol.Cell Biol.10: 458-467. 
[81] Tanida I, Ueno T, Kominami E (2004) LC3 conjugation system in mammalian 
autophagy. Int.J.Biochem.Cell Biol.36: 2503-2518. 
[82] Mijaljica D, Prescott M, Devenish RJ (2011) Microautophagy in mammalian cells: 
revisiting a 40-year-old conundrum. Autophagy.7: 673-682. 
[83] Majeski AE, Dice JF (2004) Mechanisms of chaperone-mediated autophagy. 
Int.J.Biochem.Cell Biol.36: 2435-2444. 
[84] Tanida I (2011) Autophagosome formation and molecular mechanism of autophagy. 
Antioxid.Redox.Signal.14: 2201-2214. 
[85] Yen WL, Klionsky DJ (2008) How to live long and prosper: autophagy, mitochondria, 
and aging. Physiology.(Bethesda.) ;23: 248-262. 
[86] Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G (2004) Cell 
death by mitotic catastrophe: a molecular definition. Oncogene ;23: 2825-2837. 
[87] Niikura Y, Dixit A, Scott R, Perkins G, Kitagawa K (2007) BUB1 mediation of caspase-
independent mitotic death determines cell fate. J.Cell Biol.178: 283-296. 
[88] Vitale I, Galluzzi L, Castedo M, Kroemer G (2011) Mitotic catastrophe: a mechanism for 
avoiding genomic instability. Nat.Rev.Mol.Cell Biol.12: 385-392. 
 
Cell Death and Cancer, Novel Therapeutic Strategies 
 
103 
[89] Vanlangenakker N, Vanden Berghe T, Vandenabeele P (2012) Many stimuli pull the 
necrotic trigger, an overview. Cell Death.Differ.19: 75-86. 
[90] Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, et al. (2011) 
cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell 
death complex differentially regulated by cFLIP isoforms. Mol.Cell ;43: 449-463. 
[91] Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, et al. (2011) The 
Ripoptosome, a signaling platform that assembles in response to genotoxic stress and 
loss of IAPs. Mol.Cell ;43: 432-448. 
[92] Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, et al. (2009) 
Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed 
necrosis and virus-induced inflammation. Cell ;137: 1112-1123. 
[93] Dunai Z, Bauer PI, Mihalik R (2011) Necroptosis: biochemical, physiological and 
pathological aspects. Pathol.Oncol.Res.17: 791-800. 
[94] Martinez-Lacaci I, Garcia MP, Soto JL, Saceda M (2007) Tumour cells resistance in 
cancer therapy. Clin.Transl.Oncol.9: 13-20. 
[95] Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell ;100: 57-70. 
[96] Hersey P, Zhang XD (2003) Overcoming resistance of cancer cells to apoptosis. J.Cell 
Physiol ;196: 9-18. 
[97] Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an 
inner mitochondrial membrane protein that blocks programmed cell death. Nature ;348: 
334-336. 
[98] Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM (1984) Cloning of the 
chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome 
translocation. Science ;226: 1097-1099. 
[99] Vaux DL, Cory S, Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival and 
cooperates with c-myc to immortalize pre-B cells. Nature ;335: 440-442. 
[100] Strasser A, Harris AW, Bath ML, Cory S (1990) Novel primitive lymphoid tumours 
induced in transgenic mice by cooperation between myc and bcl-2. Nature ;348: 331-333. 
[101] Strasser A, Cory S, Adams JM (2011) Deciphering the rules of programmed cell death 
to improve therapy of cancer and other diseases. EMBO J.30: 3667-3683. 
[102] Plati J, Bucur O, Khosravi-Far R (2011) Apoptotic cell signaling in cancer progression 
and therapy. Integr.Biol.(Camb.) ;3: 279-296. 
[103] Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. (1997) Somatic 
frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator 
phenotype. Science ;275: 967-969. 
[104] Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A, et al. (2005) Genome-wide 
array-based CGH for mantle cell lymphoma: identification of homozygous deletions of 
the proapoptotic gene BIM. Oncogene ;24: 1348-1358. 
[105] Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. (2010) 
The landscape of somatic copy-number alteration across human cancers. Nature ;463: 
899-905. 
 
Apoptosis and Medicine 
 
104 
[106] Garrison SP, Jeffers JR, Yang C, Nilsson JA, Hall MA, Rehg JE, et al. (2008) Selection 
against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol.Cell 
Biol.28: 5391-5402. 
[107] Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X, et al. (2010) 
Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in 
Burkitt lymphoma. Blood ;116: 2531-2542. 
[108] Kashkar H (2010) X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow 
promise. Clin.Cancer Res.16: 4496-4502. 
[109] Kaufmann T, Strasser A, Jost PJ (2012) Fas death receptor signalling: roles of Bid and 
XIAP. Cell Death.Differ.19: 42-50. 
[110] Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008) Survivin: key regulator of mitosis 
and apoptosis and novel target for cancer therapeutics. Clin.Cancer Res.14: 5000-5005. 
[111] Reichert S, Rodel C, Mirsch J, Harter PN, Tomicic MT, Mittelbronn M, et al. (2011) 
Survivin inhibition and DNA double-strand break repair: a molecular mechanism to 
overcome radioresistance in glioblastoma. Radiother.Oncol.101: 51-58. 
[112] Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, et al. (2000) 
High expression of Survivin, mapped to 17q25, is significantly associated with poor 
prognostic factors and promotes cell survival in human neuroblastoma. Oncogene ;19: 
617-623. 
[113] Hattori M, Sakamoto H, Satoh K, Yamamoto T (2001) DNA demethylase is expressed 
in ovarian cancers and the expression correlates with demethylation of CpG sites in the 
promoter region of c-erbB-2 and survivin genes. Cancer Lett.169: 155-164. 
[114] Li F, Altieri DC (1999) The cancer antiapoptosis mouse survivin gene: characterization 
of locus and transcriptional requirements of basal and cell cycle-dependent expression. 
Cancer Res.59: 3143-3151. 
[115] Mesri M, Morales-Ruiz M, Ackermann EJ, Bennett CF, Pober JS, Sessa WC, et al. (2001) 
Suppression of vascular endothelial growth factor-mediated endothelial cell protection 
by survivin targeting. Am.J.Pathol.158: 1757-1765. 
[116] Zaffaroni N, Daidone MG (2002) Survivin expression and resistance to anticancer 
treatments: perspectives for new therapeutic interventions. Drug Resist.Updat.5: 65-72. 
[117] Rufini A, Melino G (2011) Cell death pathology: the war against cancer. 
Biochem.Biophys.Res.Commun.414: 445-450. 
[118] Li G, Ho VC (1998) p53-dependent DNA repair and apoptosis respond differently to 
high- and low-dose ultraviolet radiation. Br.J.Dermatol.139: 3-10. 
[119] Gabrielli B, Brooks K, Pavey S (2012) Defective cell cycle checkpoints as targets for 
anti-cancer therapies. Front Pharmacol.3: 9. 
[120] Roos WP, Kaina B (2012) DNA damage-induced apoptosis: From specific DNA lesions 
to the DNA damage response and apoptosis. Cancer Lett. 
[121] Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell ;144: 
646-674. 
[122] Hers I, Vincent EE, Tavare JM (2011) Akt signalling in health and disease. Cell 
Signal.23: 1515-1527. 
 
Cell Death and Cancer, Novel Therapeutic Strategies 
 
105 
[123] Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex. Science ;307: 1098-1101. 
[124] Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase 
pathway in cancer. Nat.Rev.Drug Discov.8: 627-644. 
[125] Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in 
human cancer. Nat.Rev.Cancer ;2: 489-501. 
[126] Haddad JJ, Abdel-Karim NE (2011) NF-kappaB cellular and molecular regulatory 
mechanisms and pathways: therapeutic pattern or pseudoregulation? Cell 
Immunol.271: 5-14. 
[127] Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, et al. (2012) Gene 
alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance 
(review). Int.J.Oncol.40: 639-644. 
[128] Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G (2008) The 
anticancer immune response: indispensable for therapeutic success? J.Clin.Invest ;118: 
1991-2001. 
[129] Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, et al. (2012) 
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic 
cancer cell death. EMBO J.31: 1062-1079. 
[130] Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, et al. (2008) 
Molecular characteristics of immunogenic cancer cell death. Cell Death.Differ.15: 3-12. 
[131] Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et 
al. (2010) Calreticulin is the dominant pro-phagocytic signal on multiple human cancers 
and is counterbalanced by CD47. Sci.Transl.Med.2: 63ra94. 
[132] Chao MP, Weissman IL, Majeti R (2012) The CD47-SIRPalpha pathway in cancer 
immune evasion and potential therapeutic implications. Curr.Opin.Immunol.24: 225-
232. 
[133] Leontieva OV, Gudkov AV, Blagosklonny MV (2010) Weak p53 permits senescence 
during cell cycle arrest. Cell Cycle ;9: 4323-4327. 
[134] Rodier F, Campisi J (2011) Four faces of cellular senescence. J.Cell Biol.192: 547-556. 
[135] Schmitt CA (2007) Cellular senescence and cancer treatment. Biochim.Biophys.Acta 
;1775: 5-20. 
[136] Fimia GM, Stoykova A, Romagnoli A, Giunta L, Di BS, Nardacci R, et al. (2007) 
Ambra1 regulates autophagy and development of the nervous system. Nature ;447: 
1121-1125. 
[137] Liang C, Feng P, Ku B, Dotan I, Canaani D, Oh BH, et al. (2006) Autophagic and 
tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat.Cell Biol.8: 
688-699. 
[138] Mehrpour M, Esclatine A, Beau I, Codogno P (2010) Overview of macroautophagy 
regulation in mammalian cells. Cell Res.20: 748-762. 
[139] Ku B, Woo JS, Liang C, Lee KH, Jung JU, Oh BH (2008) An insight into the mechanistic 
role of Beclin 1 and its inhibition by prosurvival Bcl-2 family proteins. Autophagy.4: 
519-520. 
 
Apoptosis and Medicine 
 
104 
[106] Garrison SP, Jeffers JR, Yang C, Nilsson JA, Hall MA, Rehg JE, et al. (2008) Selection 
against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol.Cell 
Biol.28: 5391-5402. 
[107] Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X, et al. (2010) 
Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in 
Burkitt lymphoma. Blood ;116: 2531-2542. 
[108] Kashkar H (2010) X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow 
promise. Clin.Cancer Res.16: 4496-4502. 
[109] Kaufmann T, Strasser A, Jost PJ (2012) Fas death receptor signalling: roles of Bid and 
XIAP. Cell Death.Differ.19: 42-50. 
[110] Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008) Survivin: key regulator of mitosis 
and apoptosis and novel target for cancer therapeutics. Clin.Cancer Res.14: 5000-5005. 
[111] Reichert S, Rodel C, Mirsch J, Harter PN, Tomicic MT, Mittelbronn M, et al. (2011) 
Survivin inhibition and DNA double-strand break repair: a molecular mechanism to 
overcome radioresistance in glioblastoma. Radiother.Oncol.101: 51-58. 
[112] Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, et al. (2000) 
High expression of Survivin, mapped to 17q25, is significantly associated with poor 
prognostic factors and promotes cell survival in human neuroblastoma. Oncogene ;19: 
617-623. 
[113] Hattori M, Sakamoto H, Satoh K, Yamamoto T (2001) DNA demethylase is expressed 
in ovarian cancers and the expression correlates with demethylation of CpG sites in the 
promoter region of c-erbB-2 and survivin genes. Cancer Lett.169: 155-164. 
[114] Li F, Altieri DC (1999) The cancer antiapoptosis mouse survivin gene: characterization 
of locus and transcriptional requirements of basal and cell cycle-dependent expression. 
Cancer Res.59: 3143-3151. 
[115] Mesri M, Morales-Ruiz M, Ackermann EJ, Bennett CF, Pober JS, Sessa WC, et al. (2001) 
Suppression of vascular endothelial growth factor-mediated endothelial cell protection 
by survivin targeting. Am.J.Pathol.158: 1757-1765. 
[116] Zaffaroni N, Daidone MG (2002) Survivin expression and resistance to anticancer 
treatments: perspectives for new therapeutic interventions. Drug Resist.Updat.5: 65-72. 
[117] Rufini A, Melino G (2011) Cell death pathology: the war against cancer. 
Biochem.Biophys.Res.Commun.414: 445-450. 
[118] Li G, Ho VC (1998) p53-dependent DNA repair and apoptosis respond differently to 
high- and low-dose ultraviolet radiation. Br.J.Dermatol.139: 3-10. 
[119] Gabrielli B, Brooks K, Pavey S (2012) Defective cell cycle checkpoints as targets for 
anti-cancer therapies. Front Pharmacol.3: 9. 
[120] Roos WP, Kaina B (2012) DNA damage-induced apoptosis: From specific DNA lesions 
to the DNA damage response and apoptosis. Cancer Lett. 
[121] Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell ;144: 
646-674. 
[122] Hers I, Vincent EE, Tavare JM (2011) Akt signalling in health and disease. Cell 
Signal.23: 1515-1527. 
 
Cell Death and Cancer, Novel Therapeutic Strategies 
 
105 
[123] Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex. Science ;307: 1098-1101. 
[124] Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase 
pathway in cancer. Nat.Rev.Drug Discov.8: 627-644. 
[125] Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in 
human cancer. Nat.Rev.Cancer ;2: 489-501. 
[126] Haddad JJ, Abdel-Karim NE (2011) NF-kappaB cellular and molecular regulatory 
mechanisms and pathways: therapeutic pattern or pseudoregulation? Cell 
Immunol.271: 5-14. 
[127] Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, et al. (2012) Gene 
alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance 
(review). Int.J.Oncol.40: 639-644. 
[128] Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G (2008) The 
anticancer immune response: indispensable for therapeutic success? J.Clin.Invest ;118: 
1991-2001. 
[129] Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, et al. (2012) 
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic 
cancer cell death. EMBO J.31: 1062-1079. 
[130] Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, et al. (2008) 
Molecular characteristics of immunogenic cancer cell death. Cell Death.Differ.15: 3-12. 
[131] Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et 
al. (2010) Calreticulin is the dominant pro-phagocytic signal on multiple human cancers 
and is counterbalanced by CD47. Sci.Transl.Med.2: 63ra94. 
[132] Chao MP, Weissman IL, Majeti R (2012) The CD47-SIRPalpha pathway in cancer 
immune evasion and potential therapeutic implications. Curr.Opin.Immunol.24: 225-
232. 
[133] Leontieva OV, Gudkov AV, Blagosklonny MV (2010) Weak p53 permits senescence 
during cell cycle arrest. Cell Cycle ;9: 4323-4327. 
[134] Rodier F, Campisi J (2011) Four faces of cellular senescence. J.Cell Biol.192: 547-556. 
[135] Schmitt CA (2007) Cellular senescence and cancer treatment. Biochim.Biophys.Acta 
;1775: 5-20. 
[136] Fimia GM, Stoykova A, Romagnoli A, Giunta L, Di BS, Nardacci R, et al. (2007) 
Ambra1 regulates autophagy and development of the nervous system. Nature ;447: 
1121-1125. 
[137] Liang C, Feng P, Ku B, Dotan I, Canaani D, Oh BH, et al. (2006) Autophagic and 
tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat.Cell Biol.8: 
688-699. 
[138] Mehrpour M, Esclatine A, Beau I, Codogno P (2010) Overview of macroautophagy 
regulation in mammalian cells. Cell Res.20: 748-762. 
[139] Ku B, Woo JS, Liang C, Lee KH, Jung JU, Oh BH (2008) An insight into the mechanistic 
role of Beclin 1 and its inhibition by prosurvival Bcl-2 family proteins. Autophagy.4: 
519-520. 
 
Apoptosis and Medicine 
 
106 
[140] Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. (1999) 
Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature ;402: 672-
676. 
[141] Yue Z, Jin S, Yang C, Levine AJ, Heintz N (2003) Beclin 1, an autophagy gene essential 
for early embryonic development, is a haploinsufficient tumor suppressor. 
Proc.Natl.Acad.Sci.U.S.A ;100: 15077-15082. 
[142] Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, et al. (2003) Promotion of 
tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J.Clin.Invest 
;112: 1809-1820. 
[143] Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T, et al. (2007) Distinct roles 
of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated 
protein kinase and Beclin 1 in mediating autophagy. Circ.Res.100: 914-922. 
[144] Takahashi Y, Coppola D, Matsushita N, Cualing HD, Sun M, Sato Y, et al. (2007) Bif-1 
interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. 
Nat.Cell Biol.9: 1142-1151. 
[145] Ionov Y, Nowak N, Perucho M, Markowitz S, Cowell JK (2004) Manipulation of 
nonsense mediated decay identifies gene mutations in colon cancer Cells with 
microsatellite instability. Oncogene ;23: 639-645. 
[146] Kim MS, Jeong EG, Ahn CH, Kim SS, Lee SH, Yoo NJ (2008) Frameshift mutation of 
UVRAG, an autophagy-related gene, in gastric carcinomas with microsatellite 
instability. Hum.Pathol.39: 1059-1063. 
[147] Bekri S, Adelaide J, Merscher S, Grosgeorge J, Caroli-Bosc F, Perucca-Lostanlen D, et 
al. (1997) Detailed map of a region commonly amplified at 11q13-->q14 in human breast 
carcinoma. Cytogenet.Cell Genet.79: 125-131. 
[148] Lee JW, Jeong EG, Soung YH, Nam SW, Lee JY, Yoo NJ, et al. (2006) Decreased 
expression of tumour suppressor Bax-interacting factor-1 (Bif-1), a Bax activator, in 
gastric carcinomas. Pathology ;38: 312-315. 
[149] Coppola D, Khalil F, Eschrich SA, Boulware D, Yeatman T, Wang HG (2008) Down-
regulation of Bax-interacting factor-1 in colorectal adenocarcinoma. Cancer ;113: 2665-
2670. 
[150] Cuddeback SM, Yamaguchi H, Komatsu K, Miyashita T, Yamada M, Wu C, et al. 
(2001) Molecular cloning and characterization of Bif-1. A novel Src homology 3 domain-
containing protein that associates with Bax. J.Biol.Chem.276: 20559-20565. 
[151] Yang YP, Liang ZQ, Gu ZL, Qin ZH (2005) Molecular mechanism and regulation of 
autophagy. Acta Pharmacol.Sin.26: 1421-1434. 
[152] Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor 
mechanism. Oncogene ;23: 2891-2906. 
[153] Samuels Y, Velculescu VE (2004) Oncogenic mutations of PIK3CA in human cancers. 
Cell Cycle ;3: 1221-1224. 
[154] Saeki K, Yuo A, Okuma E, Yazaki Y, Susin SA, Kroemer G, et al. (2000) Bcl-2 down-
regulation causes autophagy in a caspase-independent manner in human leukemic 
HL60 cells. Cell Death.Differ.7: 1263-1269. 
 
Cell Death and Cancer, Novel Therapeutic Strategies 
 
107 
[155] Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, et al. (2005) Bcl-2 
antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell ;122: 927-939. 
[156] Maiuri MC, Le TG, Criollo A, Rain JC, Gautier F, Juin P, et al. (2007) Functional and 
physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J.26: 
2527-2539. 
[157] Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, et al. (2007) 
Autophagy suppresses tumor progression by limiting chromosomal instability. Genes 
Dev.21: 1367-1381. 
[158] Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G, Mathew R, Jin S, et al. (2007) 
Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. 
Genes Dev.21: 1621-1635. 
[159] Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, et al. 
(2008) Regulation of autophagy by cytoplasmic p53. Nat.Cell Biol.10: 676-687. 
[160] Zong WX, Thompson CB (2006) Necrotic death as a cell fate. Genes Dev.20: 1-15. 
[161] Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation 
in the initiation and promotion of malignant disease. Cancer Cell ;7: 211-217. 
[162] Vakkila J, Lotze MT (2004) Inflammation and necrosis promote tumour growth. 
Nat.Rev.Immunol.4: 641-648. 
[163] Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, et al. (2006) 
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and 
tumorigenesis. Cancer Cell ;10: 51-64. 
[164] Boya P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, et al. 
(2005) Inhibition of macroautophagy triggers apoptosis. Mol.Cell Biol.25: 1025-1040. 
[165] Majmundar AJ, Wong WJ, Simon MC (2010) Hypoxia-inducible factors and the 
response to hypoxic stress. Mol.Cell ;40: 294-309. 
[166] Mazure NM, Pouyssegur J (2010) Hypoxia-induced autophagy: cell death or cell 
survival? Curr.Opin.Cell Biol.22: 177-180. 
[167] Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouyssegur J, et al. (2009) 
Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of 
BNIP3 and BNIP3L via their BH3 domains. Mol.Cell Biol.29: 2570-2581. 
[168] Rabinowitz JD, White E (2010) Autophagy and metabolism. Science ;330: 1344-1348. 
[169] Fung C, Lock R, Gao S, Salas E, Debnath J (2008) Induction of autophagy during 
extracellular matrix detachment promotes cell survival. Mol.Biol.Cell ;19: 797-806. 
[170] Kenific CM, Thorburn A, Debnath J (2010) Autophagy and metastasis: another double-
edged sword. Curr.Opin.Cell Biol.22: 241-245. 
[171] Debnath J (2008) Detachment-induced autophagy during anoikis and lumen formation 
in epithelial acini. Autophagy.4: 351-353. 
[172] Yerbes R, Palacios C, Lopez-Rivas A (2011) The therapeutic potential of TRAIL 
receptor signalling in cancer cells. Clin.Transl.Oncol.13: 839-847. 
[173] Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 
;281: 1305-1308. 
 
Apoptosis and Medicine 
 
106 
[140] Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. (1999) 
Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature ;402: 672-
676. 
[141] Yue Z, Jin S, Yang C, Levine AJ, Heintz N (2003) Beclin 1, an autophagy gene essential 
for early embryonic development, is a haploinsufficient tumor suppressor. 
Proc.Natl.Acad.Sci.U.S.A ;100: 15077-15082. 
[142] Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, et al. (2003) Promotion of 
tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J.Clin.Invest 
;112: 1809-1820. 
[143] Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T, et al. (2007) Distinct roles 
of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated 
protein kinase and Beclin 1 in mediating autophagy. Circ.Res.100: 914-922. 
[144] Takahashi Y, Coppola D, Matsushita N, Cualing HD, Sun M, Sato Y, et al. (2007) Bif-1 
interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. 
Nat.Cell Biol.9: 1142-1151. 
[145] Ionov Y, Nowak N, Perucho M, Markowitz S, Cowell JK (2004) Manipulation of 
nonsense mediated decay identifies gene mutations in colon cancer Cells with 
microsatellite instability. Oncogene ;23: 639-645. 
[146] Kim MS, Jeong EG, Ahn CH, Kim SS, Lee SH, Yoo NJ (2008) Frameshift mutation of 
UVRAG, an autophagy-related gene, in gastric carcinomas with microsatellite 
instability. Hum.Pathol.39: 1059-1063. 
[147] Bekri S, Adelaide J, Merscher S, Grosgeorge J, Caroli-Bosc F, Perucca-Lostanlen D, et 
al. (1997) Detailed map of a region commonly amplified at 11q13-->q14 in human breast 
carcinoma. Cytogenet.Cell Genet.79: 125-131. 
[148] Lee JW, Jeong EG, Soung YH, Nam SW, Lee JY, Yoo NJ, et al. (2006) Decreased 
expression of tumour suppressor Bax-interacting factor-1 (Bif-1), a Bax activator, in 
gastric carcinomas. Pathology ;38: 312-315. 
[149] Coppola D, Khalil F, Eschrich SA, Boulware D, Yeatman T, Wang HG (2008) Down-
regulation of Bax-interacting factor-1 in colorectal adenocarcinoma. Cancer ;113: 2665-
2670. 
[150] Cuddeback SM, Yamaguchi H, Komatsu K, Miyashita T, Yamada M, Wu C, et al. 
(2001) Molecular cloning and characterization of Bif-1. A novel Src homology 3 domain-
containing protein that associates with Bax. J.Biol.Chem.276: 20559-20565. 
[151] Yang YP, Liang ZQ, Gu ZL, Qin ZH (2005) Molecular mechanism and regulation of 
autophagy. Acta Pharmacol.Sin.26: 1421-1434. 
[152] Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor 
mechanism. Oncogene ;23: 2891-2906. 
[153] Samuels Y, Velculescu VE (2004) Oncogenic mutations of PIK3CA in human cancers. 
Cell Cycle ;3: 1221-1224. 
[154] Saeki K, Yuo A, Okuma E, Yazaki Y, Susin SA, Kroemer G, et al. (2000) Bcl-2 down-
regulation causes autophagy in a caspase-independent manner in human leukemic 
HL60 cells. Cell Death.Differ.7: 1263-1269. 
 
Cell Death and Cancer, Novel Therapeutic Strategies 
 
107 
[155] Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, et al. (2005) Bcl-2 
antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell ;122: 927-939. 
[156] Maiuri MC, Le TG, Criollo A, Rain JC, Gautier F, Juin P, et al. (2007) Functional and 
physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J.26: 
2527-2539. 
[157] Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, et al. (2007) 
Autophagy suppresses tumor progression by limiting chromosomal instability. Genes 
Dev.21: 1367-1381. 
[158] Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G, Mathew R, Jin S, et al. (2007) 
Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. 
Genes Dev.21: 1621-1635. 
[159] Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, et al. 
(2008) Regulation of autophagy by cytoplasmic p53. Nat.Cell Biol.10: 676-687. 
[160] Zong WX, Thompson CB (2006) Necrotic death as a cell fate. Genes Dev.20: 1-15. 
[161] Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation 
in the initiation and promotion of malignant disease. Cancer Cell ;7: 211-217. 
[162] Vakkila J, Lotze MT (2004) Inflammation and necrosis promote tumour growth. 
Nat.Rev.Immunol.4: 641-648. 
[163] Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, et al. (2006) 
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and 
tumorigenesis. Cancer Cell ;10: 51-64. 
[164] Boya P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, et al. 
(2005) Inhibition of macroautophagy triggers apoptosis. Mol.Cell Biol.25: 1025-1040. 
[165] Majmundar AJ, Wong WJ, Simon MC (2010) Hypoxia-inducible factors and the 
response to hypoxic stress. Mol.Cell ;40: 294-309. 
[166] Mazure NM, Pouyssegur J (2010) Hypoxia-induced autophagy: cell death or cell 
survival? Curr.Opin.Cell Biol.22: 177-180. 
[167] Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouyssegur J, et al. (2009) 
Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of 
BNIP3 and BNIP3L via their BH3 domains. Mol.Cell Biol.29: 2570-2581. 
[168] Rabinowitz JD, White E (2010) Autophagy and metabolism. Science ;330: 1344-1348. 
[169] Fung C, Lock R, Gao S, Salas E, Debnath J (2008) Induction of autophagy during 
extracellular matrix detachment promotes cell survival. Mol.Biol.Cell ;19: 797-806. 
[170] Kenific CM, Thorburn A, Debnath J (2010) Autophagy and metastasis: another double-
edged sword. Curr.Opin.Cell Biol.22: 241-245. 
[171] Debnath J (2008) Detachment-induced autophagy during anoikis and lumen formation 
in epithelial acini. Autophagy.4: 351-353. 
[172] Yerbes R, Palacios C, Lopez-Rivas A (2011) The therapeutic potential of TRAIL 
receptor signalling in cancer cells. Clin.Transl.Oncol.13: 839-847. 
[173] Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 
;281: 1305-1308. 
 
Apoptosis and Medicine 
 
108 
[174] Nguyen T, Zhang XD, Hersey P (2001) Relative resistance of fresh isolates of 
melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced 
apoptosis. Clin.Cancer Res.7: 966s-973s. 
[175] Pavet V, Portal MM, Moulin JC, Herbrecht R, Gronemeyer H (2011) Towards novel 
paradigms for cancer therapy. Oncogene ;30: 1-20. 
[176] Hetschko H, Voss V, Seifert V, Prehn JH, Kogel D (2008) Upregulation of DR5 by 
proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis. 
FEBS J.275: 1925-1936. 
[177] Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer 
onset, progression and therapy. Nat.Rev.Cancer ;8: 782-798. 
[178] Speirs CK, Hwang M, Kim S, Li W, Chang S, Varki V, et al. (2011) Harnessing the cell 
death pathway for targeted cancer treatment. Am.J.Cancer Res.1: 43-61. 
[179] Martinez-Lostao L, Marzo I, Anel A, Naval J (2012) Targeting the Apo2L/TRAIL 
system for the therapy of autoimmune diseases and cancer. Biochem.Pharmacol.83: 
1475-1483. 
[180] Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged 
sword. Nat.Rev.Immunol.3: 745-756. 
[181] Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, et al. (2000) Fas 
triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP 
as effector molecule. Nat.Immunol.1: 489-495. 
[182] Vanden Berghe T, van LG, Saelens X, Van GM, Brouckaert G, Kalai M, et al. (2004) 
Differential signaling to apoptotic and necrotic cell death by Fas-associated death 
domain protein FADD. J.Biol.Chem.279: 7925-7933. 
[183] Tarhini AA, Kirkwood JM (2007) Oblimersen in the treatment of metastatic melanoma. 
Future.Oncol.3: 263-271. 
[184] Heidari N, Hicks MA, Harada H (2010) GX15-070 (obatoclax) overcomes 
glucocorticoid resistance in acute lymphoblastic leukemia through induction of 
apoptosis and autophagy. Cell Death.Dis.1: e76. 
[185] McCoy F, Hurwitz J, McTavish N, Paul I, Barnes C, O'Hagan B, et al. (2010) Obatoclax 
induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell 
Death.Dis.1: e108. 
[186] Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. 
(2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 
;435: 677-681. 
[187] van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. (2006) 
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces 
apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell ;10: 389-399. 
[188] Cragg MS, Harris C, Strasser A, Scott CL (2009) Unleashing the power of inhibitors of 
oncogenic kinases through BH3 mimetics. Nat.Rev.Cancer ;9: 321-326. 
[189] Carrington EM, Vikstrom IB, Light A, Sutherland RM, Londrigan SL, Mason KD, et al. 
(2010) BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent 
another class of selective immune modulatory drugs. Proc.Natl.Acad.Sci.U.S.A ;107: 
10967-10971. 
 
Cell Death and Cancer, Novel Therapeutic Strategies 
 
109 
[190] Chen DJ, Huerta S (2009) Smac mimetics as new cancer therapeutics. Anticancer Drugs 
;20: 646-658. 
[191] Straub CS (2011) Targeting IAPs as an approach to anti-cancer therapy. 
Curr.Top.Med.Chem.11: 291-316. 
[192] Gyrd-Hansen M, Meier P (2010) IAPs: from caspase inhibitors to modulators of NF-
kappaB, inflammation and cancer. Nat.Rev.Cancer ;10: 561-574. 
[193] Kaelin WG, Jr. (2009) Synthetic lethality: a framework for the development of wiser 
cancer therapeutics. Genome Med.1: 99. 
[194] Chan DA, Giaccia AJ (2011) Harnessing synthetic lethal interactions in anticancer drug 
discovery. Nat.Rev.Drug Discov.10: 351-364. 
[195] Bolderson E, Richard DJ, Zhou BB, Khanna KK (2009) Recent advances in cancer 
therapy targeting proteins involved in DNA double-strand break repair. Clin.Cancer 
Res.15: 6314-6320. 
[196] Dai Y, Grant S (2010) New insights into checkpoint kinase 1 in the DNA damage 
response signaling network. Clin.Cancer Res.16: 376-383. 
[197] Calvert H, Azzariti A (2011) The clinical development of inhibitors of poly(ADP-
ribose) polymerase. Ann.Oncol.22 Suppl 1: i53-i59. 
[198] Javle M, Curtin NJ (2011) The potential for poly (ADP-ribose) polymerase inhibitors in 
cancer therapy. Ther.Adv.Med.Oncol.3: 257-267. 
[199] Imre G, Larisch S, Rajalingam K (2011) Ripoptosome: a novel IAP-regulated cell death-
signalling platform. J.Mol.Cell Biol.3: 324-326. 
[200] Safa AR, Pollok KE (2011) Targeting the Anti-Apoptotic Protein c-FLIP for Cancer 
Therapy. Cancers.(Basel) ;3: 1639-1671. 
[201] Maiuri MC, Zalckvar E, Kimchi A, Kroemer G (2007) Self-eating and self-killing: 
crosstalk between autophagy and apoptosis. Nat.Rev.Mol.Cell Biol.8: 741-752. 
[202] Chen N, Karantza-Wadsworth V (2009) Role and regulation of autophagy in cancer. 
Biochim.Biophys.Acta ;1793: 1516-1523. 
[203] Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, et al. (2007) Targeting 
autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA 
to overcome Bcr-Abl-mediated drug resistance. Blood ;110: 313-322. 
[204] Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A (2008) Blocked autophagy 
sensitizes resistant carcinoma cells to radiation therapy. Cancer Res.68: 1485-1494. 
[205] Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I 
receptor/human epidermal growth factor receptor 2 heterodimerization contributes to 
trastuzumab resistance of breast cancer cells. Cancer Res.65: 11118-11128. 
[206] Esparis-Ogando A, Ocana A, Rodriguez-Barrueco R, Ferreira L, Borges J, Pandiella A 
(2008) Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-
overexpressing breast cancer cells. Ann.Oncol.19: 1860-1869. 
[207] Ropero S, Menendez JA, Vazquez-Martin A, Montero S, Cortes-Funes H, Colomer R 
(2004) Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in 
breast carcinoma. Breast Cancer Res.Treat.86: 125-137. 
[208] Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, et al. (2011) Pancreatic cancers 
require autophagy for tumor growth. Genes Dev.25: 717-729. 
 
Apoptosis and Medicine 
 
108 
[174] Nguyen T, Zhang XD, Hersey P (2001) Relative resistance of fresh isolates of 
melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced 
apoptosis. Clin.Cancer Res.7: 966s-973s. 
[175] Pavet V, Portal MM, Moulin JC, Herbrecht R, Gronemeyer H (2011) Towards novel 
paradigms for cancer therapy. Oncogene ;30: 1-20. 
[176] Hetschko H, Voss V, Seifert V, Prehn JH, Kogel D (2008) Upregulation of DR5 by 
proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis. 
FEBS J.275: 1925-1936. 
[177] Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer 
onset, progression and therapy. Nat.Rev.Cancer ;8: 782-798. 
[178] Speirs CK, Hwang M, Kim S, Li W, Chang S, Varki V, et al. (2011) Harnessing the cell 
death pathway for targeted cancer treatment. Am.J.Cancer Res.1: 43-61. 
[179] Martinez-Lostao L, Marzo I, Anel A, Naval J (2012) Targeting the Apo2L/TRAIL 
system for the therapy of autoimmune diseases and cancer. Biochem.Pharmacol.83: 
1475-1483. 
[180] Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged 
sword. Nat.Rev.Immunol.3: 745-756. 
[181] Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, et al. (2000) Fas 
triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP 
as effector molecule. Nat.Immunol.1: 489-495. 
[182] Vanden Berghe T, van LG, Saelens X, Van GM, Brouckaert G, Kalai M, et al. (2004) 
Differential signaling to apoptotic and necrotic cell death by Fas-associated death 
domain protein FADD. J.Biol.Chem.279: 7925-7933. 
[183] Tarhini AA, Kirkwood JM (2007) Oblimersen in the treatment of metastatic melanoma. 
Future.Oncol.3: 263-271. 
[184] Heidari N, Hicks MA, Harada H (2010) GX15-070 (obatoclax) overcomes 
glucocorticoid resistance in acute lymphoblastic leukemia through induction of 
apoptosis and autophagy. Cell Death.Dis.1: e76. 
[185] McCoy F, Hurwitz J, McTavish N, Paul I, Barnes C, O'Hagan B, et al. (2010) Obatoclax 
induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell 
Death.Dis.1: e108. 
[186] Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. 
(2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 
;435: 677-681. 
[187] van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. (2006) 
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces 
apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell ;10: 389-399. 
[188] Cragg MS, Harris C, Strasser A, Scott CL (2009) Unleashing the power of inhibitors of 
oncogenic kinases through BH3 mimetics. Nat.Rev.Cancer ;9: 321-326. 
[189] Carrington EM, Vikstrom IB, Light A, Sutherland RM, Londrigan SL, Mason KD, et al. 
(2010) BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent 
another class of selective immune modulatory drugs. Proc.Natl.Acad.Sci.U.S.A ;107: 
10967-10971. 
 
Cell Death and Cancer, Novel Therapeutic Strategies 
 
109 
[190] Chen DJ, Huerta S (2009) Smac mimetics as new cancer therapeutics. Anticancer Drugs 
;20: 646-658. 
[191] Straub CS (2011) Targeting IAPs as an approach to anti-cancer therapy. 
Curr.Top.Med.Chem.11: 291-316. 
[192] Gyrd-Hansen M, Meier P (2010) IAPs: from caspase inhibitors to modulators of NF-
kappaB, inflammation and cancer. Nat.Rev.Cancer ;10: 561-574. 
[193] Kaelin WG, Jr. (2009) Synthetic lethality: a framework for the development of wiser 
cancer therapeutics. Genome Med.1: 99. 
[194] Chan DA, Giaccia AJ (2011) Harnessing synthetic lethal interactions in anticancer drug 
discovery. Nat.Rev.Drug Discov.10: 351-364. 
[195] Bolderson E, Richard DJ, Zhou BB, Khanna KK (2009) Recent advances in cancer 
therapy targeting proteins involved in DNA double-strand break repair. Clin.Cancer 
Res.15: 6314-6320. 
[196] Dai Y, Grant S (2010) New insights into checkpoint kinase 1 in the DNA damage 
response signaling network. Clin.Cancer Res.16: 376-383. 
[197] Calvert H, Azzariti A (2011) The clinical development of inhibitors of poly(ADP-
ribose) polymerase. Ann.Oncol.22 Suppl 1: i53-i59. 
[198] Javle M, Curtin NJ (2011) The potential for poly (ADP-ribose) polymerase inhibitors in 
cancer therapy. Ther.Adv.Med.Oncol.3: 257-267. 
[199] Imre G, Larisch S, Rajalingam K (2011) Ripoptosome: a novel IAP-regulated cell death-
signalling platform. J.Mol.Cell Biol.3: 324-326. 
[200] Safa AR, Pollok KE (2011) Targeting the Anti-Apoptotic Protein c-FLIP for Cancer 
Therapy. Cancers.(Basel) ;3: 1639-1671. 
[201] Maiuri MC, Zalckvar E, Kimchi A, Kroemer G (2007) Self-eating and self-killing: 
crosstalk between autophagy and apoptosis. Nat.Rev.Mol.Cell Biol.8: 741-752. 
[202] Chen N, Karantza-Wadsworth V (2009) Role and regulation of autophagy in cancer. 
Biochim.Biophys.Acta ;1793: 1516-1523. 
[203] Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, et al. (2007) Targeting 
autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA 
to overcome Bcr-Abl-mediated drug resistance. Blood ;110: 313-322. 
[204] Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A (2008) Blocked autophagy 
sensitizes resistant carcinoma cells to radiation therapy. Cancer Res.68: 1485-1494. 
[205] Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I 
receptor/human epidermal growth factor receptor 2 heterodimerization contributes to 
trastuzumab resistance of breast cancer cells. Cancer Res.65: 11118-11128. 
[206] Esparis-Ogando A, Ocana A, Rodriguez-Barrueco R, Ferreira L, Borges J, Pandiella A 
(2008) Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-
overexpressing breast cancer cells. Ann.Oncol.19: 1860-1869. 
[207] Ropero S, Menendez JA, Vazquez-Martin A, Montero S, Cortes-Funes H, Colomer R 
(2004) Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in 
breast carcinoma. Breast Cancer Res.Treat.86: 125-137. 
[208] Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, et al. (2011) Pancreatic cancers 
require autophagy for tumor growth. Genes Dev.25: 717-729. 
 
Apoptosis and Medicine 
 
110 
[209] Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, et al. (2011) 
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. 
Genes Dev.25: 460-470. 
[210] Abe A, Yamada H, Moriya S, Miyazawa K (2011) The beta-carboline alkaloid harmol 
induces cell death via autophagy but not apoptosis in human non-small cell lung cancer 
A549 cells. Biol.Pharm.Bull.34: 1264-1272. 
[211] Yu L, Alva A, Su H, Dutt P, Freundt E, Welsh S, et al. (2004) Regulation of an ATG7-
beclin 1 program of autophagic cell death by caspase-8. Science ;304: 1500-1502. 
[212] Yu L, Wan F, Dutta S, Welsh S, Liu Z, Freundt E, et al. (2006) Autophagic programmed 
cell death by selective catalase degradation. Proc.Natl.Acad.Sci.U.S.A ;103: 4952-4957. 
[213] Lum JJ, DeBerardinis RJ, Thompson CB (2005) Autophagy in metazoans: cell survival 
in the land of plenty. Nat.Rev.Mol.Cell Biol.6: 439-448. 
[214] Wu YT, Tan HL, Huang Q, Kim YS, Pan N, Ong WY, et al. (2008) Autophagy plays a 
protective role during zVAD-induced necrotic cell death. Autophagy.4: 457-466. 
[215] Amaravadi RK, Thompson CB (2007) The roles of therapy-induced autophagy and 
necrosis in cancer treatment. Clin.Cancer Res.13: 7271-7279. 
[216] Lieberthal W, Triaca V, Levine J (1996) Mechanisms of death induced by cisplatin in 
proximal tubular epithelial cells: apoptosis vs. necrosis. Am.J.Physiol ;270: F700-F708. 
[217] Healy E, Dempsey M, Lally C, Ryan MP (1998) Apoptosis and necrosis: mechanisms of 
cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int.54: 
1955-1966. 
[218] Chan FK, Shisler J, Bixby JG, Felices M, Zheng L, Appel M, et al. (2003) A role for 
tumor necrosis factor receptor-2 and receptor-interacting protein in programmed 
necrosis and antiviral responses. J.Biol.Chem.278: 51613-51621. 
[219] Cho DH, Jo YK, Hwang JJ, Lee YM, Roh SA, Kim JC (2009) Caspase-mediated cleavage 
of ATG6/Beclin-1 links apoptosis to autophagy in HeLa cells. Cancer Lett.274: 95-100. 
[220] Djavaheri-Mergny M, Maiuri MC, Kroemer G (2010) Cross talk between apoptosis and 
autophagy by caspase-mediated cleavage of Beclin 1. Oncogene ;29: 1717-1719. 
[221] Hou W, Han J, Lu C, Goldstein LA, Rabinowich H (2010) Autophagic degradation of 







© 2012 Marchal et al., licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Apoptosis as a Therapeutic Target  
in Cancer and Cancer Stem Cells:  
Novel Strategies and Futures Perspectives 
María A. García, Esther Carrasco, Alberto Ramírez, Gema Jiménez,  
Elena López-Ruiz, Macarena Perán, Manuel Picón,  
Joaquín Campos, Houria Boulaiz and Juan Antonio Marchal 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/48267 
1. Introduction 
Apoptosis is an essential part of the normal development. The homeostatic balance between 
cell proliferation and cell death rate is critical for maintaining normal physiological 
processes. Aberrant regulation of apoptotic cell death mechanisms is one of the hallmarks of 
cancer development and progression, and many cancer cells exhibit significant resistance to 
apoptosis signalling [1]. Triggering of apoptosis can be achieved via the activation of two 
distinct molecular pathways, the extrinsic or death receptor pathway or via the intrinsic or 
mitochondrial apoptotic cascades. Both pathways lead to the hierarchical activation of a 
family of cysteine proteases called caspases [2], that cleave a series of cellular substrates 
which induce changes including chromatin condensation, internucleosomal DNA 
fragmentation, membrane blebbing and cell shrinkage [3]. Extrinsic pathway is activated 
from outside the cell by proapoptotic ligands that interact with specialized cell surface death 
receptors, including CD95 and TNF-related apoptosis-inducing ligand (TRAIL) receptors 
[4]. After binding to receptors apoptosis is triggered by the intracellular formation of a 
death-inducing signalling complex (DISC) that consists of FAS-associated death domain 
(FADD) and procaspase-8 and 10 [5,6]. As a result, this protein complex activates 
procaspase-8 and 10 inside itself, hence triggering procaspase-3 to execute the apoptosis 
process [7]. The mitochondria (intrinsic) pathway is activated from inside the cell by severe 
cell stress, such as DNA or cytoskeletal damage, inducing mitochondrial outer membrane 
permeabilization and transcription or post-translational activation of BH3-only proapoptotic 
B-cell leukemia/lymphoma 2 (Bcl-2) family proteins [4]. This permeabilization allows the 
release of apoptogenic proteins, including cytochrome c and second mitochondria-derived 
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1. Introduction 
Apoptosis is an essential part of the normal development. The homeostatic balance between 
cell proliferation and cell death rate is critical for maintaining normal physiological 
processes. Aberrant regulation of apoptotic cell death mechanisms is one of the hallmarks of 
cancer development and progression, and many cancer cells exhibit significant resistance to 
apoptosis signalling [1]. Triggering of apoptosis can be achieved via the activation of two 
distinct molecular pathways, the extrinsic or death receptor pathway or via the intrinsic or 
mitochondrial apoptotic cascades. Both pathways lead to the hierarchical activation of a 
family of cysteine proteases called caspases [2], that cleave a series of cellular substrates 
which induce changes including chromatin condensation, internucleosomal DNA 
fragmentation, membrane blebbing and cell shrinkage [3]. Extrinsic pathway is activated 
from outside the cell by proapoptotic ligands that interact with specialized cell surface death 
receptors, including CD95 and TNF-related apoptosis-inducing ligand (TRAIL) receptors 
[4]. After binding to receptors apoptosis is triggered by the intracellular formation of a 
death-inducing signalling complex (DISC) that consists of FAS-associated death domain 
(FADD) and procaspase-8 and 10 [5,6]. As a result, this protein complex activates 
procaspase-8 and 10 inside itself, hence triggering procaspase-3 to execute the apoptosis 
process [7]. The mitochondria (intrinsic) pathway is activated from inside the cell by severe 
cell stress, such as DNA or cytoskeletal damage, inducing mitochondrial outer membrane 
permeabilization and transcription or post-translational activation of BH3-only proapoptotic 
B-cell leukemia/lymphoma 2 (Bcl-2) family proteins [4]. This permeabilization allows the 
release of apoptogenic proteins, including cytochrome c and second mitochondria-derived 
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activator of caspase (Smac; also known as DIABLO), from the mitochondrial intermembrane 
space into the cytosol [8]. Cytochrome c assembles with apoptotic protease-activating factor-
1 (Apaf-1) to activate caspase 9. This caspase, in turn, activates the effector caspases 3, 6, and 
7, which carry out apoptosis [4]. Smac promotes caspase activation and apoptosis by 
neutralization of several IAP proteins, including XIAP, c-IAP1 and c-IAP2 [9,10] 
Chemotherapeutic agents act by inhibiting tumour cell proliferation and survival and most 
of them can kill tumour cells by activating common apoptotic pathways [11]. Therefore, 
apoptosis plays an important role in the treatment of cancer as it is a popular target of many 
treatment strategies. 5-fluorouracil (5-FU), an antimetabolite analogue of uracil employed 
primarily in the treatment of a variety of solid malignant tumours, leads to a wide range of 
biological effects which can act as triggers for apoptotic cell death [12,13]. However, 
resistance to the drug remains a major clinical problem. Given that many of the apoptotic 
regulators altered in multidrug resistant tumours have been identified, one new approach to 
therapy is to restore apoptotic potential through genetic or pharmacological methods [14]. 
Moreover, since defects in the mediators of apoptosis may account for chemo-resistance, the 
identification of new targets involved in drug-induced apoptosis is of main clinical interest. 
Recently, we have identified the ds-RNA-dependent protein kinase (PKR) as a key 
molecular target of 5-FU involved in apoptosis induction, in a p53 -independent manner. 
These results suggest the clinical importance that the PKR status could play in response to 
chemotherapy based on 5-FU. Moreover, the effectiveness of 5-FU cytotoxic activity induced 
by IFNα, especially in cancer cells expressing a mutated form or lacking p53, but with a 
functional PKR, might have relevant clinical application in patients [15] . 
The increased knowledge of some of the molecular components of the apoptosis signalling 
pathways has paved the way for the generation of more specific agents that target one 
crucial signalling component. This has allowed a change in anticancer therapy trends, from 
classic cytotoxic strategies to the development of new non-harmful therapies which target 
the apoptosis response selectively only in tumour cells. Moreover, these strategies overcome 
the adverse effects associated with cytotoxic drugs and increase their anti-cancer activity. 
Novel antitumour drugs have been synthesised such as 5-FU O,N-acetals and benzo-fused 
seven-membered O,N-acetal in which the 5-FU moiety was changed for the naturally-
occurring pyrimidine base uracil, which induced cell cycle-mediated apoptosis in breast and 
colon cancer cells [16,17,18,19]. The mechanism of action of these drugs was mainly centred 
on positive apoptosis regulatory pathway genes, and the repression of genes involved in 
carcinogenesis, proliferation and tumour invasion. In addition, these drugs were more 
selective against tumour cells with lower toxic effects in non-tumour cells [20,21].  
As over-expression of IAP proteins frequently occurs in various human cancers and has 
been linked to tumour progression, chemo-resistance and poor prognosis, it is not 
surprising that IAP proteins are considered to be attractive targets for improve outcomes for 
patients with solid tumours and hematologic malignancies [22,23]. IAPs are also attractive 
as therapeutic targets because their inhibition does not appear to be toxic to normal adult 
cells [24]. Several therapeutic strategies have been designed to target IAP, including a small-
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molecule approach that is based on mimicking the IAP-binding motif of the endogenous 
IAP antagonist Smac [25]. Other therapies involve antisense strategies and short-interfering 
RNA (siRNA) molecules [26,27]. There is increasing interest in therapeutic drug 
development targeting the IAP family.  
MicroRNAs (miRNAs) are small RNA gene products that regulate the activity of messenger 
RNAs by antisense base pairing. They are involved in stem-cell self-renewal, cellular 
development, differentiation, proliferation, and apoptosis [28]. In cancer, miRNAs function 
as regulatory molecules, acting as oncogenes or tumour suppressors [29] and they are 
strongly related to the apoptosis. New insights indicate that many miRNAs are anti-
apoptotic and mediate this effect by targeting pro-apoptotic mRNAs or positive regulators 
of pro-apoptotic mRNAs [30]. Conversely, many pro-apoptotic miRNAs target anti-
apoptotic mRNAs or their positive regulators [31]. Therefore, their inhibition leads to the 
induction of programmed cell death, suggesting a promising miRNA treatment for cancer. 
Several drugs may have the ability to modulate the expression of miRNAs by targeting 
signalling pathways that ultimately converge on the activation of transcription factors that 
regulate miRNA encoding genes.  
Evasion of apoptosis is one of the main mechanisms involved in tumourigenesis and drug 
resistance. Most cancers have a small population of tumour cells, as few as 1%, with stem 
cell characteristics and the capacity for self-renewal, termed cancer stem cells (CSCs). A 
malignant tumour can be viewed as an abnormal organ in which small populations of 
tumourigenic CSCs have escaped the normal limits of self-renewal, giving rise to 
abnormally differentiated cancer cells that contribute to tumour progression and growth 
[32]. These CSC express high levels of ATP-binding cassette (ABC) drug transporters, 
providing for a level of resistance [33]; are relatively quiescent; have higher levels of DNA 
repair and a lowered ability to enter apoptosis . Several cancer therapy approaches targeting 
ABC transporters and increasing apoptosis could be employed to selectively and more 
efficiently kill CSC. 
The current review will focus on recent development of several therapeutic strategies, which 
interfere with apoptosis and are currently used or tested for treatment of cancer. They 
induce cancer cell death or enhance the responsiveness of cancer cells and CSCs to certain 
cytotoxic drugs. Some of them such as caspases activators, indirectly modulators of 
apoptosis or agents targeting apoptosis-related proteins are still in their preclinical or 
clinical trials. We also include future approaches directed to target apoptotic pathways with 
promising application in patients with cancer. 
2. Novel apoptotic markers/targets in cancer  
The main goal in cancer therapy is the abrogation of tumour cell growth and proliferation, 
and ultimately the complete elimination of tumour cells. It is commonly accepted that 
tumour cells treated with anticancer agents undergo apoptosis, and that cells resistant to 
apoptosis often do not respond to anticancer therapy [34]. Moreover, it is widely 
demonstrated that some oncogenic mutations suppressing apoptosis may lead to tumour 
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activator of caspase (Smac; also known as DIABLO), from the mitochondrial intermembrane 
space into the cytosol [8]. Cytochrome c assembles with apoptotic protease-activating factor-
1 (Apaf-1) to activate caspase 9. This caspase, in turn, activates the effector caspases 3, 6, and 
7, which carry out apoptosis [4]. Smac promotes caspase activation and apoptosis by 
neutralization of several IAP proteins, including XIAP, c-IAP1 and c-IAP2 [9,10] 
Chemotherapeutic agents act by inhibiting tumour cell proliferation and survival and most 
of them can kill tumour cells by activating common apoptotic pathways [11]. Therefore, 
apoptosis plays an important role in the treatment of cancer as it is a popular target of many 
treatment strategies. 5-fluorouracil (5-FU), an antimetabolite analogue of uracil employed 
primarily in the treatment of a variety of solid malignant tumours, leads to a wide range of 
biological effects which can act as triggers for apoptotic cell death [12,13]. However, 
resistance to the drug remains a major clinical problem. Given that many of the apoptotic 
regulators altered in multidrug resistant tumours have been identified, one new approach to 
therapy is to restore apoptotic potential through genetic or pharmacological methods [14]. 
Moreover, since defects in the mediators of apoptosis may account for chemo-resistance, the 
identification of new targets involved in drug-induced apoptosis is of main clinical interest. 
Recently, we have identified the ds-RNA-dependent protein kinase (PKR) as a key 
molecular target of 5-FU involved in apoptosis induction, in a p53 -independent manner. 
These results suggest the clinical importance that the PKR status could play in response to 
chemotherapy based on 5-FU. Moreover, the effectiveness of 5-FU cytotoxic activity induced 
by IFNα, especially in cancer cells expressing a mutated form or lacking p53, but with a 
functional PKR, might have relevant clinical application in patients [15] . 
The increased knowledge of some of the molecular components of the apoptosis signalling 
pathways has paved the way for the generation of more specific agents that target one 
crucial signalling component. This has allowed a change in anticancer therapy trends, from 
classic cytotoxic strategies to the development of new non-harmful therapies which target 
the apoptosis response selectively only in tumour cells. Moreover, these strategies overcome 
the adverse effects associated with cytotoxic drugs and increase their anti-cancer activity. 
Novel antitumour drugs have been synthesised such as 5-FU O,N-acetals and benzo-fused 
seven-membered O,N-acetal in which the 5-FU moiety was changed for the naturally-
occurring pyrimidine base uracil, which induced cell cycle-mediated apoptosis in breast and 
colon cancer cells [16,17,18,19]. The mechanism of action of these drugs was mainly centred 
on positive apoptosis regulatory pathway genes, and the repression of genes involved in 
carcinogenesis, proliferation and tumour invasion. In addition, these drugs were more 
selective against tumour cells with lower toxic effects in non-tumour cells [20,21].  
As over-expression of IAP proteins frequently occurs in various human cancers and has 
been linked to tumour progression, chemo-resistance and poor prognosis, it is not 
surprising that IAP proteins are considered to be attractive targets for improve outcomes for 
patients with solid tumours and hematologic malignancies [22,23]. IAPs are also attractive 
as therapeutic targets because their inhibition does not appear to be toxic to normal adult 
cells [24]. Several therapeutic strategies have been designed to target IAP, including a small-
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molecule approach that is based on mimicking the IAP-binding motif of the endogenous 
IAP antagonist Smac [25]. Other therapies involve antisense strategies and short-interfering 
RNA (siRNA) molecules [26,27]. There is increasing interest in therapeutic drug 
development targeting the IAP family.  
MicroRNAs (miRNAs) are small RNA gene products that regulate the activity of messenger 
RNAs by antisense base pairing. They are involved in stem-cell self-renewal, cellular 
development, differentiation, proliferation, and apoptosis [28]. In cancer, miRNAs function 
as regulatory molecules, acting as oncogenes or tumour suppressors [29] and they are 
strongly related to the apoptosis. New insights indicate that many miRNAs are anti-
apoptotic and mediate this effect by targeting pro-apoptotic mRNAs or positive regulators 
of pro-apoptotic mRNAs [30]. Conversely, many pro-apoptotic miRNAs target anti-
apoptotic mRNAs or their positive regulators [31]. Therefore, their inhibition leads to the 
induction of programmed cell death, suggesting a promising miRNA treatment for cancer. 
Several drugs may have the ability to modulate the expression of miRNAs by targeting 
signalling pathways that ultimately converge on the activation of transcription factors that 
regulate miRNA encoding genes.  
Evasion of apoptosis is one of the main mechanisms involved in tumourigenesis and drug 
resistance. Most cancers have a small population of tumour cells, as few as 1%, with stem 
cell characteristics and the capacity for self-renewal, termed cancer stem cells (CSCs). A 
malignant tumour can be viewed as an abnormal organ in which small populations of 
tumourigenic CSCs have escaped the normal limits of self-renewal, giving rise to 
abnormally differentiated cancer cells that contribute to tumour progression and growth 
[32]. These CSC express high levels of ATP-binding cassette (ABC) drug transporters, 
providing for a level of resistance [33]; are relatively quiescent; have higher levels of DNA 
repair and a lowered ability to enter apoptosis . Several cancer therapy approaches targeting 
ABC transporters and increasing apoptosis could be employed to selectively and more 
efficiently kill CSC. 
The current review will focus on recent development of several therapeutic strategies, which 
interfere with apoptosis and are currently used or tested for treatment of cancer. They 
induce cancer cell death or enhance the responsiveness of cancer cells and CSCs to certain 
cytotoxic drugs. Some of them such as caspases activators, indirectly modulators of 
apoptosis or agents targeting apoptosis-related proteins are still in their preclinical or 
clinical trials. We also include future approaches directed to target apoptotic pathways with 
promising application in patients with cancer. 
2. Novel apoptotic markers/targets in cancer  
The main goal in cancer therapy is the abrogation of tumour cell growth and proliferation, 
and ultimately the complete elimination of tumour cells. It is commonly accepted that 
tumour cells treated with anticancer agents undergo apoptosis, and that cells resistant to 
apoptosis often do not respond to anticancer therapy [34]. Moreover, it is widely 
demonstrated that some oncogenic mutations suppressing apoptosis may lead to tumour 
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initiation, progression or metastasis [11]. Apoptosis plays a major control role in cell death 
when DNA damage is irreparable and multiple stress-inducible molecules have been 
implied in transmitting the apoptotic signal [35]. Because of the potential detrimental effects 
on cell survival in case of inappropriate activation of apoptosis programs, apoptosis 
pathways have to be tightly controlled. However, the concept that apoptosis represents the 
major mechanism by which cancer cells are eliminated may not universally apply and 
caspase-independent apoptosis or other modes of cell death have also to be considered as 
cellular response to anticancer therapy [36]. 
Different determinants of drug resistance exist, including loss of cell surface receptors or 
transporters, altered metabolism, or mutation of specific apoptotic target [37]. The apoptotic 
signalling pathways are regulated by numerous hub proteins such as p53, Bcl-2, NFkB and 
MAPKs which function in common. In the following sections, we will summarize some of 
the cellular proteins considered as potential apoptotic biomarkers in cancer. 
1- The tumour suppressor p53 is an important pro-apoptotic factor and tumour inhibitor, 
and numerous anti-tumour drugs would exert their functions through targeting p53-related 
signalling pathways. Some clinical investigations indicated that under abnormal situations 
such as chemotherapy and UV or DNA damage may occur and activate the expression of 
p53. Activated p53 protein binds to the regulatory sequences of a number of target genes to 
initiate a program of cell cycle arrest, DNA repair, apoptosis, and angiogenesis [38]. If the 
damage cannot be repaired completely, over-activation of p53 leads to the tumour growth 
stagnation or even apoptosis [39,40]. Loss of p53 function is critical in tumourigenesis, and 
alterations to the p53 gene (mutations, often resulting in protein over-expression) are 
frequent events in cancer. Associations of p53 tumour alterations with patient prognosis and 
response to adjuvant chemotherapy have been widely studied, and findings are 
contradictory. The fluoropyrimidine 5-FU is widely used in the treatment of a range of 
cancers including colorectal cancer and breast cancer [41,42,43], but resistance to the drug 
remains a major clinical problem. P53 was the first target described for 5-FU- induced 
apoptosis, however, although several reports have demonstrated that 5-FU-induced 
apoptosis is dependent on the tumour suppressor p53 protein, apoptosis can also occur in 
mutant p53 cell lines [44,45,46,47]. Moreover, the relationship between p53 status and 
sensitivity to chemotherapeutic drugs, including 5- FU, is still controversial. In clinical 
studies in which adjuvant chemotherapy– treated and non-treated groups could be 
analyzed, stage III colorectal patients whose tumours demonstrated no p53 alterations 
experienced significantly longer survival following 5-FU–based chemotherapy than patients 
whose tumours over-expressed p53 [48,49]. However, other studies in colon cancer patients 
failed to demonstrate correlations between p53 alterations and benefit from adjuvant 
therapy [50,51]. The identification of new targets involved in 5-FU-induced apoptosis could 
contribute to clarify the controversy results obtaining in clinic.  
2- Recently, we have identified the interferon-induced protein kinase PKR, as a molecular 
target of 5-FU with an interesting role in the apoptosis induced by this chemotherapeutic 
drug [15]. The double-stranded RNA (dsRNA)-dependent kinase PKR was initially 
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identified as an innate immune anti-viral protein approximately 35 years ago [52,53]. Since 
then, PKR has been linked to normal cell growth and differentiation, inflammation, cytokine 
signalling, and apoptosis [54]. PKR is a serine/threonine kinase, characterized by two 
distinct kinase activities: autophosphorylation, which represents the activation reaction, and 
phosphorylation of eIF-2α [55,56], which impairs eIF-2 activity, resulting in inhibition of 
protein synthesis [57]. In addition to its translational regulatory function, PKR has a role in 
signal transduction and transcriptional control through the IkB/NF-kB pathway [58,59]. PKR 
is activated in response to dsRNA of cellular, viral, or synthetic origin. PKR can also be 
activated by polyanions such as heparin, dextran sulfate, chondroitin sulfate, and poly-L-
glutamine [60]. A range of cellular stresses can also activate PKR, such as arsenite, 
thapsigargin, H2O2, ethanol and ceramide [61,62,63] presumably through the PKR-
associated activator (PACT)/RAX protein [64]. Moreover, it is induced by interferon type I 
and mediates in part, several functions of these cytokines. Altered PKR activity has been 
shown to play a role in neurodegenerative diseases (Alzheimer’s, Creutzfeldt–Jakob, 
Huntington’s, and Parkinson’s) and cancer [65,66,67,68,69,70,71,72,73,74]. 
Over-expression or continued activation of PKR leads to apoptosis [75,76,77]. PKR mediates 
the apoptosis induced by several viruses and cellular stresses [78] by activation of intrinsic 
and extrinsic apoptosis pathways through the FADD/caspase 8 and mitochondrial 
APAF/caspase 9 activation pathways [79,80]. Recently, PKR has been shown to play an 
important role in apoptotic cancer cell death induced by 5-FU, doxorubicin and etoposide 
[15,81,82] and the antitumour activity of tumour suppressors like p53 and PTEN [81,83]. 
Preclinical studies in mice have shown than in tumours which do not express sufficient 
levels of PKR are more resistant to doxorubicin and etoposide that tumour expressing 
higher PKR levels. We have demonstrated that PKR is up-regulated and activated in colon 
and breast cancer cell lines by inducing apoptotic cell death in response to 5-FU treatment. 
In addition, cancer cell lines deficient in PKR expression were more resistant to the cytotoxic 
effect of 5-FU with an IC50 being 2-3 fold higher than cells expressing an active PKR protein. 
Moreover, apoptosis mediated by PKR in response to 5-FU occurred independently on p53 
status highlighted the importance that both p53 and PKR play in the 5-FU-induced cancer 
cell death, and the relevance acquired by PKR in tumour cells where p53 is mutated. Such 
results raise the importance of determining PKR status in tumours from patients treated 
with 5-FU-based chemotherapy [15]. 
3- One pathway being targeted for antineoplastic therapy is the Bcl-2 family of proteins (Bcl-
2, Bcl-XL, Bcl-w, Mcl-1, Bfl1/A-1, and Bcl-B) that bind to and inactivate BH3-domain pro-
apoptotic proteins. It is controversial whether some BH3-domain proteins (Bim or tBid) 
directly activate multidomain pro-apoptotic proteins (e.g., Bax and Bak) or act via inhibition 
of those anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, Bfl1/A-1, and Bcl-B) that 
stabilize pro-apoptotic proteins [84]. Since the anti-apoptotic properties of Bcl-2 were 
discovered, the over-expression of Bcl-2 conferring chemoresistance was reported, and the 
3-D protein structure of Bcl-XL was determined. These properties have contributed to the 
development of protein inhibitors. The first agent targeting Bcl-2 that entered clinical trials 
was a Bcl-2 antisense (oblimersen sodium), which showed chemosensitizing effects when 
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initiation, progression or metastasis [11]. Apoptosis plays a major control role in cell death 
when DNA damage is irreparable and multiple stress-inducible molecules have been 
implied in transmitting the apoptotic signal [35]. Because of the potential detrimental effects 
on cell survival in case of inappropriate activation of apoptosis programs, apoptosis 
pathways have to be tightly controlled. However, the concept that apoptosis represents the 
major mechanism by which cancer cells are eliminated may not universally apply and 
caspase-independent apoptosis or other modes of cell death have also to be considered as 
cellular response to anticancer therapy [36]. 
Different determinants of drug resistance exist, including loss of cell surface receptors or 
transporters, altered metabolism, or mutation of specific apoptotic target [37]. The apoptotic 
signalling pathways are regulated by numerous hub proteins such as p53, Bcl-2, NFkB and 
MAPKs which function in common. In the following sections, we will summarize some of 
the cellular proteins considered as potential apoptotic biomarkers in cancer. 
1- The tumour suppressor p53 is an important pro-apoptotic factor and tumour inhibitor, 
and numerous anti-tumour drugs would exert their functions through targeting p53-related 
signalling pathways. Some clinical investigations indicated that under abnormal situations 
such as chemotherapy and UV or DNA damage may occur and activate the expression of 
p53. Activated p53 protein binds to the regulatory sequences of a number of target genes to 
initiate a program of cell cycle arrest, DNA repair, apoptosis, and angiogenesis [38]. If the 
damage cannot be repaired completely, over-activation of p53 leads to the tumour growth 
stagnation or even apoptosis [39,40]. Loss of p53 function is critical in tumourigenesis, and 
alterations to the p53 gene (mutations, often resulting in protein over-expression) are 
frequent events in cancer. Associations of p53 tumour alterations with patient prognosis and 
response to adjuvant chemotherapy have been widely studied, and findings are 
contradictory. The fluoropyrimidine 5-FU is widely used in the treatment of a range of 
cancers including colorectal cancer and breast cancer [41,42,43], but resistance to the drug 
remains a major clinical problem. P53 was the first target described for 5-FU- induced 
apoptosis, however, although several reports have demonstrated that 5-FU-induced 
apoptosis is dependent on the tumour suppressor p53 protein, apoptosis can also occur in 
mutant p53 cell lines [44,45,46,47]. Moreover, the relationship between p53 status and 
sensitivity to chemotherapeutic drugs, including 5- FU, is still controversial. In clinical 
studies in which adjuvant chemotherapy– treated and non-treated groups could be 
analyzed, stage III colorectal patients whose tumours demonstrated no p53 alterations 
experienced significantly longer survival following 5-FU–based chemotherapy than patients 
whose tumours over-expressed p53 [48,49]. However, other studies in colon cancer patients 
failed to demonstrate correlations between p53 alterations and benefit from adjuvant 
therapy [50,51]. The identification of new targets involved in 5-FU-induced apoptosis could 
contribute to clarify the controversy results obtaining in clinic.  
2- Recently, we have identified the interferon-induced protein kinase PKR, as a molecular 
target of 5-FU with an interesting role in the apoptosis induced by this chemotherapeutic 
drug [15]. The double-stranded RNA (dsRNA)-dependent kinase PKR was initially 
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identified as an innate immune anti-viral protein approximately 35 years ago [52,53]. Since 
then, PKR has been linked to normal cell growth and differentiation, inflammation, cytokine 
signalling, and apoptosis [54]. PKR is a serine/threonine kinase, characterized by two 
distinct kinase activities: autophosphorylation, which represents the activation reaction, and 
phosphorylation of eIF-2α [55,56], which impairs eIF-2 activity, resulting in inhibition of 
protein synthesis [57]. In addition to its translational regulatory function, PKR has a role in 
signal transduction and transcriptional control through the IkB/NF-kB pathway [58,59]. PKR 
is activated in response to dsRNA of cellular, viral, or synthetic origin. PKR can also be 
activated by polyanions such as heparin, dextran sulfate, chondroitin sulfate, and poly-L-
glutamine [60]. A range of cellular stresses can also activate PKR, such as arsenite, 
thapsigargin, H2O2, ethanol and ceramide [61,62,63] presumably through the PKR-
associated activator (PACT)/RAX protein [64]. Moreover, it is induced by interferon type I 
and mediates in part, several functions of these cytokines. Altered PKR activity has been 
shown to play a role in neurodegenerative diseases (Alzheimer’s, Creutzfeldt–Jakob, 
Huntington’s, and Parkinson’s) and cancer [65,66,67,68,69,70,71,72,73,74]. 
Over-expression or continued activation of PKR leads to apoptosis [75,76,77]. PKR mediates 
the apoptosis induced by several viruses and cellular stresses [78] by activation of intrinsic 
and extrinsic apoptosis pathways through the FADD/caspase 8 and mitochondrial 
APAF/caspase 9 activation pathways [79,80]. Recently, PKR has been shown to play an 
important role in apoptotic cancer cell death induced by 5-FU, doxorubicin and etoposide 
[15,81,82] and the antitumour activity of tumour suppressors like p53 and PTEN [81,83]. 
Preclinical studies in mice have shown than in tumours which do not express sufficient 
levels of PKR are more resistant to doxorubicin and etoposide that tumour expressing 
higher PKR levels. We have demonstrated that PKR is up-regulated and activated in colon 
and breast cancer cell lines by inducing apoptotic cell death in response to 5-FU treatment. 
In addition, cancer cell lines deficient in PKR expression were more resistant to the cytotoxic 
effect of 5-FU with an IC50 being 2-3 fold higher than cells expressing an active PKR protein. 
Moreover, apoptosis mediated by PKR in response to 5-FU occurred independently on p53 
status highlighted the importance that both p53 and PKR play in the 5-FU-induced cancer 
cell death, and the relevance acquired by PKR in tumour cells where p53 is mutated. Such 
results raise the importance of determining PKR status in tumours from patients treated 
with 5-FU-based chemotherapy [15]. 
3- One pathway being targeted for antineoplastic therapy is the Bcl-2 family of proteins (Bcl-
2, Bcl-XL, Bcl-w, Mcl-1, Bfl1/A-1, and Bcl-B) that bind to and inactivate BH3-domain pro-
apoptotic proteins. It is controversial whether some BH3-domain proteins (Bim or tBid) 
directly activate multidomain pro-apoptotic proteins (e.g., Bax and Bak) or act via inhibition 
of those anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, Bfl1/A-1, and Bcl-B) that 
stabilize pro-apoptotic proteins [84]. Since the anti-apoptotic properties of Bcl-2 were 
discovered, the over-expression of Bcl-2 conferring chemoresistance was reported, and the 
3-D protein structure of Bcl-XL was determined. These properties have contributed to the 
development of protein inhibitors. The first agent targeting Bcl-2 that entered clinical trials 
was a Bcl-2 antisense (oblimersen sodium), which showed chemosensitizing effects when 
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combined with conventional chemotherapy drugs in chronic lymphocytic leukemia (CLL) 
patients, leading to improved survival [85,86]. More recent advances include the discovery 
of small molecule inhibitors of the Bcl-2 family proteins. They are designed to bind the 
hydrophobic groove of anti-apoptotic Bcl-2 proteins in place of BH3-only proteins (i.e., BH3-
mimetics). They can oligomerize Bax or Bak, which can subsequently depolarize 
mitochondrial membrane potential to release cytochrome c. To date, one Bcl-2 antisense and 
three small molecule Bcl-2 protein inhibitors are being tested in clinical trials. Preclinical 
studies seem promising, especially in combination with additional chemotherapy agents. 
Ongoing and planned phase II clinical trials to define the activity of single agents and drug 
combinations will determine the direction of future clinical development of the Bcl-2 
inhibitors [84]. 
4- PUMA (p53 upregulated modulator of apoptosis) is a BH3-only Bcl-2 family member and a 
critical mediator of p53-dependent and -independent apoptosis induced by a wide variety of 
stimuli, including genotoxic stress, deregulated oncogene expression, toxins, altered redox 
status, growth factor/cytokine withdrawal and infection. It serves as a proximal signalling 
molecule whose expression is regulated by transcription factors in response to these stimuli. 
PUMA transduces death signals primarily to the mitochondria and acts indirectly on the Bcl-
2 family members Bax and/or Bak by relieving the inhibition imposed by anti-apoptotic 
members. It directly binds and antagonizes all known anti-apoptotic Bcl-2 family members to 
induce mitochondrial dysfunction and caspase activation [87]. Several lines of evidence 
suggest that the function of PUMA is compromised in cancer cells. PUMA expression was 
found to be reduced in malignant cutaneous melanoma, and PUMA expression appears to be 
an independent predictor of poor prognosis in patients [88]. In addition, approximately 40% 
of primary human Burkitt’s lymphomas do not express detectable levels of PUMA, which is 
attributable, in part, to DNA methylation [89]. Evidence of PUMA induction by therapeutic 
agents in patients has just begun to emerge. Analysis of tissue biopsies from breast cancer 
patients showed that PUMA mRNA was induced within 6 h of chemotherapy [90]. Increased 
expression of PUMA and Bim is associated with better prognosis in patients receiving 5-FU-
based therapy in stage II and III colon cancer, and is an independent prognostic marker for 
overall and disease-free survival [91]. PUMA ablation or inhibition leads to apoptosis 
deficiency underlying increased risks for cancer development and therapeutic resistance. 
Although elevated PUMA expression elicits profound chemo- and radio-sensitization in 
cancer cells, inhibition of PUMA expression may be useful for curbing excessive cell death 
associated with tissue injury and degenerative diseases. Therefore, PUMA is a general sensor 
of cell death stimuli and a promising drug target for cancer. 
5- The apoptosome, a complex of cytochrome-c and APAF-1, recruits and activates the 
initiator pro-caspase 9, leading to the activation of the effector caspases, in particular pro-
caspase 3, culminating in those biochemical and morphological changes associated with 
apoptotic cell death [92]. This pathway is further regulated by the inhibitor of caspase protein 
XIAP, which works through the direct inhibition of active caspases 9 and 3 [93] and is also 
implicated in the ubiquitination of caspases, targeting them for proteasomal degradation [94]. 
Moreover there is a direct interaction between XIAP and its antagonist Smac [95].  
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Because of the importance of this pathway in cancer progression and chemotherapy-induced 
cell death, apoptosome-associated proteins may be important markers for colorectal cancer 
prognosis and chemotherapy response. Several studies have examined the 
immunohistochemical expression of individual proteins associated with apoptosis execution 
in colorectal cancer [96]. Increased expression of APAF-1 has been shown to be associated 
with longer patient survival in rectal cancer patients [97] and loss of APAF-1 has been 
implicated in tumour progression and more aggressive disease [98]. Similarly, longer overall 
survival has been associated with increased Smac [99] and caspase 9 [100]. The anti-apoptotic 
XIAP has also been implicated as a potential prognostic marker for colorectal cancer, with 
increased expression correlating with poor patient outcome [101]. However, no study to date 
has provided a comprehensive analysis of these key regulatory proteins as markers for 
colorectal cancer prognosis or chemotherapy response. Recently, the pro-caspase 3 expression 
in colorectal tumours has been associated with better recurrence-free and overall survival, 
and serves as an independent prognostic marker in localised Stage II disease [102]. This result 
is in agreement with previous studies that demonstrated as caspase 3 expression is a positive 
prognostic marker in hepatocellular carcinoma [103] and diffuse large B-cell lymphoma [104].  
6- The extrinsic apoptosis pathway is triggered by the binding of death ligands of the 
tumour necrosis factor (TNF) family to their appropriate death receptors (DRs) on the cell 
surface. One TNF family member, TRAIL or Apo2L, seems to preferentially cause apoptosis 
of transformed cells and can be systemically administered in the absence of severe toxicity. 
Therefore, there has been enthusiasm for the use of TRAIL or agonist antibodies to the 
TRAIL DR4 and DR5 in cancer therapy. Nonetheless, many cancer cells are very resistant to 
TRAIL apoptosis in vitro. Therefore, there is much interest in identifying compounds that 
can be combined with TRAIL to amplify its apoptotic effects [105]. The combination of 
TRIAL DR agonists with numerous conventional and investigational anticancer drugs has 
been reported. Synergy has been described for the combination of TRAIL with a variety of 
cytotoxic agents including irinotecan, camptothecin, 5-FU, carboplatin, paclitaxel, 
doxorubicin, and gemcitabine in diverse preclinical models [106,107]. Many human and 
mouse cancer cells lines can be sensitized by proteasome inhibitors such as bortezomib 
(VELCADE) to the apoptotic effects of TRAIL DR agonists. Interestingly, non-transformed 
cells seem to be much more resistant to the apoptotic effects of bortezomib and TRAIL than 
are cancer cells. This suggests that a therapeutic window may exist in vivo where this 
combination may have a therapeutic benefit in the absence of accompanying toxicity. 
However, the molecular mechanism(s) of action whereby proteasome inhibition in cancer 
cells results in sensitization to TRAIL apoptosis remains unclear [108].  
3. Selective antitumour-drug inducers of apoptosis 
Improved clinical response may be obtained by identifying therapies that are particularly 
effective in activating apoptosis and determining how those therapies may be modified to 
effect maximum apoptosis induction. The cell cycle apparatus and apoptosis have attracted 
the attention of researchers intent on developing new types of anticancer therapy [109,110]. 
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combined with conventional chemotherapy drugs in chronic lymphocytic leukemia (CLL) 
patients, leading to improved survival [85,86]. More recent advances include the discovery 
of small molecule inhibitors of the Bcl-2 family proteins. They are designed to bind the 
hydrophobic groove of anti-apoptotic Bcl-2 proteins in place of BH3-only proteins (i.e., BH3-
mimetics). They can oligomerize Bax or Bak, which can subsequently depolarize 
mitochondrial membrane potential to release cytochrome c. To date, one Bcl-2 antisense and 
three small molecule Bcl-2 protein inhibitors are being tested in clinical trials. Preclinical 
studies seem promising, especially in combination with additional chemotherapy agents. 
Ongoing and planned phase II clinical trials to define the activity of single agents and drug 
combinations will determine the direction of future clinical development of the Bcl-2 
inhibitors [84]. 
4- PUMA (p53 upregulated modulator of apoptosis) is a BH3-only Bcl-2 family member and a 
critical mediator of p53-dependent and -independent apoptosis induced by a wide variety of 
stimuli, including genotoxic stress, deregulated oncogene expression, toxins, altered redox 
status, growth factor/cytokine withdrawal and infection. It serves as a proximal signalling 
molecule whose expression is regulated by transcription factors in response to these stimuli. 
PUMA transduces death signals primarily to the mitochondria and acts indirectly on the Bcl-
2 family members Bax and/or Bak by relieving the inhibition imposed by anti-apoptotic 
members. It directly binds and antagonizes all known anti-apoptotic Bcl-2 family members to 
induce mitochondrial dysfunction and caspase activation [87]. Several lines of evidence 
suggest that the function of PUMA is compromised in cancer cells. PUMA expression was 
found to be reduced in malignant cutaneous melanoma, and PUMA expression appears to be 
an independent predictor of poor prognosis in patients [88]. In addition, approximately 40% 
of primary human Burkitt’s lymphomas do not express detectable levels of PUMA, which is 
attributable, in part, to DNA methylation [89]. Evidence of PUMA induction by therapeutic 
agents in patients has just begun to emerge. Analysis of tissue biopsies from breast cancer 
patients showed that PUMA mRNA was induced within 6 h of chemotherapy [90]. Increased 
expression of PUMA and Bim is associated with better prognosis in patients receiving 5-FU-
based therapy in stage II and III colon cancer, and is an independent prognostic marker for 
overall and disease-free survival [91]. PUMA ablation or inhibition leads to apoptosis 
deficiency underlying increased risks for cancer development and therapeutic resistance. 
Although elevated PUMA expression elicits profound chemo- and radio-sensitization in 
cancer cells, inhibition of PUMA expression may be useful for curbing excessive cell death 
associated with tissue injury and degenerative diseases. Therefore, PUMA is a general sensor 
of cell death stimuli and a promising drug target for cancer. 
5- The apoptosome, a complex of cytochrome-c and APAF-1, recruits and activates the 
initiator pro-caspase 9, leading to the activation of the effector caspases, in particular pro-
caspase 3, culminating in those biochemical and morphological changes associated with 
apoptotic cell death [92]. This pathway is further regulated by the inhibitor of caspase protein 
XIAP, which works through the direct inhibition of active caspases 9 and 3 [93] and is also 
implicated in the ubiquitination of caspases, targeting them for proteasomal degradation [94]. 
Moreover there is a direct interaction between XIAP and its antagonist Smac [95].  
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Because of the importance of this pathway in cancer progression and chemotherapy-induced 
cell death, apoptosome-associated proteins may be important markers for colorectal cancer 
prognosis and chemotherapy response. Several studies have examined the 
immunohistochemical expression of individual proteins associated with apoptosis execution 
in colorectal cancer [96]. Increased expression of APAF-1 has been shown to be associated 
with longer patient survival in rectal cancer patients [97] and loss of APAF-1 has been 
implicated in tumour progression and more aggressive disease [98]. Similarly, longer overall 
survival has been associated with increased Smac [99] and caspase 9 [100]. The anti-apoptotic 
XIAP has also been implicated as a potential prognostic marker for colorectal cancer, with 
increased expression correlating with poor patient outcome [101]. However, no study to date 
has provided a comprehensive analysis of these key regulatory proteins as markers for 
colorectal cancer prognosis or chemotherapy response. Recently, the pro-caspase 3 expression 
in colorectal tumours has been associated with better recurrence-free and overall survival, 
and serves as an independent prognostic marker in localised Stage II disease [102]. This result 
is in agreement with previous studies that demonstrated as caspase 3 expression is a positive 
prognostic marker in hepatocellular carcinoma [103] and diffuse large B-cell lymphoma [104].  
6- The extrinsic apoptosis pathway is triggered by the binding of death ligands of the 
tumour necrosis factor (TNF) family to their appropriate death receptors (DRs) on the cell 
surface. One TNF family member, TRAIL or Apo2L, seems to preferentially cause apoptosis 
of transformed cells and can be systemically administered in the absence of severe toxicity. 
Therefore, there has been enthusiasm for the use of TRAIL or agonist antibodies to the 
TRAIL DR4 and DR5 in cancer therapy. Nonetheless, many cancer cells are very resistant to 
TRAIL apoptosis in vitro. Therefore, there is much interest in identifying compounds that 
can be combined with TRAIL to amplify its apoptotic effects [105]. The combination of 
TRIAL DR agonists with numerous conventional and investigational anticancer drugs has 
been reported. Synergy has been described for the combination of TRAIL with a variety of 
cytotoxic agents including irinotecan, camptothecin, 5-FU, carboplatin, paclitaxel, 
doxorubicin, and gemcitabine in diverse preclinical models [106,107]. Many human and 
mouse cancer cells lines can be sensitized by proteasome inhibitors such as bortezomib 
(VELCADE) to the apoptotic effects of TRAIL DR agonists. Interestingly, non-transformed 
cells seem to be much more resistant to the apoptotic effects of bortezomib and TRAIL than 
are cancer cells. This suggests that a therapeutic window may exist in vivo where this 
combination may have a therapeutic benefit in the absence of accompanying toxicity. 
However, the molecular mechanism(s) of action whereby proteasome inhibition in cancer 
cells results in sensitization to TRAIL apoptosis remains unclear [108].  
3. Selective antitumour-drug inducers of apoptosis 
Improved clinical response may be obtained by identifying therapies that are particularly 
effective in activating apoptosis and determining how those therapies may be modified to 
effect maximum apoptosis induction. The cell cycle apparatus and apoptosis have attracted 
the attention of researchers intent on developing new types of anticancer therapy [109,110]. 
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We will concentrate in this part of the review on the evolution of the chemical structures 
and on the biological properties, whilst the chemical syntheses will be referred to through 
the corresponding original references. 
3.1. Benzo-fused seven-membered derivatives linked to 5-fluorouracil (5-FU) 
We have reported the synthesis and anticancer activities of compounds 1-5 [16] and trans-6 
[17] (Figure 1). In all cases, the linkage between the 5-FU moiety and the seven-membered 
ring was carried out through its N-1 atom. The structural nature of 5 implies that this 
compound cannot be considered as a 5-FU prodrug and it was suspected that the remaining 
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Figure 1. Several 5-FU derivatives showing interesting anti-tumour activities. 
The IC50 values of the 5-FU cyclic O,N-acetals are shown in Table 1 (entries 4-9). The most 
active compounds are 1, 2 and 6 (entries 4, 5 and 9). On comparing structures 4 and 1, it is 
worth emphasizing that the bioisosteric change of carbon for oxygen and the saturation of 
the double bond in compound 1 increases the anti-proliferative activity two fold in (IC50 = 
7.00 ± 0.61 μM, entry 4). The introduction of a methoxy group into the benzene ring of 1 
provokes different influences on the anti-proliferative activities. Thus, the C-7 substitution 
produces an increase of the anti-proliferative activity (2, IC50 = 4.50 ± 0.33 μM, entry 5), 
whilst if C-9 is the substituted position it gives rise to a decrease in the anti-proliferative 
activity of 3 (IC50 = 22.0 ± 0.93 μM, entry 6). 
Apoptosis has been studied in terms of cancer development and treatment with attempts 
made to identify its role in chemotherapeutic agent-induced cytotoxicity. Cytotoxic agents 
often induce only a fraction of the cells to become apoptotic. To fully exploit apoptosis as a 
mechanism of anti-neoplastic agent response, a larger proportion of cells needs to be 
recruited into apoptosis. Paclitaxel (Taxol®), cyclophosphamide and cytosine arabinoside 
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are the only commonly used cytotoxic agents shown to elicit apoptosis in breast cancer cells 
[111,112]. Quantitation of apoptotic cells was done by monitoring the binding of fluorescein 
isothiocyanate (FITC)-labelled annexin V (a phosphatidylserine-binding protein) to cells in 
response to our title compounds as described [113]. The apoptosis study shows that 3, 4 and 
5, at their IC50 concentrations, provoke early apoptosis in the cells treated for 24 and 48 h. It 
is worth pointing out that 3 (entry 6) induces greater apoptosis at 48 h (46.73%) than at 24 h 
(40.08%). The compounds that show the most important apoptotic indexes at 24 h are 4 
(57.33%, entry 7) and 5 (54.33%, entry 8), whereas at 48 h is 4 (51.37%, entry 7). These 
compounds are more potent as apoptosis inductors against the MCF-7 human breast cancer 
cells than paclitaxel (Taxol®), which induced programmed cell death of up to 43% of the cell 
population [114]. Accordingly, the early apoptotic inductions and the low IC50 values give 
rise to a significant anti-tumour activity. 
Since the synthesized compounds induce very important apoptosis, we have carried out 
studies of the expression of some of the genes that intervene in this phenomenon, among 
which p53 and the family bcl-2 are outstanding. The tumour suppressor gene p53 protects 
the integrity of the genome so that if the DNA of the cell is damaged by an agent, an over-
expression of it is produced inducing the stopping in G1 for the repair of the damage, or if 
this is not possible, enter apoptosis [115]. On the other hand, the members of the family of 
proteins Bcl-2 work as regulators of apoptosis, Bcl-2 and Bcl-XL protecting against 
apoptosis. Bax, Bak and Bad induce such a phenomenon [116]. The treatment of the MCF-7 
cells (wild-type p53) with these compounds provoked in general an increase in the protein 
expression of p53, mainly for 5-FU and 4, and a marked decrease of the levels of bcl-2 for all 
of them. These data show that p53 activity is restored with the compounds, allowing the 
entrance of the tumour cells in apoptosis, which permits their elimination by this 
mechanism. In the same way bcl-2 inhibition facilitates the entrance of cells into the 
programmed cell death. 
 
Entry Compound IC50 (μM)a 
Cell Cycle (48 h)b Apoptosisc 
G0/G1 G2/M S 24 h 48 h 
1 Control  68.39 12.04 19.57  1.24 1.24 
2 5-FU 2.75 58.07 2.10 39.38  56.75 52.81 
3 Ftorafur 3.00  0.11 45.62 0.00 54.38  52.20 58.06 
4 1 7.00  0.61 74.41 15.77 9.82  8.45 12.17 
5 2 4.50  0.33 73.41 13.15 13.44  1.50 3.50 
6 3 22.0  0.93 71.76 10.08 18.16  40.08 46.73 
7 4 14.0  1.02 86.14 1.60 12.26  57.33 51.37 
8 5 69.0  2.31 68.61 9.60 21.79  54.33 35.49 
9 6 5.50  0.58 82.48 5.13 12.40  14.37 19.05 
aSee [117]. bDetermined by flow cytometry: see [16]. cApoptosis was determined using an annexin V-based assay [113]. 
The data indicate the percentage of cells undergoing apoptosis in each sample. All experiments were conducted in 
duplicate and gave similar results. The data are means ± SEM of three independent determinations. 
Table 1. Anti-proliferative activitiy, cell cycle dysregulation, and apoptosis induction in the MCF-7 
human breast cancer cell line after treatment for 24 and 48 h for the compounds. 
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are the only commonly used cytotoxic agents shown to elicit apoptosis in breast cancer cells 
[111,112]. Quantitation of apoptotic cells was done by monitoring the binding of fluorescein 
isothiocyanate (FITC)-labelled annexin V (a phosphatidylserine-binding protein) to cells in 
response to our title compounds as described [113]. The apoptosis study shows that 3, 4 and 
5, at their IC50 concentrations, provoke early apoptosis in the cells treated for 24 and 48 h. It 
is worth pointing out that 3 (entry 6) induces greater apoptosis at 48 h (46.73%) than at 24 h 
(40.08%). The compounds that show the most important apoptotic indexes at 24 h are 4 
(57.33%, entry 7) and 5 (54.33%, entry 8), whereas at 48 h is 4 (51.37%, entry 7). These 
compounds are more potent as apoptosis inductors against the MCF-7 human breast cancer 
cells than paclitaxel (Taxol®), which induced programmed cell death of up to 43% of the cell 
population [114]. Accordingly, the early apoptotic inductions and the low IC50 values give 
rise to a significant anti-tumour activity. 
Since the synthesized compounds induce very important apoptosis, we have carried out 
studies of the expression of some of the genes that intervene in this phenomenon, among 
which p53 and the family bcl-2 are outstanding. The tumour suppressor gene p53 protects 
the integrity of the genome so that if the DNA of the cell is damaged by an agent, an over-
expression of it is produced inducing the stopping in G1 for the repair of the damage, or if 
this is not possible, enter apoptosis [115]. On the other hand, the members of the family of 
proteins Bcl-2 work as regulators of apoptosis, Bcl-2 and Bcl-XL protecting against 
apoptosis. Bax, Bak and Bad induce such a phenomenon [116]. The treatment of the MCF-7 
cells (wild-type p53) with these compounds provoked in general an increase in the protein 
expression of p53, mainly for 5-FU and 4, and a marked decrease of the levels of bcl-2 for all 
of them. These data show that p53 activity is restored with the compounds, allowing the 
entrance of the tumour cells in apoptosis, which permits their elimination by this 
mechanism. In the same way bcl-2 inhibition facilitates the entrance of cells into the 
programmed cell death. 
 
Entry Compound IC50 (μM)a 
Cell Cycle (48 h)b Apoptosisc 
G0/G1 G2/M S 24 h 48 h 
1 Control  68.39 12.04 19.57  1.24 1.24 
2 5-FU 2.75 58.07 2.10 39.38  56.75 52.81 
3 Ftorafur 3.00  0.11 45.62 0.00 54.38  52.20 58.06 
4 1 7.00  0.61 74.41 15.77 9.82  8.45 12.17 
5 2 4.50  0.33 73.41 13.15 13.44  1.50 3.50 
6 3 22.0  0.93 71.76 10.08 18.16  40.08 46.73 
7 4 14.0  1.02 86.14 1.60 12.26  57.33 51.37 
8 5 69.0  2.31 68.61 9.60 21.79  54.33 35.49 
9 6 5.50  0.58 82.48 5.13 12.40  14.37 19.05 
aSee [117]. bDetermined by flow cytometry: see [16]. cApoptosis was determined using an annexin V-based assay [113]. 
The data indicate the percentage of cells undergoing apoptosis in each sample. All experiments were conducted in 
duplicate and gave similar results. The data are means ± SEM of three independent determinations. 
Table 1. Anti-proliferative activitiy, cell cycle dysregulation, and apoptosis induction in the MCF-7 
human breast cancer cell line after treatment for 24 and 48 h for the compounds. 
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3.2. 1-[2-(2-hydroxymethylphenoxy)-1-methoxyethyl]-5-fluorouracils 7a-f: 
antiproliferative activity, cell cycle dysregulation and apoptotic induction 
against breast cancer cells  
Acyclic 5-FU O,N-acetals 7a-f were previously reported by us (Figure 2) [17]. The aminalic 






7a  R1 = R2 = H
7b  R1 = H; R2 = OMe
7c  R1 = Cl; R2 = H
7d  R1 = Br; R2 = H
7e  R1 = NO2; R2 = H
7f  R1 = NH2; R2 = H  
Figure 2. Several acyclic 5-FU O,N-acetals previously reported by us [17]. 
The IC50 values of compounds are shown in Table 2. The most active compound is 7e (5.42 ± 
0.26 μM), with an anti-proliferative activitiy in the same order as that of Ftorafur (3.00 ± 0.11 
μM). Cell cycle regulation has attracted a great deal of attention as a promising target for 
cancer research and treatment. The use of cell-cycle-specific treatments in cancer therapy has 
greatly benefited from the major advances that have been recently made in the identification 
of the molecular actors regulating the cell cycle and from the better understanding of the 
connections between cell cycle and apoptosis. As more and more ‘cell cycle drugs’ are being 
discovered, their use as anticancer drugs is being extensively investigated [118]. To study 
the mechanisms of the anti-tumour and anti-proliferative activities of the compounds, the 
effects on the cell cycle distribution were analyzed by flow cytometry. DMSO-treated cell 
cultures contained 68.39% G0/G1-phase cells, 12.04% G2/M-phase cells and 19.57% S-phase 
cells. In contrast, MCF-7 cells treated during 48 h with the IC50 concentrations of 7a–f 
showed important differences in cell cycle progression compared with DMSO-treated 
control cells. The treatment with Ftorafur showed a decrease of the G0/G1-phase cells and a 
corresponding accumulation of S-phase cells (45.62% G0/G1-phase cells and 54.38% S-phase 
cells). Moreover, there was an almost total disappearance in the G2/M population of the cells 
treated with this drug. In general the cell cycle regulatory activities for the newly 
synthesized compounds can be divided into the following three groups: (a) 7c and 7d 
accumulated the cancerous cells in the G2/M-phase, in the former compound at the expense 
of the S-phase cells, and (b) 7e induced a S-phase cell cycle arrest (50.24%) in a similar 
percentage to that caused by Ftorafur (54.28%, Table 2). Therefore, it can be affirmed that the 
nitro derivative (7e) may act as a 5-FU prodrug. Nevertheless, this hypothesis needs to be 
corroborated by further assays. In response to 40a, the percentage of apoptotic cells 
increased, from 1.24% in control cells to a maximum of 59.9% apoptotic cells (24 h) at a 
concentration equal to its IC50 against the MCF-7 cell line. This is a remarkable property 
because the demonstration of apoptosis in MCF-7 breast cancer cells by known apoptosis-
inducing agents has proved to be difficult and only few cytotoxic agents act preferentially 
through an apoptotic mechanism in human breast cancer cells [113,114]. Finally, a fact worth 
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emphasizing is that 7e (the only compound tested) induced neither toxicity nor death in 
mice after one-month treatment when administered intravenously twice a week, with a 50 
mg/kg dose each time. 
 
Compound IC50 (M)a Cell cycle (48 h)b Apoptosis (h)c 
 G0/G1 G2/M S 24 48 





3.00 ± 0.11 45.62 0 54.38  52.20 58.06 
7a 18.5 ± 0.95 67.18 4.67 28.16 59.90 40.23 
7b 29.0 ± 1.63 62.72 1.59 35.69 33.35 37.87 
7c 18.0 ± 0.85 71.01 28.99 0.00 44.36 50.64 
7d 16.0 ± 1.18 51.45 20.66 27.88 42.24 36.37 
7e 5.42 ± 0.26 46.92 2.84 50.24 40.73 48.22 
7f 21.0 ± 1.02 67.32 9.40 23.28 41.15 37.81 
aSee [117]. bDetermined by flow cytometry: see [16]. cApoptosis was determined using an annexin V-based assay [113]. 
The data indicate the percentage of cells undergoing apoptosis in each sample. All experiments were conducted in 
duplicate and gave similar results. The data are means ± SEM of three independent determinations. 
Table 2. Anti-proliferative activitiy, cell cycle dysregulation, and apoptosis induction in the MCF-7 
human breast cancer cell line after treatment for 24 and 48 h for the compounds. 
3.3. Benzo-Fused Seven-Membered Derivatives Linked To Purines 
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Figure 3. Several cyclic O,N-acetals reported by us [119]. 
The anti-tumour potential of the target molecules is stated against the MCF-7 human breast 
cancer cell line (Table 3). The most active compound (8), that presents an allyloxy group as 
substituent at position 6 of the purine ring, shows an IC50 = 5.04 ± 1.68 μM nearly equipotent 
as 5-FU. Compounds, 9 and 10, present bulky substituents as the phenylthio and 2,4-
diclorophenylthio ones, respectively. 
To study the mechanisms of the anti-tumour and anti-proliferative activities 8-10, the effects 
on the cell cycle distribution were analyzed by flow cytometry (Table 3). DMSO-treated cell 
cultures contained a 58.62 ± 0.74 of the G0/G1-phase cells, a 33.82 ± 0.72 of the S-phase cells 
and a 7.55 ± 1.34 of the G2/M-phase cells. In contrast, MCF-7 cells treated during 48 h with 
 
Apoptosis and Medicine 120 
3.2. 1-[2-(2-hydroxymethylphenoxy)-1-methoxyethyl]-5-fluorouracils 7a-f: 
antiproliferative activity, cell cycle dysregulation and apoptotic induction 
against breast cancer cells  
Acyclic 5-FU O,N-acetals 7a-f were previously reported by us (Figure 2) [17]. The aminalic 






7a  R1 = R2 = H
7b  R1 = H; R2 = OMe
7c  R1 = Cl; R2 = H
7d  R1 = Br; R2 = H
7e  R1 = NO2; R2 = H
7f  R1 = NH2; R2 = H  
Figure 2. Several acyclic 5-FU O,N-acetals previously reported by us [17]. 
The IC50 values of compounds are shown in Table 2. The most active compound is 7e (5.42 ± 
0.26 μM), with an anti-proliferative activitiy in the same order as that of Ftorafur (3.00 ± 0.11 
μM). Cell cycle regulation has attracted a great deal of attention as a promising target for 
cancer research and treatment. The use of cell-cycle-specific treatments in cancer therapy has 
greatly benefited from the major advances that have been recently made in the identification 
of the molecular actors regulating the cell cycle and from the better understanding of the 
connections between cell cycle and apoptosis. As more and more ‘cell cycle drugs’ are being 
discovered, their use as anticancer drugs is being extensively investigated [118]. To study 
the mechanisms of the anti-tumour and anti-proliferative activities of the compounds, the 
effects on the cell cycle distribution were analyzed by flow cytometry. DMSO-treated cell 
cultures contained 68.39% G0/G1-phase cells, 12.04% G2/M-phase cells and 19.57% S-phase 
cells. In contrast, MCF-7 cells treated during 48 h with the IC50 concentrations of 7a–f 
showed important differences in cell cycle progression compared with DMSO-treated 
control cells. The treatment with Ftorafur showed a decrease of the G0/G1-phase cells and a 
corresponding accumulation of S-phase cells (45.62% G0/G1-phase cells and 54.38% S-phase 
cells). Moreover, there was an almost total disappearance in the G2/M population of the cells 
treated with this drug. In general the cell cycle regulatory activities for the newly 
synthesized compounds can be divided into the following three groups: (a) 7c and 7d 
accumulated the cancerous cells in the G2/M-phase, in the former compound at the expense 
of the S-phase cells, and (b) 7e induced a S-phase cell cycle arrest (50.24%) in a similar 
percentage to that caused by Ftorafur (54.28%, Table 2). Therefore, it can be affirmed that the 
nitro derivative (7e) may act as a 5-FU prodrug. Nevertheless, this hypothesis needs to be 
corroborated by further assays. In response to 40a, the percentage of apoptotic cells 
increased, from 1.24% in control cells to a maximum of 59.9% apoptotic cells (24 h) at a 
concentration equal to its IC50 against the MCF-7 cell line. This is a remarkable property 
because the demonstration of apoptosis in MCF-7 breast cancer cells by known apoptosis-
inducing agents has proved to be difficult and only few cytotoxic agents act preferentially 
through an apoptotic mechanism in human breast cancer cells [113,114]. Finally, a fact worth 
 
Apoptosis as a Therapeutic Target in Cancer and Cancer Stem Cells: Novel Strategies and Futures Perspectives 121 
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cultures contained a 58.62 ± 0.74 of the G0/G1-phase cells, a 33.82 ± 0.72 of the S-phase cells 
and a 7.55 ± 1.34 of the G2/M-phase cells. In contrast, MCF-7 cells treated during 48 h with 
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the IC50 concentrations of 8, 9 and 10 showed important differences in cell cycle progression 
compared with DMSO-treated control cells. The cell cycle regulatory activities can be 
divided into the following two groups: (a) the breast cancer cells showed an accumulation in 
the S-phase, up to 37.00 ± 2.00 of the cells, mainly at the expense of the G0/G1-phase 
population that decreased to a percentage of 55.63 ± 1.57 of the cells; (b) compounds 9 and 
10 accumulated the cancerous cells in the G2/M-phase (11.08 ± 1.01 and 19.16 ± 0.56, 
respectively) at the expense of the S-phase cells (26.82 ± 1.26 and 22.73 ± 0.37, respectively). 
In response to 9 (and 10), the percentage of apoptotic cells increased, from 0.22 ± 0.31 in 
control cells to a maximum of 73.37 ± 0.12 (and 65.28 ± 1.92) apoptotic cells at a 
concentration equal to their IC50 against the MCF-7 cell line. This is a remarkable property 
because the demonstration of apoptosis in MCF-7 breast cancer cells by known apoptosis-
inducing agents has proved to be difficult. 
 
Compound Cell cyclea Apoptosisb 
 IC50 (μM) G0/G1 S G2/M  
Control  58.62 ± 0.74 33.82 ± 0.72 7.55 ± 1.34 0.22 ± 0.16 
8 5.04 ± 1.68 55.63 ± 1.57 37.00 ± 2.00 7.37 ± 0.43 44.47 ± 2.98 
9 7.12 ± 0.46 59.10 ± 1.28 26.82 ± 1.26 11.08 ± 0.01 73.37 ± 0.12 
10 8.40 ± 0.91 58.10 ± 0.19 22.73 ± 0.37 19.16 ± 0.56 65.28 ± 1.92 
a Determined by flow cytometry. 3 bApoptosis was determined using an Annexin V-based assay [120]. The data indicate 
the percentage of cells undergoing apoptosis in each sample. All experiments were conducted in duplicate and gave 
similar results. The data are means ± SEM of three independent determinations. 
Table 3. Anti-proliferative activity, cell cycle distribution and apoptosis induction in the MCF-7 human 
breast cancer cell line after treatment for 48 h for the three most active compounds. 
3.4. Anti-cancer activity of 9-(2,3-Dihydro-1,4-benzoxathiin-3-ylMethyl)-9H-purines 
Compounds 1-6 may be considered as drugs with their own entity and anti-tumour activity 
independent of that of 5-FU. If the previously described compounds are not prodrugs, it is 
not necessary to maintain the O,N-acetalic characteristic with the corresponding weakness 
of the O,N-acetalic bond. Therefore, molecules are being designed in which both structural 
entities (such as the benzo-heterocyclic ring and the purine base) are linked by a 
heteroatom-C-C-base-N-atom bond. The design, synthesis and biological evaluation of a 
series of 2- and 6-disubstituted 9-(2,3-dihydro-1,4-benzoxathiin-3-ylmethyl)-9H-purine 








11  R1 = H, R2 = Cl
12  R1 = H; R2 = Br
13  R1 = Cl; R2 = Cl
 
Figure 4. Several non-acetalic purine derivatives reported by us [121]. 
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Compounds 11-13 were subjected to cell cycle and apoptosis studies on the MCF-7 human 
breast cancer cell line (Table 4). The following two consequences can be stated: (a) in 
contrast to 5-FU, the six-membered compounds 11-13 provoked a G0/G1-phase cell cycle 
arrest when the MCF-7 cells were treated during 48 h with the IC50 of the compounds, 
mainly at the expense of the S-phase populations. The fact that at similar doses the novel 
derivatives exhibit different sequences of cell cycle perturbations in comparison with 5-FU 
indicates that these compounds act by different pathways [12]. In the case of 12 it is worth 
pointing out that, moreover, there is an increase in the G2/M-phase of the cancerous cells; 
and (b) the apoptotic indices of the target compounds are very important, especially for 13 
(58.29% for 11, 63.05% for 12, and 76.22% for 13). Up to now and according to our 
knowledge, compound 13 is the most important apoptotic inducer against the MCF-7 
human breast cancer cell line so far reported. 
 
Compound  Cell cyclea Apoptosisb 
 IC50 (μM) G0/G1 S G2/M  
Control  58.62 ± 0.74 33.82 ± 0.72 7.55 ± 1.34 0.22 ± 0.16 
5-FUc 4.32 ± 0.02 58.07 ± 0.11 39.38 ± 0.98 2.10 ± 0.12 52.81 ± 1.05 
11 10.6 ± 0.66 69.71 ± 1.50 23.73 ± 1.65 6.56 ± 0.17 58.29 ± 0.75 
12 6.18 ± 1.70 62.85 ± 0.87 26.71 ± 1.25 10.43 ± 0.38 63.05 ± 0.26 
13 8.97 ± 0.83 70.30 ± 0.32 23.67 ± 2.40 6.06 ± 2.72 76.22 ± 2.02 
aDetermined by flow cytometry [12]. bApoptosis was determined using an Annexin V-based assay [12]. The data 
indicate the percentage of cells undergoing apoptosis in each sample. cData were taken from [117]. All experiments 
were conducted in duplicate and gave similar results. The data are means ± SEM of three independent determinations. 
Table 4. Anti-proliferative activity, cell cycle distribution and apoptosis induction in the MCF-7 human 
breast cancer cell line after treatment for 48 h for the three most active compounds as anti-proliferative 
agents. 
3.5. Anti-cancer activity of cyclic and acyclic O,N-acetals derived from purines 
and 5-FU 
We have recently published two O,N-acetals with outstanding anti-proliferative activities. The 
most potent antiproliferative agent against the MCF-7 adenocarcinoma cell line belongs to the 
benzoxazepine O,N-acetalic family is 9-[1-(9H-fluorenyl-9-methoxycarbonyl)-1,2,3,5-
tetrahydro-4,1-benzoxazepine-3-yl]-6-chloro-9H-purine (14, IC50 = 0.67 ± 0.18 �M), whilst 7-{2-
(N-hydroxymethylphenyl)-2-nitrobenzenesulfonamido]-1-methoxyethyl} -6-chloro-7H-purine 
(15) shows the lowest IC50 value among the family of acyclic O,N-acetals (IC50 = 3.25 ± 0.23 �M) 
(Figure 5). The global apoptotic cells caused by 14 and 15 against MCF-7 were 80.08% and 
54.85% of cell population after 48 h, respectively. cDNA microarray technology reveals 
potential drug targets, which are mainly centred on positive apoptosis regulatory pathway 
genes, and the repression of genes involved in carcinogenesis, proliferation and tumour 
invasion [21]. We demonstrated later on that, when the anthranilic alcohol-derived acyclic 5-
fluorouracil O,N-acetal 16 was administered to human breast cancer cells MCF-7, had no 
activity against classic pro-apoptotic genes such as p53, and even induced the down-regulation 
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the IC50 concentrations of 8, 9 and 10 showed important differences in cell cycle progression 
compared with DMSO-treated control cells. The cell cycle regulatory activities can be 
divided into the following two groups: (a) the breast cancer cells showed an accumulation in 
the S-phase, up to 37.00 ± 2.00 of the cells, mainly at the expense of the G0/G1-phase 
population that decreased to a percentage of 55.63 ± 1.57 of the cells; (b) compounds 9 and 
10 accumulated the cancerous cells in the G2/M-phase (11.08 ± 1.01 and 19.16 ± 0.56, 
respectively) at the expense of the S-phase cells (26.82 ± 1.26 and 22.73 ± 0.37, respectively). 
In response to 9 (and 10), the percentage of apoptotic cells increased, from 0.22 ± 0.31 in 
control cells to a maximum of 73.37 ± 0.12 (and 65.28 ± 1.92) apoptotic cells at a 
concentration equal to their IC50 against the MCF-7 cell line. This is a remarkable property 
because the demonstration of apoptosis in MCF-7 breast cancer cells by known apoptosis-
inducing agents has proved to be difficult. 
 
Compound Cell cyclea Apoptosisb 
 IC50 (μM) G0/G1 S G2/M  
Control  58.62 ± 0.74 33.82 ± 0.72 7.55 ± 1.34 0.22 ± 0.16 
8 5.04 ± 1.68 55.63 ± 1.57 37.00 ± 2.00 7.37 ± 0.43 44.47 ± 2.98 
9 7.12 ± 0.46 59.10 ± 1.28 26.82 ± 1.26 11.08 ± 0.01 73.37 ± 0.12 
10 8.40 ± 0.91 58.10 ± 0.19 22.73 ± 0.37 19.16 ± 0.56 65.28 ± 1.92 
a Determined by flow cytometry. 3 bApoptosis was determined using an Annexin V-based assay [120]. The data indicate 
the percentage of cells undergoing apoptosis in each sample. All experiments were conducted in duplicate and gave 
similar results. The data are means ± SEM of three independent determinations. 
Table 3. Anti-proliferative activity, cell cycle distribution and apoptosis induction in the MCF-7 human 
breast cancer cell line after treatment for 48 h for the three most active compounds. 
3.4. Anti-cancer activity of 9-(2,3-Dihydro-1,4-benzoxathiin-3-ylMethyl)-9H-purines 
Compounds 1-6 may be considered as drugs with their own entity and anti-tumour activity 
independent of that of 5-FU. If the previously described compounds are not prodrugs, it is 
not necessary to maintain the O,N-acetalic characteristic with the corresponding weakness 
of the O,N-acetalic bond. Therefore, molecules are being designed in which both structural 
entities (such as the benzo-heterocyclic ring and the purine base) are linked by a 
heteroatom-C-C-base-N-atom bond. The design, synthesis and biological evaluation of a 
series of 2- and 6-disubstituted 9-(2,3-dihydro-1,4-benzoxathiin-3-ylmethyl)-9H-purine 








11  R1 = H, R2 = Cl
12  R1 = H; R2 = Br
13  R1 = Cl; R2 = Cl
 
Figure 4. Several non-acetalic purine derivatives reported by us [121]. 
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Compounds 11-13 were subjected to cell cycle and apoptosis studies on the MCF-7 human 
breast cancer cell line (Table 4). The following two consequences can be stated: (a) in 
contrast to 5-FU, the six-membered compounds 11-13 provoked a G0/G1-phase cell cycle 
arrest when the MCF-7 cells were treated during 48 h with the IC50 of the compounds, 
mainly at the expense of the S-phase populations. The fact that at similar doses the novel 
derivatives exhibit different sequences of cell cycle perturbations in comparison with 5-FU 
indicates that these compounds act by different pathways [12]. In the case of 12 it is worth 
pointing out that, moreover, there is an increase in the G2/M-phase of the cancerous cells; 
and (b) the apoptotic indices of the target compounds are very important, especially for 13 
(58.29% for 11, 63.05% for 12, and 76.22% for 13). Up to now and according to our 
knowledge, compound 13 is the most important apoptotic inducer against the MCF-7 
human breast cancer cell line so far reported. 
 
Compound  Cell cyclea Apoptosisb 
 IC50 (μM) G0/G1 S G2/M  
Control  58.62 ± 0.74 33.82 ± 0.72 7.55 ± 1.34 0.22 ± 0.16 
5-FUc 4.32 ± 0.02 58.07 ± 0.11 39.38 ± 0.98 2.10 ± 0.12 52.81 ± 1.05 
11 10.6 ± 0.66 69.71 ± 1.50 23.73 ± 1.65 6.56 ± 0.17 58.29 ± 0.75 
12 6.18 ± 1.70 62.85 ± 0.87 26.71 ± 1.25 10.43 ± 0.38 63.05 ± 0.26 
13 8.97 ± 0.83 70.30 ± 0.32 23.67 ± 2.40 6.06 ± 2.72 76.22 ± 2.02 
aDetermined by flow cytometry [12]. bApoptosis was determined using an Annexin V-based assay [12]. The data 
indicate the percentage of cells undergoing apoptosis in each sample. cData were taken from [117]. All experiments 
were conducted in duplicate and gave similar results. The data are means ± SEM of three independent determinations. 
Table 4. Anti-proliferative activity, cell cycle distribution and apoptosis induction in the MCF-7 human 
breast cancer cell line after treatment for 48 h for the three most active compounds as anti-proliferative 
agents. 
3.5. Anti-cancer activity of cyclic and acyclic O,N-acetals derived from purines 
and 5-FU 
We have recently published two O,N-acetals with outstanding anti-proliferative activities. The 
most potent antiproliferative agent against the MCF-7 adenocarcinoma cell line belongs to the 
benzoxazepine O,N-acetalic family is 9-[1-(9H-fluorenyl-9-methoxycarbonyl)-1,2,3,5-
tetrahydro-4,1-benzoxazepine-3-yl]-6-chloro-9H-purine (14, IC50 = 0.67 ± 0.18 �M), whilst 7-{2-
(N-hydroxymethylphenyl)-2-nitrobenzenesulfonamido]-1-methoxyethyl} -6-chloro-7H-purine 
(15) shows the lowest IC50 value among the family of acyclic O,N-acetals (IC50 = 3.25 ± 0.23 �M) 
(Figure 5). The global apoptotic cells caused by 14 and 15 against MCF-7 were 80.08% and 
54.85% of cell population after 48 h, respectively. cDNA microarray technology reveals 
potential drug targets, which are mainly centred on positive apoptosis regulatory pathway 
genes, and the repression of genes involved in carcinogenesis, proliferation and tumour 
invasion [21]. We demonstrated later on that, when the anthranilic alcohol-derived acyclic 5-
fluorouracil O,N-acetal 16 was administered to human breast cancer cells MCF-7, had no 
activity against classic pro-apoptotic genes such as p53, and even induced the down-regulation 
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of anti-apoptotic genes such as Bcl-2. In contrast, several pro-apoptotic genes related with the 
endoplasmic reticulum (ER)-stress-induced apoptosis, such as BBC3 and Noxa, appeared up-
regulated. These results seem to show that the mechanism of action and selectivity of 16 was 
via the activation of the ER-stress-induced apoptosis. The linkage between the 5-FU moiety 


























Figure 5. Several O,N-acetalic purine derivatives reported by us [20,21]. Fmoc is the 
fluorenylmethyloxycarbonyl group; oNs is the -SO2-C6H4-oNO2 group. 
4. Inhibitor of apoptosis protein (IAP) family as therapeutic target 
In the apoptotic pathway, the balance between pro and anti-apoptotic proteins is tightly 
regulated, so an imbalance directed to the anti-apoptotic regulation involves the apparition 
of survival advantages onto the initiating cancerous cells. In this way, the role of the IAPs 
family proteins is important. This family was first identified in baculovirus and the main 
characteristic is the presence of a baculovirus IAP repeat (BIR) domain, that mediates 
interactions with a number of proteins, including caspases and also other structural 
domains such as a RING or caspase activation recruitment domain (CARD) [122] (Figure 6). 
In the IAP family we can find proteins involved in the inhibition of apoptosis through 
inhibition of caspases or modulation of the nuclear factor kB (NF-kB) signalling pathways. 
This family includes eight members in mammals (BIRC1– BIRC8), also known as neuronal 
apoptosis inhibitory protein (NAIP), cellular IAP1 (cIAP1) and IAP2 (cIAP2), Xchromosome 
linked IAP (XIAP), survivin, Apollon (BRUCE), livin (ML-IAP) and ILP2 [123] (Figure 6).  
4.1. Role of the IAPs in apoptosis 
As long as apoptosis pathway must be tightly regulated, the IAPs are the only known 
regulatory proteins that control the activity of both initiator and effectors caspases in the 
process. In this way, there are studies where XIAP was found to prevent caspase-3 
processing in response to caspase-8 activation. So it is suggested that XIAP is able to inhibit 
this extrinsic apoptotic signaling by blocking the downstream effectors caspases, avoiding 
the direct interference of the caspase-8 activation [124]. 
On the other hand, other IAPs proteins are not potent inhibitors of caspases, such as c-IAP 
proteins. They are able to bind with Smac having high affinities to prevent it from blocking 
XIAP-mediated inhibition of caspases. These IAPs also show a E3 ubiquitin ligase activity, 
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allowing the regulation of several cell death effectors and modulators, playing a key role in 
cellular survival. c-IAP1 and c-IAP2 are able to interact with TNFα-receptor-associated 
factors -1 and -2 (TRAFs) trough their association in a complex with TNFα receptor 2. The 
TNFα receptor can mediate survival and death cell signals. In this case, c-IAP1 and c-IAP2 
have been proposed to reduce the level of caspase-8 activation and protect cells from 
apoptosis in a TNFα relationship [10]. 
 
Figure 6. Identifying some of the structural motifs of IAPs. The baculoviral IAP repeat (BIR) domains; 
70–80-amino-acid cysteine- and histidine-rich domains that chelate zinc ions. The presence of at least 
one BIR domain is the defining characteristic of the IAP family. The number of BIR domains in a given 
IAP varies from one to three. Another motif is the really interesting new gene (RING) zinc finger, a 
caspase recruitment domain and ubiquitin-associated (UBA) domains are found in individual IAPs. 
Finally, the CARD motif (Caspase Recruitment Domain) is a protein–protein interaction domain that 
mediates oligomerization with other CARD-containing proteins and is found in a number of proteins 
involved in the regulation of cell death. 
There is another family member of the IAPs, called Livin, which are expressed in high levels 
in melanoma and colon cancer, in embryonic tissues and transformed cells. The over-
expression of Livin isoforms α and β blocks apoptosis induced via the extrinsic death 
receptor pathway [125]. 
Survivin is involved in the control of cell proliferation and cell death and gene expression is 
regulated in a cell cycle dependent manner in mitosis. The spliced transcription of the 
survivin gene gives rise to wild-type survivin, survivin-2α, survivin-2B, survivin-ΔEx-3 and 
survivin-3B. This protein is stabilized by phosphorylation thanks to a p34cdc2–cyclin B1 
complex during mitosis. The anti-apoptotic function of survivin has been linked with its 
interaction with Smac/DIABLO, with the stabilization of XIAP protein through its binding to 
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of anti-apoptotic genes such as Bcl-2. In contrast, several pro-apoptotic genes related with the 
endoplasmic reticulum (ER)-stress-induced apoptosis, such as BBC3 and Noxa, appeared up-
regulated. These results seem to show that the mechanism of action and selectivity of 16 was 
via the activation of the ER-stress-induced apoptosis. The linkage between the 5-FU moiety 
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family proteins is important. This family was first identified in baculovirus and the main 
characteristic is the presence of a baculovirus IAP repeat (BIR) domain, that mediates 
interactions with a number of proteins, including caspases and also other structural 
domains such as a RING or caspase activation recruitment domain (CARD) [122] (Figure 6). 
In the IAP family we can find proteins involved in the inhibition of apoptosis through 
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this extrinsic apoptotic signaling by blocking the downstream effectors caspases, avoiding 
the direct interference of the caspase-8 activation [124]. 
On the other hand, other IAPs proteins are not potent inhibitors of caspases, such as c-IAP 
proteins. They are able to bind with Smac having high affinities to prevent it from blocking 
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allowing the regulation of several cell death effectors and modulators, playing a key role in 
cellular survival. c-IAP1 and c-IAP2 are able to interact with TNFα-receptor-associated 
factors -1 and -2 (TRAFs) trough their association in a complex with TNFα receptor 2. The 
TNFα receptor can mediate survival and death cell signals. In this case, c-IAP1 and c-IAP2 
have been proposed to reduce the level of caspase-8 activation and protect cells from 
apoptosis in a TNFα relationship [10]. 
 
Figure 6. Identifying some of the structural motifs of IAPs. The baculoviral IAP repeat (BIR) domains; 
70–80-amino-acid cysteine- and histidine-rich domains that chelate zinc ions. The presence of at least 
one BIR domain is the defining characteristic of the IAP family. The number of BIR domains in a given 
IAP varies from one to three. Another motif is the really interesting new gene (RING) zinc finger, a 
caspase recruitment domain and ubiquitin-associated (UBA) domains are found in individual IAPs. 
Finally, the CARD motif (Caspase Recruitment Domain) is a protein–protein interaction domain that 
mediates oligomerization with other CARD-containing proteins and is found in a number of proteins 
involved in the regulation of cell death. 
There is another family member of the IAPs, called Livin, which are expressed in high levels 
in melanoma and colon cancer, in embryonic tissues and transformed cells. The over-
expression of Livin isoforms α and β blocks apoptosis induced via the extrinsic death 
receptor pathway [125]. 
Survivin is involved in the control of cell proliferation and cell death and gene expression is 
regulated in a cell cycle dependent manner in mitosis. The spliced transcription of the 
survivin gene gives rise to wild-type survivin, survivin-2α, survivin-2B, survivin-ΔEx-3 and 
survivin-3B. This protein is stabilized by phosphorylation thanks to a p34cdc2–cyclin B1 
complex during mitosis. The anti-apoptotic function of survivin has been linked with its 
interaction with Smac/DIABLO, with the stabilization of XIAP protein through its binding to 
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XIAP and with the inhibition of mitochondrial and apoptosis-inducing factor-dependent 
apoptotic pathways [126]. 
Other IAPs is Bruce/Apollon which is a membrane bounded protein involved in protein 
ubiquination-mediated degradation by its ability to target proteins thanks to the presence of 
a C-terminus E2 motif. It is also shown that Bruce is able to bind to caspase -3, -7 and -9 
[127]. In Bruce regulation are involved the E2 UbcH5 and the E3 Nrdp1, which ubiquitinate 
the epidermal growth factor receptor family member, ErbB3. It has been shown that a 
decrease in Bruce content by Nrdp1 over-expression induces apoptosis in different cell lines. 
These studies suggest that this IAP protein play a critical role in apoptosis inhibition in 
certain cell types avoiding pro-caspase-9 cleavage when it binds to this protein [128]. 
Naip has been studied because of the clinical relevance in tumors such as prostate or breast 
cancer. Naip has two different functions; in the first one it is involved in the inflammatory 
process by caspase-1, -4 and -5 activation, and the second one is via apoptosis regulation by 
caspase-3 and -7 inhibition [129]. Davoody et al showed the cleavage inhibition of procaspase-
3 by apoptosome activated caspase-9 and the inhibition of the autocatalytic processing of 
procaspase-9 in the apoptosome complex. This fact indicates that unlike other IAPs, Naip is 
an inhibitor of procaspase-9 [130].  
Finally, Ts-IAP, also known as ILP-2, is the product of a human testis-specific mRNA and is 
related to the C-ter region of another member of the IAPs protein family, XIAP. It is showed 
that this protein is a weak caspase-9 inhibitor, and also a highly unstable molecule. 
However, a stabilized form of this protein containing nine additional N-ter residues may 
form a complex with Smac/DIABLO [131]. 
4.2. Use of IAPs into clinic: prognostic and therapeutic values  
The expression and/or function of IAPs are deregulated in many human cancers because of 
genetic aberrations, an increase in their mRNA or protein expression or the loss of 
endogenous inhibitors such as Smac. The expression levels of IAPs and their antagonists 
have been correlated with clinical parameters and cancer prognosis in several retrospective 
trials. However, these results should be interpreted with caution due to the low numbers of 
samples studied in some reports and the limitations of currently available reagents for 
analyzing the expression of IAP proteins in tissue specimens. Therefore, additional studies 
are required to evaluate the prognostic value of IAPs in human malignancies [10].  
The issue of primary or acquired resistance to current chemotherapeutic-based treatments is 
a major impediment to effective cancer treatment. Although there are many genetic and 
biochemical alterations that occur in cancer cells, in vitro experiments demonstrate that the 
up-regulation of IAPs expression increases resistance to chemotherapy and radiation. The 
fundamental role of the IAPs in apoptosis regulation and their elevated expression in many 
tumour types suggest that there is value in exploiting the inhibition of IAP expression and 
function as a direct therapeutic strategy [125].  
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Novel drugs have been developed and some of them are in current clinical trials. Several 
strategies have been chosen for anticancer drug development targeting IAP molecules: (1) 
small-molecule IAP antagonists, (2) antisense oligonucleotides (ASOs), (3) Smac mimetic 
molecules and others [132]. Small-molecule IAP antagonists and antisense oligonucleotides 
have garnered the most attention. Also, IAP antagonists have been extensively studied in 
combination with other cytotoxic agents including anticancer drugs, small-molecule signal 
transduction inhibitors, proteasome inhibitors and death receptor ligands as well as with 
radiation therapy. 
4.2.1. Small-molecule IAP antagonists 
Owing to the differences in the mechanism of caspase inhibition by the BIR 2 and BIR 3, 
domain molecules have been developed to specically target the BIR 2 or BIR 3 region of 
XIAP. The structural data surrounding the interaction between the BIR 3 domain of XIAP 
and caspase-9, suggests that small molecules that bind the BIR 3 pocket of XIAP could 
mimic the action of Smac and inhibit the interaction between XIAP and caspase-9. These 
structural studies have facilitated a variety of chemical biology approaches including 
uorescent polarization, nuclear magnetic resonance, ‘in silico’ virtual screening and 
computer modelling to identify BIR 3 inhibitors [133]. The rst small-molecule XIAP 
inhibitors were reported by [134]. These inhibitors were identied using a high throughput 
enzymatic derepression assay in which recombinant XIAP was combined with active 
caspase-3 to inhibit caspase-mediated cleavage of the uorogenic peptide substrate. With 
this assay, they screened 160.000 compounds in 1536-well format and identied potent XIAP 
inhibitors including the compounds TWX006 and TWX024, aryl sulphonamides with 
exible acyclic diamines in the rst and third fragments. These compounds derepressed 
XIAP-mediated inhibition of caspase-3 more potently than Smac. In addition, these 
molecules bound the BIR 2-linker region of XIAP, and, in enzymatic assays, relieved the 
repression of caspase-3 more potently than Smac peptides.  
Recently, small-molecule phenylurea-based chemical inhibitors of XIAP were identified by 
large-scale combinatorial library screening. Subsequent studies have confirmed that the 
active XIAP inhibitors, but not their inactive structural analogues, could induce apoptosis in 
a variety of human cancer cell lines and xenograft. Furthermore, it was determined that 
these XIAP inhibitors act by binding to its BIR-2 domain, resulting in elevated activity of the 
downstream caspase-3 and caspase-7. Thus, the action of these exogenous XIAP inhibitors 
was found to be mechanistically distinct from that of the endogenous inhibitor second 
modulator of apoptotic proteases, which predominantly binds to the BIR-3 domain [135]. 
4.2.2. Antisense oligonucleotides 
The single-stranded antisense oligodeoxynucleotides (AS ODNs) are short stretches of 
synthetic DNA, approximately 12–30 nucleotides long, and are complementary to a specific 
mRNA strand. Hybridization of the AS ODNs to the mRNA by Watson–Crick base pairing 
prevents the target gene from being translated into protein, thereby blocking the action of 
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XIAP and with the inhibition of mitochondrial and apoptosis-inducing factor-dependent 
apoptotic pathways [126]. 
Other IAPs is Bruce/Apollon which is a membrane bounded protein involved in protein 
ubiquination-mediated degradation by its ability to target proteins thanks to the presence of 
a C-terminus E2 motif. It is also shown that Bruce is able to bind to caspase -3, -7 and -9 
[127]. In Bruce regulation are involved the E2 UbcH5 and the E3 Nrdp1, which ubiquitinate 
the epidermal growth factor receptor family member, ErbB3. It has been shown that a 
decrease in Bruce content by Nrdp1 over-expression induces apoptosis in different cell lines. 
These studies suggest that this IAP protein play a critical role in apoptosis inhibition in 
certain cell types avoiding pro-caspase-9 cleavage when it binds to this protein [128]. 
Naip has been studied because of the clinical relevance in tumors such as prostate or breast 
cancer. Naip has two different functions; in the first one it is involved in the inflammatory 
process by caspase-1, -4 and -5 activation, and the second one is via apoptosis regulation by 
caspase-3 and -7 inhibition [129]. Davoody et al showed the cleavage inhibition of procaspase-
3 by apoptosome activated caspase-9 and the inhibition of the autocatalytic processing of 
procaspase-9 in the apoptosome complex. This fact indicates that unlike other IAPs, Naip is 
an inhibitor of procaspase-9 [130].  
Finally, Ts-IAP, also known as ILP-2, is the product of a human testis-specific mRNA and is 
related to the C-ter region of another member of the IAPs protein family, XIAP. It is showed 
that this protein is a weak caspase-9 inhibitor, and also a highly unstable molecule. 
However, a stabilized form of this protein containing nine additional N-ter residues may 
form a complex with Smac/DIABLO [131]. 
4.2. Use of IAPs into clinic: prognostic and therapeutic values  
The expression and/or function of IAPs are deregulated in many human cancers because of 
genetic aberrations, an increase in their mRNA or protein expression or the loss of 
endogenous inhibitors such as Smac. The expression levels of IAPs and their antagonists 
have been correlated with clinical parameters and cancer prognosis in several retrospective 
trials. However, these results should be interpreted with caution due to the low numbers of 
samples studied in some reports and the limitations of currently available reagents for 
analyzing the expression of IAP proteins in tissue specimens. Therefore, additional studies 
are required to evaluate the prognostic value of IAPs in human malignancies [10].  
The issue of primary or acquired resistance to current chemotherapeutic-based treatments is 
a major impediment to effective cancer treatment. Although there are many genetic and 
biochemical alterations that occur in cancer cells, in vitro experiments demonstrate that the 
up-regulation of IAPs expression increases resistance to chemotherapy and radiation. The 
fundamental role of the IAPs in apoptosis regulation and their elevated expression in many 
tumour types suggest that there is value in exploiting the inhibition of IAP expression and 
function as a direct therapeutic strategy [125].  
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molecules and others [132]. Small-molecule IAP antagonists and antisense oligonucleotides 
have garnered the most attention. Also, IAP antagonists have been extensively studied in 
combination with other cytotoxic agents including anticancer drugs, small-molecule signal 
transduction inhibitors, proteasome inhibitors and death receptor ligands as well as with 
radiation therapy. 
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Owing to the differences in the mechanism of caspase inhibition by the BIR 2 and BIR 3, 
domain molecules have been developed to specically target the BIR 2 or BIR 3 region of 
XIAP. The structural data surrounding the interaction between the BIR 3 domain of XIAP 
and caspase-9, suggests that small molecules that bind the BIR 3 pocket of XIAP could 
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the gene, and resulting in the degradation of the target mRNA. The specificity in the AS 
ODN approach is based on the fact that any sequence of approximately 13 bases in RNA 
and 17 bases in DNA is estimated to be represented only once in the human genome. AS 
ODNs targeting survivin expression in human lung adenocarcinoma cell lines decreased 
survivin protein levels in a dose-dependent manner, induced apoptosis, stimulated higher 
levels of caspase-3 activation, and increased the sensitivity of cells to chemotherapeutics. 
XIAP AS ODNs effectively down-regulated both specific mRNA and protein levels in 
human non-small cell lung cancer growth both in vitro and in vivo. XIAP AS ODNs 
effectively induced apoptosis on their own and sensitized the tumor cells to the cytotoxic 
effects of several chemotherapeutics, including Taxol, etoposide and doxorubicin [26]. 
Furthermore, the administration of XIAP AS ODNs in a xenograft model of human non-
small cell lung cancer results in a significant down-regulation of XIAP protein [124]. 
AEG35156 is a 19-mer oligonucleotide targeting XIAP. Its sequence was designed to achieve 
maximal stability and potency and to minimize immunostimulation through avoiding CpG 
motifs. Phase I studies in patients with refractory malignancies established safety [136]. A 
phase I/II study of AEG35156 in combination with idarubicin and high-dose cytarabine in 
patients with relapsed or refractory AML demonstrated a dose-dependent knock-down of 
XIAP mRNA and protein and a promising response rate [137]. The molecule may rapidly 
enter randomized studies in AML while being also tested in lymphomas. The dose-limiting 
toxicity of an antisense oligonucleotide designed to inhibit surviving mRNA expression 
(LY2181308) was headache and the compound demonstrated some biological efficacy in 
decreasing survivin expression [138]. A phase II study has opened in solid tumours. The 
locked nucleic acid strategy was used to design other survivin-targeting antisense 
oligonucleotides, including SPC3042 [139] and EZN-3042 [140], which are currently being 
evaluated in Phase I clinical trials as single agents and in combination with cytotoxic drugs. 
4.2.3. Smac-mimicking IAP antagonist 
Smac mimetics may be a useful therapeutic target as over-expression of Smac may 
potentiate apoptosis by neutralizing the caspase-inhibitory function of IAPs. Following the 
discovery that an IAP-binding motif consisting of four NH2-terminal amino acid residues 
was sufficient to bind to the BIR3 domain of XIAP, Smac-peptide mimetics were constructed 
which were capable of competing with caspase-9, displacing it from the BIR3 domain of 
XIAP. The three members of the IAP family, XIAP, cIAP1, and cIAP2, are structurally 
homologous (XIAP amino acid sequence identity to cIAP1 and cIAP2 of 36% and 39%, 
respectively, the amino acid sequence identity between cIAP1 and cIAP2 is 70%). In 
particular, the BIR3 IBM region is well conserved among the three IAPs. The XIAP BIR3 
residues involved in van der Waals contacts (Val298, Lys299, and Trp310) and hydrogen 
bonds (Gly306, Leu307, and Trp323) with the inhibitory compounds are conserved. Minor 
exceptions are Leu292, replaced by Val in the cIAPs, Glu314 substituted by Asp in both 
cIAPs, and Gln319, which is Glu325 in cIAP1, and Gln311 in cIAP2. Finally, residues Thr308 
and Asp309 that were found relevant for Smac-mimetics interaction with XIAP BIR3, are 
replaced by Arg314/Arg300 and Cys315/ Cys307 in cIAP1/cIAP2, respectively [127].  
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Smac interacts with IAPs via its N-terminal tetrapeptide, Ala1- Val2-Pro3-Ile4 (AVPI). Using 
this structural information, several groups designed small molecules mimicking AVPI to 
derive proteolytically stable compounds. Monovalent Smac mimetics were designed to 
mimic the Smac AVPI-binding motif and so target the XIAP-BIR3 domain. They exhibit high 
affinities, not only to XIAP-BIR3 but also to cIAP1, cIAP2 and MLIAP proteins. Bivalent 
Smac mimetics, containing two AVPI-binding motifs, bind to XIAP-BIR2–BIR3 with an 
extremely high affinity, exceeding that of Smac protein. Preclinical profiling studies have 
shown that Smac mimetics effectively sensitize cancer cells to other therapeutic agents, but 
they are also capable as single agents of inducing apoptosis in some but not all human 
cancer cell lines. To date, two Smac mimetics have reached phase I clinical development, 
and approximately ten are in an advanced preclinical development stage and are expected 
to enter human clinical testing soon [141].  
Smac mimetic binds to XIAP and induces cIAP degradation. There are two cellular events 
that result from cIAP degradation: (1) activation of the non-canonical NF-κB pathway and 
subsequently increased production of autocrine TNF-α and (2) release of RIP1 from the 
TNF-α receptor complex, leading to caspase-8 activation, which requires TNF-α receptor to 
be activated in the first place. Accumulating evidence suggests that whether or not Smac 
mimetic induces autocrine TNF-α production is the key factor in deciding the cell's fate 
upon Smac mimetic treatment. Depending on their response to Smac mimetics cells can be 
grouped into three general classes: in class I cells, Smac mimetic induces autocrine TNF-α 
production and massive cell loss; in class II cells, Smac mimetic still induces autocrine TNF-
α production but this does not have a major effect on the cell population; and in class III 
cells, Smac mimetic has no effect on autocrine TNF-α production or on cell death. The ability 
of cells to produce TNF-α is necessary but not sufficient for Smac mimetic to induce cell 
death as a single agent [142].  
5. miRNA-based therapy 
The miRNAs, is a class of endogenous, small, non-coding RNAs of 18–25 nucleotides in 
length, that negatively regulates gene expression by degradation of mRNA or suppression 
of mRNA translation. Mature miRNA products are formed in from a longer primary 
miRNA (pri-miRNA) transcript through sequential processing by the ribonucleases Drosha 
and Dicer1 [143,144]. miRNAs are known to repress thousands of target genes because only 
partial complementarity to the target mRNA is required. Thus, one miRNA may be 
simultaneously targeting a complexity of mRNAs as well as the expression of a single 
mRNA may be regulated by many miRNAs [143].  
The miRNAs are involved in normal processes, including cellular development, differentiation, 
proliferation, apoptosis, and stem cell self-renewal [28].The aberrant expression or alteration of 
miRNAs contributes to a range of human pathologies, including cancer. Furthermore, the 
deregulation of miRNA causes evasion of apoptosis which involved tumourigenesis and drug 
resistance [122]. During tumour initiation and progression, the functionality of aberrant 
miRNAs may act as oncogenes (OncomiRs) or tumour suppressors (TSmiRs), a numbers of 
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the gene, and resulting in the degradation of the target mRNA. The specificity in the AS 
ODN approach is based on the fact that any sequence of approximately 13 bases in RNA 
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phase I/II study of AEG35156 in combination with idarubicin and high-dose cytarabine in 
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decreasing survivin expression [138]. A phase II study has opened in solid tumours. The 
locked nucleic acid strategy was used to design other survivin-targeting antisense 
oligonucleotides, including SPC3042 [139] and EZN-3042 [140], which are currently being 
evaluated in Phase I clinical trials as single agents and in combination with cytotoxic drugs. 
4.2.3. Smac-mimicking IAP antagonist 
Smac mimetics may be a useful therapeutic target as over-expression of Smac may 
potentiate apoptosis by neutralizing the caspase-inhibitory function of IAPs. Following the 
discovery that an IAP-binding motif consisting of four NH2-terminal amino acid residues 
was sufficient to bind to the BIR3 domain of XIAP, Smac-peptide mimetics were constructed 
which were capable of competing with caspase-9, displacing it from the BIR3 domain of 
XIAP. The three members of the IAP family, XIAP, cIAP1, and cIAP2, are structurally 
homologous (XIAP amino acid sequence identity to cIAP1 and cIAP2 of 36% and 39%, 
respectively, the amino acid sequence identity between cIAP1 and cIAP2 is 70%). In 
particular, the BIR3 IBM region is well conserved among the three IAPs. The XIAP BIR3 
residues involved in van der Waals contacts (Val298, Lys299, and Trp310) and hydrogen 
bonds (Gly306, Leu307, and Trp323) with the inhibitory compounds are conserved. Minor 
exceptions are Leu292, replaced by Val in the cIAPs, Glu314 substituted by Asp in both 
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cancer cell lines. To date, two Smac mimetics have reached phase I clinical development, 
and approximately ten are in an advanced preclinical development stage and are expected 
to enter human clinical testing soon [141].  
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that result from cIAP degradation: (1) activation of the non-canonical NF-κB pathway and 
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be activated in the first place. Accumulating evidence suggests that whether or not Smac 
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α production but this does not have a major effect on the cell population; and in class III 
cells, Smac mimetic has no effect on autocrine TNF-α production or on cell death. The ability 
of cells to produce TNF-α is necessary but not sufficient for Smac mimetic to induce cell 
death as a single agent [142].  
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The miRNAs, is a class of endogenous, small, non-coding RNAs of 18–25 nucleotides in 
length, that negatively regulates gene expression by degradation of mRNA or suppression 
of mRNA translation. Mature miRNA products are formed in from a longer primary 
miRNA (pri-miRNA) transcript through sequential processing by the ribonucleases Drosha 
and Dicer1 [143,144]. miRNAs are known to repress thousands of target genes because only 
partial complementarity to the target mRNA is required. Thus, one miRNA may be 
simultaneously targeting a complexity of mRNAs as well as the expression of a single 
mRNA may be regulated by many miRNAs [143].  
The miRNAs are involved in normal processes, including cellular development, differentiation, 
proliferation, apoptosis, and stem cell self-renewal [28].The aberrant expression or alteration of 
miRNAs contributes to a range of human pathologies, including cancer. Furthermore, the 
deregulation of miRNA causes evasion of apoptosis which involved tumourigenesis and drug 
resistance [122]. During tumour initiation and progression, the functionality of aberrant 
miRNAs may act as oncogenes (OncomiRs) or tumour suppressors (TSmiRs), a numbers of 
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them are strongly related to the apoptosis phenomenon. Therefore, manipulation of miRNA 
expression levels which target genes and pathways that are involved in apoptosis could be a 
potential therapeutic strategy for developing efficient therapies against cancer. In addition, 
given that cancer cells often exhibit a distinctive pattern of miRNA expression, unique profiles 
of altered miRNAs expression could be useful as molecular biomarkers for tumour diagnosis, 
prognosis of disease-specific outcomes, and evaluation of tumour aggressiveness. Based on this, 
several anticancer therapies focusing on restoring miRNA activities and repairing gene 
regulatory networks or drug sensitivity are being developed. 
There are two strategies of molecular therapy targeted at miRNA, one by the inhibition of 
oncogenic miRNAs and the other the over-expression of tumour suppressor miRNAs.  
5.1. Targeting oncogenic miRNAs 
The oncomiRs could be blocked by different approaches such as (i) antisense 
oligonucleotides, (ii) antagomirs, (iii) locked nucleic acid (LNA) constructs or (iv) sponges 
[145]. Antisense oligonucleotides work as competitive inhibitors of miRNA, leading to the 
up-regulation of tumour suppressor proteins, inducing apoptosis and blocking tumour 
formation in vitro and in vivo. Some of the potential ways to enhance miRNA stability 
include chemical modifications. In order to improve their effectiveness and stability, 
antisense oligonucleotides, have been modified on their 50 end, by adding 20-O-methyl and 
20-O-methoxyethyl groups [146]. Oligonucleotides with 2′-O-methyl groups have proved to 
be effective inhibitors of miRNA expression in several cancer cell lines [30,147,148,149]. The 
utility of anti-miRNA oligonucleotide in vivo through intravenous injection of modified 
anti-miRNA oligonucleotide O-methyl-modified cholesterol-conjugated single stranded 
RNA analogues has been studied, with phosphorothioate linkages, an ‘antagomirs’, to target 
the liver-specific miR-122. Specific miR-122 silencing for up to 23 days was conferred with 
only a single injection of 240 mg•kg-1 body weight [150]. 
On the other hand, the locked-nucleic-acid antisense oligonucleotides exhibit relatively low 
toxicity and have been optimized by reducing their molecular size which has increased their 
therapeutic potential [151]. LNA anti-miR’ constructs have been used successfully in several 
in vitro studies to knock down specific miRNA expression [151,152]. Also it has showed that 
miR-221 and miR-222 knockdown through antisense LNA oligonucleotides increases 
p27Kip1 in human prostate cancer (PC3) cells and strongly reduces their clonogenicity in 
vitro [153]. In vivo, the use of LNAs has achieved unexpected success for the treatment of 
hepatitis C in non-human primates [154]. These finding demonstrate the impressive 
potential of this strategy to overcome a major hurdle for clinical miRNA therapy.  
Moreover, other techniques have emerged as an effective way to repress expression levels of 
miRNA families. A new form of miRNA inhibitors that can be transiently expressed in cultured 
mammalian cells, “miRNA sponges”, was developed. Sponges are ectopically expressed 
mRNAs that contain multiple miRNA target sites of miRNA that share the same seed sequence 
[155]. In contrast to miRNA sponges, Xiao et al. designed alternative strategy called “miRNA 
masking” which covers up the miRNA-binding site to depress its target mRNA [156]. 
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Although several in vitro and in vivo technologies have been developed to inhibit the 
oncomiRs, it is still a long and arduous way to go for substantial applications of miRNAs in 
cancer treatments. To date, many OncomiRs seem to have a role in apoptosis (Table 5), 
therefore some have been regarded as hallmarks in tumour progressions and hot targets in 
cancer therapy. Thus, miR-21 is functionally considered oncogenic because it is 
overexpressed in various tumours [157,158]. In fact, antisense inhibition of miR-21 leads to 
the induction of programmed cell death in neuroepithelial cells, through activation of 
caspases [159]. This apoptosis induction was also confirmed in breast cancer, colon cancer, 
pancreas cancer, lung cancer, liver cancer, prostate cancer, stomach cancer and oral squamous 
cell carcinoma (OSCC) [31,160,161,162,163]. So far, multiple targets of miR-21 have been 
identified and mapped to anti-apoptotic signalling pathways which suggest a promising 
miRNA treatment for cancer [31,164]. Other examples have been reported; in breast cancer 
cells, the overexpresion of the anti-apoptotic Bcl-2 is restored by the silencing of miR-15a and 
miR-16 through the use of specific inhibitors [165]. As the anti-apoptotic Bcl-2 is frequently 
overexpressed in a number of human cancers, such as Hodgkin’s lymphoma, cell lymphoma 
and breast, miR-15 and miR-16, it could be used for therapy of cancer-associated phenotypes.  
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5.2. Restoration of tumour suppressor miRNAs 
The restoration of tumour suppressor miRNAs, as a therapeutic strategy, includes viral 
delivery or synthetic miRNA mimics. Elevation of the expression levels of miRNAs can 
restore tumour inhibitory functions in cancer cells. Adeno-associated virus delivery of 
miRNAs or miRNA antagonists has the advantage of being efficient and because the virus 
does not integrate into the genome, non-mutagenic. In Myc-induced liver tumours, 
intravenous injection of adeno-associated virus 8 (AAV8)-expressing miR-26 resulted in the 
suppression of tumourigenicity by inducing tumour-apoptosis, without signs of toxicity 
[191]. These findings indicate a possibility strategy for the treatment of liver cancer, 
however, before this approach achieve widespread clinical use, the delivery and safety of 
different treatments needs to be improved.  
Another strategy to increase the expression of a tumour-suppressor miRNA in cancer could 
be overcome by miRNA mimics, which are small, chemically modified double-stranded 
RNA molecules designed to mimic endogenous mature miRNAs [192]. Introduction of 
synthetic miRNA mimics with tumour-suppressor function in cancer cells have been 
implicated to induce cell death and block proliferation in several studies 
[30,147,178,184,186]. In prostate and AMl cell lines mimics of miR-15a and miR-29 
respectively, induced apoptosis by repression of anti-apoptotic genes Mcl-1 and Bcl-2 [184]. 
Multiple miRNAs have been found to inhibit the apoptotic pathway following their over 
expression during cancer development. Reduced expression of miR-15, miR-16, and let-7 has 
been observed in different types of cancers and as one consequence anti-apoptotic genes and 
apoptotic signalling pathways have been activated in these cancer cells [30,187,193]. As well, 
transfection of anti-miR-24 oligonucleotides has been proved to induce apoptosis in several 
cell lines [194]. It has been reported that miR-195, miR-24-2 and miR-365-2 act as negative 
regulators of the anti-apoptotic proto-oncogene Bcl2. The overexpression of these miRNAs 
caused an increase in apoptosis and also augmented the apoptotic effect of etoposide in 
breast cancer MCF7 cells [195]  
5.3. miRNAs and drug resistance 
Several miRNA, some of them related to apoptosis, have been associated with drug 
resistance. Deregulation of miR-214 is a recurrent event in human ovarian cancer and it has 
been shown that miR-214 induces cell survival and cisplatin resistance primarily through 
targeting the PTEN/Akt pathway [196]. Also, is known that the let-7 family of miRs plays a 
role in a host of cellular functions such as modulation of drug sensitivity. The miRNA let-7a 
which directly targeting caspase-3 is over-expressed in some human cancers and has been 
shown to induce resistance to a variety of drugs caspase-3-dependent apoptosis, including 
doxorubicin, paclitaxel and interferon-gamma. Let-7e was up-regulated in some ovarian 
cancer cell lines with increased resistance to doxorubicin. On other hand, it has been 
reported that let-7i is down-regulated in chemotherapy-resistant ovarian cancer, and 
reintroduction of let-7i can sensitize resistant ovarian cancer cell lines to platinum-based 
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chemotherapy [188]. In a non small cell lung cancer cell line, the down-regulation of miR-
186* which increased the expression of its direct target, Caspase-10, has been indicated the 
cause of the apoptosis induced by the chemopreventive agent curcumin [189]. Thus, the 
effect of anti-cancer drugs that modulate cell proliferation apoptosis on miRNA expression 
profiles was explored and could help for predicting apoptosis resistance. As a result, the 
knowledge of potential miRNAs implicated in apoptosis resistance could avoid unnecessary 
morbidity and may represent a novel class of biomarkers for facilitating personalized 
treatment. 
6. Cancer stem cells and apoptosis 
Some cancers are originated in cells with intrinsic self-renewal activity or in differentiated 
cells in which self-renewal is activated by oncogenic mechanisms; hence, the study of 
normal self-renewal is important to improve our understanding of these mechanisms. 
Cancers express a spectrum of aberrantly differentiated cells, ranging from those that 
appear well differentiated to those that appear undifferentiated, and these phenotypes are 
commonly evident in the same tumour. This suggests that the transformation process can 
induce defects throughout the multistep differentiation process. Recent data suggest that 
cancers arise from rare self-renewing stem cells that are biologically distinct from their more 
numerous differentiated progeny. A small number of cells identied as cancer stem cells 
(CSCs) from solid tumours usually express organ-specic markers, contribute to 
chemotherapy resistance and are able to generate a new tumour in immunodecient mice. 
Moreover, there is growing evidence that pathways regulating normal stem cell self-renewal 
and differentiation are also present in cancer cells and CSCs [197]. 
Currently, there are two theories on the origin of cancer: the classic clonal evolution theory 
or stochastic model, by which malignant transformation results from random mutations and 
subsequent clonal selection of cancer cells with similar potential to regenerate the tumour 
growth [198,199]; and the CSC hypothesis, which considers the tumour to be formed by a 
small population of cells with stem cell-like properties. The features in common with stem 
cells are: indefinite self-replication, asymmetric cell division, and resistance to toxic agents, 
owing, in part, to elevated expression of ABC transporters [199,200,201]. In addition, they 
are also characterized by genetic instability (chromosomal and microsatellite), changes of 
chromatin, transcription and epigenetics, mobilization of cellular resources, and modified 
microenvironment interactions (tumour cells, stromal cells, extracellular, endothelium) 
[202]. Both paradigms of tumour propagation are likely to exist in human cancer but only 
the CSC model is hierarchical. It is important to note that the two models are not mutually 
exclusive, as CSCs undergo clonal evolution, as shown for leukaemia stem cells [203]. 
The theory of cancer stem cells is not new, having started wonderings in the 19th century 
when comparing cancerous and embryonic tissue in the microscope and certain similarities 
were observed, annotating the idea that tumours arising from embryonic-like cells. This 
theory continued to evolve, and the isolation of four different tumour subpopulations from 
a single breast cancer in a mouse was reported in the decade of the 80s[204]. Tumour 
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5.2. Restoration of tumour suppressor miRNAs 
The restoration of tumour suppressor miRNAs, as a therapeutic strategy, includes viral 
delivery or synthetic miRNA mimics. Elevation of the expression levels of miRNAs can 
restore tumour inhibitory functions in cancer cells. Adeno-associated virus delivery of 
miRNAs or miRNA antagonists has the advantage of being efficient and because the virus 
does not integrate into the genome, non-mutagenic. In Myc-induced liver tumours, 
intravenous injection of adeno-associated virus 8 (AAV8)-expressing miR-26 resulted in the 
suppression of tumourigenicity by inducing tumour-apoptosis, without signs of toxicity 
[191]. These findings indicate a possibility strategy for the treatment of liver cancer, 
however, before this approach achieve widespread clinical use, the delivery and safety of 
different treatments needs to be improved.  
Another strategy to increase the expression of a tumour-suppressor miRNA in cancer could 
be overcome by miRNA mimics, which are small, chemically modified double-stranded 
RNA molecules designed to mimic endogenous mature miRNAs [192]. Introduction of 
synthetic miRNA mimics with tumour-suppressor function in cancer cells have been 
implicated to induce cell death and block proliferation in several studies 
[30,147,178,184,186]. In prostate and AMl cell lines mimics of miR-15a and miR-29 
respectively, induced apoptosis by repression of anti-apoptotic genes Mcl-1 and Bcl-2 [184]. 
Multiple miRNAs have been found to inhibit the apoptotic pathway following their over 
expression during cancer development. Reduced expression of miR-15, miR-16, and let-7 has 
been observed in different types of cancers and as one consequence anti-apoptotic genes and 
apoptotic signalling pathways have been activated in these cancer cells [30,187,193]. As well, 
transfection of anti-miR-24 oligonucleotides has been proved to induce apoptosis in several 
cell lines [194]. It has been reported that miR-195, miR-24-2 and miR-365-2 act as negative 
regulators of the anti-apoptotic proto-oncogene Bcl2. The overexpression of these miRNAs 
caused an increase in apoptosis and also augmented the apoptotic effect of etoposide in 
breast cancer MCF7 cells [195]  
5.3. miRNAs and drug resistance 
Several miRNA, some of them related to apoptosis, have been associated with drug 
resistance. Deregulation of miR-214 is a recurrent event in human ovarian cancer and it has 
been shown that miR-214 induces cell survival and cisplatin resistance primarily through 
targeting the PTEN/Akt pathway [196]. Also, is known that the let-7 family of miRs plays a 
role in a host of cellular functions such as modulation of drug sensitivity. The miRNA let-7a 
which directly targeting caspase-3 is over-expressed in some human cancers and has been 
shown to induce resistance to a variety of drugs caspase-3-dependent apoptosis, including 
doxorubicin, paclitaxel and interferon-gamma. Let-7e was up-regulated in some ovarian 
cancer cell lines with increased resistance to doxorubicin. On other hand, it has been 
reported that let-7i is down-regulated in chemotherapy-resistant ovarian cancer, and 
reintroduction of let-7i can sensitize resistant ovarian cancer cell lines to platinum-based 
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chemotherapy [188]. In a non small cell lung cancer cell line, the down-regulation of miR-
186* which increased the expression of its direct target, Caspase-10, has been indicated the 
cause of the apoptosis induced by the chemopreventive agent curcumin [189]. Thus, the 
effect of anti-cancer drugs that modulate cell proliferation apoptosis on miRNA expression 
profiles was explored and could help for predicting apoptosis resistance. As a result, the 
knowledge of potential miRNAs implicated in apoptosis resistance could avoid unnecessary 
morbidity and may represent a novel class of biomarkers for facilitating personalized 
treatment. 
6. Cancer stem cells and apoptosis 
Some cancers are originated in cells with intrinsic self-renewal activity or in differentiated 
cells in which self-renewal is activated by oncogenic mechanisms; hence, the study of 
normal self-renewal is important to improve our understanding of these mechanisms. 
Cancers express a spectrum of aberrantly differentiated cells, ranging from those that 
appear well differentiated to those that appear undifferentiated, and these phenotypes are 
commonly evident in the same tumour. This suggests that the transformation process can 
induce defects throughout the multistep differentiation process. Recent data suggest that 
cancers arise from rare self-renewing stem cells that are biologically distinct from their more 
numerous differentiated progeny. A small number of cells identied as cancer stem cells 
(CSCs) from solid tumours usually express organ-specic markers, contribute to 
chemotherapy resistance and are able to generate a new tumour in immunodecient mice. 
Moreover, there is growing evidence that pathways regulating normal stem cell self-renewal 
and differentiation are also present in cancer cells and CSCs [197]. 
Currently, there are two theories on the origin of cancer: the classic clonal evolution theory 
or stochastic model, by which malignant transformation results from random mutations and 
subsequent clonal selection of cancer cells with similar potential to regenerate the tumour 
growth [198,199]; and the CSC hypothesis, which considers the tumour to be formed by a 
small population of cells with stem cell-like properties. The features in common with stem 
cells are: indefinite self-replication, asymmetric cell division, and resistance to toxic agents, 
owing, in part, to elevated expression of ABC transporters [199,200,201]. In addition, they 
are also characterized by genetic instability (chromosomal and microsatellite), changes of 
chromatin, transcription and epigenetics, mobilization of cellular resources, and modified 
microenvironment interactions (tumour cells, stromal cells, extracellular, endothelium) 
[202]. Both paradigms of tumour propagation are likely to exist in human cancer but only 
the CSC model is hierarchical. It is important to note that the two models are not mutually 
exclusive, as CSCs undergo clonal evolution, as shown for leukaemia stem cells [203]. 
The theory of cancer stem cells is not new, having started wonderings in the 19th century 
when comparing cancerous and embryonic tissue in the microscope and certain similarities 
were observed, annotating the idea that tumours arising from embryonic-like cells. This 
theory continued to evolve, and the isolation of four different tumour subpopulations from 
a single breast cancer in a mouse was reported in the decade of the 80s[204]. Tumour 
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heterogeneity is reflected in different phenotypic aspects such as cell morphology, gene 
expression, metabolism, motility and proliferation, immunogenic, angiogenic and metastatic 
potential [202]. 
 
Figure 7. A. The clonal evolution model of cancer is based on the fact that accumulation of a series of 
mutations (inhibition of apoptosis, angiogenesis,…) in any somatic cell can cause a tumour. B. The 
cancer stem cell model is based on the principle that a progenitor cell capable of self-renewal and 
proliferation (stem cell characteristics) is the cause of formation of a tumour. 
TUMOUR TYPE MARKERS Reference 
Hematological malignancies CD34+ / CD38- [207] 
CNS CD133+ [208] 
Colon CD133+/ EpCAMhi / CD44+ / 
CD166+ 
[209,210] 
Breast CD24-/low /CD44+ [211] 
Lung CD133+ [212] 
Pancreas CD44+ / CD24+ / EpCAM+/ CD133+ [213] 
Liver  CD90+ [214] 
Prostate CD44+ / CD133 / α2β1hi [215] 
Bladder CD44+ / CK5+/ CD20- [216] 
Ovaries CD44+ / CD117+ [217] 
Head and neck CD44+ [218] 
Melanoma ABCB5+ [219] 
Table 6. Phenotypic markers of CSCs in various tumours. 
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Molecular characterization of CSCs is necessary to develop a targeted therapy (Table 6). 
They have been isolated from several tumour types including haematological malignancies 
(the first evidence) [205], breast, brain, colon, lung, head and neck, prostate, pancreas and 
liver cancers and melanoma. The subpopulation of CSCs self renews, differentiates, and 
regenerates a phenocopy of the original tumour when injected into immunodeficient mice 
[206]. 
Tumour stem cells may display multidrug resistance that is conferred by ABC transporters. 
These ABC transporters have been reported as CSCs markers in melanoma and 
osteosarcoma, among others. These transporters are up-regulated in CSCs, and the low-
staining fraction of cells with the ability to efux Hoechst 33342 dye is commonly known as 
the side population (SP) [33]. Targeted inactivation of ABC transporters could reinstate drug 
sensitivity in CSCs, resulting in their death. Moreover, pathways that regulate self-renewal 
of normal stem cells, such as Wnt, Notch and Hedgehog, tumor suppressor genes, such as 
PTEN and p53, have been implicated in the control of CSCs self-renewal. These pathways 
are believed to be deregulated in CSCs, leading to uncontrolled self-renewal and generation 
of tumours that are resistant to conventional therapies [220]. The above mentioned 
characteristics and the ability of CSCs to evade cell death signals contribute to the failure of 
existing therapies to eradicate malignant tumours, causing resistance to treatment and an 
increased morbidity and mortality [201,221]. Apoptosis is one of the most critical and well-
studied mechanisms, governing tissue development and homeostasis through a complex 
network of molecules that mediate death and survival signals. Escape from death program 
is a prerequisite for any tumour-initiating cell and may support the survival of CSCs in 
response to chemo- or radio-therapy. Thus, manipulating the apoptotic machinery to 
eradicate tumour-initiating cells holds enormous therapeutic potential [206]. 
Several studies have focused on apoptosis induction in CSCs by intervening in the extrinsic 
or intrinsic pathways to treat cancer. 
6.1. TRAIL 
TRAIL has been demonstrated to induce apoptosis in a wide range of cancer types both in 
vitro and also in various mouse models of human cancers [106]. In certain types of tumours 
a correlation has been established between the expression of DR and CSCs. Chemotherapy-
resistant colon cancer SP cells express high levels of DR4 [222]; in some bladder cancer cell 
lines there is an increased expression of DR5 [223], and, in glioblastoma and lung CSCs 
express DRs [206]. More importantly, several clinical trials have explored the response to the 
use of DRs as a treatment. Studies concluded that SP cells of colon cancer displayed higher 
sensitivity to TRAIL compared to the non-SP cells [222]. In bladder cancer treatment 
sensitivity was greater in those showing increased expression of DR5 [223]. Moreover, 
isolated neurospheres from glioblastomas with characteristics of stem cells showed 
differences in apoptosis after treatment with TRAIL and it was effective in those who keep 
the route intact for caspase 8. Genomic heterogeneity in glioblastomas suggests the presence 
of multiple mechanisms in TRAIL resistance in both CSCs and non-stem cells. Future 
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Molecular characterization of CSCs is necessary to develop a targeted therapy (Table 6). 
They have been isolated from several tumour types including haematological malignancies 
(the first evidence) [205], breast, brain, colon, lung, head and neck, prostate, pancreas and 
liver cancers and melanoma. The subpopulation of CSCs self renews, differentiates, and 
regenerates a phenocopy of the original tumour when injected into immunodeficient mice 
[206]. 
Tumour stem cells may display multidrug resistance that is conferred by ABC transporters. 
These ABC transporters have been reported as CSCs markers in melanoma and 
osteosarcoma, among others. These transporters are up-regulated in CSCs, and the low-
staining fraction of cells with the ability to efux Hoechst 33342 dye is commonly known as 
the side population (SP) [33]. Targeted inactivation of ABC transporters could reinstate drug 
sensitivity in CSCs, resulting in their death. Moreover, pathways that regulate self-renewal 
of normal stem cells, such as Wnt, Notch and Hedgehog, tumor suppressor genes, such as 
PTEN and p53, have been implicated in the control of CSCs self-renewal. These pathways 
are believed to be deregulated in CSCs, leading to uncontrolled self-renewal and generation 
of tumours that are resistant to conventional therapies [220]. The above mentioned 
characteristics and the ability of CSCs to evade cell death signals contribute to the failure of 
existing therapies to eradicate malignant tumours, causing resistance to treatment and an 
increased morbidity and mortality [201,221]. Apoptosis is one of the most critical and well-
studied mechanisms, governing tissue development and homeostasis through a complex 
network of molecules that mediate death and survival signals. Escape from death program 
is a prerequisite for any tumour-initiating cell and may support the survival of CSCs in 
response to chemo- or radio-therapy. Thus, manipulating the apoptotic machinery to 
eradicate tumour-initiating cells holds enormous therapeutic potential [206]. 
Several studies have focused on apoptosis induction in CSCs by intervening in the extrinsic 
or intrinsic pathways to treat cancer. 
6.1. TRAIL 
TRAIL has been demonstrated to induce apoptosis in a wide range of cancer types both in 
vitro and also in various mouse models of human cancers [106]. In certain types of tumours 
a correlation has been established between the expression of DR and CSCs. Chemotherapy-
resistant colon cancer SP cells express high levels of DR4 [222]; in some bladder cancer cell 
lines there is an increased expression of DR5 [223], and, in glioblastoma and lung CSCs 
express DRs [206]. More importantly, several clinical trials have explored the response to the 
use of DRs as a treatment. Studies concluded that SP cells of colon cancer displayed higher 
sensitivity to TRAIL compared to the non-SP cells [222]. In bladder cancer treatment 
sensitivity was greater in those showing increased expression of DR5 [223]. Moreover, 
isolated neurospheres from glioblastomas with characteristics of stem cells showed 
differences in apoptosis after treatment with TRAIL and it was effective in those who keep 
the route intact for caspase 8. Genomic heterogeneity in glioblastomas suggests the presence 
of multiple mechanisms in TRAIL resistance in both CSCs and non-stem cells. Future 
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clinical trials of TRAIL apoptotic pathway targeted therapies may consider genomic analysis 
of tumour tissue to identify the genomic status of TRAIL apoptotic genes such as caspase 8 
and use it as a genomic marker to predict tumour resistance to TRAIL apoptotic pathway-
targeted therapies [224]. In addition, recent studies are focused on combining mesenchymal 
stem cells (MSCs) expressing TRAIL and chemotherapy. These MSCs migrated to tumours 
and reduced the growth of primary cancers and metastases by induction of apoptosis, death 
and reduced colony formation of the SP and were synergistic when combined with 
traditional chemotherapy in apoptosis induction [225]. 
6.2. cFLIP 
cFLIP is overexpressed in many types of cancers like melanoma, colon lymphoma and 
thyroid cancer [226]. The CD133+ populations within the T-cell acute leukemia cell line 
Jurkat and the breast cancer cell line MCF7 were reported to express higher levels of cFLIP, 
which was associated with TRAIL resistance. The down-regulation of cFLIP using siRNA 
restored TRAIL signalling in both cell lines resulting in a dramatic reduction in 
experimental metastases and the loss of CSC self-renewal [227]. This suggests that a 
combined TRAIL/FLIPi therapy could prevent metastatic disease progression in cancers. 
6.3. IAP 
In CD133 + cells isolated from glioblastoma an increased mRNA expression of livin, 
survivin and the multidrug resistance-associated protein 1 (MRP1) was detected. Therefore, 
the effects of etoposide, a pro-apoptosis agent, on these associated protein genes in 
glioblastoma stem-like cells have been studied. Results showed that after etoposide 
treatment, glioblastoma CSCs displayed a stronger resistance to apoptosis and death. The 
anti-apoptotic gene livinβ was more related with the high survival rate and MRP1 was more 
related with transporting chemotherapeutic agent out of glioblastoma stem-like cells [228]. 
In pancreatic cancer it has been demonstrated that targeting XIAP by RNAi inside the cancer 
cells, the combination of TRAIL with MSCs suppressed metastatic growth in these tumours 
[229]. Recently, it has been demonstrated that survivin is regulated by the interleukin-4 (IL-
4) pathway in colon CSCs. Blockage of IL-4-mediated signaling pathway with leflunomide, 
Stat6 inhibitor, increased the nuclear survivin pool suggesting that the IL-4/STAT-6 pathway 
could escape cell death. IL-4 neutralization, mediated by STAT-6, could down-regulate 
survivin expression and localization, increasing the nuclear pool and in this way inducing 
chemo-sensitivity of CSCs [230].  
6.4. Bcl-2  
The proteins Bcl-2 family members are anti-apoptotic molecules known to be over-
expressed in most cancers, and are associated directly with the CSCs [231]. Therefore, recent 
studies are aimed to target these proteins. A representative example is found in pancreatic 
cancer, against which the most potent and clinically acceptable Bcl-2 inhibitor AT-101 is 
currently in 20 different clinical trials around the world [232]. In glioblastoma, high 
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expression levels of the anti-apoptoticc Bcl-2 protein, Mcl-1, were associated with resistance 
to treatment with Bcl-2 inhibitor ABT-737 in glioma stem cells [233]. In hematopoietic 
malignances, it has been showed that despite the over-expression of Bcl-2 this is not the 
critical point for the generation, selection and maintenance of leukemia stem cells [234].  
6.5. NF-kB 
The transcription factor NF-κB has been connected to multiple aspects of oncogenesis, 
including inhibition of apoptosis by increasing the expression of survival factor. In fact, 
aberrant regulation of NF-κB has been observed in many cancers, including both solid and 
hematopoietic tumours [235]. A fairly representative example is found in pancreatic cancer, 
where there is a clear correlation between the basal activity of NF-kB and the ability to 
generate angiogenesis and metastasis of pancreatic tumour cells [236] and, more recently it 
has been found that not only in this way, but also in the non-canonical NF-kB is also 
activated and functional [237]. A very interesting study by [238] showed that in CD44+ 
breast CSCs the expression of CD24 potentiated DNA-induced apoptosis by suppressing 
anti-apoptotic NF-κB signaling. Several therapies are being developed to inhibit this factor 
because there are many tumours which relate the decrease in the activity of NF-kB with a 
decrease in the size and tumor growth [239,240,241,242,243]. 
6.6. DNA repair capacity 
A classic mechanism involved in the induction of apoptosis is in response to DNA damage 
by p53 action. This gene is mutated in most human cancers and inactivated in about 50% of 
cancers [244]. p53 was found to repress the CSC marker gene CD44 in an experimental 
breast tumour model and the over-expression of CD44 blocked p53-dependent apoptosis, 
leading to expansion of tumour-initiating cells [245]. Moreover, glioma CSCs resist radiation 
through preferential activation of the retainer DNA damage response and an increase in 
DNA repair capacity. In addition, the radioresistance of CD133+ glioma stem cells could be 
reversed with a specific inhibitor of Chk1 and Chk2 checkpoint kinases [208]. Another 
report reinforces the tumour-promoting effect of DNA damage response activation in 
leukemia stem cells by demonstrating that cell-cycle inhibitor p21 was indispensable for 
maintaining self-renewal of these CSCs [246]. 
6.7. miRNAs, apoptosis and CSCs 
Recently, miRNAs have emerged as key regulators of "stemness", collaborating in the 
maintenance of pluripotency, control of self-renewal, and differentiation of stem cells. 
Moreover, certain miRNAs involved in apoptosis appear to influence the CSC fate by 
controlling self-renewal. It has been shown that restoration of miR-34 modulates self-
renewal in pancreatic CSCs by directly regulating down-stream target gene Notch and Bcl-2 
[247]. Also the restoration of miR-34, inhibit p53-mutant gastric cancer tumourspheres 
growth in vitro and tumour formation in vivo, which is reported to be correlated to the self-
renewal of CSCs [248]. As miR-34 is a significant tumour suppressor of CSCs by regulation 
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clinical trials of TRAIL apoptotic pathway targeted therapies may consider genomic analysis 
of tumour tissue to identify the genomic status of TRAIL apoptotic genes such as caspase 8 
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restored TRAIL signalling in both cell lines resulting in a dramatic reduction in 
experimental metastases and the loss of CSC self-renewal [227]. This suggests that a 
combined TRAIL/FLIPi therapy could prevent metastatic disease progression in cancers. 
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the effects of etoposide, a pro-apoptosis agent, on these associated protein genes in 
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treatment, glioblastoma CSCs displayed a stronger resistance to apoptosis and death. The 
anti-apoptotic gene livinβ was more related with the high survival rate and MRP1 was more 
related with transporting chemotherapeutic agent out of glioblastoma stem-like cells [228]. 
In pancreatic cancer it has been demonstrated that targeting XIAP by RNAi inside the cancer 
cells, the combination of TRAIL with MSCs suppressed metastatic growth in these tumours 
[229]. Recently, it has been demonstrated that survivin is regulated by the interleukin-4 (IL-
4) pathway in colon CSCs. Blockage of IL-4-mediated signaling pathway with leflunomide, 
Stat6 inhibitor, increased the nuclear survivin pool suggesting that the IL-4/STAT-6 pathway 
could escape cell death. IL-4 neutralization, mediated by STAT-6, could down-regulate 
survivin expression and localization, increasing the nuclear pool and in this way inducing 
chemo-sensitivity of CSCs [230].  
6.4. Bcl-2  
The proteins Bcl-2 family members are anti-apoptotic molecules known to be over-
expressed in most cancers, and are associated directly with the CSCs [231]. Therefore, recent 
studies are aimed to target these proteins. A representative example is found in pancreatic 
cancer, against which the most potent and clinically acceptable Bcl-2 inhibitor AT-101 is 
currently in 20 different clinical trials around the world [232]. In glioblastoma, high 
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expression levels of the anti-apoptoticc Bcl-2 protein, Mcl-1, were associated with resistance 
to treatment with Bcl-2 inhibitor ABT-737 in glioma stem cells [233]. In hematopoietic 
malignances, it has been showed that despite the over-expression of Bcl-2 this is not the 
critical point for the generation, selection and maintenance of leukemia stem cells [234].  
6.5. NF-kB 
The transcription factor NF-κB has been connected to multiple aspects of oncogenesis, 
including inhibition of apoptosis by increasing the expression of survival factor. In fact, 
aberrant regulation of NF-κB has been observed in many cancers, including both solid and 
hematopoietic tumours [235]. A fairly representative example is found in pancreatic cancer, 
where there is a clear correlation between the basal activity of NF-kB and the ability to 
generate angiogenesis and metastasis of pancreatic tumour cells [236] and, more recently it 
has been found that not only in this way, but also in the non-canonical NF-kB is also 
activated and functional [237]. A very interesting study by [238] showed that in CD44+ 
breast CSCs the expression of CD24 potentiated DNA-induced apoptosis by suppressing 
anti-apoptotic NF-κB signaling. Several therapies are being developed to inhibit this factor 
because there are many tumours which relate the decrease in the activity of NF-kB with a 
decrease in the size and tumor growth [239,240,241,242,243]. 
6.6. DNA repair capacity 
A classic mechanism involved in the induction of apoptosis is in response to DNA damage 
by p53 action. This gene is mutated in most human cancers and inactivated in about 50% of 
cancers [244]. p53 was found to repress the CSC marker gene CD44 in an experimental 
breast tumour model and the over-expression of CD44 blocked p53-dependent apoptosis, 
leading to expansion of tumour-initiating cells [245]. Moreover, glioma CSCs resist radiation 
through preferential activation of the retainer DNA damage response and an increase in 
DNA repair capacity. In addition, the radioresistance of CD133+ glioma stem cells could be 
reversed with a specific inhibitor of Chk1 and Chk2 checkpoint kinases [208]. Another 
report reinforces the tumour-promoting effect of DNA damage response activation in 
leukemia stem cells by demonstrating that cell-cycle inhibitor p21 was indispensable for 
maintaining self-renewal of these CSCs [246]. 
6.7. miRNAs, apoptosis and CSCs 
Recently, miRNAs have emerged as key regulators of "stemness", collaborating in the 
maintenance of pluripotency, control of self-renewal, and differentiation of stem cells. 
Moreover, certain miRNAs involved in apoptosis appear to influence the CSC fate by 
controlling self-renewal. It has been shown that restoration of miR-34 modulates self-
renewal in pancreatic CSCs by directly regulating down-stream target gene Notch and Bcl-2 
[247]. Also the restoration of miR-34, inhibit p53-mutant gastric cancer tumourspheres 
growth in vitro and tumour formation in vivo, which is reported to be correlated to the self-
renewal of CSCs [248]. As miR-34 is a significant tumour suppressor of CSCs by regulation 
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of both apoptosis and self-renewal properties, restoration of miR-34 may hold significant 
promise for a novel molecular therapy. Data also suggest that let-7 regulates apoptosis and 
CSC differentiation, which is considered as a key “keeper” of the differentiated state. In this 
context decreased expression of these TSmiRs implicated in self-renewal could lead to 
further cancer progression. 
7. Conclusion 
In this chapter we have summarized the research in the discovery of molecules, biomarkers 
for predicting therapeutic response and regulatory pathways implicated in apoptosis 
induction. These strategies are contributing to design cancer-targeted therapies that 
diminish or circumvent toxicity and improve life quality and overall survival of patients. 
The selective eradication of cancer cells can be achieve with small molecules and 
monoclonal antibodies, used as single agents or in combination with conventional 
chemotherapy, that interfere with the deregulated cellular signals that promote proliferation 
and survival to block tumor growth or sensitize cancer cells to apoptosis while leaving 
normal cells unaffected. Moreover, targeted therapies reactivating death program in CSCs 
may synergize with established therapies and increase efficacy in the clinic.  
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Regiospecific microwave-assisted synthesis and cytotoxic activity against human breast 
cancer cells of (RS)-6-substituted-7-or 9-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)-7H- 
or-9H-purines. European Journal of Medicinal Chemistry 43: 1742-1748. 
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of both apoptosis and self-renewal properties, restoration of miR-34 may hold significant 
promise for a novel molecular therapy. Data also suggest that let-7 regulates apoptosis and 
CSC differentiation, which is considered as a key “keeper” of the differentiated state. In this 
context decreased expression of these TSmiRs implicated in self-renewal could lead to 
further cancer progression. 
7. Conclusion 
In this chapter we have summarized the research in the discovery of molecules, biomarkers 
for predicting therapeutic response and regulatory pathways implicated in apoptosis 
induction. These strategies are contributing to design cancer-targeted therapies that 
diminish or circumvent toxicity and improve life quality and overall survival of patients. 
The selective eradication of cancer cells can be achieve with small molecules and 
monoclonal antibodies, used as single agents or in combination with conventional 
chemotherapy, that interfere with the deregulated cellular signals that promote proliferation 
and survival to block tumor growth or sensitize cancer cells to apoptosis while leaving 
normal cells unaffected. Moreover, targeted therapies reactivating death program in CSCs 
may synergize with established therapies and increase efficacy in the clinic.  
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1. Introduction 
A growing body of clinical and experimental evidence has revealed a strong impact of drug 
resistance on clinical outcomes, especially in cancer therapy, since carcinogenesis is a multi-
step, multi-pathway and multi-focal process, which involves a series of epigenetic and ge-
netic alterations [1-3]. In order to solve the serious issue facing clinical treatment, combina-
tion therapy is now widely advocated for clinical use and has been shown to have a benefi-
cial effect on patient satisfaction [3, 4]. For instance, 5-fluorouracil (5-FU) and leucovorin 
with either irinotecan or oxaliplatin have been widely used for the treatment of patients 
with colorectal cancer [5, 6]. Furthermore, recently, various types of molecular target-based 
drugs, such as cetuximab and bevacizumab, are being used clinically. Although these con-
tinuous efforts to exploit potential combination therapies are ongoing, there is still a grow-
ing concern about treatment resistance, disease relapse and side effects of drugs clinically 
used. Of note, numerous components of edible plants, collectively termed phytochemicals 
that have beneficial effects for health, are increasingly being reported in the scientific litera-
ture and these compounds are now widely recognized as potential therapeutic compounds 
[1, 2, 4, 7, 8]. In fact, natural product derived substances, especially polyphenolic com-
pounds with very little toxic effects on normal cells, have attracted great attention in the 
therapeutic arsenal in clinical oncology due to their chemopreventive, antitumoral, radio-
sensibilizing and chemosensibilizing activities against various types of aggressive and re-
current cancers [1, 8-10].   
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Apoptosis, or programmed cell death, plays a key role in the development and growth 
regulation of normal cells, and is often dysregulated in cancer cells [11, 12]. It has been 
accepted that the aim of anticancer therapy is generally focused on apoptosis induction in 
premalignant and malignant cells, although other multiple molecular mechanisms such as 
modulation of carcinogen metabolism, anti-angiogenesis and induction of differentiation are 
also known to be implicated in its anticancer activity [4, 13]. So far, two principal signal 
pathways of apoptosis have been identified [11, 12]. The intrinsic mechanism of apoptosis 
involves a mitochondrial pathway. Apoptosis stimuli destruct mitochondrial membrane 
structure under the control of Bcl-2 (B-cell leukemia/lymphoma) family, resulting in the 
release of mitochondrial proteins including cytochrome c. Once cytochrome c is released it 
activates caspase-9 (initiator caspase) through the interaction with Apaf-1 (apoptotic 
protease activating factor-1) and dATP [14, 15], which ultimately leads to caspase-3 and -7 
(effector caspases) activation [16]. On the other hand, the extrinsic pathway induced by 
death receptors, such as tumor necrosis factor receptor (TNFR) and Fas, is responsible for 
the activation of caspase-8 and caspase-10 (initiator caspase) accompanied by the activation 
of caspase-3 and -7 [16]. The effector caspases are the final mediators in the intrinsic and 
extrinsic pathways that cleave substrates and lead to cell death. Moreover, a third pathway 
involving endoplasmic reticulum (ER) stress and caspase-12 has been reported to be 
associated in apoptosis [4, 13]. A number of markers have been utilized to reveal apoptosis 
status including cell viability, cytochrome c release, caspase-3 activation, poly (ADP-ribose) 
polymerase (PARP) cleavage, and DNA fragmentation [17].  
Reactive oxygen species (ROS) have been widely believed to play a pivotal role in a wide 
variety of cellular functions, including cell proliferation and differentiation [3, 11]. Further-
more, oxidative stress, as a result of alterations of redox homeostasis due to an imbalance 
between ROS production and elimination, is known to be involved in many diseases such as 
hypoxic injury [11, 18]. Therefore, maintaining ROS homeostasis is crucial for normal cell 
growth and survival. Generally, cancer cells appear to generate more ROS than do normal 
cells due to its increased aerobic glycolysis. Furthermore, cancer cells exhibit increased ROS 
production and altered redox status. Recent studies suggest that these biochemical charac-
teristics of cancer cells can be exploited for therapeutic benefits [3, 18]. Especially, tumors in 
advanced stage frequently exhibit multiple genetic alterations and high oxidative stress, 
suggesting that it is possible to preferentially eliminate these cells by pharmacological ROS 
insults. However, the upregulation of antioxidant capacity in adaptation to intrinsic oxida-
tive stress in cancer cells can confer drug resistance [3, 18]. Thus, abrogation of such drug-
resistant mechanisms by redox modulation could have significant therapeutic implications 
[2, 3, 18, 19]. Indeed, it has been known that altered redox status is closely associated with 
apoptosis induction in various cancer cells [2, 3, 18, 19]. Collectively, manipulating ROS 
levels by redox modulation is a way to selectively kill cancer cells without causing signifi-
cant toxicity to normal cells. 
Polyphenolic compounds such as flavonoids and curcumin have been shown to induce 
apoptosis in various malignant cells including solid tumors and hematologic malignant cells 
[1, 2, 7-9, 20-22]. Interestingly, the mechanisms underlying the apoptosis induction, 
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associated with their antitumoral, chemopreventive and chemotherapeutic activities, have 
been shown to be implicated in alteration of redox status, since polyphenolic compounds 
are well known to possess both antioxidant and prooxidant activity [1, 2, 7, 8, 10, 20, 22-26].      
In this chapter, we will highlight the recent advances on the cancer preventative activities of 
the polyphenolic compounds, including flavonoids such as anthocyanins, and Vitex agnus-
castus fruit extract (Vitex) in which flavonoids are one of major components, as well as 
curcumin based on the most recent results from in vitro cell culture and in vivo animal 
model tumor systems. We will further summarize the detailed mechanisms underlying their 
cytocidal effects focusing on apoptosis induction. We will also provide detailed insight into 
potential future clinical application of these promising candidates endowed with potent 
antitumor activities, alone or in combination with other anticancer clinical drugs based on 
preclinical and clinical trial results.  
2. Cancer preventative activities of the polyphenolic compounds, 
anthocyanins, Vitex, and curcumin 
2.1. Resource and chemistry of anthocyanins, Vitex, and curcumin    
The most abundant flavonoid constituents of fruits and vegetables are anthocyans (i.e. 
anthocyanins (glycosides), and their aglycones, anthocyanidins) that confer bright red or 
blue coloration on berries and other fruits and vegetables [8, 20]. Anthocyanins are 
especially interesting with respect to other flavonoids because they occur in the diet at 
relatively high concentrations. The daily intake of anthocyanins in the US diet has been 
suggested to be 180-255 mg/day, in contrast, the daily intake of most other dietary 
flavonoids, including genistein, quercetin and apigenin, is estimated to be only 20-25 
mg/day [27]. Anthocyanidins are a diphenylpropane-based polyphenolic ring structure, and 
are limited to a few structure variants including cyanidin, delphinidin, malvidin, 
pelargonidin, peonidin and petunidin (Figure 1), with a distribution in nature of 50%, 12%, 
12%, 12%, 7%, and 7%, respectively, and they present almost exclusively as glycosides, 
anthocyanins [28]. Furthermore, epidemiological evidence has demonstrated that 
consumption of fruits and berries has been associated with decreased risk of developing 
cancer [29]. 
Vitex agnus-castus is a shrub of the Verbenaceae family and is found naturally in the Middle 
East and Southern Europe. Ripe fruit of Vitex agnus-castus has been used as a folk medicine 
for the treatment of various obstetric and gynecological disorders in Europe [30, 31]. 
Itokawa and colleagues have reported that Vitex (an extract from dried ripe Vitex agnus-
castus) possesses cytocidal effects on P388, a mouse leukemia cells, suggesting its antitumor 
activity, and that flavonoids such as luteolin (Figure 2) are one of its major constituents  
[32, 33].  
Curcumin, a hydrophobic polyphenol, also known as turmeric, is a major bioactive 
ingredient extracted from the rhizome of the plant Curcuma longa [34, 35]. Curcumin has 
been used as a dietary supplement as well as therapeutic agent in Chinese medicine and 
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Figure 1. Chemical structure of anthocyanidins 
 
Figure 2. Chemical structure of luteolin 
 
Figure 3. Chemical structures of naturally occurring curcumin. The scheme shows the diketone and 
keto-enol forms of curcumin. Curcumin exists as an equilibrium mixture of two tautomeric forms in 
solution. The enol structure of curcumin, which is stabilized by intramolecular H-bonding, is the most 
energetically stabilized and favored form. 
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other Asian medicines for centuries due to its safety and tolerance [34, 35]. Curcumin has a 
unique conjugated structure including two methylated phenols linked by the enol form of a 
heptadiene-3,5-diketone that gives the compound a bright yellow color (Figure 3) [7, 35]. 
2.2. Involvement of altered redox status in apoptosis induction triggered by 
polyphenolic compounds 
2.2.1. Anthocyans 
It has been demonstrated that anthocyanin-rich extracts from berries and grapes, and sever-
al pure anthocyanins and anthocyanidins, exhibit pro-apoptotic effects in multiple cell types 
such as colon [23, 36], breast [37, 38], prostate [39, 40], and leukemia cancer cells [10, 41]. 
They induce apoptosis through both intrinsic (mitochondrial) and extrinsic (Fas) pathways. 
In the intrinsic pathway, the treatment of cancer cells with anthocyanin results in destabili-
zation of the mitochondrial membrane, cytochrome c release and activation of caspase-9, 
and -3 as well as pro-apoptotic protein such as apoptosis inducing factor [10, 37, 40]. In the 
extrinsic pathway, anthocyanins modulate the expression of Fas and FasL (Fas ligand) in 
cancer cells, which result in the activation of caspase-8, then cleaves Bid to tBid, and ulti-
mately stimulates cytochrome c release [41]. Of note, several lines of evidence have indicat-
ed that oxidative stress resulted from stimulation of ROS production and/or insufficient 
ROS elimination is implicated in anthocyanins-triggered apoptosis induction in cancer cells, 
although broad biological activities including antimutagenesis and anticarcinogenesis of 
anthocyanins are generally attributed to their antioxidant activity [2, 7, 10, 22-25]. Indeed, it 
has been demonstrated that the most common type of anthocyanins, cyanidin-3-rutinoside, 
induced apoptosis in a human myeloid leukemia cell line, HL-60, in a dose- and time-
dependent manner accompanied by accumulation of peroxides [10]. Cyanidin-3-rutinoside 
treatment resulted in ROS-dependent activation of p38 mitogen-activated protein kinase 
(MAPK) and c-Jun N-terminal kinase (JNK), which contributed to cell death by activating 
the mitochondrial pathway mediated by Bim, one of proapoptotic gene of Bcl-2 family [10]. 
More importantly, cyanidin-3-rutinoside treatment did not lead to increased ROS accumula-
tion in normal human peripheral blood mononuclear cells (PBMNC) without inducing cyto-
toxic effects on these cells [10] as indicated by our preliminary data concerning treatment of 
HL-60 and PBMNC with anthocyanidin (unpublished data). These results suggest that cya-
nidin-3-rutinoside could be used in leukemia therapy with the advantages of being widely 
available and selective against tumors. More recently, delphinidin and cyanidin were re-
ported to induce apoptosis in a human metastatic colorectal cancer cell line, LoVo and 
LoVo/ADR, a doxorubicin-resistant LoVo, but not in cells originating from a primary tumor 
site, i.e. Caco-2 [23]. Furthermore, LoVo/ADR was more sensitive to anthocyanins than LoVo 
cells [23]. It has been reported that the rate of lactate production is significantly higher in 
LoVo/ADR than in LoVo cells [42]. Therefore, the differences in changes of cellular energy 
metabolism associated with neoplastic transformation has been suggested to contribute the 
differential sensitivities to these anthocyanins [43]. Moreover, ROS accumulation, inhibition 
of glutathione reductase, and depletion of GSH were observed in the apoptosis triggered by 
anthocyanidins in these metastatic colorectal cancer cell lines [23]. These experimental re-
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other Asian medicines for centuries due to its safety and tolerance [34, 35]. Curcumin has a 
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2.2. Involvement of altered redox status in apoptosis induction triggered by 
polyphenolic compounds 
2.2.1. Anthocyans 
It has been demonstrated that anthocyanin-rich extracts from berries and grapes, and sever-
al pure anthocyanins and anthocyanidins, exhibit pro-apoptotic effects in multiple cell types 
such as colon [23, 36], breast [37, 38], prostate [39, 40], and leukemia cancer cells [10, 41]. 
They induce apoptosis through both intrinsic (mitochondrial) and extrinsic (Fas) pathways. 
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induced apoptosis in a human myeloid leukemia cell line, HL-60, in a dose- and time-
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More importantly, cyanidin-3-rutinoside treatment did not lead to increased ROS accumula-
tion in normal human peripheral blood mononuclear cells (PBMNC) without inducing cyto-
toxic effects on these cells [10] as indicated by our preliminary data concerning treatment of 
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LoVo/ADR, a doxorubicin-resistant LoVo, but not in cells originating from a primary tumor 
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sults are in good agreement with previous reports on a possible role of flavonoids, as well as 
other phytochemicals, in modulating the glutathione (GSH) antioxidant activity, including 
regulation of intracellular GSH levels through targeting its synthesis, induction of multiple 
resistant protein 1 mediated GSH efflux, or inhibition of glutathione peroxidase enzyme 
activity observed in hematopoietic malignant and solid cancer cells in vitro and in vivo [19, 
24, 44]. Furthermore, an in vitro study showed that anthocyanidins inhibit glutathione re-
ductase (GR) in an oxygen-dependent manner, presumably via the effect of superoxide [45]. 
Therefore, these results suggest that anthocyanidins may be used as sensitizing agents 
through modulating intracellular redox status in various cancer therapy.  
Intriguingly, a good correlation has been found between anthocyanin chemical structure 
and chemoprotective activity. Indeed, several lines of evidence have shown that the 
number of hydroxyl groups on the B-ring of anthocyanidins is associated with the potency 
of prooxidative [45-47], apoptotic induction [48], anti-transformation [49], as well as anti-
oxidative activities [1, 8]. For instance, delphinidin and cyanidin that possess ortho-
dihydroxyphenyl structure on the B-ring, showed stronger apoptotic induction in human 
leukemia cells [48] and inhibitory effect on 12-O-tetradecanoylphorbol-13-acetate (TPA)-
induced cell transformation [49]. Furthermore, a similar trend of structure-activity 
relationship was also observed in the suppression of transcription factors closely associated 
with intracellular redox status, such as activator protein-1 (AP-1), nuclear factor-κB (NF-
κB), and CCAAT/enhancer-binding protein (C/EBPδ) [20, 49, 50]. Structure-activity studies 
also suggested that the potency as inhibitors of epidermal growth factor receptor (EGFR), a 
target of an expanding class of anticancer therapies [51], might be positively correlated 
with the presence of hydroxyl functions in positions 3’ and 5’ of ring B of the 
anthocyanidinos molecule, and inversely with the presence of methoxy groups in these 
positions. All of these findings provide important molecular basis for the antitumor 
properties of anthocyanidins.      
2.2.2. Vitex 
We have been interesting the effects of naturally derived flavonoids on the growth of 
various types of cancer cells. Of those, we have demonstrated that Vitex exhibits cytotoxic 
activities against various types of solid tumor cells, such as KATO-III (a human gastric 
signet ring carcinoma cell line), COLO 201 (a human colon adenocarcinoma cell line), MCF-7 
(a human breast carcinoma cell line) [52]. More interestingly, no apparent cytotoxicity was 
observed in non-tumor cells, such as human uterine cervical canal fibroblast (HCF) and 
human embryo fibroblast (HE-21) when treated with concentrations showing significant 
cytotoxicity in tumor cells, suggesting a selective cytotoxic activity against tumor cells [52]. 
We further demonstrated that Vitex induced apoptosis accompanied by an accumulation of 
intracellular ROS along with the decrease in the levels of intracellular GSH in KATO-III cells 
[22]. At the same time, our experimental data demonstrated a decrease in the amount of Bcl-
2, Bcl-xL and Bid proteins; an increase in Bad protein; activation of caspase-8, -9 and -3; a 
leakage of cytochrome c from mitochondria in the cells [22]. Furthermore, the addition of an 
antioxidant, N-acetyl-L-cysteine (NAC), or exogenous GSH significantly abrogated the  
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effects of Vitex [22]. Together, our results suggest that a crosstalk between intrinsic and 
extrinsic pathway via Bid activation as a result of oxidative stress plays a critical role in 
Vitex-induced apoptosis in KATO-III cells. We also demonstrated that apoptosis induction 
was observed in Vitex-treated COLO 201, concomitantly with a significant increase in heme 
oxygenase-1 (HO-1) gene expression as observed in KATO-III cells [53]. On the other hand, 
unlike KATO-III, apoptosis induction was not abrogated in the presence of antioxidants, 
such as NAC [53]. We further demonstrated that after treatment with Vitex, the upregula-
tion of ER stress-related genes, such as glucose-regulated protein 78 (GRP78) and C/EBP-
homologous protein (CHOP) along with the activation of caspase-9 and -3 were observed in 
COLO 201 [21]. However, an inhibitor for JNK significantly suppressed the apoptosis induc-
tion associated with caspase-3 activation [21]. These results thus suggest that the activation 
of JNK, and caspase-9 and -3 resulted from ER stress contributed to the apoptosis induction 
in Vitex-treated COLO 201 cells. Taken together, it seems that either oxidative stress-
dependent or ER stress-dependent apoptosis would be triggered in cancer cells treated with 
Vitex depending on different cell types. Most importantly, our in vivo experimental data 
revealed that the administration of Vitex significantly suppressed tumor growth in COLO 
201 xenograft mice, although more studies must be conducted to understand detailed in 
vivo pharmacological characterization of Vitex treatment [21]. In addition, as shown in Fig-
ure 4, we recently demonstrated a significant dose-dependent cytocidal effect in both a well-
differentiated hepatocellular carcinoma (HCC) cell line, HepG2 and an undifferentiated 
HCC cell line, HLE, although the levels of cytotoxic activities of Vitex varied between two 
cells. Similarly, a significant dose-dependent cytocidal effect was also observed in both cells 
when treated with as high as 20 μg/ml luteolin, one of major constituents of Vitex. However, 
there was a trend to increase cell proliferation in both cells when treated with a relatively 
lower concentration of luteolin. On the other hand, 5-FU induced a dose-dependent cyto-
cidal effect on HLE, but not in HepG2. These results indicated that while the cytocidal effect 
of 5-FU was more selective against undifferentiated hepatocellular carcinoma HLE, Vitex 
and luteolin exhibited significant cytocidal effects on both well-differentiated and undiffer-
entiated hepatocellular carcinoma cells, suggesting a possible broad usefulness of these 
compounds to hepatocellular carcinoma therapy. Of note, Vitex has been used to treat pa-
tients with various obstetric and gynecological disorders in Europe [30, 31]. Moreover, it is 
interesting to note that Vitexins, which are isolated from the seed of Chinese herb Vitex 
Negundo and bear a basic flavonoid structure, show cytotoxic and antitumor effects against 
breast, prostate and ovarian cancer cells through apoptosis induction via an intrinsic path-
way based on in vitro and in vivo xenograft tumor models [54]. Therefore, our results pro-
vide a new insight into the clinical use of Vitex for colon cancer and hepatocellular carcino-
ma besides those cancers mentioned above.  
2.2.3. Curcumin 
Curcumin has emerged worldwide as a potent therapeutic substance for treating diverse 
human diseases including various types of cancer, such as leukemia, colon cancer and pan-
creatic cancer [7, 25, 35, 55, 56]. Although the precise mode of action of this compound is  
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2.2.3. Curcumin 
Curcumin has emerged worldwide as a potent therapeutic substance for treating diverse 
human diseases including various types of cancer, such as leukemia, colon cancer and pan-
creatic cancer [7, 25, 35, 55, 56]. Although the precise mode of action of this compound is  
 




Figure 4. Cytocidal effects of Vitex, luteolin and 5-FU on HepG2 and HLE cells. Hepatocellular carci-
noma (HCC) cell lines, HepG2 (well-differentiated) and HLE (undifferentiated) were kindly provided 
by Dr. Yamato Kikkawa (Laboratory of Clinical Biochemistry, School of Pharmacy, Tokyo University of 
Pharmacy and Life Sciences, Tokyo, Japan). After treatment with Vitex (final concentrations: 1, 10, 50 
and 100 μg/ml), luteolin (final concentrations: 0.1, 1, 10 and 20 μg/ml) or 5-FU (1, 10 and 100 μM) for 48 
h, cell viability was determined by XTT dye-reduction assay according to the method described previ-
ously [53]. Significant differences between treatment group and control (*: p<0.05; §: p<0.01; †: p<0.001) 
not yet elucidated, studies have shown that chemopreventive action of curcumin might be 
due to its ability to induce apoptosis through multiple signaling pathways, including 
intrinsic and extrinsic pathways as well as ER stress pathway [7, 57]. It has been suggested 
that curcumin-induced apoptosis is associated with ROS production and/or oxidative stress 
in cancer cells, in spite of its normal antioxidant capacity [7, 57]. Indeed, it has been 
demonstrated that curcumin can generate ROS as a prooxidant in the presence of copper in 
HL-60 cells, resulting in DNA damages and apoptotic cell death [58]. Furthermore, the 
prooxidant action of curcumin may be related to the conjugated β-diketone structure of this 
compound [58]. Kuo et al. also demonstrated that curcumin induced a dose- and time-
dependent apoptotic cell death in the same cells, concomitant with a decrease of Bcl-2 
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expression [59]. However, the antioxidants, NAC, L-ascorbic acid, alpha-tocopherol, catalase 
and superoxide dismutase, all effectively prevented curcumin-induced apoptosis, 
suggesting that curcumin-mediated apoptosis was closely related to the increase in 
intracellular ROS [59]. Besides hematopoietic cancer cells, curcumin-mediated apoptosis in 
human breast epithelial cells (H-ras MCF10A) involved generation of ROS as well as down-
regulation of Bcl-2 and up-regulation of Bax, suggesting redox signaling as a mechanism 
responsible for curcumin-induced apoptosis in these cells [60]. Syng-Ai et al. also 
demonstrated that curcumin-induced apoptosis in human breast tumor cell lines (MCF-7, 
MDAMB) and HepG2 cells is also mediated through the generation of ROS, and that 
depletion of glutathione by buthionine sulfoximine (BSO) promoted the increased 
generation of ROS, thereby further sensitizing the cells to curcumin [61]. Interestingly, 
curcumin had no cytocidal effect on normal rat hepatocytes, because of no superoxide 
generation [61]. These observations suggest that curcumin with broad biological actions 
could be developed into an effective chemopreventive and chemotherapeutic agent based 
on its ability to modulate intracellular redox status. However, the use of curcumin as a 
therapeutic agent has met with considerable skepticism, since as much as 75% of curcumin 
is excreted in the feces [62] and also undergoes repaid inactivation by glucuronidation [63], 
similar to metabolisms of flavonoids [2]. Recently, in order to increase its metabolic stability, 
numerous approaches have been undertaken, such as generating the fluoro-analog of 
curcumin termed Diflourinated-Curcumin (referred to as CDF) that exhibits increased 
metabolic stability [64, 65]. Furthermore, the CDF has been found to exhibit superior growth 
inhibitory properties against cancer cells to the parental compound curcumin [56, 64, 65]. 
3. Potential future application of polyphenolic compounds, alone or in 
combination with, anticancer drugs 
As mentioned in the previous section, the deregulation and sustained activation of multiple 
tumorigenic pathways are typically implicated in cancer development and progression with 
locally advanced and aggressive nature. Consequently, the use of therapeutic agents acting 
on different deregulated gene products, alone or in combination therapy, may represent a 
potentially better strategy than the targeting on one specific oncogenic product to overcome 
treatment resistance and prevent cancer development and disease recurrence [2-4, 7]. So far, 
one of the most successful models for combinatory cancer therapies is all-trans retinoic acid 
(ATRA)/arsenic trioxide (ATO, arsenite) combination as a synergistic therapy for acute 
promyelocytic leukemia (APL) patients, in which ATRA synergizes ATO activity to provide 
a superior efficacy of combination therapy in patient through promoting the effects of ATO 
on several signaling pathway, such as apoptosis induction, differentiation as well as the 
degradation of PML-RARα [a fusion gene between promyelocytic leukemia (PML) gene and 
retinoic acid receptor (RAR) α], a causative gene for APL [4, 13]. In order to understand the 
mode of action of ATO and provide an effective treatment protocol for individual APL 
patients, we recently conducted studies on the pharmacokinetics of ATO in APL patients 
using biological samples such as peripheral blood (PB) and cerebrospinal fluid, and 
demonstrated that not only inorganic arsenic but also methylated arsenic metabolites 
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accumulated in red blood cells during the consecutive administration of ATO to APL 
patients [66]. Furthermore, we have demonstrated for the first time that these arsenic 
metabolites also existed in cerebrospinal fluid [67], in which the concentrations of arsenic 
reached levels necessary for differentiation induction [68, 69]. We further investigated for 
the first time the arsenic speciation in plasma of bone marrow (BM), and demonstrated that 
speciation profiles of BM plasma were very similar to those of PB plasma, suggesting that 
speciation analysis of PB plasma could be predicative for BM speciation [70]. These findings 
on the pharmacokinetics of ATO in APL patients provide a new insight into clinical 
applications of ATO, and may contribute to better therapeutic protocols [4]. Recently, in 
order to understand the clinical side effects of arsenite, we also investigated the effects of 
arsenite on human-derived normal cells, since the clinical side effects of drugs are always 
found as a harmful and undesired effect on normal cells and/or tissues. Based on a study 
using a unique in vitro cell culture system comprising the primary culture chorion and 
amnion cells established in our laboratory [71-73], we demonstrated for the first time that 
transporter genes, such as aquaporin 9 and multidrug resistance associated protein 2 are 
involved in controlling intracellular arsenic accumulation in these primary cultured normal 
cells, which then contribute to differential sensitivity to arsenite cytotoxicity among these 
cells [74].  
The successful clinical efficacy of ATO in the treatment of APL patients has led to 
investigations on exploring potential treatment applications for other malignancies, 
including ATO-resistant hematopoietic cancer and solid tumors [75, 76]. In order to further 
extend our previous study and promote the clinical application of arsenite, we have been 
seeking to explore potential candidate agents, which are expected to not only potentiate the 
efficacy of ATO but also possibly reduce its dosages [4]. In this regard, using HL-60 cells 
which are reported to show resistance to arsenite, we found that delphinidin showed 
selective cytotoxic effects on the cells, but minimal effects on PBMNC, and sensitized the 
cells to arsenite, resulting in the enhancement of arsenite cytotoxicity (Yuan et al. 
manuscript in preparation). Therefore, our experimental data suggest that sensitization of 
HL-60 cells to arsenite achieved by the combination with delphinidin could benefit a 
reduced dosages of arsenite in clinical application, contributing to minimize side effect. The 
clinical trial planning is now underway.  
Of note, it is well known that oxidative stress is involved in the mechanisms underlying 
the therapeutic efficacy of arsenite and plays a major role in the toxicity of arsenite [4, 13, 
77]. In fact, in order to maximally exploit effective ROS-mediated cell death without 
causing significant toxicity to normal cells, redox-based drug combination strategies have 
been proposed [3, 11, 18]. Based on the strategies, ROS-generating reagents including 
natural products derived substances, especially phenolic compounds, have received much 
attention due to their cytocidal effects on tumor cells but little on normal cells. In this 
regard, like the cytocidal effects of cyanidin-3-rutinoside on leukemia cells [10], 
delphinidin 3-sambubioside has also been demonstrated to induce apoptosis in HL-60 
through ROS-mediated mitochondria pathway [78], suggesting these anthocyanins are 
good candidates for ROS-generating reagents, thereby possibly potentiate the action of 
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ATO. Indeed, quercetin and/or genistein are flavonoid with multiple biochemical effects 
such as downregulation of phosphoinositide 3-kinase/Akt signaling pathway and NF-κB 
transcription factor activity [79, 80], tyrosine kinase inhibition [81, 82]. Furthermore, both 
quercetin and genistein have been reported to selectively potentiate ATO-induced 
apoptosis via ROS generation resulted from intracellular GSH depletion, and activation of 
intrinsic and extrinsic apoptotic pathway in human leukemia cell lines such as HL-60, U937 
and THP-1, but not in phytohemagglutinin-stimulated non-tumor peripheral blood 
lymphocytes [24, 83]. These results thus suggest that these flavonoids might be used to 
increase the clinical efficacy of ATO. Similar to flavonoids, subcytotoxic concentrations of 
curcumin also has been demonstrated to stimulate ROS production and potentiate 
apoptosis induction by ATO in leukemia cell lines via deregulation of Akt phosphorylation 
[25].  
With these considerations in mind, a lot of preclinical and clinical trials have been carried 
out. For instance, we recently reported for the first time that 5-FU in combination with Vitex 
achieved an enhanced cytocidal effect on COLO 201 cells, but lesser cytotoxic effect on 
human PBMNC [9]. It has also been demonstrated that delphinidin induces apoptosis and 
inhibited NF-κB signaling in prostate tumor cells in vitro and in a human prostate tumor 
xenograft in nude mice in vivo [39]. Furthermore, twenty-five colon cancer patients without 
receiving prior therapy and surgery consumed 60 g/day (20 g/3x/day) of black raspberry 
powder daily for 2–4 weeks. Biopsies of normal-appearing and tumor tissues were taken 
from these patients before and after berry treatment. Intake of berries reduced proliferation 
rates and increased apoptosis in colon tumors but not in normal-appearing crypts [8]. On 
the other hand, supplementation of anthocyanins in the diet of cancer patients receiving 
chemotherapy did not result in increased inhibition of tumor development when compared 
to chemotherapy alone [84]. These conflicting findings suggest that a large scale of clinical 
trial is needed. 
A phase I clinical trial has shown that quercetin, another one of flavonoids, can be safely 
administered to patients with ovarian cancer or hepatoma by intravenous injection of bolus 
at a dose of 1400 mg/m2 [82]. Moreover, the evidence of antitumor activity was seen in the 
clinical trial based on sustained fall in serum CA 125 levels, which is proposed for the use as 
a surrogate marker of response [85]. Furthermore, similar to our previous report [9], CDF (a 
difluorinated analog of curcumin), alone or in combination with 5-FU and oxaliplatin, was 
more potent than curcumin alone in reducing the number of chemoresistant HCT-116 and 
HT-29 colon cancer cells expressing CD44 and CD166 stem cell-like markers [56]. 
Concomitantly, cell growth inhibition, apoptosis induction and disintegration of 
colonospheres in these colon cancer cells were also observed in the study [56]. Moreover, 
clinical trials have confirmed the safety and feasibility to use curcumin in combination 
therapy with current chemotherapeutic treatments [7]. More recent results from a phaseI/II 
study on 21 advanced pancreatic cancer patients with gemcitabine-based chemotherapy 
have indicated that the median overall survival time of the patients after a treatment with 
curcumin plus gemcitabine or gemcitabine/S-1 combination was 161 days and 1-year 
survival rate of 19% (95% confidence interval) [86]. Among eighteen evaluable patients, no 
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patients experienced a partial or complete response and five patients (28%) demonstrated 
stable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) [86].  
Although many encouraging results of in vitro and in vivo studies suggest polyphenolic 
compounds as a promising candidate for cancer therapy, either alone or in combination 
with current anticancer drugs, the therapeutic applications of these compounds in humans 
are limited by their high metabolic instability as well as poor absorption and bioavailability 
[1, 7, 8, 20, 87]. In this regard, the selective delivery of nanotechnology-based formulations 
of these polyphenolic compounds to tumors, alone or in combination with other anticancer 
drugs, has been of great interest [7, 26, 88]. For instance, pegylated liposomal quercetin was 
shown to significantly improve its solubility and bioavailability and be a potential applica-
tion in the treatment of tumor based on a study using CT26 (a mouse colorectal carcinoma 
cell line), LL/2 (Lewis lung cancer cell line) and H22 (a hepatoma cell line) xenograft mice 
[88]. Furthermore, diverse curcumin formulations have been developed with different nano-
technology consisting of its encapsulation or conjugation with nanoparticles, polymeric 
micelles or liposomes to improve its stability, bioavailability and specific and sustained 
delivery into cancer cells and, consequently, its anticarcinogenic effects [7]. In particular, the 
systemic administration of gemcitabine plus polymeric micelle-encapsulated curcumin 
formulation enhanced greater bioavailability in plasma and tissues as compared to that of 
free curcumin in xenograft models of human pancreatic cancer established in athymic mice 
[89]. In consequence, the combinatory administration efficiently block tumor growth and 
metastases in this animal model of pancreatic cancer. Furthermore, an inhibition of NF-κB 
and its targeted genes are implicated in the tumor growth inhibition [89]. Therefore, the use 
of nanotechnology-based formulations of polyphenolic compounds and their novel chemical 
analogs probably represents a potential alternative strategy of great clinical interest for 
overcoming the high metabolic instability and poor bioavailability of these compounds, 
which are among the principal factors limiting their therapeutic applications. 
4. Conclusion 
A striking global research on substances derived from natural products including 
polyphenolic compounds is being explored to understand the detailed mechanisms of their 
chemopreventive, antitumoral and chemosensibilizing activities against various types of 
aggressive and recurrent cancers. Besides the involvement of altered redox status in 
apoptosis induction triggered by these compounds, anti-inflammatory effects, anti-
angiogenesis, anti-invasiveness and induction of differentiation are well known to be 
implicated in their broad biological functions. It is worthy of note that flavonoids have 
been revealed to inhibit the function of ATP-binding cassette transporters such as 
multidrug resistance-associated proteins as well as P-glycoprotein [90], similar to our 
recent study [91]. On the other hand, a recent study demonstrated that berry anthocyanins, 
such as cyanidin-3-galactosidee, and cyanidin-3-glucoside as well as peonidin-3-glucosid, 
exhibit affinities for the efflux transporters breast cancer resistance protein (BCRP) and 
consequently may be actively transported out of intestinal tissues and endothelia [92]. 
However, the same report also demonstrated that some berry anthocyanins and 
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anthocyanidins, such as delphinidin, cyanidin and cyanidin-3-rutinoside, act as BCRP 
inhibitor, while some of them, such as malvidin, malvidin-3-galactoside and petunidin, 
exhibited bimodal activities serving as BCRP substrates and inhibitors at low 
concentrations and high concentrations, respectively [92]. These findings suggest that a 
variety of biological activities of anthocyanins and anthocyanidins may be attributed in 
part to their inhibitory effects on those drug transporters, paradoxically, may be abolished 
as a result of efflux through those transporters. These findings also raised a 
pharmacological and pharmaceutical concern about formulatability of the dietary 
constituent, and warn us against the casual use of herbs and/or other botanicals in cancer 
patient care. 
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tion in the treatment of tumor based on a study using CT26 (a mouse colorectal carcinoma 
cell line), LL/2 (Lewis lung cancer cell line) and H22 (a hepatoma cell line) xenograft mice 
[88]. Furthermore, diverse curcumin formulations have been developed with different nano-
technology consisting of its encapsulation or conjugation with nanoparticles, polymeric 
micelles or liposomes to improve its stability, bioavailability and specific and sustained 
delivery into cancer cells and, consequently, its anticarcinogenic effects [7]. In particular, the 
systemic administration of gemcitabine plus polymeric micelle-encapsulated curcumin 
formulation enhanced greater bioavailability in plasma and tissues as compared to that of 
free curcumin in xenograft models of human pancreatic cancer established in athymic mice 
[89]. In consequence, the combinatory administration efficiently block tumor growth and 
metastases in this animal model of pancreatic cancer. Furthermore, an inhibition of NF-κB 
and its targeted genes are implicated in the tumor growth inhibition [89]. Therefore, the use 
of nanotechnology-based formulations of polyphenolic compounds and their novel chemical 
analogs probably represents a potential alternative strategy of great clinical interest for 
overcoming the high metabolic instability and poor bioavailability of these compounds, 
which are among the principal factors limiting their therapeutic applications. 
4. Conclusion 
A striking global research on substances derived from natural products including 
polyphenolic compounds is being explored to understand the detailed mechanisms of their 
chemopreventive, antitumoral and chemosensibilizing activities against various types of 
aggressive and recurrent cancers. Besides the involvement of altered redox status in 
apoptosis induction triggered by these compounds, anti-inflammatory effects, anti-
angiogenesis, anti-invasiveness and induction of differentiation are well known to be 
implicated in their broad biological functions. It is worthy of note that flavonoids have 
been revealed to inhibit the function of ATP-binding cassette transporters such as 
multidrug resistance-associated proteins as well as P-glycoprotein [90], similar to our 
recent study [91]. On the other hand, a recent study demonstrated that berry anthocyanins, 
such as cyanidin-3-galactosidee, and cyanidin-3-glucoside as well as peonidin-3-glucosid, 
exhibit affinities for the efflux transporters breast cancer resistance protein (BCRP) and 
consequently may be actively transported out of intestinal tissues and endothelia [92]. 
However, the same report also demonstrated that some berry anthocyanins and 
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anthocyanidins, such as delphinidin, cyanidin and cyanidin-3-rutinoside, act as BCRP 
inhibitor, while some of them, such as malvidin, malvidin-3-galactoside and petunidin, 
exhibited bimodal activities serving as BCRP substrates and inhibitors at low 
concentrations and high concentrations, respectively [92]. These findings suggest that a 
variety of biological activities of anthocyanins and anthocyanidins may be attributed in 
part to their inhibitory effects on those drug transporters, paradoxically, may be abolished 
as a result of efflux through those transporters. These findings also raised a 
pharmacological and pharmaceutical concern about formulatability of the dietary 
constituent, and warn us against the casual use of herbs and/or other botanicals in cancer 
patient care. 
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1. Introduction 
The number of scientific papers devoted to the study of caspases has lately being constantly 
growing. Caspases are a family of cysteine-dependent aspartate specific proteases. Caspases 
play an essential role in the apoptosis, necrosis and inflammation processes. Apoptosis is 
asynchronous programmed cell death, which helps maintain the physiological balance and 
genetic stability of the organism through self-destruction of genetically modified defect 
cells. Apoptosis may happen also in normal cells, e.g., during embryogenesis. During 
apoptosis, activated endogenous nucleases cleave DNA into fragments, but cell membranes 
and the intracellular matter remain intact, nor is there tissue damage or leukocytic 
infiltration. In contrast to apoptosis, necrosis is a pathological form of cell death caused by 
acute damage, rupture of the membrane, release of the cytoplasm content, and the 
inflammatory process induced thereby [1, 2]. 
As of now, at lease 14 caspases have been described from mammals: 8 caspases are involved 
in apoptosis, 5 activate anti-inflammatory cytokines, and one acts in keratinocyte 
differentiation. This division is, however, rather arbitrary – we know from a number of 
papers that some apoptotic caspases may, depending on the conditions, participate in other 
cell life processes, such as proliferation [3], differentiation [4, 5], modification of 
susceptibility to leukocyte lysis [2, 6].  
During apoptosis, different caspases perform different functions. Depending on the phase at 
which those proteins enter the apoptotic cascade one distinguishes initiator (apical) and 
effector (executioner) caspases. E.g., caspase-2, -8, -9, -10, and -12 are initiator ones; caspase-
3, -6, -7 – effector ones. All caspases are originally inactive, but activated when needed by 
cleavage of a small fragment by initiator caspases. Initiator caspase activation is more 
sophisticated – by special protein complexes: apoptosomes, PIDDosomes, DISC (death-
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inducing signalling complexes) [7, 8]. Under certain conditions effector caspases may act as 
initiator ones to accelerate apoptotic reactions. 
Research into the phenomenon of programmed cell death started in the late 1960s. One of 
the pioneers in the sphere was John Kerr, who studied the death of hepatocytes in rats with 
acute liver failure [9]. In 1972, a team of British scientists headed by Kerr first coined the 
term apoptosis to denote programmed cell death. The authors described two phases of the 
process (formation of apoptotic bodies, and their phagocytosis by other cells), and stressed 
that apoptosis is an active and controlled process. Yet, nothing was known at the time about 
the factors and mechanisms of this type of cell death. Studies of the structure of caspases 
began only in 1994 [10, 11]. In 1996, it was found that cytochrome c together with ATP 
promote activation of caspase-3 [12]. Caspases are now investigated in various model 
systems both in vitro and in vivo. The most popular systems in use are tumor cell lines of 
various histogenesis. Most studies employ hemopoietic tumor cells (lines К562, HL-60, Raji, 
HEL, etc.), cells derived from solid tumors (lines HeLa, RPTC, НСТ 116, etc.), as well as stem 
cells. Through this approach one can not just study the structure, activation mechanisms 
and basic functions of caspases in normal cells, but also identify the biological role of these 
enzymes in emerging and progressing pathological processes, first of all, oncologic and 
immuno-inflammatory ones. Besides, the chemical reagents used in those model systems 
usually activate or inhibit cell processes, including apoptosis. These facts open up immense 
opportunities in the analysis of the activity of the substances considered for applicability as 
components of new targeted drugs. The clue to the effectiveness of the chemical reagents for 
the treated cells will be the changes in the susceptibility of those cells to cytotoxic lysis of 
blood leukocytes, namely natural killer cells and cytotoxic Т-lymphocytes. Since proteases 
play an important part in cytotoxic lysis, caspases in this case can also be viewed as 
candidate molecules whose activity can be modulated to accelerate or damp apoptosis, as 
well as modify the susceptibility of pathological cells to leukocytolysis. 
Hence, the primary objective of the chapter is to demonstrate by means of the experimental 
data the crucial role of caspases in the induction and progress of tumor cell apoptosis, as 
well as in the modification of tumor cell susceptibility to the cytotoxic lysis of natural killer 
cells upon treatment with chemical compounds, part of which have been newly synthesized. 
The model system used in our study was the human erythromyeloid leukemic cell line К562 
(Russian Cell Culture Collection, Institute of Cytology, Russian Academy of Sciences, St. 
Petersburg, Russia), as well as К562/2-DQO and К562/4-NQO subline cells. To induce 
apoptosis and modulate cell susceptibility to the lytic action of blood leukocytes we used a 
group of N-bearing heterocyclic reagents – derivatives of quinoline and pyridine:  
quinoline – Q, 2-methylquinoline – 2-MeQ, quinoline-1-oxide – QO, 2-methylquinoline-1-
oxide – 2-MeQO, 4-nitroquinoline-1-oxide – 4-NQO, 2-methyl-4-nitroquinoline-1-oxide  
– 2-Me-4-NQO, 2-(4’-dimethylaminostyryl)quinoline-1-oxide – 2-DQO,  
4-(4’-dimethylaminostyryl)quinoline-1-oxide – 4-DQO, 2-(4’-nitrostyryl)quinoline-1- 
oxide – 2-NSQO, 4-(4’-nitrostyryl)quinoline-1-oxide – 4-NSQO, and 4-(4’-
dimethylaminostyryl)pyridine-1-oxide – 4-DPyO (Figure 1).  
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In current clinical practices, quinoline derivatives are used as drugs with high 
pharmacological potential – photoprotective, anti-inflammatory, immunomodulating, 
antioxidant, antiproliferative, antiaggregatory, hypolipidemic, and hypoglycemic. This 
group of chemical compounds and their intracellular metabolites can be highly competitive 
as structural analogs of key molecules of the cell (nitrogen bases, nucleosides, nucleotides, 
various co-enzymes, etc.), and take effect by activating or inhibiting a certain cell process. 
The compounds with such biological effects most frequently used in the oncology practice 
are 5-fluorouracil, cytarabine, methotrexate, vinblastine, dactinomycin, and others. 
Derivatives of N-bearing heterocycles are very effective in treatment of tumors of various 
histogenesis and location, including leukemia, but many of them have limited applicability 
because of high toxicity. Finding the compounds that feature both high anti-tumor activity 
and low side effects is therefore an important task. 
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2. Body 
A major problem in modern cell biology is the search for intracellular targets for 
pharmacologically active substances, and subsequent development of new generation 
medicines based on the resultant data. As a rule, molecules involved in basic processes of 
cell life are viewed as such intracellular targets. The molecules participating in two or more 
vital processes are of greatest interest. Such are caspases. They are synthesized in the cell as 
precursors (procaspases). Caspase precursors consist of a prodomain and two subunits: a 
small one and a large one. Some caspases contain a short linker sequence (around 10 amino 
acids) between the subunits. Caspases can activate one another: the prodomain is cleaved 
from the procaspase, and the small and large subunits of the two caspases form an active 
caspase – heterotetramer (Figure 2), which contains two active centres. Caspases of the 
initiator (pro-apoptotic and pro-inflammatory) type contain a long prodomain made up of 
approximately 100 amino acids, whereas the short prodomain of effector caspases contains 
only 30 amino acid residues. Long prodomains contain various motifs, mainly DED (death 
effector domain) and CARD (caspase recruitment domain), but also DID (death inducing domain). 
Each of the procaspases-8 and -10 contains two tandem copies of the DED, whereas CARD 
was found in caspases-1, -2, -4, -5, -9, -11, -12. Homotypic interactions between DED and 
CARD recruit procaspases into initiator complexes, activate them and trigger the caspase 
cascade [13]. 
 
Figure 2. Proteolytic caspase activation (adopted from http://www.muldyr.ru/a/a/apoptoz_-
_fazyi_apoptoza) 
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Apart from distinctions in the prodomain structure, caspases can be grouped by substrate 
specificity. E.g., caspases-6, -8 and -9 show preference for cleaving substrates with the 
valine/leucine−glutamate−threonine/histidine−aspartate (V/L−E−T/H−D) sequence,  
whereas caspases-3 and -7 selectively cleave the motif made up of the 
aspartate−glutamate−valine−aspartate (D−E−V−D) sequence. An optimal target for caspase-1 
and its related caspases-4 and -5 are the sequences tyrosine−valine−alanine−aspartate 
(Y−V−A−D) or tryptophan/leucine−glutamate−histidine−aspartate (W/L−E−H−D) [14]. 
Various forms of post-translational modifications can influence the activity of caspases. 
Thus, phosphorylation of caspase-9 by the serine/threonine protein kinase Akt inhibits 
its activity. Such phosphorylation occurs away from the caspase active centre, and 
presumably hinders the clustering of the caspase subunits into the tetramer [13, 15]. 
Another variant of post-translational modification of caspases is S-nitrosylation. The NO 
radical group is tranfered to the cysteine of the caspase active centre and the R−S−NO 
group is formed [16, 17]. Furthermore, caspases are susceptible to oxidative 
modifications induced by active forms of oxygen, with disulphides formed in the 
process. 
Apoptosis can be triggered by various mechanisms that activate caspases. Two major 
pathways are distinguished: activation involving cell receptors, and mitochondria-mediated 
activation. 
Caspase activation involving cell receptors. The process of apoptosis often begins with 
ligation of specific extracellular ligands with cell death receptors on the membrane surface. 
Receptors of the apoptotic signal belong to the TNF (tumor necrosis factor) receptors 
superfamily [18]. The best studied death receptors, whose role in apoptosis has been 
identified and described, are CD95 (Fas or APO-1), and TNFR1 (p55 or CD120a) (Figure 3). 
Additional receptors are CARI, DR3 (death receptor 3), DR4, DR5, and DR6. All death 
receptors are transmembrane proteins which share a sequence of 80 amino acids at the 
cytoplasmic face termed the death domain (DD). It is required for apoptotic signalling [7, 
18]. Extracellular regions of death receptors interact with ligand trimers (CD95L, TNF, 
Apo3L, Apo2L, etc.), and the latter trimerize the death receptors (crosslink 3 molecules of 
the receptor) [19, 20]. The thus activated receptor interacts with a corresponding 
intracellular adaptor(s). The adaptor for the CD95 (Fas/APO-1) receptor is FADD (Fas-
associated DD-protein). The adaptor for the TNFR1 and DR3 receptors is TRADD (TNFR1-
associated DD-protein) (Figure 3). 
The adaptor associated with the death receptor interacts with caspases. The 
“ligand−receptor−adaptor−effector” interaction chain results in the formation of aggregates 
in which caspases are activated. These aggregates are called apoptosomes, apoptotic 
chaperones, or death-inducing signalling complexes (DISC). An example of apoptosome is 
the FasL−Fas−FADD−procaspase-8 complex, in which caspase-8 is activated (Figure 3) [7, 
21]. Death receptors can mediate activation of caspases-2; -8, and -10 [22]. The activated 
initiator caspases then activate effector caspases. 
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Figure 3. Receptors of the apoptotic signal (adopted from http://www.muldyr.ru/a/a/apoptoz_-
_fazyi_apoptoza) 
Mitochondria-mediated caspase activation. The mitochondrial apoptotic signalling 
pathway is realized through release of apoptogenic proteins from the intermembrane region 
into the cell cytoplasm. Presumably, there are two major pathways for the release of 
apoptogenic proteins: through formation of a giant pore followed by rupture of the 
mitochondrial membrane, or through opening of highly permeable channels on the 
mitochondrial outer membrane [23]. The apoptosome formation model can be represented 
as “Cytochrome c−Apaf-1−CARD−procaspase-9”. Apaf-1 (apoptosis protease activating factor-
1) undergoes conformational modifications induced by the reaction involving the loss of 
ATP energy. Procaspase-9 gets access to the CARD of Apaf-1. The thus activated caspase-9 
recruits procaspase-3, which is, in turn, activated to form caspase-3 [24, 25].  
In some apoptotic models the cytochrome is released by activation of the РТР (permeability 
transition роrе) [26]. This pore is a compound complex made up of adenine nucleotide 
transporter (in the inner mitochondrial membrane), voltage-dependent anion channel, 
otherwise termed porin (in the outer mitochondrial membrane), and cyclophilin D (in the 
matrix of mitochondria). The 2.6−2.9 nm giant pore is non-specific, and molecules up to 1.5 
Da can pass. Pore opening leads to mitochondrial swelling and rupture of the outer 
membrane. In addition to cytochrome с mitochondria emit other pro-apoptotic factors [23, 
25]. Pore opening can be stimulated by inorganic phosphate, caspases, SH-reagents, cell 
exhaustion by reduced glutathione, formation of active forms of oxygen, uncoupling of 
oxidative phosphorylation, rise in Ca2+ content in the cytoplasm, effect of ceramide, 
depletion of the mitochondrial ATP pool, etc. [24, 27, 28]. 
 
Cellular Caspases: New Targets for the Action of Pharmacological Agents 181 
A presumable alternative pathway for the release of apoptotic proteins from the 
mitochondrial intermembrane region is formation of a protein channel in the outer 
mitochondrial membrane. Whichever the pathway, the substances released into the 
cytoplasm are cytochrome c, procaspases-2, -3, -9, and AIF (apoptosis inducing factor) [14]. The 
release is promoted by Bcl-2 family proteins (Вах-protein). The flavoprotein AIF released 
from the mitochondrial intermembrane region is an apoptosis effector that would then act 
independently of caspases [24, 29]. 
The caspases activated through these pathways directly or indirectly promote the 
destruction of cell structures. Nuclear lamina proteins are hydrolysed, the cytoskeleton is 
disrupted, proteins regulating cytoadherence are degraded. Another essential function of 
effector caspases is inactivation of apoptosis-blocking proteins. To wit, they cleave the 
inhibitor DFF (DNA fragmentation factor), which prevents activation of the apoptotic CAD 
(caspase-activated DNase). Anti-apoptotic proteins of the Bcl-2 family are cleaved. Finally, the 
action of effector caspases results in dissociation of the regulatory and effector domains of 
the proteins involved in DNA replication and repair, mRNA splicing [30, 31].  
No matter which apoptotic mechanism the cell chooses, the process can be modulated. At 
present, the structure and action mechanisms of a great number of apoptosis modulating 
chemical compounds are known. Most of them influence DNA either directly or indirectly. 
Nonetheless, if apoptosis can be modulated, then modification of caspase expression is also 
possible (although there exists caspase-independent apoptosis). The tumor cell apoptosis 
modulators used in this study are derivatives of two heterocyclic compounds – quinoline 
and pyridine (Figure 1). This group of reagents, most of which are N-oxide derivatives, 
holds good promise for in vitro study of cell systems, because these compounds comprise 
several functional activity centres (at the heterocyclic nucleus, functional groups, and 
radicals). Most published data on the biological activity of quinoline N-oxide derivatives are 
focused on 4-nitroquinoline-1-oxide (4-NQO), whereas information on the activity of other 
structural analogs of the reagents is, unfortunately, almost totally missing. 
4-NQO is a chemical carcinogen whose biological effects on cells are in many ways similar to 
the effect of UV light [32]. The action of 4-NQO is studied using various model systems: 
prokaryotic cells in vitro [33], eukaryotic cells in vitro [34], multicellular organisms [35]. The 
range of the investigated cell life processes and intracellular biomolecules is also diverse. For 
the neoplastic effect to take place 4-NQO has to be metabolically activated in the cells to the 
proximate carcinogen 4-hydroxyaminoquinoline-1-oxide, which, after being acetylated, can 
covalently bind to DNA, namely adenine and guanine, to form stable monoadducts [36, 37]. 
Xanthine oxidase can metabolise 4-NQO to a more reactive superoxide anion (5.5-dimethyl-
1-pyrroline-N-oxide superoxide radical). Formation of substantial amounts of such 
structures first of all disturbs the processes of DNA replication and repair, thus inducing 
apoptosis (or necrosis). If, however, this does not happen, accumulation of multiple 
mutations in the genome would cause normal cells to transform into tumor cells. Some 
questions logically arise in this connection: how much similarity is there between the 
biological effects of the structural analogs of 4-NQO and those of 4-NQO itself? Would the 
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application of these compounds enable activation of apoptosis in tumor cells by modulating 
the activity of caspases? Will the susceptibility of the reagent-treated cells lead to leukolysis 
change? It is these and other questions that we shall try to answer below. 
3. Materials and methods  
Cells of the human erythromyeloid leukemic cell line К562 were incubated in the 
following medium: 89% RPMI 1640 (Institute of Poliomyelitis and Viral Encephalitides, 
Russian Academy of Medical Sciences, Moscow) supplemented with 11% fetal bovine 
serum (Institute of Epidemiology and Microbiology, Russian Academy of Medical 
Sciences, Moscow), 2 mM L-glutamine, 40 µg/ml gentamicin sulphate, 50 µM 2-
mercaptoethanol (Ferak, Germany) in 95% O2 and 5% С02 at 370С. The cultures were 
seeded to 1 ml (3 ml) of the medium with the seeding density of 105 (106) cells/well, 
respectively. Quinoline derivatives in concentrations detailed in the text and figure 
captions were added to the medium. Cells were counted in Goryaev’s chamber. EC50 cells 
incubated with the reagents were ascertained using the technique [38]. The viability was 
assessed using the test with 3-(4.5-dimethylthiasol-2-yl)-2.5-diphenyltetrazolium bromide 
(МТТ) (Sigma, USA).  
Assessment of viability (МТТ-test). The technique was described in [39]. 100 µL aliquots of 
cell suspension (105 cells/well) were seeded to a 96-well flat bottom culture plate and treated 
with 100 µL of the chemical compound solution of the corresponding concentration. All 
assays were performed in three replicates. The plates were left to incubate for 24, 48, 72, and 
96 hours. Three hours before the end of the incubation period the wells were stained with 
МТТ solution (3-(4.5-dimethylthiasol-2-yl)-2.5-diphenyltetrazolium bromide (Sigma, USA)) 
to a final concentration of 0.25 mg/ml, and re-incubated in the dark in a humidified 
atmosphere at 37оС. Then, the supernatants were carefully removed and 200 µL aliquots of 
DMSO were added to each well. The residue was re-suspended and incubated for 15 min in 
the dark at room temperature. The optical density was measured at 540 nm with a 
Labsystems Multiscan Plus reader (LKB, Finland). In this case, staining of the cells incubated 
in the absence of chemical compounds was regarded as the control. Specific cell death was 
calculated by formula (1): 
 Induced death, % = (1 – (Dexp – Denv / Dc – Denv)) × 100 %         (1) 
where Dc is the optical density in control wells (cells without chemical reagent); Dexp – 
optical density in treated assays (cells with chemical reagent); Denv – optical density of the 
control environment. 
Tumor cell clones resistant to 2-DQO and 4-NQO were obtained as described in [38]. Cell 
resistance to xenobiotics was induced by long-term (over a month) exposure in a culture 
medium containing 2-DQO (10-9 M) or 4-NQO (10-12 M). The concentration of the substances 
in the culture medium was increased every 14−21 days. The final doses for which resistant 
cell lines were obtained were 10-5 and 10-8 M, respectively. 
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Real-time PCR. Total RNA from peripheral blood leukocytes and tumor cells was extracted 
with the “YellowSolve” kit (Clonogen, Russia) following the manufacturer’s guidelines. The 
extracted RNA template was treated with DNase (Sigma, USA). The concentration and 
purity of the RNA template was determined by spectrophotometry (“SmartSpec Plus”, 
BioRad, USA). RNA nativity was determined by agarose gel electrophoresis. 
Complementary DNA was synthesized from 1 µg of total RNA using random hexaprimers 
and MMLV reverse transcriptase following the protocol proposed by the manufacturer 
(Sileks, Russia). RNA and cDNA samples were stored at -80°С. Gene expression was 
estimated by real-time PCR. The fluorophore for product detection was the intercalating 
SYBR Green I dye. Amplification was performed in an “iCycler Thermal Cycler”  (BioRad, 
USA) with “iQ5 Optical System” V2.0 software (BioRad, USA) using real-time PCR assay 
kits in the presence of SYBR Green I. The PCR reaction mixture was prepared with the 
component volumes recommended by the manufacturer: we mixed 2.5 µl 
deoxynucleosidetriphosphates (2.5 mM), 2.5 µl 10-fold PCR buffer with SYBR Green I, 2.5 µl 
MgCl2 (25 mM), 1 µl aliquots of forward and reverse primers (20 pmol/µl), 0.25 µl Taq-
DNA-polymerase (5 U/µl), 2 µl template cDNA, deionized water – up to 25 µl per test tube. 
The PCR protocol was 15 sec at 95С, 50 sec at 60С (45 cycles). To determine the specificity 
of primer annealing PCR fragments were melted: for 1 min at 95С, 1 min at 60С, 10 sec at 
60С (80 cycles, the temperature raised by 0.5С in each cycle). To exclude the possibility of 
the template cDNA being contaminated by the genomic DNA PCR was performed for each 
template under the same conditions with the RNA matrix. Primers for the nucleotide 
sequences of the investigated genes and the reference gene GAPDH were selected using the 
Primer Premier software (“Premier Biosoft”, USA) or published sources (Table 1). 
Oligonucleotides were synthesized by the Syntol company (Russia). Gene expression was 
measured against the amount of GAPDH mRNA using the 2–∆∆Ct method [40]. The resultant 
reaction products were separated in 8% polyacrilamide gel using the tris-borate buffer. PCR 
products were stained with 1% ethidium bromide solution and visualized in transmitted UV 
light using the low-molecular (501–567 bp) pUC19/Msp I fragment length marker (Syntol, 
Russia). 
Gene GeneBank № Sequence Source 




GAPDH R: 5'-GAAGATGGTGATGGGATTTC-3' 




CASPASE 6 R: 5'-CAGCGTGTAAACGGAG-3' 




CASPASE 3 R: 5'-ATCACGCATCAATTCCACAA-3' 




CASPASE 9 R: 5'-CACGGCAGAAGTTCACATTG-3' 
Table 1. Primers for the nucleotide sequences of the caspase genes under study and the reference gene 
GAPDH 
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DMSO were added to each well. The residue was re-suspended and incubated for 15 min in 
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calculated by formula (1): 
 Induced death, % = (1 – (Dexp – Denv / Dc – Denv)) × 100 %         (1) 
where Dc is the optical density in control wells (cells without chemical reagent); Dexp – 
optical density in treated assays (cells with chemical reagent); Denv – optical density of the 
control environment. 
Tumor cell clones resistant to 2-DQO and 4-NQO were obtained as described in [38]. Cell 
resistance to xenobiotics was induced by long-term (over a month) exposure in a culture 
medium containing 2-DQO (10-9 M) or 4-NQO (10-12 M). The concentration of the substances 
in the culture medium was increased every 14−21 days. The final doses for which resistant 
cell lines were obtained were 10-5 and 10-8 M, respectively. 
 
Cellular Caspases: New Targets for the Action of Pharmacological Agents 183 
Real-time PCR. Total RNA from peripheral blood leukocytes and tumor cells was extracted 
with the “YellowSolve” kit (Clonogen, Russia) following the manufacturer’s guidelines. The 
extracted RNA template was treated with DNase (Sigma, USA). The concentration and 
purity of the RNA template was determined by spectrophotometry (“SmartSpec Plus”, 
BioRad, USA). RNA nativity was determined by agarose gel electrophoresis. 
Complementary DNA was synthesized from 1 µg of total RNA using random hexaprimers 
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The enzyme activity of caspases was determined by standard technique using specific 
substrates labeled with fluorescent marker (7-amino-4-trifluoromethylcumarin – AFC) 
(BioRad, USA), detected by variations in fluorescence or optical density [2]. 50 µl of lytic 
buffer prepared by mixing 920 µl of bidistilled Н2О, 40 µl of 25-fold reaction buffer and 
10 µl of each of the four inhibitors: PMSF (phenylmethylsulfonyl fluoride) (35 mg/ml), 
pepstatin А (1 mg/ml), aprotinin (1 mg/ml), and leupeptin (1 mg/ml), was added to the 
tumor cells (106 cells). The 25-fold reaction buffer included the following components: 
250 мМ HEPES, рН 7.4, 50 mM EDTA, 2.5% CHAPS (3-((3-
chloramidopropyl)dimethylammonio)-1-propanesulfonate), 125 mM dithiothreitol. After 
that, the cells were frozen three times in liquid nitrogen, the cell lysate then centrifuged 
in a microcentrifuge at 17 000 G (40 С) for 30 min, and the supernatant (template) 
collected. The activity of caspases-3, -6 and -9 was determined in the reaction buffer by 
mixing the template with the corresponding specific substrate. The substrate for caspase-
3 was DEVD (Asp–Glu–Val–Asp), for caspase-6 – VEID (Val–Glu–Ile–Asp), for caspase-9 
– LEНD (Leu–Glu–His–Asp). The amount of cleaved AFC was measured by 
spectrophotometry in FluoroMax (“Horiba-Scientific”, Japan) at 395 nm 30, 60, 90, 120, 
150, 180 min after the onset of the reaction. Then, the curve of caspase activity depending 
on the template and substrate incubation time was plotted. Plot ∆S versus ∆t and 
calculate the slope (∆S/∆t). 
 ∆S = [S(ti) – B(ti)] – [S(t0) – B(t0)],       ∆t = (ti – t0),                        (2) 
S – sample signal at time t, and B – blank signal at time t; ti – time of measurement, t0 – time 
of initial measurement. 
Cytochrome c reductase activity of microsomes was measured by spectrophotometry in 
FluoroMax (“Horiba-Scientific”, Japan) at 250 С. The reaction medium contained 
microsomes (30 µg protein/ml), NADPH or NADH (50 µM), 2-NSQO or 4-NSQO (1−100 
µM), and cytochrome с (20 µM).  
Determination of the susceptibility of tumor cells to the cytotoxic lysis of human 
leukocytes. Lysis was studied in a homologous system. Human peripheral blood leukocytes 
were isolated from the blood of healthy males by a two-step procedure involving 
fractionation on a Ficoll-Hypaque gradient, followed by erythrocyte lysis by distilled water. 
The viability of leukocytes, estimated by the Trypan blue test, was at least 93–95 %. 
The test for cytotoxicity of human leukocytes (effector cells) for К562 cells (target cells) 
incubated with quinoline derivatives and labeled with 3Н-uridine followed the protocol [44]. 
Pre-assay incubation of the cultures with the reagents lasted 48 h and 96 h in all variants. 
The effector cell/target cell ratio was 50:1. The cytotoxic index (CI, %) was calculated by 
formula (3): 
 Cytotoxic index = 1 – (cpm) in experimental tests / (cpm) in control tests × 100 %,    (3) 
where the control was К562 cell cultures labeled with 3Н-uridine and free of effector-cells. 
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Quinoline derivatives were kindly provided by Prof. V.P. Andreev (St. Petersburg State 
University, Russia). The composition and structure of the resultant compounds were 
ascertained by elemental analysis, mass, IR-, NMR spectroscopy (1H, 13C, 15N). 
Reliability of the results was estimated using Student’s t-test, and the non-parametric 
Mann−Whitney test. 
4. Results 
The first stage of the investigation of the biological activity of quinoline and pyridine 
derivatives was experiments to determine the effect of varying concentrations of Q, 2-MeQ, 
QO, 2-MeQO, 4-NQO, 2-Me-4-NQO, 2-DQO, 4-DQO, 2-NSQO, 4-NSQO, and 4-DPyO on the 
viability of К562 cells. The resultant data were processed to calculate ЕС50 values of each 
compound. The results are detailed in Table 2 (the reagents are arranged in the order of 
decreasing toxicity). It follows from the results that the greatest toxic effect on tumor cells 
under the stated conditions was demonstrated by 2-Me-4-NQO and 4-NQO, and the lowest – 
by 2-NSQO and 4-NSQO.  







1. 2-DQO  2. 208.93 
3. 4-DQO  4. 221.28 
5. QO  6. 316.23  
7. 2-NSQO 8. 570.10 
9. 4-NSQO 10. 600.50 
Table 2. Reagent concentrations resulting in 50% death of К562 cells (ЕС50) 
The data presented in Table 2 indicate also that when the methyl radical (Q → 2-MeQ, QO → 
2-MeQO, 4-NQO → 2-Me-4-NQO) and the nitro group (QO → 4-NQO, 2-MeQO → 2-Me-4-
NQO) were attached to the quinoline heterocycle, the toxicity of the compounds for К562 
cells increased. For example, the ЕС50 of Q was 4.47 µM, 2-MeQ – 1.26 µM; QO – 316.23 µM, 
2-MeQO – 23.44 µM; 4-NQO – 1.05 µM, 2-Me-4-NQO – 1.04 µM, ЕС50 in the QO/4-NQO and 
2-MeQO/2-Me-4-NQO pairs was 316.23 µM, 1.05 µM and 23.44 µM, 1.04 µM, respectively. 
When К562 cells were incubated with reagents comprising the N-oxide group (QO, 2-
MeQO), the cell survival rate was, on the contrary, higher than for the cells incubated with Q 
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or 2-MeQ, respectively (see ЕС50). The toxic effect of the compounds was reduced also by 
addition of the “styryl tail” with the nitro group (2-NSQO, 4-NSQO) to the reagent, whereas 
substitution of the nitro group with the dimethylamino group (2-DQO, 4-DQO) resulted 
in a 2.72-fold rise in the toxicity (see ЕС50). Translocation of the styryl group within the 
quinoline ring was also significant: if the group was located closer to the heteroatom (Fig. 
1), the compound also became more toxic (EC50 of 2-DQO was 208.93 µM, that of 4-DQO – 
221.28 µM; EC50 of 2-NSQO – 570.10 µM, that of 4-NSQO – 600.50 µM). When the 
quinoline cycle in the chemical compound was substituted with the pyridine cycle the 
reagent’s toxicity for the cells increased 6.68-fold, e.g., 4-DQO EC50 was 221.28 µM, 
whereas 4-DPyO EC50 was 33.11 µM. This pattern was observed both on the 48 h and on 
the 96 h of incubation. 
The results above suggest that the toxic effect of the investigated reagents on tumor cells 
depends on the presence/absence of certain type substituents (electron donors or electron 
acceptors) in the quinoline cycle, as well as on the direct bond of the named substituents to 
the quinoline cycle. Thus, attachment of the nitro group (electron acceptor) to the cycle – QO 
→ 4-NQO, 2-MeQO → 2-Me-4-NQO – rendered the substance more toxic, whereas inclusion 
of the substituent in the “styryl tail” (4-NQO → 4-NSQO) reduced the toxic effect of the 
reagent 571.90 fold (see ЕС50). 
Intracellular activation of aromatic nitrogen-bearing compounds, including 4-NQO and 
other quinoline derivatives, is known to involve cytochrome Р-450 and NADPH-dependent 
cytochrome Р-450 reductase [45], glutathione-S-transferase, and quinone reductase [46]. As 
the result, there appears a set of metabolites most of which have a higher biological activity, 
and are potentially capable of interacting with high-molecular cell compounds (proteins, 
nucleic acids). Since an essential component part of research into the biological activity of 
chemical reagents in vitro is the study of their apoptosis inhibiting action, we shall now 
report the results on the effect of the investigated group of heterocycles on the expression (at 
the mRNA level) and enzymatic activity of cellular caspases. 
Data on modifications of caspase-3, -6 and -9 mRNA expression in К562 cells treated with Q, 
QO and 4-NQO for 48 h are presented in Figure 4 (a−c). The reagent concentrations applied 
are detailed in the figure. The results suggest that cell incubation with 4-NQO caused a rise 
in mRNA expression in all caspases; treatment with Q induced a rise in caspase-3 and -9 
mRNA expression; whereas QO did not induce caspase expression under the given 
treatment conditions. A similar pattern was observed in the enzymatic activity (Figure 5 
a−c). Cell incubation with 4-NQO promoted the activity of all the caspases, whereas 
treatment with Q activated only caspases-3 and -9 (caspase-6 in this case was induced only 
on the 96 h). QО exhibited an activating effect on caspase-3 also on the 96 h of tumor cell 
treatment. Note that the activity of caspase-6 in the cells (р<0.05) (Figure 5 b) treated with 4-
NQO rose much less than that of caspases-3 and -9 (р<0.01) (Figure 5 a, c). 
Caspase expression in К562 cells incubated with 2-MeQ, 2-MeQO, and 2-Me-4-NQO did not 
differ from their expression in Q, QO, and 4-NQO treatments, respectively.  
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Results are presented as the ratio of caspase to GAPDH expression relative to a standard curve for each assay. Drug 
concentrations: Q – 0.3 µМ, QO – 10 µМ, 4-NQO – 0.001 µМ. Incubation time – 48 h. Viability of cultured cells – 
93−95%.   
Y axis – relative expression, conventional unit; * − p<0.05 
Figure 4. Caspase-3 (a), -6 (b) and -9 (c) mRNA levels were determined by quantitative real-time RT-
PCR in K562 cells treated with Q, QO and 4-NQO respectively.  
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Results are presented as the ratio of caspase to GAPDH expression relative to a standard curve for each assay. Drug 
concentrations: Q – 0.3 µМ, QO – 10 µМ, 4-NQO – 0.001 µМ. Incubation time – 48 h. Viability of cultured cells – 
93−95%.   
Y axis – relative expression, conventional unit; * − p<0.05 
Figure 4. Caspase-3 (a), -6 (b) and -9 (c) mRNA levels were determined by quantitative real-time RT-
PCR in K562 cells treated with Q, QO and 4-NQO respectively.  
 
Apoptosis and Medicine 188 
 
Drug concentrations: Q – 0.3 µМ, QO – 10 µМ, 4-NQO – 0.001 µМ. Incubation time – 48 h.  
Viability of cultured cells – 93−95%. Y axis – ∆S/∆t × 10-4; * − p<0.05 
Figure 5. Caspase -3 (a), -6 (b) and -9 (c) activity in K562 cells treated with Q, QO and 4-NQO 
respectively.  
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Styryl derivatives also produced caspase inhibiting effects on К562 cells. The results 
portrayed in Figures 6 and 7 evidence that treatment of tumor cells with 2-DQO, 4-DQO, 2-
NSQO, and 4-NSQO promoted the activity of caspases-3 and -6, but with the latter two 
reagents the activity of the stated caspases was higher, and the rise in caspase-9 activity was 
recorded on the 24 h of application of the compounds to the incubation medium. Expression 
at the mRNA level correlated with data on the activity at the enzyme level. 
  
Drug concentrations – 1 µМ. Incubation time – 48 h., Viability of cultured cells – 93−95%. Y axis – ∆S/∆t × 10-4;  
* − p<0.05, ** p<0.01;  
  caspase-3;   caspase-6 
Figure 6. Caspase-3  and -6 activity in K562 cells treated with 2-DQO, 4-DQO, 2-NSQO, 4-NSQO 
respectively. 
 
Drug concentrations – 1 µМ. Incubation time – 24 h,  Viability of cultured cells – 93−95%. Y axis – ∆S/∆t × 10-4;  
* − p<0.05, ** p<0.01 
Figure 7. Caspase-9 activity in K562 cells treated with 2-DQO, 4-DQO, 2-NSQO, 4-NSQO respectively 
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We have already mentioned that the release of cytochrome c from mitochondrial interior to 
the cell cytoplasm is a crucial stage in the activation of caspase cascades and triggering of 
apoptosis. In addition to involvement in the reactions of cellular caspase activation, 
“cytoplasmic” forms of cytochrome c also act as a substrate for microsomal NADPH-
dependent cytochrome P-450 reductase [47]. This reductase facilitates electron transport to 
cytochrome P-450, which, in turn, participates in the metabolism of many heterocycles, 
including those investigated in the present paper. Figure 8 shows the kinetic curve of 
cytochrome c reduction by microsomes with no and with 10 µM 2-NSQO. Addition of 2-
NSQO to the medium containing microsome suspension, NADPH, and cytochrome с causes 
a deceleration of cytochrome c reduction, which progresses with time. Depending on the 
reagent concentration, the reduction rate decreased at the greatest pace in the first 1−5 min 
of the reaction. Pre-incubation of microsomes with 2-NSQO for 5 min, followed by the 
addition of NADPH and cytochrome c to the reaction medium did not change the protein 
reduction rate as compared with the variant described above. After the NADPH-cytochrome 
с reductase activity had been totally inhibited by 2-NSQO, addition of NADH to the 
incubation medium partially restored cytochrome c reduction, whereas addition of NADPH 
and/or cytochrome c did not promote the reaction rate (p>0.05) (Figure 8).  
 
Cytochrome c and NADPH were added immediately after application of 2-NSQO to the microsome suspension (2) or 
after 5 min of pre-treatment of the microsomes with the reagent (3). NADH (50 µM) (4) or NADPH (50 µM) (5) were 
added to system 2 on the minute of the reading event. Light absorption by the system was measured in phosphate 
buffer on Labsystems Multiscan Plus  reader (LKB, Finland) at 553 nm 
Figure 8. Cytochrome c reduction by microsomes of К562 cells with no (1), and with 10 µM 2-NSQO  
(2–5). 
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Substitution of 2-NSQO with its structural analog (4-NSQO) yielded a similar pattern, but 
inhibition of the NADPH-cytochrome с reductase activity proceeded much slower, and 
addition of NADH to the incubation medium fully restored cytochrome c reduction. 
Dependence of the NADPH-cytochrome с reductase activity on the concentration of 2-
NSQO and 4-NSQO is shown in Figure 9. The microsomal protein content being 30 µg/ml, 2-
NSQO in a concentration of 10 µM inhibited the system’s enzymatic activity by 50%, and at 
a concentration of 50 µM and higher the activity dropped by more than 80%. The 10 µM 
concentration of 4-NSQO inhibited the enzymatic activity of microsomes by 15%, and the 
100 µM concentration – by 50%. The above results suggest that the apoptosis inducing effect 
of 2-NSQO and its structural analogs on the cells may be due to the irreversible inhibition of 
microsomal enzymes with NADPH-cytochrome c reductase activity. Where this effect 
happens, functioning of the whole electron transport chain in the cells is usually disrupted, 
there form large amounts of genotoxic products, and the cell eventually dies through 
apoptosis (or necroptosis). 
 
X axis– 2-NSQO and 4-NSQO concentrations, µM (logarithmic scale); Y axis – inhibition of the reaction  rate (%) 
relative to the control. Modifications to the system were made in the first 5 min of the reaction 
Figure 9. Effect of 2-NSQO (1) and 4-NSQO (2) on   NADPH-cytochrome c reductase activity of the 
microsomes of К562 cells. 
Another important fact is that when some quinoline derivatives interacted with DNA the 
greatest hypochromic shift in DNA UV spectra (which evidences the formation of 
complexes) was observed in treatments with 4-NQO, 4-NSQO, 4-DQO, 4-DPyO, whereas 
mixing of Q or 2-MeQ with DNA did not cause changes in the absorption spectra (Table 3). 
This fact supports the assumption that for such biological effect to appear the latter two 
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Another important fact is that when some quinoline derivatives interacted with DNA the 
greatest hypochromic shift in DNA UV spectra (which evidences the formation of 
complexes) was observed in treatments with 4-NQO, 4-NSQO, 4-DQO, 4-DPyO, whereas 
mixing of Q or 2-MeQ with DNA did not cause changes in the absorption spectra (Table 3). 
This fact supports the assumption that for such biological effect to appear the latter two 
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reagents must first undergo metabolic activation in the cell, and form electrophilic centres 
within the molecule. Other N-bearing heterocyclic compounds are potentially able to bind to 
DNA without prior intracellular activation (e.g., through intercalation), so that their 
biological effects would appear sooner. 
Reagent Percent of the reagents-related hypochromic 








Table 3. Hypochromic effect of DNA upon binding with quinoline and pyridine derivatives. DNA 
from chicken erythrocytes was used in the experiment. The spectra were obtained in phosphate buffer 
on a Labsystems Multiscan Plus reader (LKB, Finland) at  260 nm. 
Many chemical compounds, including anticancer drugs, can induce tumor cell apoptosis 
both in vivo and in vitro [48−50]. However, a major cause of failure in the application of 
cytostatic agents in clinical practice is the multiple drug resistance (MDR) phenotype 
induced in the tumor cells. Multidrug resistance is a condition when tumor cells are 
unsusceptible to a variety of chemotherapeutic agents differing in chemical structure and 
the mechanisms through which they affect the cell. MDR is a serious hindrance to success in 
the treatment of malignant tumors, including leukosis. Latest studies have demonstrated 
that the molecular mechanisms of MDR are multifarious, and the drug resistance of a cell 
can depend on various mechanisms triggered at different stages of the toxic impact of the 
agent on the cell – from restricted accumulation of the drug in the cell to cancellation of the 
substance-induced cell death programme. Interplay of several protective mechanisms is not 
uncommon, but one mechanism usually prevails. The best studied mechanisms, whose 
clinical significance for certain neoplastic forms (such as chronic myeloid leukemia or 
chronic lymphatic leukemia) has been ascertained, are: activation of transmembrane 
transport proteins that remove various substances from the cell (namely, Р-glycoprotein – 
Pgp); activation of the glutathione system enzymes that detoxify the drugs; modifications in 
the genes and proteins that control apoptosis and cell survival [51]. 
We have therefore obtained К562 cell sublines resistant to 2-DQO and 4-NQO (К562/2-DQO, 
К562/4-NQO), and characterized their capacity to undergo induced apoptosis under the 
effect of structurally different chemical reagents as compared with the parental line cells.  
The MDR development mechanisms related to inhibition of cytostatic-induced apoptosis 
have lately been actively investigated. Of greatest interest among the cytostatic agents are 
DNA-tropic compounds (adriamycin, actinomycin D), antimetabolites (5-fluorouracil, 
methotrexate), reagents interacting with the mitotic spindle microtubules (vincristine, 
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vinblastine, taxol), and others. К562/4-NQO and К562/2-DQO cells were tested for 
susceptibility to the following chemical compounds: DNA intercalating agent ethidium 
bromide, microtubule polymerization inhibitor colchicine; and quinoline derivatives – 2-






Colchicine 4-NQO 2-DQO 
К562 2.5 0.002 1.06 79.7 
К562/4-NQO 39.8 0.0004 ― 398.2 
К562/2-DQO 7.9 0.120 79.0 ― 
Table 4. Susceptibility of К562/4-NQO and К562/2-DQO cells to cytostatic agents.  Clones resistant to 
4-NQO and 2-DQO were obtained after [38]. Cell resistance to the xenobiotics was induced by long-term 
(over 1 month) exposure to 10-12 M 4-NQO or 10-9 M 2-DQO in the culture medium. The concentration of 
the substances was then increased every 14th−21st days. The final concentrations of the reagents for 
which resistant cell lines were obtained were 10-8 M for 4-NQO, and 10-5 M for 2-DQO. 
 
а – cells were treated with 4-NQO: 1 – Viability of К562/2-DQO cells, 2 – Viability of К562 cells; 
b – cells were treated with 2-DQO: 1 – Viability of К562/4-NQO cells, 2 – Viability of К562 cells; 
с – cells were treated with colchicines: 1 – Viability of К562/2-DQO cells, 2 – Viability of К562 cells; 
d – cells were treated with ethidium bromide: 1 – Viability of К562/2-DQO cells, 2 – Viability of К562 cells. 
X axis – drug concentration (М). Incubation time – 48 h. 
Figure 10. Viability of K562, К562/2-DQO and К562/4-NQO cell lines treated with different xenobiotics. 
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Measurements of the viability of the cells of the parental line and the derived sublines, 
incubated for 48 h in the presence of various concentrations of the reagents, revealed 
substantial differences in the toxic effect of the xenobiotics on the tumor cells. К562/4-NQO 
cells were highly resistant to ethidium bromide and 2-DQO, but susceptible to colchicine 
(Table 4, Figure 10). Contrastingly, К562/2-DQO cells demonstrated quite high resistance to 
colchicine and 4-NQO, but lower resistance to ethidium bromide (Table 4, Figure 10). One 
should mention that the resistance of К562/2-DQO cells to ethidium bromide was 5.03 times 
lower than that of К562/4-NQO cells. 
It is now solid knowledge that when subjected to stepped selection for resistance to some 
cytotoxic agents (plant alkaloids, antibiotics), cells of tumor lines in vitro become cross-
resistant to quite a number of cytostatics, which differ both in the structure and genesis, and 
in the effect on different cellular targets [52−54]. The spectra of the drugs to which the cells 
develop cross-resistance, as well as the mechanisms behind it may vary depending on the 
selection agent. Grinchuk et al. [55] isolated three adriamycin-resistant clones С9, В2, and 
В3, through multi-step selection from the К562 cell population. The cells of the adriamycin-
resistant clones displayed cross-resistance to colchicine, actinomycin D, and ethidium 
bromide – agents of the multidrug resistance group. Amplification of the gene mdr1 was 
detected in the cells of the resistant clones at DNA hybridization with Southern blot. 
Karyological analysis of the resistant cells performed at early stages of their incubation with 
adriamycin showed the genome contained extra genetic material (morphological markers of 
amplification – double minichromosomes in clones В2 and В3, and uniformly stained 
regions in the chromosomes of clone С9 cells). The karyotype modifications are attributed to 
destabilization of the К562/adriamycin cell genome as the cells acquired the MDR 
phenotype. Thus, distinctions in the resistance to the toxic effect of xenobiotics among cells 
of different sublines may be related to specific characteristics of the expression of mdr genes 
and then Р glycoprotein, expression of other MDR proteins, genome destabilization, and, 
not least, changes in the activity of cellular enzymes involved in the first (e.g., cytochrome Р-
450) and second (e.g., glutathione-S-transferase) phases of the reagent metabolism in the 
cells. These and other factors can, under certain conditions, play a decisive role in the 
modulation of the functional activity of apoptosis inducing agents, including caspases. 
Figure 11a shows the results on relative expression of caspase-3, -6, and -9 genes in the cells 
of the К562 parental line and the derivative sublines (data from RT-PCR analysis). One can 
see that the mRNA expression of the named caspases in К562/4-NQO and К562/2-DQO cells 
is significantly lower (p<0.05) than in the parental К562, and that is a potential explanation 
of the resistance of the tumor cells to 4-NQO and 2-DQO.  
In the treatment with colchicine mRNA expression of caspases-3, -6, and -9 was significantly 
promoted in the parental line К562 and К562/4-NQO – p<0.05 (Figure 11 b). In К562/2-DQO 
cells only caspase-6 expression was activated (p<0.05). Incubation of tumor cells with 
ethidium bromide promoted the mRNA expression of the three investigated caspases in the 
parent cells; caspase-3 expression was promoted in К562/2-DQO cells; no significant changes 
in caspase mRNA expression was observed in the К562/4-NQO line. Changes in the 
enzymatic activity correlated with mRNA expression. 
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The results above prove that the cell sublines we have obtained have become cross-resistant 
to chemical reagents of the MDR group, and that such resistance may be due, i.a., to 
modifications in caspase expression. 
 
Results are presented as the ratio of caspase to GAPDH expression relative to a standard curve for each assay. Drug 
concentrations: 0.1 µМ for К562/2-DQO cells, 0.001 µМ for K562 cells, 0.001 µМ for К562/4-NQO cells. Incubation time 
– 48 h. Viability of cultured cells – 93−95%. Z axis – relative expression, conventional unit. 
Figure 11. Caspase-3, -6 and -9 mRNA levels were determined by quantitative real-time RT-PCR in 
K562, К562/2-DQO and К562/4-NQO cell lines (a) treated with  colchicine (b) respectively.  
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One of the preconditions for in vivo development and progress of tumors is that the tumor 
cells gain another type of resistance – resistance to factors of anti-tumor immunity. Such 
factors are, first of all, natural killer (NK) cells and cytotoxic T lymphocytes. The 
mechanisms of identification of de novo tumor cells in the organism by natural killers have 
not been fully elucidated, but the mechanisms of the lysis of such cells are quite well 
studied. NK cells and antigen-specific cytotoxic T lymphocytes, as well as these IL-2 
activated cells are known to lyse target cells both by perforin-dependent cytolysis, and by 
inducing Fas-dependent apoptosis [56, 57]. In this case, the target cells can modulate the rate 
of release of the cytolytic granule content, including perforin and granzymes, or suppress 
killer activation by reducing the frequency and affinity of the formation of target cell-
effector cell conjugates, the latter being a quite frequent phenomenon in the system [58]. 
Perforin is structurally homologous to the С9 complement component, and has a similar 
action mechanism (formation of polyperforin pores made up of 12–18 monomers, with the 
inner diameter of 10–20 nm) [56]. On the other hand, no DNA fragmentation occurs when 
the complement acts on the cells, wherefore we presume that the action of perforin involves 
also other factors (namely serine proteases of the granzyme family [58], which can permeate 
the target cell cytosol via perforin-generated pores in the plasma membrane and trigger 
apoptotic events, for instance by means of caspase activation. 
Some authors have demonstrated in their papers that treatment of tumor cells with chemical 
reagents modifies their susceptibility to the cytotoxic lysis of homologous effector cells, and 
the modification may be either for amplification or for reduction of the effect depending on 
the cell line and the treatment settings. E.g., treatment of К562 cells with sodium butyrate 
[59], fagaronine, adriamycin, aclacinomycin А [60] makes the named cells less susceptible to 
natural killer lysis. Quite a number of lymphoma cell lines (Raji and Daudi lymphoma cell 
lines, human lymphoblastoid cell line NAD-7, human Т-lymphoblastoid line Molt-4) treated 
with PMA, sodium butyrate, retinoic acid demonstrate higher susceptibility to the cytotoxic 
activity of natural killers [61−63]. An interesting effect was observed in the case of CB-1 B 
cell lines. Clone 26CB-1 is more resistant to NK cells than clone 13CB-1. After they had been 
treated with sodium butyrate, iodinated deoxyuridine, 5-azacytidine, tunicamycin, the 
susceptibility of clone 26CB-1 cells to cytotoxic lysis increased, whereas the susceptibility of 
clone 13CB-1 cells remained nearly unmodified [64]. 
Distinctions in the chemical inducers’ structure and mechanisms of action on cells may have 
different effects on modulation of the expression of positive and negative apoptosis 
regulators, which quantitative ratios may contribute to establishment of both the initial 
susceptibility of the cells to natural killer lysis and the post-treatment susceptibility. This 
may as well be valid for the cell sublines with a more or less differentiated phenotype. 
Data in Figure 12 (a, b) show that the treatment of tumor cells with 4-NQO, 2-NSQO, and 4-
NSQO for 48 h caused a significant rise (р<0.05) in susceptibility to the lysis of human 
leukocytes containing NK cells. Caspase expression and cell apoptosis induction were also 
promoted in this case. In treatments with other quinoline derivatives the cytotoxic index in the 
cultures did not change. A similar pattern was observed also when incubation lasted 96 h. 
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Drug concentrations:  Q – 0.3 µМ, QO – 10 µМ, 4-NQO – 0.001 µМ, styryl derivatives – 1 µМ. X-axis: cytotoxic index 
ratio of effector cells with treated cell lines to control cell lines without treatment, % (cytotoxic index value of control 
cells is 100 %). Effector cells to target cells ratio is 50:1. Incubation time – 48 h; * p<0.05.  
Figure 12. The К562 cell line sensitivity to cytotoxic lysis by human peripheral blood white cells after 
treatment with quinoline and pyridine derivatives 
When cells of sublines К562/4-NQO and К562/2-DQO were used as the targets, changes in 
susceptibility to the leukocyte lysis effect were recorded only in the К562/4-NQO−colchicine 
system (Figure 13). 
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Figure 12. The К562 cell line sensitivity to cytotoxic lysis by human peripheral blood white cells after 
treatment with quinoline and pyridine derivatives 
When cells of sublines К562/4-NQO and К562/2-DQO were used as the targets, changes in 
susceptibility to the leukocyte lysis effect were recorded only in the К562/4-NQO−colchicine 
system (Figure 13). 
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Drug concentrations – 0.1 µМ for К562/2-DQO cells, 0.001 µМ for K562 cells, 0.001 µМ for К562/4-NQO cells. X-axis: 
cytotoxic index ratio of effector cells with treated cell lines to control cell lines without treatment, % (cytotoxic index 
value of control cells is 100 %). Effector cells to target cells ratio is 50:1. Incubation time – 48 h; * p<0.05. 
Figure 13. The К562 cell line sensitivity to cytotoxic lysis by human peripheral blood white cells after 
treatment with colchicines. 
Thus, treatment of tumor cells with chemical compounds may simultaneously induce cell 
apoptosis and modulate their susceptibility to the cytotoxic lysis of blood leukocytes. In 
these treatment conditions the expression and/or activity of intracellular apoptosis 
regulators, namely caspases, changes, and this change may tell on the effectiveness of the 
leukocyte lysis effect, which is based on induction of target cell apoptosis. It is essential that 
the susceptibility of tumor cells to the lysis of leukocytes containing NK cells changed in 
those variants where the expression and activity of caspases-3, -6, -9 were promoted 
(cultures treated with 4-NQO, 2-NSQO, and 4-NSQO). On the other hand, the equivocal 
nature of the results proves that the process involves extra intracellular factors. One can 
therefore assume that similar patterns of the response of tumor cells to treatment with 
chemical compounds can occur in vivo in humans and animals treated with the anticancer 
drugs stimulating cell apoptosis. This effect can persist when nontoxic or low-toxicity doses 
are applied, and caspases, being a cell’s major apoptosis inducing factor, can be viewed as 
potential targets for pharmacologically active agents. 
5. Conclusions  
Over 40 years have passed since the first publication devoted to apoptosis. Since then, the 
problem of apoptosis regulation mechanisms has become central to pharmacology, genetics, 
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virology, cytology, immunology, biochemistry, embryology, and other areas of modern 
science at the cellular and molecular levels. It is obvious that the problem addressed in 
this chapter is of high applied value, for the key aim of the effort is to enhance the 
effectiveness of anticancer therapy. The industry of rational drug design is becoming 
more and more widespread in practical medicine. The principal concepts in drug design 
are the target and the drug. The target is a low-molecular biological structure presumably 
linked to a certain function which disruption would lead to disease, and to which a 
certain impact should be applied. The most common targets are receptors, enzymes, 
hormones. The drug is most often a chemical compound (usually a low-molecular one) 
that specifically interacts with the target, modifying the cell response in one way or 
another. One of the earliest and most seminal stages of drug design is accurate 
identification of the target by influencing which one can specifically regulate certain 
biochemical processes, leaving others unaffected as much as possible. This is not however 
always feasible: by no means are all diseases caused by dysfunction of just one protein or 
gene. Preference should therefore be given to the processes’ principal biomolecules. In 
terms of apoptosis, caspases clearly are such biomolecules. Hence, the choice of methods 
for experimental validation of caspases as potential specific targets for drugs is a topical 
challenge for the nearest future. 
6. Abbreviations: 
Quinoline – Q, 2-methylquinoline – 2-MeQ, quinoline-1-oxide – QO, 2-methylquinoline-1-
oxide – 2-MeQO, 4-nitroquinoline-1-oxide – 4-NQO, 2-methyl-4-nitroquinoline-1-oxide – 2-Me-
4-NQO, 2-(4’-dimethylaminostyryl)quinoline-1-oxide – 2-DQO, 4-(4’-dimethylaminostyryl)-
quinoline-1-oxide – 4-DQO, 2-(4’-nitrostyryl)quinoline-1-oxide – 2-NSQO, 4-(4’-nitrostyryl)-
quinoline-1-oxide – 4-NSQO, and 4-(4’-dimethylaminostyryl)pyridine-1-oxide – 4-DPyO; death 
effector domain – DED, caspase recruitment domain – CARD, death inducing domain – DID, 
р53-induced protein with a death domain – PIDD, death-inducing signalling complex – DISC, 
DNA fragmentation factor – DFF, caspase-activated DNase – CAD, permeability transition 
роrе – РТР, apoptosis inducing factor – AIF, tumor necrosis factor receptor – TNFR, death 
domain – DD, death receptor – DR, Fas-associated DD-protein – FADD, TNFR1-associated 
DD-protein – TRADD. 
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1. Introduction 
For development of novel strategy for the treatment of hepatic diseases, in which changes in 
apoptosis are targeted, it is most important to understand the molecular mechanisms by 
which apoptotic process is regulated. Rapid and efficient removal of unwanted cells such as 
aged, damaged, genetically mutated, or virally-infected ones is indispensable in the 
maintenance of the health of the liver. Means for removal of such cells are provided by 
nature as apoptosis, a well-controlled and programmed cell death process, which is 
especially important in the liver where cells are exposed to various toxins and viruses [1]. In 
a healthy adult body, the number of cells removed by apoptotic process in a certain period 
of time is comparable to the number of cells that proliferate by mitosis. Proper homeostasis 
of organs is thus maintained. However, under certain pathophysiological conditions, the 
balance between the growth and the loss of the cells is often upset, due to the onset of some 
liver diseases resulting in the loss of tissue homeostasis. Insufficient apoptosis will promote 
the growth of hepatocarcinoma or biliary carcinoma by failing the removal of cells growing 
uncontrollably in genetically mutated cells or in chronic or persistent inflammations [2-5]. 
Persistent stimulation causing apoptosis may be a factor to promote high rate regeneration 
of cancer cells in the tissue, elevating the risk of errors in mitosis. In contrast, excessive 
and/or persistent apoptosis may lead to acute damages such as fulminant hepatitis or 
reperfusion injury [6, 7], or chronic persistent damages such as alcoholic liver diseases, 
cholestatic liver disease, or viral hepatitis [8-11]. Inhibition of apoptosis in the liver injury or 
selective killing of malignant cells in tumors will provide strategies for treatment of hepatic 
diseases. In fact, new drug development is ongoing targeting apoptosis through the 
understanding of molecular process and pathophysiological role of apoptosis, and such 
substances are now tested in clinical trial or used as new options for certain human diseases. 
In this review, we focus the subject on the role of apoptosis in cholestatic liver diseases or 
alcoholic liver injury in which we carried out some investigations [12-15]. 
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2. Cholestasis and hydrophilic or hydrophobic bile acids 
It has been demonstrated that hydrophobic bile acids damage cellular functions by affecting 
intracellular organelle and signaling system at the concentrations 100-500 µM, which are 
lower than those at which they show cytotoxic or detergent actions. Combettes and his co-
workers reported that lithocholic acid (LCA) and taurolithocholic acid (TLCA) induce 
release of calcium ion (Ca2+) from the endoplasmic reticulum (ER) and the increased level of 
Ca2+ within the cell mediates cytotoxicity due to these hydrophobic bile acids [16]. 
Combettes and his colleagues speculated that this increase in intracellular Ca2+ levels occurs 
because LCA activates the inositol (1,4,5)-triphosphate (IP3) receptor, independent from IP3 
itself, resulting in the release of Ca2+ from the intracellular organelle, ER [17]. On the other 
hand, there is a report that the increase in intracellular Ca2+ level induced by hydrophobic 
bile acid depends on extracellular Ca2+ level [18]. Spivey and his colleagues reported that at 
250 µM, glycochenodeoxycholic acid (GCDCA) induces the impairment of mitochondrial 
function and cellular ATP depletion, followed by a sustained rise in cytosolic Ca2+ resulting 
from an influx of extracellular Ca2+ leading to the death of hepatocytes, and that this 
cytotoxicity decreases in the order of GCDCA>CDCA>tauro-CDCA [19].  
GCDCA is also reported to enhance the mitochondrial membrane permeability and induce 
cytotoxicity, while ursodeoxycholic acid (UDCA) shows suppression of GCDCA-induced 
enhancement of mitochondrial membrane permeability and cytotoxicity [20, 21]. Bile acid-
induced enhancement of mitochondrial membrane permeability was also shown in the in 
vivo study of cholestasis [22]. Considering the data that increase in reactive oxygen species 
(ROS) generation in hepatocyte and generation of H2O2 stimulated by tauro-CDCA 
(TCDCA) in mitochondria preceded TCDCA-induced hepatocyte necrosis, it was speculated 
that generation of ROS by hydrophobic bile acid constitutes one of the causative factors of 
hepatic injury in cholestasis [23].  
In cholestatic liver disease, loss of hepatocytes or appearance of apoptotic body in 
hepatocytes was morphologically observed, and involvement of apoptosis was suggested in 
the hepatocyte injury in cholestasis [24]. Patel and his colleagues reported for the first time 
that low concentration of glycodeoxycholic acid induced apoptosis in hepatocytes, and 
pointed out that bile acids may induce necrosis at higher concentrations and apoptosis at 
lower concentrations in hepatocytes [25, 26]. Furthermore, Sokol and his colleagues reported 
that hydrophobic bile acid induced lipid peroxidation and mitochondrial dysfunction via 
enhancement of mitochondrial membrane permeability [27], and we ourselves also reported 
mitochondria-mediated time- and concentration-dependent apoptotic cell death and 
endoplasmic reticulum (ER) stress-mediated apoptosis of hepatocytes induced by GCDCA 
[28, 29].  
Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, has been widely used as a 
therapeutic agent for primary biliary cirrhosis (PBC) or cholestasis [30]. Suggested 
mechanism of action of UDCA includes promotion of bile secretion, detoxification 
metabolism in the liver, and antioxidant stress response, but its molecular mechanism is still 
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not clarified in detail. In vivo studies showed that UDCA is protecting hepatocytes from 
hydrophobic bile acid-induced apoptosis [31]. Furthermore, tauro-conjugated form of 
UDCA, tauro-UDCA (TUDCA), was shown to protect hepatocytes in ischemia-reperfusion 
injury in rats [32], and ethanol-fed rats [33]. When toxic bile acid is given to rats, apoptosis is 
induced in the liver, but when UDCA is given in combination, apoptosis is suppressed by 
inhibition of translocation of pro-apoptotic protein Bax from cytosol to mitochondria and 
ROS generation. This suppression is observed in cells other than hepatocytes, and UDCA 
was shown to act on classic mitochondrial-mediated pathway in different types of cells [34]. 
Taurourusodeoxycholic acid (TUDCA), a substance in which UDCA is conjugated with 
taurine, was shown to play an important role in various disorders including some liver 
diseases, type-II diabetes and metabolic syndrome [35, 36] possibly by its actions shown in 
isolated mitochondria to stabilize mitochondrial membrane directly through affecting 
channel formation by Bax [37], and bringing changes in ER stress-mediated pathways by 
decreasing caspase-12 activity and decrease in Ca2+ releases.  
However, in a clinical trial for reevaluation of effectiveness in PBC patients, the effectiveness 
of UDCA was not acknowledged [38]. In rat isolated primary cultured hepatocytes, UDCA, 
given in combination with hydrophobic bile acids, was shown to be cytotoxic [39] and 
activates the pro-apoptotic pathway in some condition [40].  
3. Apoptosis induced by hydrophobic bile acids in rat hepatocytes 
Bile acids are synthesized from cholesterol in the liver, and act as surfactants that help 
digestion and absorption of lipids, and lipid-soluble vitamins. Major bile acids found in 
human bile are cholic and chenodeoxycholic acids, and they are secreted into bile as 
conjugates with taurine or glycine, via amide-bond. Most of bile acids secreted into the 
duodenum are reabsorbed by active transport in the terminal ileum, and returned to the 
liver. Bile acids are not so potently toxic as to injure hepatocytes in healthy subjects, but if 
the bile acid levels in the liver are too high or the ratio of hydrophobic bile acids to 
hydrophilic bile acids increases, as in the cases when there is some abnormality in bile acid 
synthesis, they induce apoptosis or necrosis [41]. The potency of their hepatotoxicity is, in 
the decreasing order, LCA > deoxycholic acid (DCA) > CDCA > CA > UDCA > 
dehydrocholic acid. The total bile acid in the liver tissue in normal subjects is not more than 
10 µM when determined as serum bile acid level, but in patients with cholestasis, CDCA 
level in the liver tissue increases to about 20 times higher than in the normal case, and the 
serum bile acid level elevated to 10 to 30 times (100-300 µM) higher than normal, of which 
hydrophobic bile acid accounted for about 50-60 % [42, 19]. Cholestatic liver diseases are 
associated with bile duct obstruction by the formation of biliary stones, genetic defects, 
hepatotoxicity, hepatobiliary tumors [43]. Acute and chronic cholestasis induces 
hepatocelluar injury, biliary dilatation, hepatic fibrosis, cirrhosis, and ultimately hepatic 
failure [44]. Decrease in bile flow or total obstruction of bile duct upon cholestasis is induced 
by the stasis of metabolized products such as cholesterol and bile acids in the liver which are 
normally eliminated into bile. Especially some hydrophobic bile acids induce cytotoxicity in 
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Taurourusodeoxycholic acid (TUDCA), a substance in which UDCA is conjugated with 
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diseases, type-II diabetes and metabolic syndrome [35, 36] possibly by its actions shown in 
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channel formation by Bax [37], and bringing changes in ER stress-mediated pathways by 
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However, in a clinical trial for reevaluation of effectiveness in PBC patients, the effectiveness 
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normally eliminated into bile. Especially some hydrophobic bile acids induce cytotoxicity in 
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cultured hepatocytes [45]. In a major hypothesis on the mechanisms of hepatocyte injury, 
bile acids accumulated in the hepatocytes are regarded to be the major cause of cell death 
[23]. While bile acids such as taurolithocholic acid (TLCA), deoxycholic acid (DCA), 
glycodeoxycholic acid (GDCA), glycochenodeoxycholic acid (GCDCA) are known to induce 
necrosis of hepatocytes via increase in oxidative stress mediated by hydroperoxide 
generation by mitochondria [23], attention is recently focused on apoptotic cell death 
associated with these bile acids [45, 46].  
The mechanism and pathways of bile acid-induced apoptosis in hepatocytes are reported to 
include death receptor-mediated pathway [9] and increase in ROS generation [31]. We 
ourselves reported that, in primary cultured hepatocytes isolated from healthy rats, 
apoptosis is induced by a hydrophobic bile acid in a concentration- and time-dependent 
manner [28]. When hepatocyte was cultured with 200 µM of GCDCA for 6 hours, ssDNA 
and caspase-3 activity which are measures of apoptosis increased about 10 times higher than 
in the untreated cultured hepatocytes (Fig. 1). Also, in hepatocytes treated with 200 µM 
GCDCA for 4hours, the level of mRNA of Fas and activities of caspase-8 and caspase-3 were 
significantly increased compared with those in untreated hepatocytes. Further, 
mitochondrial membrane potential difference of 200 µM GCDCA-treated hepatocytes was 
decreased by 60% compared with the same in untreated hepatocytes. GDCDA, a 
hydrophobic bile acid, was demonstrated to induce an increase in Fas death receptors 
located in cell membrane to activate apoptotic pathway.  
 
Figure 1. The effect of GCDCA on detection of apoptotic cells. Isolated hepatocytes (1x106 cells/well) 
were treated with GCDCA at 37 C. Formamide-denaturable DNA was detected in apoptotic 
hepatocytes. The ssDNA was stained with the primary antibody (anti-ssDNA-mAb) and peroxidase-
labelled secondary antibody for color development. Each value represents the mean+SEM of 6-12 
samples. Statistically significant changes are indicated as *p<0.05 compared with the untreated 
hepatocytes. 
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On the other hand, oriental traditional pharmacognosy has utilized bear bile as a medicine 
for improving gastrointestinal symptoms. The effective ingredient of the bear bile is UDCA, 
which has been used widely as a choleretic or calculolytic drug for cholesterol gallstone. 
UDCA is now used for a wide range of liver disease treatment, and the evidence for its 
effectiveness has been reported one after another. The indications of UDCA include primary 
biliary sclerosis (PBC), calculolysis, prevention of gallstone formation and UDCA is 
demonstrated to be effective in most of these. However, there has been a report that in a 
clinical trial for reevaluation of effectiveness in PBC patients, the effectiveness of UDCA was 
not acknowledged [47]. In rat isolated primary cultured hepatocytes, when given in 
combination with hydrophobic bile acids, UDCA was reported to be cytotoxic [48] and 
activates the proapoptotic pathway [49]. We ourselves examined the action of UDCA on 
GCDCA-induced apoptosis in rat primary cultured hepatocytes [28]. When hepatocytes 
were incubated in the co-presence of UDCA and GCDCA, UDCA significantly inhibited 
GCDCA-induced apoptosis in a short incubation (4 hours), but a prolonged incubation (20-
hour incubation) potentiated the apoptosis (Fig. 2). In the study of decrease in mitochondrial 
membrane potential difference, a further decrease in the potential was observed in co-
incubation of hepatocytes with UDCA and GCDCA even in a short incubation. It was 
suggested that when cholestatic condition is severe and hepatotoxicity of bile acids is more 
potent, UDCA might potentiate the toxicity and we pointed out the need for attention in the 
clinical use [28].  
 
 
Figure 2. Effect of UDCA on ssDNA in GCDCA-induced apoptotic hepatocytes. Each value 
represents the mean+SEM of 5-15 samples. Other culture conditions were the same as in Fig. 1. *p < 0.05: 
significant difference from untreated cells, # p < 0.05: significant difference from GCDCA-treated cells. 
 
Apoptosis and Medicine  208 
cultured hepatocytes [45]. In a major hypothesis on the mechanisms of hepatocyte injury, 
bile acids accumulated in the hepatocytes are regarded to be the major cause of cell death 
[23]. While bile acids such as taurolithocholic acid (TLCA), deoxycholic acid (DCA), 
glycodeoxycholic acid (GDCA), glycochenodeoxycholic acid (GCDCA) are known to induce 
necrosis of hepatocytes via increase in oxidative stress mediated by hydroperoxide 
generation by mitochondria [23], attention is recently focused on apoptotic cell death 
associated with these bile acids [45, 46].  
The mechanism and pathways of bile acid-induced apoptosis in hepatocytes are reported to 
include death receptor-mediated pathway [9] and increase in ROS generation [31]. We 
ourselves reported that, in primary cultured hepatocytes isolated from healthy rats, 
apoptosis is induced by a hydrophobic bile acid in a concentration- and time-dependent 
manner [28]. When hepatocyte was cultured with 200 µM of GCDCA for 6 hours, ssDNA 
and caspase-3 activity which are measures of apoptosis increased about 10 times higher than 
in the untreated cultured hepatocytes (Fig. 1). Also, in hepatocytes treated with 200 µM 
GCDCA for 4hours, the level of mRNA of Fas and activities of caspase-8 and caspase-3 were 
significantly increased compared with those in untreated hepatocytes. Further, 
mitochondrial membrane potential difference of 200 µM GCDCA-treated hepatocytes was 
decreased by 60% compared with the same in untreated hepatocytes. GDCDA, a 
hydrophobic bile acid, was demonstrated to induce an increase in Fas death receptors 
located in cell membrane to activate apoptotic pathway.  
 
Figure 1. The effect of GCDCA on detection of apoptotic cells. Isolated hepatocytes (1x106 cells/well) 
were treated with GCDCA at 37 C. Formamide-denaturable DNA was detected in apoptotic 
hepatocytes. The ssDNA was stained with the primary antibody (anti-ssDNA-mAb) and peroxidase-
labelled secondary antibody for color development. Each value represents the mean+SEM of 6-12 
samples. Statistically significant changes are indicated as *p<0.05 compared with the untreated 
hepatocytes. 
 
Some Findings on Apoptosis in Hepatocytes 209 
On the other hand, oriental traditional pharmacognosy has utilized bear bile as a medicine 
for improving gastrointestinal symptoms. The effective ingredient of the bear bile is UDCA, 
which has been used widely as a choleretic or calculolytic drug for cholesterol gallstone. 
UDCA is now used for a wide range of liver disease treatment, and the evidence for its 
effectiveness has been reported one after another. The indications of UDCA include primary 
biliary sclerosis (PBC), calculolysis, prevention of gallstone formation and UDCA is 
demonstrated to be effective in most of these. However, there has been a report that in a 
clinical trial for reevaluation of effectiveness in PBC patients, the effectiveness of UDCA was 
not acknowledged [47]. In rat isolated primary cultured hepatocytes, when given in 
combination with hydrophobic bile acids, UDCA was reported to be cytotoxic [48] and 
activates the proapoptotic pathway [49]. We ourselves examined the action of UDCA on 
GCDCA-induced apoptosis in rat primary cultured hepatocytes [28]. When hepatocytes 
were incubated in the co-presence of UDCA and GCDCA, UDCA significantly inhibited 
GCDCA-induced apoptosis in a short incubation (4 hours), but a prolonged incubation (20-
hour incubation) potentiated the apoptosis (Fig. 2). In the study of decrease in mitochondrial 
membrane potential difference, a further decrease in the potential was observed in co-
incubation of hepatocytes with UDCA and GCDCA even in a short incubation. It was 
suggested that when cholestatic condition is severe and hepatotoxicity of bile acids is more 
potent, UDCA might potentiate the toxicity and we pointed out the need for attention in the 
clinical use [28].  
 
 
Figure 2. Effect of UDCA on ssDNA in GCDCA-induced apoptotic hepatocytes. Each value 
represents the mean+SEM of 5-15 samples. Other culture conditions were the same as in Fig. 1. *p < 0.05: 
significant difference from untreated cells, # p < 0.05: significant difference from GCDCA-treated cells. 
 
Apoptosis and Medicine  210 
4. Endoplasmic reticulum involvement in hydrophobic bile acid-induced 
apoptosis in rat hepatocytes 
In addition to the major two intracellular apoptotic pathways, that is, death receptor- 
mediated and mitochondria-mediated pathways, attention has recently been focused on the 
ER stress-mediated pathway. The response against the accumulation of unfolded proteins in 
ER is called unfolded protein response (UPR) and this is featured by activation of three 
different signaling pathways, inositol-requiring (IRE)-1�, protein kinase RNA-activated 
(PKR)-like ER kinase (PERK), activating transcription factor (ATF)-6�. Changes in ER 
functions are induced by various stimulations, extrinsic chemicals administered 
pharmacologically, or increase in physiologically secreted proteins, and these upsets are 
called ER stress, which can be detected by the UPR transducer activation. ER stress is 
observed in many liver diseases, and UPR activity is correlated with hepatic resistance 
against insulin in obesity and fatty liver. Chronic viral B and C hepatitis, alcohol-induced 
liver injury, ischemic re-perfusion damages, and cholestatic liver injury are also correlated 
with UPR activity. Prolonged or potent ER stress induces apoptosis.  
Just like an anti-apoptotic protein Bcl-2, pro-apoptotic proteins Bax and Bak are localized in 
membranes of ER, and regulate homeostasis of Ca2+ within the cell. Release of Ca2+ from ER 
activates calpain, which in turn activates caspase-12 (in human cells, caspase-4), and initiates 
apoptosis. Ca2+ intake by mitochondria leads to enhancement of mitochondrial membrane 
permeability, and cytochrome c is released from mitochondria. Membranes of mitochondria 
and ER are connected through protein junctions [50]. These junctions seem to facilitate 
transports of Ca2+ and phospholipids, and are possibly associated with apoptosis. However, 
the exact signaling pathway that mediates ER stress-induced apoptosis in hepatocytes is not 
clarified yet. UPR is activated for restoration of ER homeostasis. The upset of ER 
homeostasis induced by damages or activations of UPR sensors is observed in some liver 
diseases, and ER stress is observed in various liver diseases. Drugs that are hepatotoxic 
activate several intracellular stress responses (for example, lysosome disorder, increased 
permeability of mitochondrial membrane, oxidative stress, inflammation and so on) in 
hepatocytes.  
Correlations have been observed between these responses and ER dysfunction. Steatosis 
occurs in the liver after an acute ER stress mediated by a transcription factor for lipid 
regulation, sterol regulatory element-binding protein (SREBP)-1c and SREBP-2c. Activation 
of nuclear factor kappa B (NF-кB) occurs in the downstream of ER upset in alpha-1 
antitrypsin (AAT) deficiency disease. Chronic viral hepatitis (hepatitis C virus HCV, 
hepatitis B virus HBV) accompanies ER dysfunction. Prolonged ER stress leads to apoptosis 
by activation of C/enhancer binding protein (EBP) homologous protein (CHOP), change in 
Ca2+ homeostasis and premature resuming of mRNA translation.  
In cholestasis, toxic hydrophobic bile acid/salts are retained in the liver due to impaired 
biliary excretion. Sodium deoxycholate (DC) induced expressions of UPR genes BIP and 
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CHOP in vitro [51]. When hepatocytes of CHOP-null mice were incubated with toxic 
GCDCA, cell death was decreased [52]. In a hereditary model of intrahepatic cholestasis, 
accumulation of bile acids in the liver was correlated with ER stress [53]. We ourselves 
studied the effects of GCDCA treatment in hepatocytes, and found that when the culture 
medium contained Ca2+, persistent increase in intracellular Ca2+ was observed while only 
transient increase in intracellular Ca2+ was observed when cells were cultured in Ca2+ free 
medium, showing that GCDCA promotes Ca2+ influx from extracellular matrix and release 
of Ca2+ from ER. Activations of calpain and caspase-12 due to the increase in intracellular 
Ca2+ were also observed, and we reported that GCDCA induces apoptosis mediated by ER 
stress [29]. Furthermore, we reported the correlation between ER stress associated with 
GCDCA and caspase-8 activation. GCDCA activates caspase-8 via Fas death receptor, but 
when hepatocytes were pretreated with a caspase-8 inhibitor, z-IETD-FMK, expressions of 
BIP, an ER chaperone molecule, and CHOP, an ER stress response transcription factor, were 
suppressed. From these, we speculated that caspase-8 activated by GCDCA regulates ER 
stress [54].  
5. Detailed mechanism of hydrophobic bile acid-induced apoptosis in 
HepG2 cells 
A hydrophobic bile acid GCDCA activates caspase-8 in hepatocytes via Fas death receptor 
in the cell membrane. Activated caspase-8 enhances mitochondrial membrane 
permeability to facilitate the release of cytochrome c, a pro-apoptotic protein, activates 
caspase-9 and caspase-3 to induce apoptosis. Caspase-8 activated by GCDCA cleaves 
BAP31 protein in ER membrane and may possibly be associated with Ca2+ release from 
mitochondria from ER. BAP31 is cleaved to be BAP20 which is an activated form. As 
shown in Fig. 3, intact (uncleaved) BAP31 protein is observed in ER in untreated hepatic 
cells, but in GCDCA-treated hepatic cells, the content of intact BAP31 protein is 
decreased. The decrease in intact BAP31 observed in GCDCA-treated hepatocytes was 
suppressed by pretreatment with z-IETD-FMK. When recombinant active caspase-8 was 
added to hepatocytes, decrease in intact BAP31 was observed. GCDCA-induced increased 
intracellular Ca2+ interacted with mitochondria and caused its dysfunction, followed by 
increase in mitochondrial membrane permeability and release of pro-apoptotic factors 
from mitochondria. Also, calpain was activated by the increase in Ca2+ release followed by 
activation of caspases. Furthermore, ER chaperone BIP is usually bound to an ER stress 
sensor located within the lumen of ER, but GCDCA treatment causes the increase in 
unfolded protein, and promotes the release of BIP from the stress sensor and increases the 
expression of CHOP, an ER stress-related transcription factor that works in the 
downstream of PERK, an ER stress sensor (Fig. 4). CHOP induces the transcription of Bim, 
a pro-apoptotic BH3 only protein [55]. Membranes of mitochondria and ER are connected 
by complexes composed of tethering proteins [50].  
These complexes facilitate the transport of calcium and phospholipids and possibly are 
associated with apoptosis. GCDCA is known to induce apoptosis via mitochondria- and ER 
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CHOP in vitro [51]. When hepatocytes of CHOP-null mice were incubated with toxic 
GCDCA, cell death was decreased [52]. In a hereditary model of intrahepatic cholestasis, 
accumulation of bile acids in the liver was correlated with ER stress [53]. We ourselves 
studied the effects of GCDCA treatment in hepatocytes, and found that when the culture 
medium contained Ca2+, persistent increase in intracellular Ca2+ was observed while only 
transient increase in intracellular Ca2+ was observed when cells were cultured in Ca2+ free 
medium, showing that GCDCA promotes Ca2+ influx from extracellular matrix and release 
of Ca2+ from ER. Activations of calpain and caspase-12 due to the increase in intracellular 
Ca2+ were also observed, and we reported that GCDCA induces apoptosis mediated by ER 
stress [29]. Furthermore, we reported the correlation between ER stress associated with 
GCDCA and caspase-8 activation. GCDCA activates caspase-8 via Fas death receptor, but 
when hepatocytes were pretreated with a caspase-8 inhibitor, z-IETD-FMK, expressions of 
BIP, an ER chaperone molecule, and CHOP, an ER stress response transcription factor, were 
suppressed. From these, we speculated that caspase-8 activated by GCDCA regulates ER 
stress [54].  
5. Detailed mechanism of hydrophobic bile acid-induced apoptosis in 
HepG2 cells 
A hydrophobic bile acid GCDCA activates caspase-8 in hepatocytes via Fas death receptor 
in the cell membrane. Activated caspase-8 enhances mitochondrial membrane 
permeability to facilitate the release of cytochrome c, a pro-apoptotic protein, activates 
caspase-9 and caspase-3 to induce apoptosis. Caspase-8 activated by GCDCA cleaves 
BAP31 protein in ER membrane and may possibly be associated with Ca2+ release from 
mitochondria from ER. BAP31 is cleaved to be BAP20 which is an activated form. As 
shown in Fig. 3, intact (uncleaved) BAP31 protein is observed in ER in untreated hepatic 
cells, but in GCDCA-treated hepatic cells, the content of intact BAP31 protein is 
decreased. The decrease in intact BAP31 observed in GCDCA-treated hepatocytes was 
suppressed by pretreatment with z-IETD-FMK. When recombinant active caspase-8 was 
added to hepatocytes, decrease in intact BAP31 was observed. GCDCA-induced increased 
intracellular Ca2+ interacted with mitochondria and caused its dysfunction, followed by 
increase in mitochondrial membrane permeability and release of pro-apoptotic factors 
from mitochondria. Also, calpain was activated by the increase in Ca2+ release followed by 
activation of caspases. Furthermore, ER chaperone BIP is usually bound to an ER stress 
sensor located within the lumen of ER, but GCDCA treatment causes the increase in 
unfolded protein, and promotes the release of BIP from the stress sensor and increases the 
expression of CHOP, an ER stress-related transcription factor that works in the 
downstream of PERK, an ER stress sensor (Fig. 4). CHOP induces the transcription of Bim, 
a pro-apoptotic BH3 only protein [55]. Membranes of mitochondria and ER are connected 
by complexes composed of tethering proteins [50].  
These complexes facilitate the transport of calcium and phospholipids and possibly are 
associated with apoptosis. GCDCA is known to induce apoptosis via mitochondria- and ER 
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stress-mediated pathways via death receptor, but mitochondria and ER themselves seem to 
be interrelated to each other.  
6. Some new findings with effects of ethanol-induced oxidative stress on 
apoptosis in SK-Hep1 cells 
Overconsumption of alcohol is associated with deaths of about 2 million people per year 
throughout the world. In its early stage, fatty liver is induced, which may progress to liver 
disorders accompanied with hepatocyte death, inflammation, and fibrosis, further to 
cirrhosis and hepatocarcinoma [56, 57]. Rate of incidences of acute alcohol intoxication and 
heavy alcohol drinking indifferent to one’s health is globally increasing and acute liver 
injury caused by alcohol is attracting attention [58]. Suggested molecular mechanisms for 
liver disorders induced by alcohol include increase of ROS and changes in various signaling 
pathways, but the molecular mechanism for hepatocyte death was not clarified yet. In 
experimental studies using model animals of ethanol-induced liver injury, it was 
emphasized that apoptosis is playing an important role in the pathogenesis of alcoholic  
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Figure 4. The effect of GCDCA on the CHOP mRNA expression in isolated heaptocytes. (A) CHOP 
mRNA expression was determined by semiquantitative PCR. Line graphs representation of the 
observed fold induction normalized to β-actin for each time point. (B) RT-PCR analysis of CHOP and β-
actin expression at each incubation time after treatment with GCDCA. (C) Reaction cycles-PCR product 
yield curves of each reaction mixture were plotted. The intensity of fluorescence was fitted to the data in 
the linear portion of curves. The resulting CHOP mRNA / β-actin mRNA ratio is represented as the 
mean+SEM of 8-15 samples. *p<0.05 and **p<0.01: significant difference from untreated hepatocytes 
(control). 
hepatitis or alcoholic liver cirrhosis [3, 59]. Clinical studies suggested similar findings. 
Various factors including cytotoxicity by alcohol and its metabolites, changes in 
metabolizing enzymes, invasion of inflammatory cells, reactive oxygen species, cytokines,  
hepatic microcirculation, nutritional factors, etc. are involved in the onset of apoptosis. 
Among others, correlation between ROS or oxidative stress and hepatocyte apoptosis is 
attracting attention. Orally fed ethanol is absorbed in the upper digestive organs, mainly 
small intestine, and 90% of it is metabolized in the liver. Upon metabolization, ROS is 
generated in the liver by alcohol dehydrogenase, microsome-ethanol oxydizing system 
(MEOS) via cytochrome P450, and NADPH oxidase (NOX) in the cell membrane, which is a 
center for ROS generation (Fig. 5). In general, oxidative stress inflicts cytotoxicity when 
excessive ROS is generated in the cells. Antioxidant was shown to reduce hepatocyte 
apoptosis in acute ethanol-addicted rats [60]. On the other hand, several death receptors and 
their ligands (especially Fas/FasL) are over-expressed in the liver cells of alcoholic hepatitis 
patients compared with those in healthy subjects. The levels of Fas and FasL are increased in 
serious alcoholic hepatitis patients, but there are still many uncertainties about the details of 
their mediators and biological importance [61]. The increase in FasL might be mediated by 
ROS or increase in NF-кB which increases the transcription of Fas and FasL genes based on 
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TNF-α inducing activity [62]. In fact, serum TNF-α level increases also in alcoholic hepatitis 
patients, and plays an important role in inflicting hepatotoxicity [63]. Chronic ethanol 
administration increases expressions of TNF-R in hepatocytes [64], and during the exposure 
to ethanol, hepatocytes underwent apoptosis induced by TNF-α. TNF-α/ TNF-R1 system 
seems to be required in the cell death mediated by Fas. In fact, recent studies showed that in 
TNF-R1/TNF-R2 double knockout mice, apoptosis mediated by TNF-α did not occur, and 
the mice showed resistance against induced fulminant hepatic failure [65]. The activation of 
TNF-α/TNF-R1 complex may be co-working with the signaling conveyed by Fas for 
inducing hepatocyte apoptosis.  
 
Figure 5. The effect of ethanol on ROS generation in SK-HEP1 cells. SK-HEP1 cells (1×106 cells/ well) 
were treated with ethanol (25-300 mM) for 5 hours at 37C. The generation of ROS in SK-HEP1 treated 
with ethanol was analyzed spectrofluorometrically. Each value represents the mean ± S.E.M. of 6-12 
samples. *:p<0.05: significant difference from untreated SK-HEP-1 cells. 
Histologically, nick-end label positive apoptotic cells were abundantly found around 
Mallory body in biopsied tissue from patients with alcoholic liver injury [66]. In in vivo 
animal studies, hepatocyte apoptosis is increased in animals fed with alcohol-containing 
feed, and long-term alcohol administration is suggested to induce hepatocyte death [67]. 
Apoptotic cells are observed even in normal cells in some part around the central vein, but 
in rats fed with alcohol for a long term, many apoptotic cells were observed in various parts 
around the central vein.  
We ourselves reported the ethanol-induced apoptosis in cultured hepatocytes, and showed 
that apoptosis is induced in vitro in the presence of alcohol. We also found that at ethanol 
concentrations lower than those that induce apoptosis, significant increase in ROS 
generation was observed. It was suggested that in the process of apoptosis induced by 
ethanol, ROS generation by NOX was important as inducer of apoptosis [68]. As shown in 
Fig. 6, in the presence of 200 µM ethanol, the mRNA expression of p22phox, which is a protein 
constitutively bound to NOX to enhance the action of NOX4, was found significantly 
increased and the increase of the expression was suppressed by the pretreatment with N-
acetyl-L-cysteine (NAC), a precursor of glutathione and an antioxidant.  
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Figure 6. The effect of ethanol on NOX-4 and p22phox mRNA in SK-HEP-1 cells. (A): The expression of 
NOX-4 mRNA in SK-HEP1 treated with ethanol (200 mM) and NAC (10 mM). (B): The expression of 
p22phox mRNA in SK-HEP1 treated with ethanol and NAC. The resulting NOX-4 or p22phox mRNA/β-
actin mRNA ratio is represented as the mean ± S.E.M. of 8-12 samples. (C): RT-PCR analysis of NOX-4 
or p22phox and β-actin expression after treatment with ethanol or ethanol+NAC. Lane1, 2: untreated SK-
HEP1 cells, Lane3, 4: 200 mM ethanol, Lane5, 6: ethanol+NAC, Lane7, 8: 10 mM NAC. *p < 0.05: 
significant difference from untreated cells, # p < 0.05: significant difference from 200 mM ethanol-treated 
cells. 
In a recent study on the actions of ethanol on hepatocytes, the importance of mitogen-
activated protein kinases (MAPKs) (mainly, ERK1/2, p38 and JNK1/2) and histone 
modification (acetylation, methylation, or phosphorylation) is emphasized. MAPK pathway 
is correlated with many signaling pathways including tyrosine, serine/threonine kinase, G 
protein and calcium signals [69]. MAPKs are a family of protein kinases of which main 
members are ERK1 and ERK2, p38MAPK, and c-Jun-N-terminal kinase/stress-activated 
protein kinase (JNK/SAPK). MAPKs regulate various biological processes including cell 
growth, proliferation, movement, inflammation, fatty degeneration, necrosis and apoptosis 
[70]. In a primary culture of rat hepatocytes, ethanol showed modest activation of ERK1/2 
and notable activation of JNK [71]. In rat cultured hepatocytes, when ERK1/2 
phosphorylation was inhibited by U-0126 (a MEK1/2 inhibitor), phosphorylation of JNK by 
ethanol was increased [72]. In previous studies on neurons, ethanol was found to activate 
MAPK cascade and increase ROS generation via p38MAPK pathway [73, 74].  
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We found that exposure of cultured hepatocytes to ethanol increase generation of ROS and 
MAPK (p38MAPK and JNK) phosphorylation activity. However, ROS generation was not 
significantly affected when hepatocytes were pretreated with MAPK inhibitors (SB202190 
for p38MAPK, and SP600125 for JNK) [75]. These results suggest that ROS may be generated 
by the upstream effector of p38 MAPK (Fig. 7).  
 
Figure 7. The effect of MAPK inhibitors on ROS generation in ethanol-induced apoptotic SK-Hep1 
cells. Generation of ROS in SK-Hep1 cells treated with 200 mM ethanol or MAPK inhibitors (SB202190: 
p38 inhibitor, SP600125: JNK inhibitor) + 200 mM ethanol was analyzed spectrofluorometrically. *p < 
0.05: significant difference from untreated cells, # p < 0.05: significant difference from 200 mM ethanol-
treated cells. 
Furthermore, as described above, overconsumption of alcohol induces various pathological 
stress responses and a part of them is endoplasmic reticulum (ER) stress response. ER stress 
is associated with alcoholic injury in such organs as the liver, pancreas, heart and brain. The 
possible mechanism for triggering alcoholic ER stress response is directly or indirectly 
correlated with alcohol metabolism, which, in turn, is correlated with toxic acetaldehyde 
and homocysteine, oxidative stress, upset of calcium or iron homeostasis, decrease in the 
ratio of S-adenosylmethionine/S-adenosyl- homocysteine and abnormal epigenetic 
modifications. Inhibition of triggering process of ER stress could hopefully be beneficial in 
the treatment of alcoholic diseases.  
In the study of genetic expression in ethanol-fed mice, remarkable increase in caspase-12 
mRNA and BIP, a ER chaperone, and CHOP mRNA [76]. When the protein levels were 
examined, BIP, CHOP and caspase-12 were increased. When CHOP null mice was fed with 
ethanol, apoptosis of hepatocyte was found to be dependent on CHOP [77], showing that 
ethanol-induced hepatic injury was associated with hepatocyte apoptosis mediated by 
CHOP. Furthermore, when micropigs were fed with ethanol, fatty liver and apoptosis are 
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found to be correlated with the increase in mRNAs of CYP2E1, GRP78, SREBP-1c and also 
increase in protein levels of CYP2E1, GRP78, nuclear SREBP-1c and caspase-12 activity [78].  
We found that when human hepatocarcinoma cell line, SK-Hep1, were exposed to ethanol, 
expressions of mRNAs of BIP, CHOP, and sXBP-1 were increased. The ethanol-induced 
increase in expressions were suppressed by NAC, an antioxidant, and we speculated the 
increase to be associated with oxidative stress induced by ethanol. We also observed a 
transient increase in intracellular Ca2+ and calpain activity, but they were not suppressed by 
NAC, and we believe these were independent from ethanol-induced oxidative stress. It was 
suggested, therefore, there are two pathways of ethanol-induced apoptosis mediated by ER 
stress, that is, ethanol-induced oxidative stress-dependent and independent pathways [79].  
Possible approaches for the treatment of ER stress induced by ethanol include decreasing 
homocysteine and increase in SAM by betain or folic acid [80-82], improvement of protein 
folding using chemical chaperone, PBA(sodium phenylbutyrate) and TUDCA [81, 83, 84], 
inhibition of dephosphorylation of eukaryotic initiation factor-2α (eIF2α) using its inhibitor 
salubrinal [85], and reducing oxidative stress by decreasing ROS generation from oxidized 
protein using antioxidants. However, the results of clinical study cannot be obtained. 
Mechanism of ethanol-induced ER stress is too complex, and the approaches for treatment 
in human may not be so simple or universal. It may be necessary to employ properly 
combined therapy of every known beneficial medication. 
7. Proposed conceptual diagram of apoptosis process in hepatocytes 
Apoptosis is an indispensable process in line with cell proliferation for maintenance of 
tissue homeostasis and health by removal of injured and/or aged cells. This is especially 
important in the liver where cells are exposed to toxins and viruses [1]. Any loss of balance 
between cell death and proliferation due to excessive or insufficient apoptosis always leads 
to pathologic conditions due to unstable state. In the liver, massive hepatocyte apoptosis is 
observed in acute hepatic failure, and persistent hepatocyte apoptosis is associated with 
fibrilization, chronic dysfunction and cancerous transformation of the liver [86]. Apoptosis 
is induced by various intracellular and extracellular stimuli. In all types of hepatocytes, 
death receptors (especially Fas) are universally expressed [87], and hepatocyte apoptosis is 
usually transmitted by external pathways. Especially, activations of Fas and TNF-R1 are 
correlated with hepatocyte apoptosis in various liver diseases including viral hepatitis, 
fulminant hepatitis, cholestatic liver disease, alcoholic hepatitis, non-alcoholic fatty-liver 
disease (NAFLD) and non-alcoholic steatohepatitis (NASH), Wilson’s disease, and ischemia-
reperfusion injury [88]. In the study of cholestasis, because no liver injury was observed 
after ligation of the common bile duct (a model of extrahepatic cholestasis) in Fas-knockout 
mice, high levels of toxic intracellular bile salts were speculated to increase Fas in the cell 
membrane resulting in the activation of the receptor [89, 10]. Furthermore, apoptosis is 
induced via ER stress. Caspase-8 activated via death receptor may regulate ER stress 
mediated by BAP31 on ER [54]. In alcoholic liver injury, ROS generation is enhanced via 
NOX, and the excessive ROS interact with Fas death receptor [8] to induce mitochondria-
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mediated and ER stress-mediated apoptosis. Taken together, we propose a diagram 
showing the mechanism of hepatocyte apoptosis as seen in Fig. 8.  
 
Figure 8. Schematic diagram of apoptotic pathway. 
8. Conclusion 
Apoptosis is involved in various diseases, and affects a wide variety of organs including the 
liver, kidney, central nervous system, and heart. This field of research has been increasingly 
active in both basic medical sciences and clinical levels, and in the future, when novel 
findings are obtained on how changes in the process of apoptosis lead to aggravation or 
improvement of diseases, an innovative strategy for more effective therapy will be designed. 
Progress of elucidation of apoptotic process is greatly sought after.  
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Apoptosis is involved in various diseases, and affects a wide variety of organs including the 
liver, kidney, central nervous system, and heart. This field of research has been increasingly 
active in both basic medical sciences and clinical levels, and in the future, when novel 
findings are obtained on how changes in the process of apoptosis lead to aggravation or 
improvement of diseases, an innovative strategy for more effective therapy will be designed. 
Progress of elucidation of apoptotic process is greatly sought after.  
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1. Introduction 
For screening and detailed studying of antidiabetic medications, various genetic and non-
genetic experimental models of diabetes mellitus were used (Islam S., Loots D.T. 2009). And 
though they are not absolutely equivalent to etiopathogenetic mechanisms of human 
pathological conditions, each of them represents itself as an integral tool for research into 
genetic, endocrine, metabolic, morphological changes of this disease (Sarvilina I.V., 
Maclakov Y.S. 2008). 
The most commonly used diabetic experimental models are non-genetic models that use 
hydrophilic β-cell glucose analogues, such as alloxan, streptozotocin, chlorozotocin, 
cyproheptadine, etc. The common mechanism of action of these substance includes 
degradation of pancreatic islet β-cells by means of: 1) generation of oxygen free radicals that 
destroy the integrity of a cell, 2) alkylation of DNA and subsequent activation of poly-ADP-
ribose-synthetase - reduction of NAD to β-cell, and 3) inhibition of active transport of 
calcium and calmodulin-activated protein kinase (Rees D.A., Alcolado J.C. 2005). In this type 
of experimental models of diabetes mellitus streptozotocin (an N-nitrosourea derivative of 
glucosamine) is most commonly used (McNeill J.H. 1999). Depending on cytotoxin dosage 
used in the experiment (45-70 mg/kg) and route of administration (i.p., i.v.), it is possible to 
model and simulate different states of carbohydrate metabolism based on a specific clinical 
type of diabetes mellitus (DM mixed (type 1-2) latent or «hidden» diabetes) (Srinivasan K. et 
al. 2007). Although diabetes mellitus usually has obvious clinical symptoms such as 
hyperglycemia, glucosuria, polyuria, polydipsia, severe weight loss, it is difficult to measure 
the contribution of each of the links to the pathogenesis of diabetes and to assess the extent 
of pancreatic islet β-cell damage and death. The toxic effect of alloxan and streptozotocin on 
cells in pancreatic islets manifests itself not only by necrosis but also by apoptosis of 
pancreatic islet β-cells (Daisy Mythili M., et al. 2004). The study of apoptotic mechanisms 
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will enable us to identify specific targets for purposeful creation and development of anti-
diabetic medications. 
2. Materials and methods 
The experiments were performed on 180 adult male Wistar rats weighing from 280.0 to 300.0 
g (Table 1). The animals were kept under standard vivarium conditions at pharmacology 
department of Volgograd Medical University, and were provided with a nutritionally 
balanced diet that the laboratory animals consume consistently. A pilot study was approved 
by the Central Regional Independent Ethics Committee (protocol № 1-06; № 43-2006; № 70-
2008; № 89-2009), and was performed in accordance with GLP when conducting preclinical 
studies in Russia. All animal experimentation was carried out in compliance with the 
International Guidelines of the European Convention for the Protection of Vertebrate 
Animals used in experimental studies (1997). 
 
Group Day of experiment Amount of animals 
Intact control 3, 7, 14, 28 40 
Alloxan-induced diabetes 3, 7, 14, 28 40 
Streptozotocin-induced diabetes 7, 28 20 
Immune-dependent diabetes 3, 7, 14, 28 40 
Streptozotocin-nicotinamide-induced diabetes 3, 7, 14, 28 40 
Table 1. Group distribution of experimental animals  
Plasma glucose, insulin and C-peptide concentrations were measured in experimental 
laboratory animals. The blood glucose was determined in samples obtained from the tail 
vein of rats by enzymatic method, using "Glucose FKD" assay kits (Russia) on SF-46 
spectrophotometer at λ=450 nm in 10 mm cuvettes. Animals with blood glucose levels >15 
mmol/L were enrolled in the experiment (Akbarzadeh A. et al. 2007). Plasma insulin and C-
peptide concentrations were determined on an automated enzyme immunoassay 
«SUNRISE» analyzer (TECAN, Austria), using DRG Insulin ElisaKit and DRG C-peptide 
ElisaKit. 
Alloxan-induced diabetes simulation model was developed by means of intraperitoneal 
administration of alloxan at a dose of 120 mg/kg. Tissue samples of animals were collected 
and submitted for routine histopathological investigation at 3, 7, 14 and 28 days of the 
experiment. 
Experimental streptozotocin-induced diabetes simulation model was developed using 
streptozotocin (Sigma) (45 mg/kg, intravenously once a day) (Baranov V.G. 1983). Tissue 
samples were collected and submitted for routine histopathological investigation at 7 and 28 
days of the experiment. 
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Experimental immune-dependent diabetes simulation model was developed by giving a 
subcutaneous injection of 0.2 ml of complete Freund's adjuvant (CFA) (Grand Island Biological 
Company, USA). Subsequently, daily intravenous injections of streptozotocin (Sigma, USA) 
(20 mg/kg) were given to the animals for 5 days, resulting in the development of insulin-
dependent diabetes (Ziegler B. 1990). Tissue samples were collected and submitted for routine 
histopathological investigation at 3, 7, 14 and 28 days of the experiment. 
Streptozotocin-nicotinamide-induced diabetes model was developed by giving an injection 
of streptozotocin (Sigma, USA) (intraperitoneally - 65 mg/kg citrate buffer, pH = 4.5) with a 
preliminary (15 minutes prior to the procedure) administration of nicotinamide 
(intraperitoneally - 230 mg/kg prepared in 0.9 % solution of sodium chloride) (Islam S., et al. 
2009). Tissue samples were collected and submitted for routine histopathological 
investigation at 3, 7, 14 and 28 days of the experiment. 
Pancreatic tissue was divided into three segments including intestinal, gastric and splenic 
parts, and then they were fixed in 10% solution of neutral buffered formalin (pH 7.4) for 24 
hours. 5-6-mm thick slices were obtained on rotary microtomes and were mounted on 
slides. Tissue sections were stained with hematoxylin and eosin using standard histological 
stain techniques (Korzhevsky D.E. 2005). 
For detection of α-and β- endocrine cells in the islets of Langerhans the primary antibodies 
against insulin and glucagon were used (Table 2). To study apoptosis, the primary 
antibodies to proteins, such as caspase 3, TRAIL (TNF-related apoptosis-inducing ligand), 
MDM2, Bcl 2, p53, Bax, NF-kB, as well as eNOS were used. 
 
№ Antibody Clone Manufacturer
1 Insulin Polyclonal DakoCytomation, Denmark 
Ab-6 (INS04 + INS05) LabVision, UK 
2D11-H5 Novocastra, UK 
2 Glucagon Polyclonal Novocastra, UK 
3 Caspase 3 JHM62 Novocastra, UK 
Rb-1197-P0 NeoMarkers, USA 
4 TRAIL 27B12 Novocastra, UK 
5 MDM2 1B10 Novocastra, UK 
6 Bcl 2 sc-7382 Santa Cruz Biotechnology, USA 
124 Dako Cytomation, Denmark 
7 p53 Polyclonal Dako Cytomation, Denmark 
Ab-1 (Pab 240) MS-104-
P0 
NeoMarkers, USA 
8 Bax Polyclonal BD Biosciences Pharmingen, USA 
9 NOS-3 RN5 Novocastra, UK 
10 NF-kB Polyclonal Diagnostic BioSystems, USA 
Table 2. IHC Primary Antibodies  
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Immunohistochemistry was performed according to manufacturers' protocols using ABC 
(Novocastra, UK), «UltraVision» (Lab Vision, UK) and «EnVision» (Dako Cytomation, 
Denmark) antibody detection systems and a chromogen, diaminobenzidine under the 
protocol on high temperature antigen unmasking technique using «Pascal» mini autoclave 
(Dako Cytomation, Denmark) (Kumar G.L. et al. 2009). The reliability of the obtained results 
was defined using both positive and negative control antigens, as well as negative control 
antibodies. 
Immunohistochemical reaction was based on visual evaluation, taking into account the 
intensity of color, or on determination of the specific amount of positively stained cells 
(Allred DC, et al. 1998). 
Photo images were captured with an «AxioScope» microscope (Carl Zeiss, Germany) and a 
«PowerShot» digital camera (Canon, Japan). Morphometric analysis was performed using 
"VideoTestMorfo-4" software (Russia). In the course of the study we determined the 
relationship between the total α-and β- endocrine cell area and the total area of the islet 
(S,%), between the volume fraction (ML, %) of islets and exocrine glands, as well as the area 
of β-cell nuclei (S, µm2). We also measured apoptotic index (AI), i.e. the relative amount of 
β-endocrine cells with apoptotic structural and immunohistochemical changes. 
The research results were processed using basic statistical analysis techniques as well as 
"Video TestMorfo-4», Excel Microsoft Office (Microsoft, USA) and STATISTICA 6.0 software 
(StatSoft Inc., USA). The analysis of the parameters for normally-distributed values was 
performed using Student's t test. Nonparametric statistics was calculated using Mann-
Whitney test. To compare qualitative variables, the chi-square test and the Fisher exact test 
were used. Differences were considered significant if error probability was p <0.05. 
3. Results 
All animals in the intact control group showed stable plasma biochemical parameters which 
did not exceed the physiological norms during an observation period (glucose - 4,02 ± 0,1 
mmol/L (Fig. 1), insulin - 1,65 ± 0,04 mU/ml., C-peptide - 4,65 ± 0,16 ng/ml. 
Morphological study of the intact control group showed that the exocrine part of the pancreas 
has an alveolar-tubular structure which exhibited a division into lobules separated by 
interlobular connective tissue. Exocrinotcytes tended to be highly differentiated and they 
formed acini. Pancreatic islets in all parts of the pancreas were round or slightly oval in shape. 
They were single or were arranged in clusters around the intralobular excretory ducts. The 
total volume fraction of islet tissue in the gastric and splenic segments was almost twice as 
much as the volume fraction of islets of the intestinal segment (Table 3). The total area of 
nuclear β-endocrine cells in all segments of the pancreas had no statistically significant 
differences during all periods of observation. Insulin-positive cells were predominantly found 
in the central part of the pancreatic islets; however, glucagon-positive cells were more 
frequently encountered at the periphery. In this case there was a statistically significant 
increase (p <0.05) in β-cell area of the splenic segment compared with the intestinal and gastric 
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segments of the pancreas (Fig. 2A). The maximum α-endocrine cell area was determined in the 
intestinal and gastric segments of the pancreas; however, this area was statistically significant 
lower (p <0.05) in the splenic segment (Table 3). There was a statistically significant (p ≤ 0.05) 
direct relationship between the total volume fraction of pancreatic islets and the area of β- 
endocrine cells depending on their location. The amount of islets and β-endocrine cells tended 
to increase in the following segments of the pancreas: intestinal →gastric → splenic. 
 
Figure 1. Blood glucose dynamics (mmol/L) in rats with different models of experimental diabetes. * - 
Significant changes compared with the intact control group. 
 
Indicator Day of experiment 
Segment of the pancreas 
Intestinal Gastric Splenic 
Volume fraction 
of islets,% 
3 6,8±2,5 12,6±6,0 13,8±7,3 
7 6,7±2,2 12,0±4,5 12,9±2,1 
14 6,9±3,1 12,1±5,2 14,0±2,9 
28 6,6±4,2 12,8±4,5 14,3±5,2 
Total area of β-
cells,% 
3 51,3±9,2 64,6±9,1 78,2±6,1** 
7 53,8±7,6 63,4±7,0 75,4±8,7** 
14 52,1±5,5 64,5±8,7 79,4±4,6** 
28 54,3±5,4 66,2±3,6 77,3±4,3** 
Total area of α-
cells,% 
3 37,4±5,2 31,2±3,5 22,2±3,4** 
7 39,3±4,3 30,4±4,0 21,3±3,0** 
14 38,5±3,5 32,4±3,2 19,7±2,3** 
28 37,1±1,0 30,2±1,2 17,9±1,3** 
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Immunohistochemistry was performed according to manufacturers' protocols using ABC 
(Novocastra, UK), «UltraVision» (Lab Vision, UK) and «EnVision» (Dako Cytomation, 
Denmark) antibody detection systems and a chromogen, diaminobenzidine under the 
protocol on high temperature antigen unmasking technique using «Pascal» mini autoclave 
(Dako Cytomation, Denmark) (Kumar G.L. et al. 2009). The reliability of the obtained results 
was defined using both positive and negative control antigens, as well as negative control 
antibodies. 
Immunohistochemical reaction was based on visual evaluation, taking into account the 
intensity of color, or on determination of the specific amount of positively stained cells 
(Allred DC, et al. 1998). 
Photo images were captured with an «AxioScope» microscope (Carl Zeiss, Germany) and a 
«PowerShot» digital camera (Canon, Japan). Morphometric analysis was performed using 
"VideoTestMorfo-4" software (Russia). In the course of the study we determined the 
relationship between the total α-and β- endocrine cell area and the total area of the islet 
(S,%), between the volume fraction (ML, %) of islets and exocrine glands, as well as the area 
of β-cell nuclei (S, µm2). We also measured apoptotic index (AI), i.e. the relative amount of 
β-endocrine cells with apoptotic structural and immunohistochemical changes. 
The research results were processed using basic statistical analysis techniques as well as 
"Video TestMorfo-4», Excel Microsoft Office (Microsoft, USA) and STATISTICA 6.0 software 
(StatSoft Inc., USA). The analysis of the parameters for normally-distributed values was 
performed using Student's t test. Nonparametric statistics was calculated using Mann-
Whitney test. To compare qualitative variables, the chi-square test and the Fisher exact test 
were used. Differences were considered significant if error probability was p <0.05. 
3. Results 
All animals in the intact control group showed stable plasma biochemical parameters which 
did not exceed the physiological norms during an observation period (glucose - 4,02 ± 0,1 
mmol/L (Fig. 1), insulin - 1,65 ± 0,04 mU/ml., C-peptide - 4,65 ± 0,16 ng/ml. 
Morphological study of the intact control group showed that the exocrine part of the pancreas 
has an alveolar-tubular structure which exhibited a division into lobules separated by 
interlobular connective tissue. Exocrinotcytes tended to be highly differentiated and they 
formed acini. Pancreatic islets in all parts of the pancreas were round or slightly oval in shape. 
They were single or were arranged in clusters around the intralobular excretory ducts. The 
total volume fraction of islet tissue in the gastric and splenic segments was almost twice as 
much as the volume fraction of islets of the intestinal segment (Table 3). The total area of 
nuclear β-endocrine cells in all segments of the pancreas had no statistically significant 
differences during all periods of observation. Insulin-positive cells were predominantly found 
in the central part of the pancreatic islets; however, glucagon-positive cells were more 
frequently encountered at the periphery. In this case there was a statistically significant 
increase (p <0.05) in β-cell area of the splenic segment compared with the intestinal and gastric 
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segments of the pancreas (Fig. 2A). The maximum α-endocrine cell area was determined in the 
intestinal and gastric segments of the pancreas; however, this area was statistically significant 
lower (p <0.05) in the splenic segment (Table 3). There was a statistically significant (p ≤ 0.05) 
direct relationship between the total volume fraction of pancreatic islets and the area of β- 
endocrine cells depending on their location. The amount of islets and β-endocrine cells tended 
to increase in the following segments of the pancreas: intestinal →gastric → splenic. 
 
Figure 1. Blood glucose dynamics (mmol/L) in rats with different models of experimental diabetes. * - 
Significant changes compared with the intact control group. 
 
Indicator Day of experiment 
Segment of the pancreas 
Intestinal Gastric Splenic 
Volume fraction 
of islets,% 
3 6,8±2,5 12,6±6,0 13,8±7,3 
7 6,7±2,2 12,0±4,5 12,9±2,1 
14 6,9±3,1 12,1±5,2 14,0±2,9 
28 6,6±4,2 12,8±4,5 14,3±5,2 
Total area of β-
cells,% 
3 51,3±9,2 64,6±9,1 78,2±6,1** 
7 53,8±7,6 63,4±7,0 75,4±8,7** 
14 52,1±5,5 64,5±8,7 79,4±4,6** 
28 54,3±5,4 66,2±3,6 77,3±4,3** 
Total area of α-
cells,% 
3 37,4±5,2 31,2±3,5 22,2±3,4** 
7 39,3±4,3 30,4±4,0 21,3±3,0** 
14 38,5±3,5 32,4±3,2 19,7±2,3** 
28 37,1±1,0 30,2±1,2 17,9±1,3** 
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Indicator Day of experiment 
Segment of the pancreas 
Intestinal Gastric Splenic 
Total area of β-
cell nuclei, µm2 
3 24,2±1,2 24,4±1,0 23,9±0,2 
7 24,3±1,3 23,8±1,2 24,7±1,0 
14 24,3±1,2 24,8±1,3 24,6±1,3 
28 24,4±1,0 24,3±1,2 24,7±2,0 
* - Significant difference in the intestinal segment of the pancreas (p <0.05), 
** - Significant difference in the gastric segment of the pancreas (p <0.05). 
Table 3. Morphometric indicators of pancreatic islets in the intact control group (M ± m). 
Bax protein expression was negative in all islet cells. A weak positive cytoplasmic staining 
of islet cells in the central part of the islet for Bcl-2 protein was reported. In the nuclei of 
individual β-endocrine cells ambiguous or weak expression of p53 protein was determined. 
Most of β-islet cells had a positive nuclear staining for MDM2 protein. In some β-endocrine 
cells cytoplasmic expression of caspase 3 and TRAIL was poorly defined or ambiguous 

















3 - + + - + ++ - ++ 
7 - + + - + ++ - ++ 
14 - + + - + ++ - ++ 




3 - + + - + +++ - ++ 
7 - + + - + +++ - ++ 
14 - + + - + +++ - ++ 
28 - + + - + +++ - ++ 
Table 4. Immunohistochemical characteristics of β-cells 
Alloxan-induced diabetes  
In alloxan-induced diabetes simulation model a significant increase in blood glucose of rats 
compared with the intact control was reported (Fig. 1). 
At day 3 of the experiment a well pronounced interstitial edema associated with hyperemia 
of blood vessels and capillaries in the acinar tissue of pancreatic islets was determined 
histologically. Compared with the intact control group, the total volume fraction of the 
pancreatic islets was not significantly reduced. However, there was a slight decrease in the 
area of β-cells in all segments of the pancreas (Table 5). The cells with moderate dystrophic 
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and destructive changes were revealed in the central part of the islets of Langerhans. 
Immunohistochemical reaction in the central part of the pancreatic islets revealed insulin-
positive cells with marked expression of insulin. A slight increase in the size of β-cell nuclei 
was reported. Compared with the intact control group, the total area of islet cells in all 
segments of the pancreas was slightly reduced. The total glucagon-positive cell area did not 
change as compared with the control group (Table 5). 
At day 7 the islets were swollen, hyperemic and collapsed. There was no statistically 
significant reduction in the total volume fraction of islets in all segments of the pancreas. In the 
central part of the islets we observed moderate necrobiotic changes associated with a 
significant decrease (p <0.05) in the total β-cell area predominantly in the gastric and splenic 
segments when compared with the intact control group (Table 5). There was a statistically 
significant increase (p <0.05) in the area of α-endocrine cells in the gastric and splenic segments 
of the pancreas. β-cell necrosis was accompanied by moderate leukocyte infiltration of the 
stroma and acinar cells with only few leukocytes in the islets. The area of nuclear β-islet cells in 
all segments of the pancreas increased by 4.5 µm2; however, no statistically significant changes 
were identified when compared with the intact control group. 
Edema significantly reduced by day 14; however, blood vessels of the acinar tissue and 
capillaries of the islets of Langerhans were still slightly hyperemic. There were focal sclerotic 
changes in some islets. Compared with the control group, there were not any statistically 
significant changes in the islet volume fraction in all segments of the pancreas. Insulin-
positive cells tended to be located in a random pattern; however, glucagon-positive cells 
were predominantly found at the periphery. The total β-endocrine cell area in the gastric 
and splenic segments, as compared with the intact control group, was significantly 
decreased (p <0.05), while the total α-cell area was increased (p <0.05) (Table 5) (Fig.2B). 
There was moderate hypertrophy of β-cell nuclei in all segments of the pancreas. 
At 28 day edema, hyperemia of blood vessels and inflammatory infiltration were replaced 
by focal sclerotic changes of the acinar tissue and pancreatic islets. As before, a slight 
decrease in the islet volume fraction in all segments of the pancreas was reported. Also, in 
all segments of the pancreas the total area of β-cells was slightly increased, compared with 
day 14 of the experiment, but was significantly lower (p <0.05) as compared with the 
animals in the intact control group. The volume fraction of α-endocrine cells slightly 
decreased but was statistically greater (p <0.05) than in the intact control group (Table 5). 
The average area of nuclei was slightly decreased as compared with the intact control group 
and with day 14 of the experiment. 
 
Indicator Day of experiment
Segment of the pancreas




3 intact 6,8±2,5 12,6±6,0 13,8±7,3 
diabetes 6,7±2,1 11,8±5,4 13,9±10,2 
7 intact 6,7±2,2 12,0±4,5 12,9±2,1 
diabetes 4,5±3,1 11,2±3,2 11,1±5,2 
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Indicator Day of experiment 
Segment of the pancreas 
Intestinal Gastric Splenic 
Total area of β-
cell nuclei, µm2 
3 24,2±1,2 24,4±1,0 23,9±0,2 
7 24,3±1,3 23,8±1,2 24,7±1,0 
14 24,3±1,2 24,8±1,3 24,6±1,3 
28 24,4±1,0 24,3±1,2 24,7±2,0 
* - Significant difference in the intestinal segment of the pancreas (p <0.05), 
** - Significant difference in the gastric segment of the pancreas (p <0.05). 
Table 3. Morphometric indicators of pancreatic islets in the intact control group (M ± m). 
Bax protein expression was negative in all islet cells. A weak positive cytoplasmic staining 
of islet cells in the central part of the islet for Bcl-2 protein was reported. In the nuclei of 
individual β-endocrine cells ambiguous or weak expression of p53 protein was determined. 
Most of β-islet cells had a positive nuclear staining for MDM2 protein. In some β-endocrine 
cells cytoplasmic expression of caspase 3 and TRAIL was poorly defined or ambiguous 

















3 - + + - + ++ - ++ 
7 - + + - + ++ - ++ 
14 - + + - + ++ - ++ 




3 - + + - + +++ - ++ 
7 - + + - + +++ - ++ 
14 - + + - + +++ - ++ 
28 - + + - + +++ - ++ 
Table 4. Immunohistochemical characteristics of β-cells 
Alloxan-induced diabetes  
In alloxan-induced diabetes simulation model a significant increase in blood glucose of rats 
compared with the intact control was reported (Fig. 1). 
At day 3 of the experiment a well pronounced interstitial edema associated with hyperemia 
of blood vessels and capillaries in the acinar tissue of pancreatic islets was determined 
histologically. Compared with the intact control group, the total volume fraction of the 
pancreatic islets was not significantly reduced. However, there was a slight decrease in the 
area of β-cells in all segments of the pancreas (Table 5). The cells with moderate dystrophic 
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and destructive changes were revealed in the central part of the islets of Langerhans. 
Immunohistochemical reaction in the central part of the pancreatic islets revealed insulin-
positive cells with marked expression of insulin. A slight increase in the size of β-cell nuclei 
was reported. Compared with the intact control group, the total area of islet cells in all 
segments of the pancreas was slightly reduced. The total glucagon-positive cell area did not 
change as compared with the control group (Table 5). 
At day 7 the islets were swollen, hyperemic and collapsed. There was no statistically 
significant reduction in the total volume fraction of islets in all segments of the pancreas. In the 
central part of the islets we observed moderate necrobiotic changes associated with a 
significant decrease (p <0.05) in the total β-cell area predominantly in the gastric and splenic 
segments when compared with the intact control group (Table 5). There was a statistically 
significant increase (p <0.05) in the area of α-endocrine cells in the gastric and splenic segments 
of the pancreas. β-cell necrosis was accompanied by moderate leukocyte infiltration of the 
stroma and acinar cells with only few leukocytes in the islets. The area of nuclear β-islet cells in 
all segments of the pancreas increased by 4.5 µm2; however, no statistically significant changes 
were identified when compared with the intact control group. 
Edema significantly reduced by day 14; however, blood vessels of the acinar tissue and 
capillaries of the islets of Langerhans were still slightly hyperemic. There were focal sclerotic 
changes in some islets. Compared with the control group, there were not any statistically 
significant changes in the islet volume fraction in all segments of the pancreas. Insulin-
positive cells tended to be located in a random pattern; however, glucagon-positive cells 
were predominantly found at the periphery. The total β-endocrine cell area in the gastric 
and splenic segments, as compared with the intact control group, was significantly 
decreased (p <0.05), while the total α-cell area was increased (p <0.05) (Table 5) (Fig.2B). 
There was moderate hypertrophy of β-cell nuclei in all segments of the pancreas. 
At 28 day edema, hyperemia of blood vessels and inflammatory infiltration were replaced 
by focal sclerotic changes of the acinar tissue and pancreatic islets. As before, a slight 
decrease in the islet volume fraction in all segments of the pancreas was reported. Also, in 
all segments of the pancreas the total area of β-cells was slightly increased, compared with 
day 14 of the experiment, but was significantly lower (p <0.05) as compared with the 
animals in the intact control group. The volume fraction of α-endocrine cells slightly 
decreased but was statistically greater (p <0.05) than in the intact control group (Table 5). 
The average area of nuclei was slightly decreased as compared with the intact control group 
and with day 14 of the experiment. 
 
Indicator Day of experiment
Segment of the pancreas




3 intact 6,8±2,5 12,6±6,0 13,8±7,3 
diabetes 6,7±2,1 11,8±5,4 13,9±10,2 
7 intact 6,7±2,2 12,0±4,5 12,9±2,1 
diabetes 4,5±3,1 11,2±3,2 11,1±5,2 
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Indicator Day of experiment
Segment of the pancreas
Intestinal Gastric Splenic 
14 intact 6,9±3,1 12,1±5,2 14,0±2,9 
diabetes 4,2±1,4 8,4±1,6 9,3±2,1 
28 intact 6,8±2,1 11,9±3,7 13,7±3,2 
diabetes 3,1±1,1 7,6±2,3 9,5±2,4 
Total area 
of β-cells, % 
3 intact 51,3±9,2 64,6±9,1 78,2±6,1 
diabetes 50,4±8,5 65,9±8,2 69,8±4,9 
7 intact 53,8±7,6 63,4±7,0 75,4±7,7 
diabetes 42,2±2,1 45,5±1,4* 58,1±1,4* 
14 intact 52,1±5,5 64,5±8,7 79,4±4,6 
diabetes 40,4±2,4 39,7±2,2* 57,4±2,0* 
28 intact 51,1±7,5 65,2±6,0 77,4±4,4 




3 intact 37,4±5,2 31,2±3,5 22,2±3,4 
diabetes 36,5±4,8 30,8±2,5 25,7±2,4 
7 intact 39,3±4,3 30,4±4,0 21,3±3,0 
diabetes 41,1±4,1 49,3±2,1* 35,4±2,2* 
14 intact 38,5±3,5 32,4±3,2 19,7±2,3 
diabetes 32,2±1,5 47,4±2,0* 32,2±2,1* 
28 intact 30,0±4,4 31,4±3,9 18,9±3,2 




3 intact 24,2±1,2 24,4±1,0 23,9±0,2 
diabetes 27,8±5,9 27,5±5,5 26,6±4,6 
7 intact 24,3±1,3 23,8±1,2 24,7±1,0 
diabetes 29,5±4,3 28,4±3,2 29,6±4,3 
14 intact 24,3±1,2 24,8±1,3 24,6±1,3 
diabetes 30,3±3,2 29,6±2,3 30,4±3,4 
28 intact 23,9±1,2 24,2±1,2 24,6±1,2 
diabetes 28,5±5,1 27,4±3,4 28,5±4,0 
* - Significant difference compared with the intact control group (p <0.05). 
Table 5. Morphometric indicators of pancreatic islets in rats with alloxan-induced diabetes (M ± m) 
Immunohistochemical study which, was performed at day 3 and day 28, showed negative 
staining of β-endocrine cells for p53, TRAIL, endothelial NO-synthase and Bcl-2 proteins 
(Fig. 3B) in all segments of the pancreas. At day 3 we observed mild cytoplasmic staining for 
anti-caspase-3 and anti-Bax-antibody in some endocrine cells. Compared with the intact 
control group, apoptotic index was significantly increased (p <0.05) during all observation 
periods. The expression of NF-kB and MDM2 proteins tended to decrease. At 7-14 day 
moderate cytoplasmic staining for caspase-3 and Bax proteins accompanied by decreased 
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amount of cells with NF-kB-and MDM2-positive stained nuclei was reported. At day 7 there 
was a significant (p <0.05) increase in the amount of apoptotic β-cells, compared with day 3 
of the experiment, which was followed by a significant (p <0.05) decrease by day 14 (Table 
12). At day 28 the amount of cells and the intensity of expression of apoptotic markers 
significantly decreased and anti-apoptotic proteins were expressed in large quantities in the 
endocrine cells of pancreatic islets. Apoptotic index was significantly decreased as 
compared with day 7; however, it was still statistically more significant than in the intact 
control group (Table 6). 
 
Group Day of experiment 
Primary antibodies   










3 - + + - + ++ - ++ 
7 - + + - + ++ - ++ 
14 - + + - + ++ - ++ 
28 - + + - + ++ - ++ 
Diabetes 3 - + - + - ++ - ++ 
7 - ++ - ++ - + - + 
14 - ++ - ++ - + - + 




3 - + + - + +++ - ++ 
7 - + + - + +++ - ++ 
14 - + + - + +++ - ++ 
28 - + + - + +++ - ++ 
Diabetes 3 - + - + - + - + 
7 - ++ - ++ - ++ - + 
14 - ++ - ++ - ++ - + 
28 - + - + - ++ - + 
Table 6. Immunohistochemical characteristics of β-endocrine cells in alloxan-induced diabetes 
Within the period from day 7 to day 14 we observed cytoplasmic staining for caspase-3 and 
Bax proteins accompanied by decreased amount of cells with NF-kB-and MDM2-positive 
stained nuclei (Fig. 4B). At day 7 there was a significant (p <0.05) increase in the amount of 
apoptotic β-cells compared with day 3 of the experiment, which was followed by a 
significant (p <0.05) decrease by day 14 (Table 12). 
Thus, in alloxan-induced diabetes we observe a decrease in the total β-cell area from day 7 
to day 28 of observation which is accompanied by a simultaneous increase in the total α-cell 
area. These changes occur in all segments of the pancreas; however, they are predominantly 
obvious and are statistically significant in the gastric and splenic segments. Along with 
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Indicator Day of experiment
Segment of the pancreas
Intestinal Gastric Splenic 
14 intact 6,9±3,1 12,1±5,2 14,0±2,9 
diabetes 4,2±1,4 8,4±1,6 9,3±2,1 
28 intact 6,8±2,1 11,9±3,7 13,7±3,2 
diabetes 3,1±1,1 7,6±2,3 9,5±2,4 
Total area 
of β-cells, % 
3 intact 51,3±9,2 64,6±9,1 78,2±6,1 
diabetes 50,4±8,5 65,9±8,2 69,8±4,9 
7 intact 53,8±7,6 63,4±7,0 75,4±7,7 
diabetes 42,2±2,1 45,5±1,4* 58,1±1,4* 
14 intact 52,1±5,5 64,5±8,7 79,4±4,6 
diabetes 40,4±2,4 39,7±2,2* 57,4±2,0* 
28 intact 51,1±7,5 65,2±6,0 77,4±4,4 




3 intact 37,4±5,2 31,2±3,5 22,2±3,4 
diabetes 36,5±4,8 30,8±2,5 25,7±2,4 
7 intact 39,3±4,3 30,4±4,0 21,3±3,0 
diabetes 41,1±4,1 49,3±2,1* 35,4±2,2* 
14 intact 38,5±3,5 32,4±3,2 19,7±2,3 
diabetes 32,2±1,5 47,4±2,0* 32,2±2,1* 
28 intact 30,0±4,4 31,4±3,9 18,9±3,2 




3 intact 24,2±1,2 24,4±1,0 23,9±0,2 
diabetes 27,8±5,9 27,5±5,5 26,6±4,6 
7 intact 24,3±1,3 23,8±1,2 24,7±1,0 
diabetes 29,5±4,3 28,4±3,2 29,6±4,3 
14 intact 24,3±1,2 24,8±1,3 24,6±1,3 
diabetes 30,3±3,2 29,6±2,3 30,4±3,4 
28 intact 23,9±1,2 24,2±1,2 24,6±1,2 
diabetes 28,5±5,1 27,4±3,4 28,5±4,0 
* - Significant difference compared with the intact control group (p <0.05). 
Table 5. Morphometric indicators of pancreatic islets in rats with alloxan-induced diabetes (M ± m) 
Immunohistochemical study which, was performed at day 3 and day 28, showed negative 
staining of β-endocrine cells for p53, TRAIL, endothelial NO-synthase and Bcl-2 proteins 
(Fig. 3B) in all segments of the pancreas. At day 3 we observed mild cytoplasmic staining for 
anti-caspase-3 and anti-Bax-antibody in some endocrine cells. Compared with the intact 
control group, apoptotic index was significantly increased (p <0.05) during all observation 
periods. The expression of NF-kB and MDM2 proteins tended to decrease. At 7-14 day 
moderate cytoplasmic staining for caspase-3 and Bax proteins accompanied by decreased 
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amount of cells with NF-kB-and MDM2-positive stained nuclei was reported. At day 7 there 
was a significant (p <0.05) increase in the amount of apoptotic β-cells, compared with day 3 
of the experiment, which was followed by a significant (p <0.05) decrease by day 14 (Table 
12). At day 28 the amount of cells and the intensity of expression of apoptotic markers 
significantly decreased and anti-apoptotic proteins were expressed in large quantities in the 
endocrine cells of pancreatic islets. Apoptotic index was significantly decreased as 
compared with day 7; however, it was still statistically more significant than in the intact 
control group (Table 6). 
 
Group Day of experiment 
Primary antibodies   










3 - + + - + ++ - ++ 
7 - + + - + ++ - ++ 
14 - + + - + ++ - ++ 
28 - + + - + ++ - ++ 
Diabetes 3 - + - + - ++ - ++ 
7 - ++ - ++ - + - + 
14 - ++ - ++ - + - + 




3 - + + - + +++ - ++ 
7 - + + - + +++ - ++ 
14 - + + - + +++ - ++ 
28 - + + - + +++ - ++ 
Diabetes 3 - + - + - + - + 
7 - ++ - ++ - ++ - + 
14 - ++ - ++ - ++ - + 
28 - + - + - ++ - + 
Table 6. Immunohistochemical characteristics of β-endocrine cells in alloxan-induced diabetes 
Within the period from day 7 to day 14 we observed cytoplasmic staining for caspase-3 and 
Bax proteins accompanied by decreased amount of cells with NF-kB-and MDM2-positive 
stained nuclei (Fig. 4B). At day 7 there was a significant (p <0.05) increase in the amount of 
apoptotic β-cells compared with day 3 of the experiment, which was followed by a 
significant (p <0.05) decrease by day 14 (Table 12). 
Thus, in alloxan-induced diabetes we observe a decrease in the total β-cell area from day 7 
to day 28 of observation which is accompanied by a simultaneous increase in the total α-cell 
area. These changes occur in all segments of the pancreas; however, they are predominantly 
obvious and are statistically significant in the gastric and splenic segments. Along with 
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pronounced necrotic changes in the cells of the insular apparatus of the pancreas, there is 
also an increase in apoptogenic activity of β-endocrine cells due to the damage to 
mitochondrial membranes (increased expression of Bax and inhibition of Bcl-2 proteins), 
which might be caused by impaired intracellular calcium homeostasis and activation of the 
mitochondrial apoptotic pathway with subsequent activation of caspase cascade without the 
involvement of p53 protein (Table 12). 
Streptozotocin-induced diabetes 
In streptozotocin-induced diabetes a statistically significant elevation of plasma glucose 
levels, as compared with those in the intact control animals, was reported (Fig. 1). 
Histological investigation which was performed at day 7 showed pronounced hyperemia of 
blood vessels associated with lymphocytic infiltration and marked edema of the interlobular 
connective tissue. There were not any statistically significant differences in the total volume 
fraction of islets either with regard to the intact control group, or to different segments of the 
pancreas. We revealed marked necrotic changes in endocrine cells both in the central part 
and at the periphery of the islets (Fig. 2C). We also stated a statistically significant decrease 
(p <0.05) in the area of β-cells in all segments of the pancreas. However, a significant 
increase (p <0.05) in the volume fraction of α-cells exclusively in the gastric and splenic 
segments of the pancreas was reported. There was marked hypertrophy of β-islet cell nuclei 
(p <0.05) predominantly in the splenic segment of the pancreas (Table 7). 
By day 28 moderate hyperemia of blood capillaries of pancreatic islets and accumulation of 
lymphocytes at some sites were observed. Focal necrotic changes were reported in some islets, 
whereas other islets underwent sclerotic changes. No significant changes in the islet volume 
fraction were observed. The total β-islet cell area was still significantly lower (p <0.05) 
compared with the intact control group during the same period of observation. The total 
volume fraction of α-endocrine cells was significantly increased (p <0.05) exclusively in the 
splenic segment of the pancreas. The nuclei of β-cells were hypertrophic and hypertrophy was 
statistically significant (p <0.05) in the cells of the splenic segment of the pancreas (Table 7). 
 
Indicator Day of experiment 
Segment of the pancreas




7 intact 6,7±2,2 12,0±4,5 12,9±2,1 
diabetes 4,7±3,1 10,2±6,7 11,8±1,5 
28 intact 6,8±2,1 11,9±3,7 13,7±3,2 
diabetes 3,2±2,1 8,2±3,1 9,7±2,3 
Total area of 
β-cells,% 
7 intact 53,8±7,6 63,4±7,0 75,4±8,7 
diabetes 24,3±2,1* 39,2±3,2* 40,1±2,0* 
28 intact 51,1±7,5 65,2±6,0 77,4±4,4 
diabetes 29,8±5,5* 43,2±5,4* 47,7±8,2* 
Total area of 
α-cells,% 
7 intact 39,3±4,3 30,4±4,0 21,3±3,0 
diabetes 44,2±4,5 42,3±2,2* 29,8±2,1* 
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Indicator Day of 
experiment 
Segment of the pancreas
Intestinal Gastric Splenic 
28 intact 40,0±4,4 31,4±3,9 18,9±3,2 
diabetes 40,9±4,8 42,7±4,8 30,3±4,7* 
Total area of 
β-cell nuclei, 
µm2 
7 intact 24,3±1,3 23,8±1,2 24,7±1,0 
diabetes 23,8±3,1 25,7±2,5 29,5±1,8* 
28 intact 23,9±1,2 24,2±1,2 24,6±1,2 
diabetes 25,3±1,2 25,9±1,0 29,3±1,1* 
* - Significant difference compared with the intact control group (p <0.05). 
Table 7. Morphometric indicators of pancreatic islets in rats with streptozotocin-induced diabetes (M ± m) 
Immunohistochemical reaction, which was performed at day 7, revealed that most 
endocrine cells exhibited marked expression of proapoptotic proteins, such as caspase-3, 
TRAIL and Bax (Fig. 3C, 4C). Activation of apoptosis was accompanied by inhibited 
expression of anti-apoptotic Bcl-2, MDM2, nuclear factor NF-kB proteins (Table 8). There 
was a statistically significant increase in the amount of cells with morphological features of 
apoptosis when compared with the intact control group (Table 8). 
By day 28 there was a decrease in the amount of β-cells as well as in the intensity of 
expression of caspase 3 in the surviving cells (Table 12). We did not observe any significant 
changes in expression of either mitochondrial proapoptotic Bax protein or membrane TRAIL 
(Table 8). Compared with the intact control group, there was a statistically significant 
increase in apoptotic index. With regard to day 7 of observation, a statistically significant 
decrease in apoptotic index was stated (Table 8). Moderate expression of endothelial NO-
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Intact control 7 - + + - + ++ - ++ 
28 - + + - + ++ - ++ 
Diabetes 7 - +++ + ++ - + + + 
28 - ++ + ++ - + + + 
Amount of cells
Intact control 7 - + + - + +++ - ++ 
28 - + + - + +++ - ++ 
Diabetes 7 - ++ + + - + + + 
28 - + + + - ++ + ++ 
Table 8. Immunohistochemical characteristics of β-endocrine cells in streptozotocin-induced diabetes 
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pronounced necrotic changes in the cells of the insular apparatus of the pancreas, there is 
also an increase in apoptogenic activity of β-endocrine cells due to the damage to 
mitochondrial membranes (increased expression of Bax and inhibition of Bcl-2 proteins), 
which might be caused by impaired intracellular calcium homeostasis and activation of the 
mitochondrial apoptotic pathway with subsequent activation of caspase cascade without the 
involvement of p53 protein (Table 12). 
Streptozotocin-induced diabetes 
In streptozotocin-induced diabetes a statistically significant elevation of plasma glucose 
levels, as compared with those in the intact control animals, was reported (Fig. 1). 
Histological investigation which was performed at day 7 showed pronounced hyperemia of 
blood vessels associated with lymphocytic infiltration and marked edema of the interlobular 
connective tissue. There were not any statistically significant differences in the total volume 
fraction of islets either with regard to the intact control group, or to different segments of the 
pancreas. We revealed marked necrotic changes in endocrine cells both in the central part 
and at the periphery of the islets (Fig. 2C). We also stated a statistically significant decrease 
(p <0.05) in the area of β-cells in all segments of the pancreas. However, a significant 
increase (p <0.05) in the volume fraction of α-cells exclusively in the gastric and splenic 
segments of the pancreas was reported. There was marked hypertrophy of β-islet cell nuclei 
(p <0.05) predominantly in the splenic segment of the pancreas (Table 7). 
By day 28 moderate hyperemia of blood capillaries of pancreatic islets and accumulation of 
lymphocytes at some sites were observed. Focal necrotic changes were reported in some islets, 
whereas other islets underwent sclerotic changes. No significant changes in the islet volume 
fraction were observed. The total β-islet cell area was still significantly lower (p <0.05) 
compared with the intact control group during the same period of observation. The total 
volume fraction of α-endocrine cells was significantly increased (p <0.05) exclusively in the 
splenic segment of the pancreas. The nuclei of β-cells were hypertrophic and hypertrophy was 
statistically significant (p <0.05) in the cells of the splenic segment of the pancreas (Table 7). 
 
Indicator Day of experiment 
Segment of the pancreas




7 intact 6,7±2,2 12,0±4,5 12,9±2,1 
diabetes 4,7±3,1 10,2±6,7 11,8±1,5 
28 intact 6,8±2,1 11,9±3,7 13,7±3,2 
diabetes 3,2±2,1 8,2±3,1 9,7±2,3 
Total area of 
β-cells,% 
7 intact 53,8±7,6 63,4±7,0 75,4±8,7 
diabetes 24,3±2,1* 39,2±3,2* 40,1±2,0* 
28 intact 51,1±7,5 65,2±6,0 77,4±4,4 
diabetes 29,8±5,5* 43,2±5,4* 47,7±8,2* 
Total area of 
α-cells,% 
7 intact 39,3±4,3 30,4±4,0 21,3±3,0 
diabetes 44,2±4,5 42,3±2,2* 29,8±2,1* 
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Indicator Day of 
experiment 
Segment of the pancreas
Intestinal Gastric Splenic 
28 intact 40,0±4,4 31,4±3,9 18,9±3,2 
diabetes 40,9±4,8 42,7±4,8 30,3±4,7* 
Total area of 
β-cell nuclei, 
µm2 
7 intact 24,3±1,3 23,8±1,2 24,7±1,0 
diabetes 23,8±3,1 25,7±2,5 29,5±1,8* 
28 intact 23,9±1,2 24,2±1,2 24,6±1,2 
diabetes 25,3±1,2 25,9±1,0 29,3±1,1* 
* - Significant difference compared with the intact control group (p <0.05). 
Table 7. Morphometric indicators of pancreatic islets in rats with streptozotocin-induced diabetes (M ± m) 
Immunohistochemical reaction, which was performed at day 7, revealed that most 
endocrine cells exhibited marked expression of proapoptotic proteins, such as caspase-3, 
TRAIL and Bax (Fig. 3C, 4C). Activation of apoptosis was accompanied by inhibited 
expression of anti-apoptotic Bcl-2, MDM2, nuclear factor NF-kB proteins (Table 8). There 
was a statistically significant increase in the amount of cells with morphological features of 
apoptosis when compared with the intact control group (Table 8). 
By day 28 there was a decrease in the amount of β-cells as well as in the intensity of 
expression of caspase 3 in the surviving cells (Table 12). We did not observe any significant 
changes in expression of either mitochondrial proapoptotic Bax protein or membrane TRAIL 
(Table 8). Compared with the intact control group, there was a statistically significant 
increase in apoptotic index. With regard to day 7 of observation, a statistically significant 
decrease in apoptotic index was stated (Table 8). Moderate expression of endothelial NO-
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Intact control 7 - + + - + ++ - ++ 
28 - + + - + ++ - ++ 
Diabetes 7 - +++ + ++ - + + + 
28 - ++ + ++ - + + + 
Amount of cells
Intact control 7 - + + - + +++ - ++ 
28 - + + - + +++ - ++ 
Diabetes 7 - ++ + + - + + + 
28 - + + + - ++ + ++ 
Table 8. Immunohistochemical characteristics of β-endocrine cells in streptozotocin-induced diabetes 
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Thus, the development of streptozotocin-induced diabetes is associated not only with 
hyperglycemia, but also with marked necrotic changes in endocrine cells of pancreatic islets, 
decreased β-islet cell area accompanied by hyperplasia of their nuclei, increased α-
endocrine cell area, as well as increased apoptotic index (Table 12). High expression levels of 
endothelial NO-synthase in the capillaries of pancreatic islets are indicative of endothelial 
dysfunction. 
Immune-dependent diabetes 
Persistent hyperglycemia and a reduction in plasma insulin by 67.8% were reported in 
immune-dependent diabetes (Fig. 1), as compared with the intact control group. 
Microscopic examination, which was performed at day 7, found that the total volume 
fraction of the islets decreased when compared with the intact control group. The islets had 
an irregular shape due to marked necrotic changes in the endocrine cells, hyperemia of the 
capillaries, as well as mild lymphocytic infiltration. There were single insulin-positive cells 
or they were arranged in small clusters in the central part of the islets around the capillaries. 
We observed a significant decrease (p <0.05) in the total β-cell area in all segments of the 
pancreas as compared with the intact controls (Table 9). The total α-endocrine cell area was 
significantly increased exclusively in the splenic segment of the pancreas. 
At day 14 some symptoms of insulitis, i.e. inflammation of insular cells, persisted. 
Compared with the intact control group, the area covered by β-endocrine cells in all 
segments of the pancreas tended to become smaller (p <0.05) due to marked necrotic 
changes in β-endocrine cells (Fig. 2D). However, we observed moderate hypertrophy of the 
nuclei of β-islet cells as well as an increase in the area covered by α-endocrine cells in the 
splenic segment of the pancreas (Table 9). Some pancreatic islets were reported to undergo 
sclerotic changes. 
By day 28, as before, a statistically significant reduction (p <0.05) in the area covered by β-
islet cells in all segments of the pancreas, as compared with the intact control group, was 
observed. Inflammatory infiltration, swelling and hyperemia of blood vessels tended to 
reduce, too. However, the amount of islets which developed sclerotic changes increased and 
β-endocrine cells had moderately hypertrophic nuclei. There was an increase in the area 
covered by α-endocrine cells in the gastric and splenic segments of the pancreas (Table 9). 
 
Indicator Day of experiment 
Section of the pancreas




7 intact 6,7±2,2 12,0±4,5 12,9±2,1 
diabetes 4,7±3,1 10,2±6,7 11,8±1,5 
14 intact 6,9±3,1 12,1±5,2 14,0±2,9 
diabetes 4,2±1,2 8,9±2,0 9,2±2,2 
28 intact 6,8±2,1 11,9±3,7 13,7±3,2 
diabetes 4,4±1,0 7,4±1,3 8,7±3,4 
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Indicator Day of 
experiment 
Section of the pancreas
Intestinal Gastric Splenic 
Total area of 
β-cells,% 
7 intact 53,8±7,6 63,4±7,0 75,4±8,7 
diabetes 29,8±5,5* 43,2±5,4* 47,7±8,2* 
14 intact 52,1±5,5 64,5±8,7 79,4±4,6 
diabetes 25,4±3,2* 40,1±3,2* 42,3±1,2* 
28 intact 51,1±7,5 65,2±6,0 77,4±4,4 
diabetes 30,2±4,5* 44,3±2,3* 40,1±3,2* 
Total area of 
α-cells,% 
7 intact 39,3±4,3 30,4±4,0 21,3±3,0 
diabetes 45,2±1,2 40,4±5,1 56,7±4,6* 
14 intact 38,5±3,5 32,4±3,2 19,7±2,3 
diabetes 44,1±2,1 42,3±4,2 56,4±3,4* 
28 intact 40,0±4,4 31,4±3,9 18,9±3,2 
diabetes 33,9±3,2 49,5±4,4* 50,9±3,2* 
Total area of 
β-cell nuclei, 
µm2 
7 intact 24,3±1,3 23,8±1,2 24,7±1,0 
diabetes 25,8±1,1 25,2±2,3 27,5±2,2 
14 intact 24,3±1,2 24,8±1,3 24,6±1,3 
diabetes 25,6±2,3 24,6±2,3 26,4±2,1 
28 intact 23,9±1,2 24,2±1,2 24,6±1,2 
diabetes 24,9±2,0 25,1±1,2 25,8±2,2 
* - Significant difference compared with the intact control group (p <0.05). 
Table 9. Morphometric indicators of pancreatic islets in rats with insulin-dependent diabetes (M ± m) 
Immunohistochemical study during all observation periods showed absence or doubtful 
expression of p53, Bax, MDM2 as well as Bcl-2 proteins in certain β-islet cells. Within the 
period from day 7 to day 14 we observed increased expression of TRAIL proapoptotic 
protein and caspase 3 protein (compared with the intact control group and at day 14 
compared with day 7 of the experiment) (Table 10, 12, Fig. 3D, 4D) in most β-cells 
accompanied by a slight reduction by day 28. Simultaneously, apoptotic index during all 
observation periods was significantly increased compared with the intact control group 
(Table 5). The expression of NO-synthase in the endothelium of the pancreatic islet 
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7 - + + - + ++ - ++ 
14 - + + - + ++ - ++ 
28 - + + - + ++ - ++ 
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Thus, the development of streptozotocin-induced diabetes is associated not only with 
hyperglycemia, but also with marked necrotic changes in endocrine cells of pancreatic islets, 
decreased β-islet cell area accompanied by hyperplasia of their nuclei, increased α-
endocrine cell area, as well as increased apoptotic index (Table 12). High expression levels of 
endothelial NO-synthase in the capillaries of pancreatic islets are indicative of endothelial 
dysfunction. 
Immune-dependent diabetes 
Persistent hyperglycemia and a reduction in plasma insulin by 67.8% were reported in 
immune-dependent diabetes (Fig. 1), as compared with the intact control group. 
Microscopic examination, which was performed at day 7, found that the total volume 
fraction of the islets decreased when compared with the intact control group. The islets had 
an irregular shape due to marked necrotic changes in the endocrine cells, hyperemia of the 
capillaries, as well as mild lymphocytic infiltration. There were single insulin-positive cells 
or they were arranged in small clusters in the central part of the islets around the capillaries. 
We observed a significant decrease (p <0.05) in the total β-cell area in all segments of the 
pancreas as compared with the intact controls (Table 9). The total α-endocrine cell area was 
significantly increased exclusively in the splenic segment of the pancreas. 
At day 14 some symptoms of insulitis, i.e. inflammation of insular cells, persisted. 
Compared with the intact control group, the area covered by β-endocrine cells in all 
segments of the pancreas tended to become smaller (p <0.05) due to marked necrotic 
changes in β-endocrine cells (Fig. 2D). However, we observed moderate hypertrophy of the 
nuclei of β-islet cells as well as an increase in the area covered by α-endocrine cells in the 
splenic segment of the pancreas (Table 9). Some pancreatic islets were reported to undergo 
sclerotic changes. 
By day 28, as before, a statistically significant reduction (p <0.05) in the area covered by β-
islet cells in all segments of the pancreas, as compared with the intact control group, was 
observed. Inflammatory infiltration, swelling and hyperemia of blood vessels tended to 
reduce, too. However, the amount of islets which developed sclerotic changes increased and 
β-endocrine cells had moderately hypertrophic nuclei. There was an increase in the area 
covered by α-endocrine cells in the gastric and splenic segments of the pancreas (Table 9). 
 
Indicator Day of experiment 
Section of the pancreas




7 intact 6,7±2,2 12,0±4,5 12,9±2,1 
diabetes 4,7±3,1 10,2±6,7 11,8±1,5 
14 intact 6,9±3,1 12,1±5,2 14,0±2,9 
diabetes 4,2±1,2 8,9±2,0 9,2±2,2 
28 intact 6,8±2,1 11,9±3,7 13,7±3,2 
diabetes 4,4±1,0 7,4±1,3 8,7±3,4 
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Indicator Day of 
experiment 
Section of the pancreas
Intestinal Gastric Splenic 
Total area of 
β-cells,% 
7 intact 53,8±7,6 63,4±7,0 75,4±8,7 
diabetes 29,8±5,5* 43,2±5,4* 47,7±8,2* 
14 intact 52,1±5,5 64,5±8,7 79,4±4,6 
diabetes 25,4±3,2* 40,1±3,2* 42,3±1,2* 
28 intact 51,1±7,5 65,2±6,0 77,4±4,4 
diabetes 30,2±4,5* 44,3±2,3* 40,1±3,2* 
Total area of 
α-cells,% 
7 intact 39,3±4,3 30,4±4,0 21,3±3,0 
diabetes 45,2±1,2 40,4±5,1 56,7±4,6* 
14 intact 38,5±3,5 32,4±3,2 19,7±2,3 
diabetes 44,1±2,1 42,3±4,2 56,4±3,4* 
28 intact 40,0±4,4 31,4±3,9 18,9±3,2 
diabetes 33,9±3,2 49,5±4,4* 50,9±3,2* 
Total area of 
β-cell nuclei, 
µm2 
7 intact 24,3±1,3 23,8±1,2 24,7±1,0 
diabetes 25,8±1,1 25,2±2,3 27,5±2,2 
14 intact 24,3±1,2 24,8±1,3 24,6±1,3 
diabetes 25,6±2,3 24,6±2,3 26,4±2,1 
28 intact 23,9±1,2 24,2±1,2 24,6±1,2 
diabetes 24,9±2,0 25,1±1,2 25,8±2,2 
* - Significant difference compared with the intact control group (p <0.05). 
Table 9. Morphometric indicators of pancreatic islets in rats with insulin-dependent diabetes (M ± m) 
Immunohistochemical study during all observation periods showed absence or doubtful 
expression of p53, Bax, MDM2 as well as Bcl-2 proteins in certain β-islet cells. Within the 
period from day 7 to day 14 we observed increased expression of TRAIL proapoptotic 
protein and caspase 3 protein (compared with the intact control group and at day 14 
compared with day 7 of the experiment) (Table 10, 12, Fig. 3D, 4D) in most β-cells 
accompanied by a slight reduction by day 28. Simultaneously, apoptotic index during all 
observation periods was significantly increased compared with the intact control group 
(Table 5). The expression of NO-synthase in the endothelium of the pancreatic islet 
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7 - + + - + ++ - ++ 
14 - + + - + ++ - ++ 
28 - + + - + ++ - ++ 
 







Primary antibodies   
p53 Caspase-3 TRAIL Bax Bcl-2 MDM2 NOS-3 NF-kB 
Diabetes 7 - +++ +++ ++ - + ++ + 
14 - +++ ++ ++ - + ++ + 
28 - ++ + + - ++ ++ + 
Amount of cells 
Intact 
control 
7 - + + - + +++ - ++ 
14 - + + - + +++ - ++ 
28 - + + - + +++ - ++ 
Diabetes 7 - ++ + ++ - ++ + + 
14 - ++ + ++ - ++ + + 
28 - ++ + + - ++ + + 
Table 10. Expression of pro-and β-anti-apoptotic proteins in endocrine cells of insulin-dependent 
diabetic rats 
Thus, it was found that immuno-dependent diabetes is characterized by the following 
changes: hyperglycemia, reduced area of β-islet cells, inflammatory infiltration of islets, 
marked β-necrotic changes in endocrine cells, focal sclerosis of the islets of Langerhans. 
Streptozotocin-nicotinamide-induced diabetes 
The results of the 28-day streptozotocin-nicotinamide-induced diabetes study indicated that 
plasma C-peptide concentration in the control animals with diabetes increased by 36.8% 
(p<0,05), as compared with intact rats. Blood glucose levels in rats with strep-tozototsin-
nicotinamide-induced diabetes during the entire experiment was significantly superior to 
glycemia in intact animals (Fig. 1). 
Histologically, the maximum reduction in the volume fraction of islets was found at day 3 
with a tendency to increase by day 28 in all segments of the pancreas. 
At day 3 the pancreatic tissue appeared unevenly swollen and hyperemic. There were minor 
destructive changes of endocrine cells in pancreatic islets. The proportion of β-islet cells in 
all segments of the pancreas markedly decreased. At the same time no significant changes in 
the area of β-cells in islets were observed. The islets showed uneven accumulation of 
insulin-positive cells. Along with the cells which exhibited a marked accumulation of 
insulin, endocrine cells showing uneven distribution of immunopositive material in the 
cytoplasm with moderate or weak staining were singled out. Endocrine cells in the splenic 
segment of the pancreas were characterized by moderate hypertrophy of the nuclei and it 
was statistically significant, as compared to the intact control (Table 11). 
By day 7 swelling hyperemia decreased and a microscopic mosaic image was observed. Both 
histologically intact and impaired islets of Langerhans were found. In a number of islets we 
could observe focal necrotic changes of endocrine cells, while others exhibited focal 
proliferation of connective tissue, and sometimes poorly defined intralobular and periductal 
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sclerotic changes. Compared with the intact control group, there was a statistically 
significant reduction in the area of β-cells in the splenic segment. Immunopositive material 
was unevenly distributed both in the insular cells and within the cytoplasm of an insular 
cell. Hypertrophy of the nuclei of islet cells was reported in all segments of the pancreas. 
At day 14 a mosaic pattern of cell damage was still noted. Both histologically intact islets 
and islets revealing sclerotic changes were defined. Their amount tended to decrease in all 
segments of the pancreas. Simultaneously, the total β-cell area decreased in the gastric and 
splenic segments of the pancreas. Hypertrophy of the nuclei of β-cells persisted in all 
segments of the pancreas (Fig. 2E). 
By day 28 a statistically significant reduction in β-cell area in the gastric segment of the 
pancreas was reported, as compared with the control group. Hypertrophy of the nuclei of β-
cells persisted (Table 11). 
 
Indicator Day of experiment 
Segment of the pancreas




3 intact 6,8±2,5 12,6±6,0 13,8±7,3 
diabetes 3,8±1,0 8,3±1,0 5,4±3,2 
7 intact 6,7±2,2 12,0±4,5 12,9±2,1 
diabetes 4,2±1,2 7,8±1,4 6,7±2,5 
14 intact 6,8±2,1 11,9±3,7 13,7±3,2 
diabetes 5,4±1,3 6,9±1,2 8,9±4,2 
28 intact 6,6±4,2 12,8±4,5 14,3±5,2 
diabetes 5,3±1,1 7,9±1,0 11,3±2,1 
Total area of 
β-cells,% 
3 intact 51,3±9,2 64,6±9,1 78,2±6,1 
diabetes 43,4±4,9 52,4±3,4 65,7±3,4 
7 intact 53,8±7,6 63,4±7,0 75,4±7,7 
diabetes 44,6±4,2 53,2±6,1 57,7±3,3* 
14 intact 51,1±7,5 65,2±6,0 77,4±4,4 
diabetes 37,4±5,6 47,6±4,3* 56,2±4,2* 
28 intact 54,3±5,4 66,2±3,6 77,3±4,3 
diabetes 41,2±2,3 50,2±3,1* 67,8±2,6 
Total area of 
β-cell nuclei, 
µm2 
3 intact 24,2±1,2 24,4±1,0 23,9±0,2 
diabetes 26,4±1,1 26,8±1,0 26,5±0,9* 
7 intact 24,3±1,3 23,8±1,2 24,7±1,0 
diabetes 29,8±1,0* 29,6±1,2* 30,1±0,6* 
14 intact 23,9±1,2 24,2±1,2 24,6±1,2 
diabetes 29,1±1,3* 29,6±1,0* 30,0±1,0* 
28 intact 24,4±1,0 24,3±1,2 24,7±2,0 
diabetes 28,7±1,2* 28,7±1,1* 29,7±1,2* 
* - Significant difference compared with the intact control (p <0.05). 
Table 11. Morphometric indicators of pancreatic islets in rats with experimental streptozotocin-
nicotinamide-induced diabetes (M ± m) 
 







Primary antibodies   
p53 Caspase-3 TRAIL Bax Bcl-2 MDM2 NOS-3 NF-kB 
Diabetes 7 - +++ +++ ++ - + ++ + 
14 - +++ ++ ++ - + ++ + 
28 - ++ + + - ++ ++ + 
Amount of cells 
Intact 
control 
7 - + + - + +++ - ++ 
14 - + + - + +++ - ++ 
28 - + + - + +++ - ++ 
Diabetes 7 - ++ + ++ - ++ + + 
14 - ++ + ++ - ++ + + 
28 - ++ + + - ++ + + 
Table 10. Expression of pro-and β-anti-apoptotic proteins in endocrine cells of insulin-dependent 
diabetic rats 
Thus, it was found that immuno-dependent diabetes is characterized by the following 
changes: hyperglycemia, reduced area of β-islet cells, inflammatory infiltration of islets, 
marked β-necrotic changes in endocrine cells, focal sclerosis of the islets of Langerhans. 
Streptozotocin-nicotinamide-induced diabetes 
The results of the 28-day streptozotocin-nicotinamide-induced diabetes study indicated that 
plasma C-peptide concentration in the control animals with diabetes increased by 36.8% 
(p<0,05), as compared with intact rats. Blood glucose levels in rats with strep-tozototsin-
nicotinamide-induced diabetes during the entire experiment was significantly superior to 
glycemia in intact animals (Fig. 1). 
Histologically, the maximum reduction in the volume fraction of islets was found at day 3 
with a tendency to increase by day 28 in all segments of the pancreas. 
At day 3 the pancreatic tissue appeared unevenly swollen and hyperemic. There were minor 
destructive changes of endocrine cells in pancreatic islets. The proportion of β-islet cells in 
all segments of the pancreas markedly decreased. At the same time no significant changes in 
the area of β-cells in islets were observed. The islets showed uneven accumulation of 
insulin-positive cells. Along with the cells which exhibited a marked accumulation of 
insulin, endocrine cells showing uneven distribution of immunopositive material in the 
cytoplasm with moderate or weak staining were singled out. Endocrine cells in the splenic 
segment of the pancreas were characterized by moderate hypertrophy of the nuclei and it 
was statistically significant, as compared to the intact control (Table 11). 
By day 7 swelling hyperemia decreased and a microscopic mosaic image was observed. Both 
histologically intact and impaired islets of Langerhans were found. In a number of islets we 
could observe focal necrotic changes of endocrine cells, while others exhibited focal 
proliferation of connective tissue, and sometimes poorly defined intralobular and periductal 
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sclerotic changes. Compared with the intact control group, there was a statistically 
significant reduction in the area of β-cells in the splenic segment. Immunopositive material 
was unevenly distributed both in the insular cells and within the cytoplasm of an insular 
cell. Hypertrophy of the nuclei of islet cells was reported in all segments of the pancreas. 
At day 14 a mosaic pattern of cell damage was still noted. Both histologically intact islets 
and islets revealing sclerotic changes were defined. Their amount tended to decrease in all 
segments of the pancreas. Simultaneously, the total β-cell area decreased in the gastric and 
splenic segments of the pancreas. Hypertrophy of the nuclei of β-cells persisted in all 
segments of the pancreas (Fig. 2E). 
By day 28 a statistically significant reduction in β-cell area in the gastric segment of the 
pancreas was reported, as compared with the control group. Hypertrophy of the nuclei of β-
cells persisted (Table 11). 
 
Indicator Day of experiment 
Segment of the pancreas




3 intact 6,8±2,5 12,6±6,0 13,8±7,3 
diabetes 3,8±1,0 8,3±1,0 5,4±3,2 
7 intact 6,7±2,2 12,0±4,5 12,9±2,1 
diabetes 4,2±1,2 7,8±1,4 6,7±2,5 
14 intact 6,8±2,1 11,9±3,7 13,7±3,2 
diabetes 5,4±1,3 6,9±1,2 8,9±4,2 
28 intact 6,6±4,2 12,8±4,5 14,3±5,2 
diabetes 5,3±1,1 7,9±1,0 11,3±2,1 
Total area of 
β-cells,% 
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Table 11. Morphometric indicators of pancreatic islets in rats with experimental streptozotocin-
nicotinamide-induced diabetes (M ± m) 
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* - Significant difference compared with the intact control (p <0.05) ^ - significant difference compared with day 3 of 
experiment (p <0.05); # - significant difference compared with day 7 of experiment (p <0.05). 
Table 12. Apoptotic index of β-cells (%) 
Thus, hyperglycemia as well as reduced plasma C-peptide concentrations are common to 
experimental streptozotocin-nicotinamide-induced diabetes. Along with biochemical 
changes, it displays some characteristic morphological changes, including a statistically 
significant decrease in insular cell area associated with hypertrophy of β-cell nuclei, mosaic 
islet damage resulting in the destruction of endocrine cells as well as sclerotic changes of 
pancreatic islets during long-term observation period. 
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Figure 2. Reduction in the amount of cells under different experimental diabetes conditions, day 14 
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E. Streptozotocin-nicotinamide-induced diabetes 
Figure 3. TRAIL expression in pancreatic islet cells under different experimental diabetes conditions, 
day 14 (Streptozotocin-induced diabetes, day 7), splenic segment of the pancreas. TRAIL primary 
antibody, DAB staining. Magnification: х400. 
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E. Streptozotocin-nicotinamide-induced diabetes 
Figure 4. Apoptotic cells under different experimental diabetes conditions, day 14 (Streptozotocin-
induced diabetes, day 7), splenic segment of the pancreas. Caspase 3 primary antibody, DAB staining. 
Magnification: х400. 
4. Discussion 
It is known that type I diabetes develops when pancreatic β-cells are damaged due to certain 
inflammatory, autoimmune and other pathological processes. Selective organ-specific tissue 
destruction of the insulin-producing pancreatic β-cells is associated with insulin deficiency 
resulting in impairment of glucose homeostasis. A large body of experimental evidence 
emphasizes the key role of apoptosis in the pathogenesis of diabetes mellitus (Kim B.M. et 
al. 2001; Severgina E.S. 2002; Butler A.E. et al. 2003; Bertalli E. et al. 2005; Rees D.A., et al. 
2005; Srinivasan K., et al. 2007; Islam S., et al. 2009; Pisarev V.B. et al. 2009). Toxic effects of 
certain chemicals (e.g. alloxan, streptozotocin, etc.) used to induce diabetes specifically in 
pancreatic β-cells, manifest themselves by alkylation of DNA and formation of toxic 
compounds, such as superoxide anion, peroxynitrite, and nitric oxide. Damage to DNA and 
intracellular structures causes necrosis and activates apoptosis of pancreatic β-cells (Daisy 
Mythili M., et al. 2004). 
Selective toxicity of streptozotocin can be explained by destruction of antiradical protective 
system and pancreatic β-cell DNA fragmentation. Numerous experiments show that the 
principal cause of streptozotocin-induced β-cell death is alkylation of DNA. Exposure of 
cells to streptozotocin results in the formation of toxic compounds, such as superoxide 
anion, peroxynitrite, and nitric oxide (NO). However, the contribution of NO to the 
cytotoxic activity remains controversial, because low concentrations of NO in the cells 
inhibit the inducible forms of NO-synthase, thus reducing DNA fragmentation (Szkudelski 
T. 2001; Lenzen S. 2008). 
Receptor- or mitochondrial-mediated pathway may trigger programmed pancreatic β-cell 
death (Szkudelski T. 2001). Induction of β-cell apoptosis can occur through a TRAIL-
mediated mechanism. DNA damage can activate p53 gene which regulates the expression of 
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It is known that type I diabetes develops when pancreatic β-cells are damaged due to certain 
inflammatory, autoimmune and other pathological processes. Selective organ-specific tissue 
destruction of the insulin-producing pancreatic β-cells is associated with insulin deficiency 
resulting in impairment of glucose homeostasis. A large body of experimental evidence 
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intracellular structures causes necrosis and activates apoptosis of pancreatic β-cells (Daisy 
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Selective toxicity of streptozotocin can be explained by destruction of antiradical protective 
system and pancreatic β-cell DNA fragmentation. Numerous experiments show that the 
principal cause of streptozotocin-induced β-cell death is alkylation of DNA. Exposure of 
cells to streptozotocin results in the formation of toxic compounds, such as superoxide 
anion, peroxynitrite, and nitric oxide (NO). However, the contribution of NO to the 
cytotoxic activity remains controversial, because low concentrations of NO in the cells 
inhibit the inducible forms of NO-synthase, thus reducing DNA fragmentation (Szkudelski 
T. 2001; Lenzen S. 2008). 
Receptor- or mitochondrial-mediated pathway may trigger programmed pancreatic β-cell 
death (Szkudelski T. 2001). Induction of β-cell apoptosis can occur through a TRAIL-
mediated mechanism. DNA damage can activate p53 gene which regulates the expression of 
 
Apoptosis and Medicine 
 
244 
DR5 and/or DR4 death receptors, thus enhancing TRAIL-induced apoptosis (Haupt S., et al. 
2003; Kelley R.F., et al. 2005). Our studies provide evidence for activation of TRAIL-induced 
apoptosis in pancreatic β-cells by administration of streptozotocin on models of 
streptozotocin-induced and immune-dependent diabetes. 
Mitochondrial-mediated apoptotic pathway plays an important role in the development of 
pancreatic islet damage in diabetes mellitus (Sakurai K., et al. 2001). In alloxan-induced 
diabetes intracellular calcium homeostasis is typically impaired. In vitro and in vivo 
experiments have shown that cytoplasmic calcium concentrations increase in the cells of 
pancreatic islets. This effect is due to depolarization of cell and mitochondrial membranes of β-
endocrine cells which is associated with excessive entry of calcium from the extracellular fluid 
and intracellular calcium mobilization (Crow M.T., et al. 2004; Jung J.Y., et al. 2004). Thus, 
considerable gross damage to the intracellular structures by free radicals, oxidation of SH- 
proteins and impairment of intracellular calcium homeostasis typically result in necrosis and 
apoptosis, with necrotic processes being more common in alloxan-induced diabetes. 
Comparison of morphological data and the dynamics of impairment of β-cell functional 
activity in experimental models (alloxan-, streptozotocin-, nicotinamide-streptozotocin-
induced and immune-dependent diabetes) gives insight into the pathogenesis of 
experimental diabetes. A high apoptotic index and the prevalence of destructive processes, 
which enable us to assess not only the extent of pancreatic tissue damage but also to 
evaluate biochemical parameters, such as plasma glucose, insulin, C-peptide, etc., can be 
used as markers of severity of experimental diabetes (Snigur G.L., Smirnov A.V. 2010). 
Thus, apoptosis is a complex, multi-step, poorly regulated process. Any regulatory 
impairment can lead to the development of pathological changes in the endocrine apparatus 
of pancreatic islets including the development of experimental diabetes (Reed J.C., Green 
D.R. 2011). Each level and element of this system is a potential drug target. The significance 
of apoptosis determines the need for the refocusing of biomedical research from theoretical 
biology to clinical medicine. Investigation of apoptotic mechanisms in various pathological 
conditions enable us to make more accurate diagnoses and prognoses as well as to adjust 
therapy. The possibility of deliberate control of apoptotic processes is considered to be the 
basis for developing new medications used to treat many socially important diseases, 
including the development of anti-diabetic drugs. 
Experimental diabetic rats exhibited significant pathohistological changes in the pancreatic 
islets caused by cytotoxine (streptozotocin+CFA) at all levels of tissue structure. The 
development of diabetes mellitus was associated with decreased volume fraction of 
pancreatic islets and β-cells due to inflammation (insulitis) and pronounced destructive 
changes (e.g. necrosis and apoptosis). 
Author details 
A.V. Smirnov and G.L. Snigur 
Department of Pathologic Anatomy, Volgograd State Medical University, Russia 
 




Department of Pharmacology, Volgograd State Medical University, Russia 
Acknowledgement 
We express our gratitude to the Head of pharmacology department of Volgograd State 
Medical University, Academician of Russian Academy for Medical Sciences, Honored 
Scientist of Russia, MD, full professor, Spasov Alexander A., assistant professor of 
pharmacology department of Volgograd State Medical University, PhD, Cheplyaeva Natalia 
I., assistant professor of pharmacology department of Volgograd State Medical University, 
PhD, Chepurnova Mariya V. for their assistance in conducting the present study. 
5. References 
[1] Akbarzadeh A., et al. (2007) Induction of diabetes by streptozotocin in rats. Indian 
Journal of Clinical Biochemistry Vol. 22. №2. pp.60-64 
[2] Allred D.C., Harvey J.M., Berardo M., Clark G.M. (1998) Prognostic and predictive 
factors in breast cancer by immunohistochemical analysis. Mod. Pathol.11. pp.155-68 
[3] Baranov V.G. (1983) Experimental diabetes mellitus. Leningrad 
[4] Bertalli E., Bendayan M. (2005) Association between endocrine pancreas and ductal 
system. More than an epiphenomenon of endocrine differentiation and development? J. 
Histochem. & Cytochem. Vol.53. N3. pp.1071-1086 
[5] Butler A.E., Janson J., Bonner-Weir S., et al. (2003) β-cell deficit and increased β-cell 
apoptosis in humans with type 2 diabetes. Diabetes Vol. 52. N1.pp.102-110 
[6] Crow M.T., Mani K., Nam Y.J., et. al. (2004) The mitochondrial death pathway and 
cardiac myocyte apoptosis. Circ Res. Vol. 95. N 10. pp.957-70 
[7] Daisy M., Rashmi V., Akila G., Gunasekaran S. (2004) Effect of streptozotocin on the 
ultrastructure of rat pancreatic islets. Microsc. Res. Tech. Vol.63. N 5. pp.274 – 281 
[8] Haupt S., Berger M., Goldberg Z., Haupt Y. (2003) Apoptosis - the p53 network. J. Cell 
Sci. Vol. 116. N 20. pp.4077-85 
[9] Islam S., Loots D.T. (2009) Experimental rodent models of type 2 diabetes: a review. 
Methods Find Exp. Clin. Pharmacol. Vol. 4. N31. pp.249-261 
[10] Jung J.Y., Kim W.J. (2004) Involvement of mitochondrial- and Fas-mediated dual 
mechanism in CoCl(2)-induced apoptosis of rat PC12 cells. Neurosci Lett. Vol. 371. N 2-
3. pp.85-90 
[11] Kelley R.F., Totpal K., Lindstrom S.H., et al. (2005) Receptor-selective mutants of 
Apo2L/TRAIL reveal a greater contribution of DR5 than DR4 to apoptosis signaling. J 
Biol Chem. Vol. 280. N 3. pp.2205-12 
[12] Kim B.M., Ham Y.M., Shin Y.J., et al. (2001) Clusterin expression during regeneration of 
pancreatic islet β-cell in streptozotocin-induced diabetic rats. Diabetologia. Vol. 44. N 
12. pp.2192-2202 
[13] Korzhevsky A. (2005) Summary of the foundations of histological techniques for 
doctors, laboratory technicians as well as histologists. St. Petersburg 
 
Apoptosis and Medicine 
 
244 
DR5 and/or DR4 death receptors, thus enhancing TRAIL-induced apoptosis (Haupt S., et al. 
2003; Kelley R.F., et al. 2005). Our studies provide evidence for activation of TRAIL-induced 
apoptosis in pancreatic β-cells by administration of streptozotocin on models of 
streptozotocin-induced and immune-dependent diabetes. 
Mitochondrial-mediated apoptotic pathway plays an important role in the development of 
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experiments have shown that cytoplasmic calcium concentrations increase in the cells of 
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1. Introduction 
The most important part of forensic pathology is investigation of the cause and process of 
death, especially in violent and unexpected sudden deaths, which involve social and 
medicolegal issues of ultimate, personal and public concern. Forensic pathologists are 
expected to respond to social requests by reliable interpretation of these issues in routine 
casework on the basis of research activities to develop, improve and sophisticate the 
procedures as well as to establish an autopsy database within the framework of social and 
legal systems. Systematic investigations are needed for comprehensive assessment of 
pathological findings, making full use of the available procedures; while classical 
morphology remains a core procedure to investigate deaths in forensic pathology, a 
spectrum of ancillary procedures has been developed and incorporated to detail the 
pathology. In addition to postmortem biochemistry, experimental and practical 
investigations using molecular biological procedures in the context of forensic pathology 
(molecular forensic pathology) have suggested the usefulness of detecting dynamic 
functional changes involved in the dying process that cannot be detected by morphology 
(pathophysiological vital reactions) (Maeda et al., 2010; Maeda et al., 2011). These 
procedures may effectively be included in routine casework as part of forensic laboratory 
investigations (forensic molecular pathology). The purpose of forensic molecular pathology 
is to provide a general explanation of the process or pathophysiology of human death 
caused by insults involving forensic issues as well as the assessment of individual deaths on 
the basis of biological molecular evidence; in forensic investigation of death, the genetic 
background, dynamics of gene expression (up-/down-regulation), and vital phenomena, 
involving biological mediators and degenerative products, are detected by DNA analysis, 
relative quantification of mRNA transcripts using real-time reverse transcription-PCR (RT-
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1. Introduction 
The most important part of forensic pathology is investigation of the cause and process of 
death, especially in violent and unexpected sudden deaths, which involve social and 
medicolegal issues of ultimate, personal and public concern. Forensic pathologists are 
expected to respond to social requests by reliable interpretation of these issues in routine 
casework on the basis of research activities to develop, improve and sophisticate the 
procedures as well as to establish an autopsy database within the framework of social and 
legal systems. Systematic investigations are needed for comprehensive assessment of 
pathological findings, making full use of the available procedures; while classical 
morphology remains a core procedure to investigate deaths in forensic pathology, a 
spectrum of ancillary procedures has been developed and incorporated to detail the 
pathology. In addition to postmortem biochemistry, experimental and practical 
investigations using molecular biological procedures in the context of forensic pathology 
(molecular forensic pathology) have suggested the usefulness of detecting dynamic 
functional changes involved in the dying process that cannot be detected by morphology 
(pathophysiological vital reactions) (Maeda et al., 2010; Maeda et al., 2011). These 
procedures may effectively be included in routine casework as part of forensic laboratory 
investigations (forensic molecular pathology). The purpose of forensic molecular pathology 
is to provide a general explanation of the process or pathophysiology of human death 
caused by insults involving forensic issues as well as the assessment of individual deaths on 
the basis of biological molecular evidence; in forensic investigation of death, the genetic 
background, dynamics of gene expression (up-/down-regulation), and vital phenomena, 
involving biological mediators and degenerative products, are detected by DNA analysis, 
relative quantification of mRNA transcripts using real-time reverse transcription-PCR (RT-
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PCR), and immunohisto-/immunocytochemistry combined with biochemistry, respectively. 
These observations will also contribute to understanding life-threatening events after 
traumas in the clinical management of critical patients. 
In forensic and clinical medicine, head injury is a major trauma, and primary or secondary 
brain damage, e.g. due to ischemic, hypoxic and toxic insults, is involved in most fatal 
traumas and diseases; thus, the investigation of brain damage after such insults is essential 
to assess the etiology and evaluate the severity of brain impairment relevant to central 
nervous system (CNS) dysfunction (Oehmichen et al., 2006). Necrosis and apoptosis are 
involved in morphological deterioration of the brain, involving cell and tissue decay 
(Fawthrop et al., 1991). Neuronal apoptosis is involved in both early and delayed responses 
after insults; however, this type of neuronal degeneration and cell death is of greater 
importance in connection with delayed or intermittent CNS dysfunction (Martin et al., 1998). 
This chapter reviews neuronal apoptosis and related pathologies in the brain after fatal 
traumas and diseases as demonstrated in forensic autopsy casework, summarizing previous 
observations (Michiue et al., 2008; Wang et al., 2011a; Wang et al., 2012a; Wang et al., 2012b). 
2. Brain neuronal apoptosis in human death 
Apoptosis is programmed cell death, regulated by specific ‘death genes.’ The process 
involves active protein synthesis, initiated by changes in the microenvironment and 
impaired metabolic and tropic supply (Alison & Sarraf, 1992), with the participation of 
immediate early gene transcription factors (e.g. c-jun, jun-B, jun-D, c-fos, AP-1, ATF and 
nuclear factor (NF)-κB), proteases (e.g. calpains and caspases), and glutamate-mediate 
toxicity, including free radicals, protein kinases, Ca2+ homeostasis, and second messenger 
systems (Vaux & Strasser, 1996). It is known that microglial cells have an anti-apoptotic 
function to protect neurons from apoptotic death (Polazzi et al., 2001). Mechanical brain 
injury is accompanied by the apoptosis of neurons and glial cells surrounding the site of 
contusion and hemorrhage, which undergoes cell degeneration and necrosis (Oehmichen et 
al., 2006). Apoptosis begins hours after a traumatic event, and remains demonstrable for 
about 3 days (Yakovlev & Faden, 2001). These survival time-dependent changes are useful 
for timing brain contusions and hemorrhages in forensic pathology (Hausmann et al., 2004); 
however, apoptosis has been detected in the white matter as long as 1 year after injury 
(Williams et al., 2001). Apoptosis is also induced by other insults, including cerebral 
ischemia and hypoxia/asphyxia (Rosenblum, 1997), carbon monoxide (CO) intoxication 
(Piantadosi et al., 1997) and drug toxicity (Cadet & Krasnova, 2009). It is of particular 
importance that apoptosis may be involved in delayed neuronal loss (Becker & Bonni, 2004), 
which may contribute to delayed death or posttraumatic neurological disorders and 
sequelae. 
Neuronal apoptosis is usually detected by in situ labeling of DNA fragments, e.g. terminal 
deoxynucleotidyl-transferase-mediated dUDP nick end-labeling (TUNEL) or in situ nick 
translation (ISNT) (Clark et al., 2001; Gavrieli et al., 1992; Rink et al., 1995). However, 
experimental studies have shown that single-stranded DNA (ssDNA) degradation precedes 
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DNA double-strand breaks (DNAdsb) during a delayed neuronal death process caused by 
reperfusion after transient brain ischemia or intracerebral hemorrhage, possibly due to 
oxidative stress (Chen et al., 1997; Gong et al., 2001; Love, 1999; Nakamura et al., 2005). 
Thus, ssDNA can be used as an earlier marker of apoptosis and programmed cell death, 
which causes neuronal loss (Chen et al., 1997; Frankfurt et al., 1996; Michiue, 2008). This 
marker may contribute to the investigation of neuronal damage in acute death and also the 
timing of brain injury in the early phase (Chen et al., 1997; Hausmann et al., 2004). 
Animal experimentation has shown that ssDNA positivity could be detected after as little as 
1 min of reperfusion following transient brain ischemia, showing a progressive increase, and 
exclusively in neurons exhibiting normal nuclear morphology within the first hour of 
reperfusion before the appearance of DNAdsb, whereas DNAdsb was first detected after 1 h 
of reperfusion. Thereafter, at 16–72 h of reperfusion, both ssDNA and DNAdsb positivity 
were found in many neurons and astrocytes, showing morphological changes consistent 
with apoptosis (Chen et al., 1997). Alternatively, ssDNA-positive neurons may be decreased 
after several hours of reperfusion, possibly due to active DNA repair. These findings 
suggest that damage to nuclear DNA is an early event after neuronal ischemia and that the 
accumulation of unrepaired DNA single-strand breaks due to oxidative stress may 
contribute to delayed ischemic neuronal death by triggering apoptosis. Other experimental 
studies have suggested that oxidative stress contributes to DNA damage and brain injury 
after intracerebral hemorrhage (Gong et al., 2001; Nakamura et al., 2005). These observations 
indicate that neuronal ssDNA positivity can be a marker of early brain damage, possibly 
within the first hour after an insult involving oxidative stress, including reperfusion and 
hemorrhage (Michiue et al., 2008). The detection of neuronal ssDNA may depend on the 
cause of death and survival time after a fatal insult. Brain reperfusion during 
cardiopulmonary resuscitation (CPR) may also contribute to positivity. 
Astrocytes are essential for the structural integrity of neurons and also for maintaining their 
physiological environment, involving electrolyte and water homeostasis, pH and osmotic 
regulation, and elimination of transmitter amino acids and plasma proteins, as well as the 
control of vascular tone and intercellular transport of molecules from the vessel to the 
neuron, supporting the blood-brain barrier (BBB) (Nag, 2011). In forensic neuropathology, 
glial fibrillary acidic protein (GFAP) and S100β, as specific markers of differentiated 
astrocytes in the brain, are used to detect their morphological and functional alterations 
involved in brain damage (Liedtke et al., 1996; Stroick et al., 2006). GFAP is normally 
detected in fibrous astrocytes in the white matter and molecular layer of the cerebral cortex, 
but is usually not detectable in protoplasmatic astrocytes in the cerebral cortex by a routine 
immunohistochemical procedure (Li et al., 2009b; Oehmichen et al., 2006). GFAP is essential 
for fibrous astrocyte functions, including maintenance of the integrity of CNS white matter 
and the blood-brain barrier (Liedtke et al., 1996), and can therefore be used to detect the 
morphological and functional alterations of astrocytes due to brain damage; the decrease of 
white matter GFAP immunopositivity indicates the disruption of astrocytes, while reactive 
astrogliosis involves an increase in the gray matter (Wang et al., 2011a; Wang et al., 2012a). 
S100β is a calcium-binding peptide and is used as a clinical parameter of glial activation 
 
Apoptosis and Medicine 248 
PCR), and immunohisto-/immunocytochemistry combined with biochemistry, respectively. 
These observations will also contribute to understanding life-threatening events after 
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brain damage, e.g. due to ischemic, hypoxic and toxic insults, is involved in most fatal 
traumas and diseases; thus, the investigation of brain damage after such insults is essential 
to assess the etiology and evaluate the severity of brain impairment relevant to central 
nervous system (CNS) dysfunction (Oehmichen et al., 2006). Necrosis and apoptosis are 
involved in morphological deterioration of the brain, involving cell and tissue decay 
(Fawthrop et al., 1991). Neuronal apoptosis is involved in both early and delayed responses 
after insults; however, this type of neuronal degeneration and cell death is of greater 
importance in connection with delayed or intermittent CNS dysfunction (Martin et al., 1998). 
This chapter reviews neuronal apoptosis and related pathologies in the brain after fatal 
traumas and diseases as demonstrated in forensic autopsy casework, summarizing previous 
observations (Michiue et al., 2008; Wang et al., 2011a; Wang et al., 2012a; Wang et al., 2012b). 
2. Brain neuronal apoptosis in human death 
Apoptosis is programmed cell death, regulated by specific ‘death genes.’ The process 
involves active protein synthesis, initiated by changes in the microenvironment and 
impaired metabolic and tropic supply (Alison & Sarraf, 1992), with the participation of 
immediate early gene transcription factors (e.g. c-jun, jun-B, jun-D, c-fos, AP-1, ATF and 
nuclear factor (NF)-κB), proteases (e.g. calpains and caspases), and glutamate-mediate 
toxicity, including free radicals, protein kinases, Ca2+ homeostasis, and second messenger 
systems (Vaux & Strasser, 1996). It is known that microglial cells have an anti-apoptotic 
function to protect neurons from apoptotic death (Polazzi et al., 2001). Mechanical brain 
injury is accompanied by the apoptosis of neurons and glial cells surrounding the site of 
contusion and hemorrhage, which undergoes cell degeneration and necrosis (Oehmichen et 
al., 2006). Apoptosis begins hours after a traumatic event, and remains demonstrable for 
about 3 days (Yakovlev & Faden, 2001). These survival time-dependent changes are useful 
for timing brain contusions and hemorrhages in forensic pathology (Hausmann et al., 2004); 
however, apoptosis has been detected in the white matter as long as 1 year after injury 
(Williams et al., 2001). Apoptosis is also induced by other insults, including cerebral 
ischemia and hypoxia/asphyxia (Rosenblum, 1997), carbon monoxide (CO) intoxication 
(Piantadosi et al., 1997) and drug toxicity (Cadet & Krasnova, 2009). It is of particular 
importance that apoptosis may be involved in delayed neuronal loss (Becker & Bonni, 2004), 
which may contribute to delayed death or posttraumatic neurological disorders and 
sequelae. 
Neuronal apoptosis is usually detected by in situ labeling of DNA fragments, e.g. terminal 
deoxynucleotidyl-transferase-mediated dUDP nick end-labeling (TUNEL) or in situ nick 
translation (ISNT) (Clark et al., 2001; Gavrieli et al., 1992; Rink et al., 1995). However, 
experimental studies have shown that single-stranded DNA (ssDNA) degradation precedes 
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DNA double-strand breaks (DNAdsb) during a delayed neuronal death process caused by 
reperfusion after transient brain ischemia or intracerebral hemorrhage, possibly due to 
oxidative stress (Chen et al., 1997; Gong et al., 2001; Love, 1999; Nakamura et al., 2005). 
Thus, ssDNA can be used as an earlier marker of apoptosis and programmed cell death, 
which causes neuronal loss (Chen et al., 1997; Frankfurt et al., 1996; Michiue, 2008). This 
marker may contribute to the investigation of neuronal damage in acute death and also the 
timing of brain injury in the early phase (Chen et al., 1997; Hausmann et al., 2004). 
Animal experimentation has shown that ssDNA positivity could be detected after as little as 
1 min of reperfusion following transient brain ischemia, showing a progressive increase, and 
exclusively in neurons exhibiting normal nuclear morphology within the first hour of 
reperfusion before the appearance of DNAdsb, whereas DNAdsb was first detected after 1 h 
of reperfusion. Thereafter, at 16–72 h of reperfusion, both ssDNA and DNAdsb positivity 
were found in many neurons and astrocytes, showing morphological changes consistent 
with apoptosis (Chen et al., 1997). Alternatively, ssDNA-positive neurons may be decreased 
after several hours of reperfusion, possibly due to active DNA repair. These findings 
suggest that damage to nuclear DNA is an early event after neuronal ischemia and that the 
accumulation of unrepaired DNA single-strand breaks due to oxidative stress may 
contribute to delayed ischemic neuronal death by triggering apoptosis. Other experimental 
studies have suggested that oxidative stress contributes to DNA damage and brain injury 
after intracerebral hemorrhage (Gong et al., 2001; Nakamura et al., 2005). These observations 
indicate that neuronal ssDNA positivity can be a marker of early brain damage, possibly 
within the first hour after an insult involving oxidative stress, including reperfusion and 
hemorrhage (Michiue et al., 2008). The detection of neuronal ssDNA may depend on the 
cause of death and survival time after a fatal insult. Brain reperfusion during 
cardiopulmonary resuscitation (CPR) may also contribute to positivity. 
Astrocytes are essential for the structural integrity of neurons and also for maintaining their 
physiological environment, involving electrolyte and water homeostasis, pH and osmotic 
regulation, and elimination of transmitter amino acids and plasma proteins, as well as the 
control of vascular tone and intercellular transport of molecules from the vessel to the 
neuron, supporting the blood-brain barrier (BBB) (Nag, 2011). In forensic neuropathology, 
glial fibrillary acidic protein (GFAP) and S100β, as specific markers of differentiated 
astrocytes in the brain, are used to detect their morphological and functional alterations 
involved in brain damage (Liedtke et al., 1996; Stroick et al., 2006). GFAP is normally 
detected in fibrous astrocytes in the white matter and molecular layer of the cerebral cortex, 
but is usually not detectable in protoplasmatic astrocytes in the cerebral cortex by a routine 
immunohistochemical procedure (Li et al., 2009b; Oehmichen et al., 2006). GFAP is essential 
for fibrous astrocyte functions, including maintenance of the integrity of CNS white matter 
and the blood-brain barrier (Liedtke et al., 1996), and can therefore be used to detect the 
morphological and functional alterations of astrocytes due to brain damage; the decrease of 
white matter GFAP immunopositivity indicates the disruption of astrocytes, while reactive 
astrogliosis involves an increase in the gray matter (Wang et al., 2011a; Wang et al., 2012a). 
S100β is a calcium-binding peptide and is used as a clinical parameter of glial activation 
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and/or death in a spectrum of CNS disorders (Stroick et al., 2006); S100β levels in serum and 
cerebrospinal fluid (CSF) can be used as a marker of brain damage in clinical and 
postmortem investigations (Korfias et al., 2006; Li et al., 2006a; Li et al., 2009a). Basic 
fibroblast growth factor (bFGF) is closely involved in neuronal protection and repair after 
ischemic, metabolic or traumatic brain injury, and has emerged as a central player in acute 
brain damage (Bikfalvi et al., 1997); the increase of glial bFGF positivity indicates a self-
protective response (Wang et al., 2011a; Wang et al., 2012a; Wang et al., 2012b). Thus, bFGF 
can be used to monitor the self-protective capacity of the brain after injury. 
Previous studies of neuronal apoptosis in forensic pathology have mostly focused on the 
healing process at the site of brain injury for wound timing in the forensic context 
(Hausmann et al., 2004; Tao et al., 2006); however, it is of great forensic and clinical 
importance to investigate overall brain damage to evaluate the severity of insults. 
Immunohistochemistry of neuronal apoptosis and related molecular pathology using 
biological markers, including ssDNA, bFGF, GFAP and S100β, demonstrated various type of 
brain damage due to head injury, ischemia/hypoxia or asphyxia, intoxication, burns, and 
extreme ambient temperatures (hyperthermia and hypothermia) (Wang et al., 2011a; Wang 
et al., 2012a; Wang et al., 2012b). Details are described below. 
3. Brain injury 
3.1. General considerations 
Mechanical brain injury is a major trauma in both forensic and clinical medicine and is 
caused by various insults, resulting in various types of brain damage, often accompanied by 
secondary brain dysfunction, involving brain edema, swelling and compression; these are 
subdivided into focal and diffuse brain injury (Greenfield & Ellison, 2008; Knight & Saukko, 
2004; Oehmichen et al., 2006). Classic concepts of CNS dysfunction due to mechanical brain 
injury comprise the disruption of brain structures by laceration and contusion, subarachnoid 
hemorrhage (SAH), compression by space-occupying intracranial hematoma or increased 
intracranial pressure due to edema, axonal injury, ischemic brain damage and primary acute 
brain swelling, especially in infancy. Brain compression or swelling accompanied by 
increased intracranial pressure is critical for survival in the early phase after brain injury in 
most cases. Previous studies have made great strides in investigating the morphology and 
causal mechanism of brain injury and dysfunction; forensic neuropathological case studies 
have demonstrated findings useful for establishing practical investigation procedures. 
Estimation of the age of brain injury and hematomas at the site or in the area adjacent to the 
injury has especially important criminological implications (Bratzke, 2004; Dressler et al., 
2007; Hausmann & Betz, 2001; Hausmann et al., 1999; Hausmann et al., 2000; Oehmichen et 
al., 2003; Takamiya et al., 2007); however, some patients may survive for months or years 
after severe brain injury, while it may be difficult to explain the causal relationship between 
a focal brain injury and death in some fatalities. Cerebral edema/swelling alone may be a 
distinct finding of brain injury at autopsy, with mild or even no other structural lesions, to 
explain the cause of death, involving increased intracranial pressure affecting vital centers in 
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the brainstem. Animal experiments have demonstrated the rapid onset of brain edema 
following injury (Byard et al., 2009). Considering the anatomical and metabolic species 
differences, however, it is necessary to investigate human materials. Moreover, human brain 
injury is rarely as simple as in experimental models; thus, the changes to the whole human 
brain after injury should be clarified to establish the relationship to death. Brain damage to a 
part distant from primary lesions may provide more significant information about the 
whole brain condition. In particular, the evaluation of human brain damage with regard to 
parahippocampal herniation or secondary brainstem hemorrhage of Duret as a macroscopic 
sign of brain swelling and compression is important since they are believed to be closely 
related to a fatal outcome, causing brainstem dysfunction. 
Immunohistochemical investigation of the expressions of bFGF and GFAP in glial cells as 
well as ssDNA positivity in the neurons as a sign of neuronal apoptosis at sites distant from 
the primary injury to detect survival time-dependent changes in forensic autopsy cases of 
fatal mechanical brain injury demonstrated characteristic posttraumatic glial and neuronal 
changes in regions that were not involved in the primary injury, with regard to the influence 
of brain swelling and compression (Fig. 1 and Table 1). These changes involved early glial 
changes in peracute to subacute death with survival time within 12 h and neuronal loss in 
prolonged death after 3 days, which depended on brain swelling and compression, 
irrespective of the type of primary brain injury, as follows. 
 
Figure 1. Immunohistochemistry of single-stranded DNA (ssDNA), basic fibroblast growth factor 
(bFGF) and glial fibrillary acidic protein (GFAP) in the parietal cortex of mechanical brain injury cases: 
1) early death without Duret hemorrhage (2-day survival), showing low ssDNA (a) and high bFGF (b) 
positivity with unaffected GFAP positivity (c); 2) prolonged death with Duret hemorrhage (9 days 
survival), showing high ssDNA (d), and low bFGF (e) and GFAP (f) positivity 
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and/or death in a spectrum of CNS disorders (Stroick et al., 2006); S100β levels in serum and 
cerebrospinal fluid (CSF) can be used as a marker of brain damage in clinical and 
postmortem investigations (Korfias et al., 2006; Li et al., 2006a; Li et al., 2009a). Basic 
fibroblast growth factor (bFGF) is closely involved in neuronal protection and repair after 
ischemic, metabolic or traumatic brain injury, and has emerged as a central player in acute 
brain damage (Bikfalvi et al., 1997); the increase of glial bFGF positivity indicates a self-
protective response (Wang et al., 2011a; Wang et al., 2012a; Wang et al., 2012b). Thus, bFGF 
can be used to monitor the self-protective capacity of the brain after injury. 
Previous studies of neuronal apoptosis in forensic pathology have mostly focused on the 
healing process at the site of brain injury for wound timing in the forensic context 
(Hausmann et al., 2004; Tao et al., 2006); however, it is of great forensic and clinical 
importance to investigate overall brain damage to evaluate the severity of insults. 
Immunohistochemistry of neuronal apoptosis and related molecular pathology using 
biological markers, including ssDNA, bFGF, GFAP and S100β, demonstrated various type of 
brain damage due to head injury, ischemia/hypoxia or asphyxia, intoxication, burns, and 
extreme ambient temperatures (hyperthermia and hypothermia) (Wang et al., 2011a; Wang 
et al., 2012a; Wang et al., 2012b). Details are described below. 
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3.1. General considerations 
Mechanical brain injury is a major trauma in both forensic and clinical medicine and is 
caused by various insults, resulting in various types of brain damage, often accompanied by 
secondary brain dysfunction, involving brain edema, swelling and compression; these are 
subdivided into focal and diffuse brain injury (Greenfield & Ellison, 2008; Knight & Saukko, 
2004; Oehmichen et al., 2006). Classic concepts of CNS dysfunction due to mechanical brain 
injury comprise the disruption of brain structures by laceration and contusion, subarachnoid 
hemorrhage (SAH), compression by space-occupying intracranial hematoma or increased 
intracranial pressure due to edema, axonal injury, ischemic brain damage and primary acute 
brain swelling, especially in infancy. Brain compression or swelling accompanied by 
increased intracranial pressure is critical for survival in the early phase after brain injury in 
most cases. Previous studies have made great strides in investigating the morphology and 
causal mechanism of brain injury and dysfunction; forensic neuropathological case studies 
have demonstrated findings useful for establishing practical investigation procedures. 
Estimation of the age of brain injury and hematomas at the site or in the area adjacent to the 
injury has especially important criminological implications (Bratzke, 2004; Dressler et al., 
2007; Hausmann & Betz, 2001; Hausmann et al., 1999; Hausmann et al., 2000; Oehmichen et 
al., 2003; Takamiya et al., 2007); however, some patients may survive for months or years 
after severe brain injury, while it may be difficult to explain the causal relationship between 
a focal brain injury and death in some fatalities. Cerebral edema/swelling alone may be a 
distinct finding of brain injury at autopsy, with mild or even no other structural lesions, to 
explain the cause of death, involving increased intracranial pressure affecting vital centers in 
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the brainstem. Animal experiments have demonstrated the rapid onset of brain edema 
following injury (Byard et al., 2009). Considering the anatomical and metabolic species 
differences, however, it is necessary to investigate human materials. Moreover, human brain 
injury is rarely as simple as in experimental models; thus, the changes to the whole human 
brain after injury should be clarified to establish the relationship to death. Brain damage to a 
part distant from primary lesions may provide more significant information about the 
whole brain condition. In particular, the evaluation of human brain damage with regard to 
parahippocampal herniation or secondary brainstem hemorrhage of Duret as a macroscopic 
sign of brain swelling and compression is important since they are believed to be closely 
related to a fatal outcome, causing brainstem dysfunction. 
Immunohistochemical investigation of the expressions of bFGF and GFAP in glial cells as 
well as ssDNA positivity in the neurons as a sign of neuronal apoptosis at sites distant from 
the primary injury to detect survival time-dependent changes in forensic autopsy cases of 
fatal mechanical brain injury demonstrated characteristic posttraumatic glial and neuronal 
changes in regions that were not involved in the primary injury, with regard to the influence 
of brain swelling and compression (Fig. 1 and Table 1). These changes involved early glial 
changes in peracute to subacute death with survival time within 12 h and neuronal loss in 
prolonged death after 3 days, which depended on brain swelling and compression, 
irrespective of the type of primary brain injury, as follows. 
 
Figure 1. Immunohistochemistry of single-stranded DNA (ssDNA), basic fibroblast growth factor 
(bFGF) and glial fibrillary acidic protein (GFAP) in the parietal cortex of mechanical brain injury cases: 
1) early death without Duret hemorrhage (2-day survival), showing low ssDNA (a) and high bFGF (b) 
positivity with unaffected GFAP positivity (c); 2) prolonged death with Duret hemorrhage (9 days 
survival), showing high ssDNA (d), and low bFGF (e) and GFAP (f) positivity 
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ST, survival time; SAH, subarachnoid hemorrhage; SDH, subdural hemorrhage or hematoma; ssDNA, single-stranded 
DNA, bFGF, basic fibroblast growth factor; GFAP, glial fibrillary acidic protein 
Table 1. Immunohistochemical findings of apoptosis-related biomarkers in mechanical brain injury 
with regard to the survival time 
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3.2. Diffuse brain injury 
Diffuse mechanical brain injury clinically involves primary and secondary CNS dysfunction, 
which may result in permanent disability or fatal outcome. This type of mechanical brain 
injury is morphologically associated with specific white matter injury, usually termed 
diffuse axonal injury (DAI); however, other non-specific factors, including disrupted BBB, 
ischemia and vascular injury, also contribute to posttraumatic CNS dysfunction (Oehmichen 
et al., 2006). The macropathology may present with brain swelling and hemorrhages in the 
deep part of white matter, for which histology often involves focal edema and 
demyelination, accompanied by axonal injury, along the junction of gray and white matter, 
but these findings cannot be detected in very short survival cases. In such cases of peracute 
or instantaneous death within minutes, involving severe open head injury and apparently 
fatal structural brain damage, immunohistochemistry detected decreased glial GFAP 
positivity in the parietal white matter without glial or neuronal loss; however, this finding 
was not evident in the cerebral cortex (Wang et al., 2012b). GFAP as a marker of fibrous 
astrocytes in the white matter and molecular layer of the cerebral cortex is usually not 
detectable in protoplasmatic astrocytes or neurons in the cerebral cortex by routine 
immunohistochemistry (Li et al., 2009b). An increase in GFAP immunoreactivity in the 
cerebral cortex may be detected in classic astrocytic activation or astrogliosis; however, 
GFAP immunopositivity in the cerebral cortex showed no difference among all mechanical 
brain injury and control groups, irrespective of survival times, indicating a morphologically 
intact cerebral cortex. In peracute death, however, a significant decrease of white matter 
GFAP immunopositivity indicated the immediate, diffuse disruption of brain white matter; 
such findings were not detected in the hippocampus. Similar findings were detected in 
acute and subacute deaths (survival time <12 h) due to closed head injury without 
parahippocampal hernia as a brain compression sign, irrespective of the type of brain injury. 
This glial change in the parietal white matter may represent damage to the whole brain 
white matter immediately due to mechanical brain injury, suggesting fatal CNS dysfunction 
without brain swelling (Graham et al., 1988). 
3.3. Brain swelling and compression 
Brain swelling and compression, which cause brainstem dysfunction, are critically life-
threatening events in clinical trauma care. In patients with a brain compression sign, 
accompanied by increased brain weight, glial bFGF positivity in the parietal cerebral cortex 
was increased in acute death (survival time <0.5 h), followed by an increase of glial bFGF 
positivity in the parietal white matter in subacute death (survival time of 6–8 h). Such a 
finding was not detected in the hippocampus in acute–subacute deaths. The bFGF has been 
well documented as a neuroprotective and neurotrophic factor, both in vitro and in vivo 
(Bikfalvi et al., 1997; Dietrich et al., 1996; Louis et al., 1993); thus, the increase of glial bFGF 
positivity in these cases suggests a self-protective response to maintain BBB function in the 
early phase of brain swelling after trauma (Deguchi et al., 2002), which may start in the 
cerebral cortex and spread into the white matter, despite the fatal brain compression, as 
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deep part of white matter, for which histology often involves focal edema and 
demyelination, accompanied by axonal injury, along the junction of gray and white matter, 
but these findings cannot be detected in very short survival cases. In such cases of peracute 
or instantaneous death within minutes, involving severe open head injury and apparently 
fatal structural brain damage, immunohistochemistry detected decreased glial GFAP 
positivity in the parietal white matter without glial or neuronal loss; however, this finding 
was not evident in the cerebral cortex (Wang et al., 2012b). GFAP as a marker of fibrous 
astrocytes in the white matter and molecular layer of the cerebral cortex is usually not 
detectable in protoplasmatic astrocytes or neurons in the cerebral cortex by routine 
immunohistochemistry (Li et al., 2009b). An increase in GFAP immunoreactivity in the 
cerebral cortex may be detected in classic astrocytic activation or astrogliosis; however, 
GFAP immunopositivity in the cerebral cortex showed no difference among all mechanical 
brain injury and control groups, irrespective of survival times, indicating a morphologically 
intact cerebral cortex. In peracute death, however, a significant decrease of white matter 
GFAP immunopositivity indicated the immediate, diffuse disruption of brain white matter; 
such findings were not detected in the hippocampus. Similar findings were detected in 
acute and subacute deaths (survival time <12 h) due to closed head injury without 
parahippocampal hernia as a brain compression sign, irrespective of the type of brain injury. 
This glial change in the parietal white matter may represent damage to the whole brain 
white matter immediately due to mechanical brain injury, suggesting fatal CNS dysfunction 
without brain swelling (Graham et al., 1988). 
3.3. Brain swelling and compression 
Brain swelling and compression, which cause brainstem dysfunction, are critically life-
threatening events in clinical trauma care. In patients with a brain compression sign, 
accompanied by increased brain weight, glial bFGF positivity in the parietal cerebral cortex 
was increased in acute death (survival time <0.5 h), followed by an increase of glial bFGF 
positivity in the parietal white matter in subacute death (survival time of 6–8 h). Such a 
finding was not detected in the hippocampus in acute–subacute deaths. The bFGF has been 
well documented as a neuroprotective and neurotrophic factor, both in vitro and in vivo 
(Bikfalvi et al., 1997; Dietrich et al., 1996; Louis et al., 1993); thus, the increase of glial bFGF 
positivity in these cases suggests a self-protective response to maintain BBB function in the 
early phase of brain swelling after trauma (Deguchi et al., 2002), which may start in the 
cerebral cortex and spread into the white matter, despite the fatal brain compression, as 
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suggested by parahippocampal herniation. However, in some cases of acute death with or 
without the brain compression sign, the above-mentioned findings were not detected, 
suggesting other mechanisms of acute death, including rapid cardiorespiratory failure 
induced by SAH around the brainstem (Macmillan et al., 2002). 
In early and prolonged death cases (survival time >12 h), parahippocampal hernia may not be 
identified because of brain softening (encephalomalacia) around the hippocampus, but Duret 
hemorrhage in the brainstem as a sign of advanced descending transtentorial herniation can be 
used as an indicator of fatally severe high intracranial pressure (Graham et al., 1987; Parizel et 
al., 2002). In early deaths (survival time of 12 h–3 days), cases without Duret hemorrhage, 
irrespective of craniotomy, as well as those with Duret hemorrhage without depression 
craniotomy had increased glial bFGF positivity in the parietal cortex and white matter as well 
as the hippocampus, without significant glial loss; however, GFAP positivity in parietal white 
matter began to decrease in cases with the sign of brain compression (Fig. 1) (Wang et al., 
2012b). The up-regulation of bFGF in these cases may reflect the self-protective responses of 
the brain after brain injury. Furthermore, the bFGF may be involved in the anti-apoptosis 
pathways; exogenous application of bFGF could prevent apoptosis (Ay et al., 2001; Tamatani 
et al., 1998). In these early death cases, mostly involving subdural hemorrhage/hematoma 
(SDH), high glial bFGF positivity accompanied by low neuronal ssDNA expression is 
consistent with the function of endogenous bFGF as an anti-apoptosis factor in traumatized 
brains (Wang et al., 2011a); self-protective activity in the cerebrum is maintained despite a fatal 
outcome, even in patients with Duret hemorrhage as a sign of fatal brainstem compression. In 
patients without such a brain compression sign, death may be attributed to overall brain 
damage without brain swelling, accompanied by SDH (Graham et al., 1988). 
Early deaths with Duret hemorrhage and decompressive craniectomy (survival time of 12–
60 h), often involving massive contusions, presented quite different findings, involving glial 
and neuronal losses in the parietal cortex and/or hippocampus, accompanied by decreased 
glial GFAP positivity in the parietal white matter and hippocampus, with overall low glial 
bFGF positivity and high neuronal ssDNA positivity (Fig. 1) (Wang et al., 2012b). These 
findings suggest that the brain failed to generate sufficient bFGF to prevent apoptosis as a 
consequence of serious brain damage involving uncontrollable progressive brain edema and 
swelling, which developed fatal brainstem compression and Duret hemorrhage. 
In prolonged deaths (survival time >3 days), patients without Duret hemorrhage as a brain 
compression sign, irrespective of craniotomy, had increased glial bFGF positivity in the 
parietal cortex and white matter as well as the hippocampus without glial loss; however, 
neuronal loss without a significant increase of neuronal ssDNA positivity was detected in 
the parietal cortex, showing no neuronal loss in the hippocampus. This suggests gradual 
cortical neurodegeneration after trauma despite anti-apoptotic neuroprotective activity, as 
indicated by increased glial bFGF positivity, and different mechanisms of cell death 
involved in mechanical brain injury besides apoptosis (Castejon & Arismendi, 2006; Stoica & 
Faden, 2010). The fatal complication of secondary pneumonia was more frequent in these 
cases than in deaths with Duret hemorrhage; secondary complications may play an 
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important role in patients without a brain compression sign. Prolonged deaths with Duret 
hemorrhage, however, showed advanced glial and neuronal losses in the parietal cortex and 
hippocampus, accompanied by decreased GFAP positivity in the parietal white matter and 
hippocampus, overall low glial bFGF positivity, and high neuronal ssDNA positivity in the 
parietal cortex and hippocampus, which were more evident than in the early deaths with 
Duret hemorrhage and decompressive craniectomy described above. These findings 
suggested fatal CNS dysfunction due to posttraumatic progressive deterioration of whole 
brain involving the hippocampus, lacking glial bFGF and GFAP activation for 
neuroprotection and repair, as a consequence of unimproved brain swelling. 
Of note, there were significantly different findings depending on the survival time in cases of 
brain compression, as mentioned above. Acute and subacute death cases (survival time <12 h) 
as well as early death cases without decompressive craniectomy had higher glial bFGF and 
GFAP, and lower neuronal ssDNA positivity without glial and neuronal losses, whereas glial 
and neuronal losses, accompanied by lower glial bFGF and GFAP, and higher neuronal 
ssDNA positivity, were evident in early death despite decompressive craniectomy and 
prolonged death, suggesting different pathologies and mechanisms of brain edema/swelling, 
depending on the time after brain injury (Wang et al., 2012b). In a classic concept, brain edema 
is divided into two types based on its pathogenesis (Klatzo, 1994; Unterberg et al., 2004): a) 
‘vasogenic (extracellular)’ edema due to BBB disruption, resulting in extracellular water 
accumulation, and b) ‘cytotoxic (intracellular)’ edema due to sustained intracellular water 
collection. However, brain edema after mechanical brain injury is considered to be a mixed 
form; vasogenic edema may be predominant in the acute phase, followed by prolonged 
cytotoxic edema (Barzo et al., 1997). In acute and subacute phases, the mechanical/physical 
impact on the brain may injure blood vessels with subsequent disruption of endothelial 
membranes (Hellal et al., 2004) and minor damage to astrocytes, leading to BBB opening. 
Thereafter, in longer survival cases, increased intracranial pressure may be involved with 
diffuse cytotoxic brain edema (Marmarou et al., 2000; Unterberg et al., 2004), in which glial 
swelling is a major mediator (Kimelberg, 1995). The activation of glial bFGF in acute and 
subacute death cases and decreased glial GFAP positivity in longer survival cases with brain 
swelling suggest a self-protective response to maintain BBB function in the early phase after 
mechanical brain injury and the structural damage of astrocytes caused by cytotoxic edema, 
respectively. Furthermore, astrocyte damage can in turn deteriorate the extracellular 
microenvironment (e.g. persistent increase of extracellular glutamate levels), which causes 
both glial and neuronal damage (Barbeito et al., 2004; Matute et al., 2006). 
To summarize, characteristic immunohistochemical findings were detected with regard to the 
influence of cerebral compression and survival time in mechanical brain injury (Table 1) 
(Wang et al., 2012b). Peracute deaths with severe open head injury without brain swelling 
presented with glial injury in the parietal white matter. Other fatalities without a brain 
compression sign did not show a significant loss of glial cells; however, glial injury in the 
parietal white matter was seen during a survival time of <12 h, while glial responses involving 
bFGF positivity were detected overall after 12 h–3-day survival, and delayed neuronal loss 
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suggested by parahippocampal herniation. However, in some cases of acute death with or 
without the brain compression sign, the above-mentioned findings were not detected, 
suggesting other mechanisms of acute death, including rapid cardiorespiratory failure 
induced by SAH around the brainstem (Macmillan et al., 2002). 
In early and prolonged death cases (survival time >12 h), parahippocampal hernia may not be 
identified because of brain softening (encephalomalacia) around the hippocampus, but Duret 
hemorrhage in the brainstem as a sign of advanced descending transtentorial herniation can be 
used as an indicator of fatally severe high intracranial pressure (Graham et al., 1987; Parizel et 
al., 2002). In early deaths (survival time of 12 h–3 days), cases without Duret hemorrhage, 
irrespective of craniotomy, as well as those with Duret hemorrhage without depression 
craniotomy had increased glial bFGF positivity in the parietal cortex and white matter as well 
as the hippocampus, without significant glial loss; however, GFAP positivity in parietal white 
matter began to decrease in cases with the sign of brain compression (Fig. 1) (Wang et al., 
2012b). The up-regulation of bFGF in these cases may reflect the self-protective responses of 
the brain after brain injury. Furthermore, the bFGF may be involved in the anti-apoptosis 
pathways; exogenous application of bFGF could prevent apoptosis (Ay et al., 2001; Tamatani 
et al., 1998). In these early death cases, mostly involving subdural hemorrhage/hematoma 
(SDH), high glial bFGF positivity accompanied by low neuronal ssDNA expression is 
consistent with the function of endogenous bFGF as an anti-apoptosis factor in traumatized 
brains (Wang et al., 2011a); self-protective activity in the cerebrum is maintained despite a fatal 
outcome, even in patients with Duret hemorrhage as a sign of fatal brainstem compression. In 
patients without such a brain compression sign, death may be attributed to overall brain 
damage without brain swelling, accompanied by SDH (Graham et al., 1988). 
Early deaths with Duret hemorrhage and decompressive craniectomy (survival time of 12–
60 h), often involving massive contusions, presented quite different findings, involving glial 
and neuronal losses in the parietal cortex and/or hippocampus, accompanied by decreased 
glial GFAP positivity in the parietal white matter and hippocampus, with overall low glial 
bFGF positivity and high neuronal ssDNA positivity (Fig. 1) (Wang et al., 2012b). These 
findings suggest that the brain failed to generate sufficient bFGF to prevent apoptosis as a 
consequence of serious brain damage involving uncontrollable progressive brain edema and 
swelling, which developed fatal brainstem compression and Duret hemorrhage. 
In prolonged deaths (survival time >3 days), patients without Duret hemorrhage as a brain 
compression sign, irrespective of craniotomy, had increased glial bFGF positivity in the 
parietal cortex and white matter as well as the hippocampus without glial loss; however, 
neuronal loss without a significant increase of neuronal ssDNA positivity was detected in 
the parietal cortex, showing no neuronal loss in the hippocampus. This suggests gradual 
cortical neurodegeneration after trauma despite anti-apoptotic neuroprotective activity, as 
indicated by increased glial bFGF positivity, and different mechanisms of cell death 
involved in mechanical brain injury besides apoptosis (Castejon & Arismendi, 2006; Stoica & 
Faden, 2010). The fatal complication of secondary pneumonia was more frequent in these 
cases than in deaths with Duret hemorrhage; secondary complications may play an 
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important role in patients without a brain compression sign. Prolonged deaths with Duret 
hemorrhage, however, showed advanced glial and neuronal losses in the parietal cortex and 
hippocampus, accompanied by decreased GFAP positivity in the parietal white matter and 
hippocampus, overall low glial bFGF positivity, and high neuronal ssDNA positivity in the 
parietal cortex and hippocampus, which were more evident than in the early deaths with 
Duret hemorrhage and decompressive craniectomy described above. These findings 
suggested fatal CNS dysfunction due to posttraumatic progressive deterioration of whole 
brain involving the hippocampus, lacking glial bFGF and GFAP activation for 
neuroprotection and repair, as a consequence of unimproved brain swelling. 
Of note, there were significantly different findings depending on the survival time in cases of 
brain compression, as mentioned above. Acute and subacute death cases (survival time <12 h) 
as well as early death cases without decompressive craniectomy had higher glial bFGF and 
GFAP, and lower neuronal ssDNA positivity without glial and neuronal losses, whereas glial 
and neuronal losses, accompanied by lower glial bFGF and GFAP, and higher neuronal 
ssDNA positivity, were evident in early death despite decompressive craniectomy and 
prolonged death, suggesting different pathologies and mechanisms of brain edema/swelling, 
depending on the time after brain injury (Wang et al., 2012b). In a classic concept, brain edema 
is divided into two types based on its pathogenesis (Klatzo, 1994; Unterberg et al., 2004): a) 
‘vasogenic (extracellular)’ edema due to BBB disruption, resulting in extracellular water 
accumulation, and b) ‘cytotoxic (intracellular)’ edema due to sustained intracellular water 
collection. However, brain edema after mechanical brain injury is considered to be a mixed 
form; vasogenic edema may be predominant in the acute phase, followed by prolonged 
cytotoxic edema (Barzo et al., 1997). In acute and subacute phases, the mechanical/physical 
impact on the brain may injure blood vessels with subsequent disruption of endothelial 
membranes (Hellal et al., 2004) and minor damage to astrocytes, leading to BBB opening. 
Thereafter, in longer survival cases, increased intracranial pressure may be involved with 
diffuse cytotoxic brain edema (Marmarou et al., 2000; Unterberg et al., 2004), in which glial 
swelling is a major mediator (Kimelberg, 1995). The activation of glial bFGF in acute and 
subacute death cases and decreased glial GFAP positivity in longer survival cases with brain 
swelling suggest a self-protective response to maintain BBB function in the early phase after 
mechanical brain injury and the structural damage of astrocytes caused by cytotoxic edema, 
respectively. Furthermore, astrocyte damage can in turn deteriorate the extracellular 
microenvironment (e.g. persistent increase of extracellular glutamate levels), which causes 
both glial and neuronal damage (Barbeito et al., 2004; Matute et al., 2006). 
To summarize, characteristic immunohistochemical findings were detected with regard to the 
influence of cerebral compression and survival time in mechanical brain injury (Table 1) 
(Wang et al., 2012b). Peracute deaths with severe open head injury without brain swelling 
presented with glial injury in the parietal white matter. Other fatalities without a brain 
compression sign did not show a significant loss of glial cells; however, glial injury in the 
parietal white matter was seen during a survival time of <12 h, while glial responses involving 
bFGF positivity were detected overall after 12 h–3-day survival, and delayed neuronal loss 
 
Apoptosis and Medicine 256 
without an increase of neuronal ssDNA positivity was seen after 3 days at the time of death, 
mostly due to complications. Fatalities with signs of brain swelling and compression showed 
gradual losses of glial cells and neurons with an early increase of glial bFGF positivity in the 
parietal cerebral cortex, which was followed by an increase of glial bFGF positivity in the 
parietal white matter and hippocampus, and final decreases of glial bFGF and GFAP positivity 
with increased neuronal ssDNA positivity in the parietal lobe and hippocampus, suggesting 
the involvement of neuronal apoptosis in progressive brain damage after injury. Such findings 
were detected earlier in death despite decompression craniotomy. These observations 
suggested different mechanisms of whole brain damage in the death process, depending on 
the severity of brain compression. ssDNA, bFGF and GFAP immunohistochemistry is useful to 
investigate such different death processes after brain injury with regard to the survival time. 
These findings may also contribute to wound timing when the pathology of the primary injury 
involving brain contusion and hematoma is considered. 
4. Cerebral ischemia and hypoxia/asphyxia 
4.1. General considerations 
Ischemia implies a local loss of blood supply due to arterial occlusion/disruption or 
vasoconstriction, or as part of systemic circulatory insufficiency or blood loss, resulting in 
a lack of oxygen (ischemic hypoxia), while other causes are also involved in hypoxia 
(oxygen deficiency), for which ischemic hypoxia is the simplest model (Table 2). Brain 
ischemia and hypoxia are common consequences of trauma or disease involving severe 
cardiac and peripheral vascular injury; the brain is more susceptible to ischemia/hypoxia 
than other viscera. Asphyxia in the forensic context implies systemic hypoxia associated 
with carbon dioxide retention due to a mechanical insult, causing acidosis, which 
aggravates tissue damage involving the brain; however, a lack of atmospheric oxygen 
(suffocation) is also included. Susceptibility of neurons in the brain to oxygen deficiency 
depends on the vasculature and the vulnerability of individual neurons; ischemic hypoxia 
first affects the watershed/arterial border zone of the frontal gyri, the globus pallidus, the 
Ammon horn (hippocampus), and the cerebral cortex (Oehmichen et al., 2006). These site-
dependent susceptibilities of the brain to ischemia/hypoxia present with various 
pathologies of neurons and glial cells following cardiac arrest and asphyxia, depending 
on the survival time. 
4.2. Cerebral ischemia 
It is known that transient cerebral ischemia induces neuronal apoptosis (Chan, 2004); 
however, the usual feature of global ischemia involves neuronal necrosis in the cerebral 
cortex (watershed/arterial border zone of the frontal gyri), the globus pallidus, the 
hippocampus and the celebellar Purkinje cells. Immunohistochemistry detected no evident 
changes of the brain in sudden death due to acute heart attack (simple cerebral ischemia); 
however, prolonged deaths under intensive medical care, possibly involving reperfusion, 
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showed higher parietal glial bFGF positivity and neuronal loss with low ssDNA positivity, 
indicating incomplete necrosis or selective neuronal necrosis without positive evidence of 
apoptosis (Table 3) (Wang et al., 2011a). 
 
I Hypoxia: 1. Ischemic hypoxia – diminished blood supply 
  2. Hypoxic hypoxia – reduced blood oxygenation in the lung 
  3. Others: e.g. anemic, stagnant, oxygen affinity and histotoxic hypoxia 
II Asphyxia: 1. Neck compression – hanging and ligature/manual strangulation 
  2. Smothering – obstruction of the airway orifices (nose and mouth) 
  3. Choking – foreign body in the airway 
  4. Suffocation – lack of atmospheric oxygen 
Table 2. Major causes of hypoxia and asphyxia in the forensic context 
4.3. Cerebral hypoxia – Asphyxia 
The classification of asphyxia in the forensic context is not uniform (Byard, 2011; 
Sauvageau & Boghossian, 2010). From a practical point of view, however, the causes of 
mechanical asphyxia can grossly be divided into types with and without neck 
compression; the former (strangulation) involves lethal factors including brain 
ischemia/congestion due to closure of the blood vessels and/or air passages of the neck, 
whereas the latter (choking and smothering) causes hypoxia due to obstruction of the air 
passages. In addition, neurogenic cardiac suppression may be involved in both types 
(Oehmichen et al., 2006). The diagnosis of mechanical asphyxia as a cause of death is one 
of the most difficult tasks in forensic pathology, especially in cases lacking significant 
pathological evidence, even when ‘classic signs of asphyxia’ are apparent; for example, a 
very careful examination is needed to discriminate between smothering and sudden 
cardiac attack in cases without bruises or abrasions around the nose and mouth. The 
diagnosis of choking may also be obstructed when a foreign body has been removed in 
resuscitation measures. Furthermore, it is difficult to determine whether a food bolus in 
the air passages was the cause of death or a result of agonal or postmortem spillage; 
therefore, various procedures have been developed to detect and explain the 
pathophysiology of asphyxial death (Ishida et al., 2002; Zhu et al., 2000). In prolonged 
death cases, however, it is difficult to differentiate asphyxia from heart attack. With 
respect to this, immunohistochemistry of the brain detected no specific findings in acute 
asphyxial death, compared with sudden cardiac death; however, prolonged asphyxial 
death showed lower parietal glial GFAP positivity and neuronal loss with increased 
ssDNA positivity as a sign of apoptosis following advanced brain hypoxia, which was 
usually not detected in cardiac death (Table 3) (Wang et al., 2011a). 
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without an increase of neuronal ssDNA positivity was seen after 3 days at the time of death, 
mostly due to complications. Fatalities with signs of brain swelling and compression showed 
gradual losses of glial cells and neurons with an early increase of glial bFGF positivity in the 
parietal cerebral cortex, which was followed by an increase of glial bFGF positivity in the 
parietal white matter and hippocampus, and final decreases of glial bFGF and GFAP positivity 
with increased neuronal ssDNA positivity in the parietal lobe and hippocampus, suggesting 
the involvement of neuronal apoptosis in progressive brain damage after injury. Such findings 
were detected earlier in death despite decompression craniotomy. These observations 
suggested different mechanisms of whole brain damage in the death process, depending on 
the severity of brain compression. ssDNA, bFGF and GFAP immunohistochemistry is useful to 
investigate such different death processes after brain injury with regard to the survival time. 
These findings may also contribute to wound timing when the pathology of the primary injury 
involving brain contusion and hematoma is considered. 
4. Cerebral ischemia and hypoxia/asphyxia 
4.1. General considerations 
Ischemia implies a local loss of blood supply due to arterial occlusion/disruption or 
vasoconstriction, or as part of systemic circulatory insufficiency or blood loss, resulting in 
a lack of oxygen (ischemic hypoxia), while other causes are also involved in hypoxia 
(oxygen deficiency), for which ischemic hypoxia is the simplest model (Table 2). Brain 
ischemia and hypoxia are common consequences of trauma or disease involving severe 
cardiac and peripheral vascular injury; the brain is more susceptible to ischemia/hypoxia 
than other viscera. Asphyxia in the forensic context implies systemic hypoxia associated 
with carbon dioxide retention due to a mechanical insult, causing acidosis, which 
aggravates tissue damage involving the brain; however, a lack of atmospheric oxygen 
(suffocation) is also included. Susceptibility of neurons in the brain to oxygen deficiency 
depends on the vasculature and the vulnerability of individual neurons; ischemic hypoxia 
first affects the watershed/arterial border zone of the frontal gyri, the globus pallidus, the 
Ammon horn (hippocampus), and the cerebral cortex (Oehmichen et al., 2006). These site-
dependent susceptibilities of the brain to ischemia/hypoxia present with various 
pathologies of neurons and glial cells following cardiac arrest and asphyxia, depending 
on the survival time. 
4.2. Cerebral ischemia 
It is known that transient cerebral ischemia induces neuronal apoptosis (Chan, 2004); 
however, the usual feature of global ischemia involves neuronal necrosis in the cerebral 
cortex (watershed/arterial border zone of the frontal gyri), the globus pallidus, the 
hippocampus and the celebellar Purkinje cells. Immunohistochemistry detected no evident 
changes of the brain in sudden death due to acute heart attack (simple cerebral ischemia); 
however, prolonged deaths under intensive medical care, possibly involving reperfusion, 
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showed higher parietal glial bFGF positivity and neuronal loss with low ssDNA positivity, 
indicating incomplete necrosis or selective neuronal necrosis without positive evidence of 
apoptosis (Table 3) (Wang et al., 2011a). 
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Sauvageau & Boghossian, 2010). From a practical point of view, however, the causes of 
mechanical asphyxia can grossly be divided into types with and without neck 
compression; the former (strangulation) involves lethal factors including brain 
ischemia/congestion due to closure of the blood vessels and/or air passages of the neck, 
whereas the latter (choking and smothering) causes hypoxia due to obstruction of the air 
passages. In addition, neurogenic cardiac suppression may be involved in both types 
(Oehmichen et al., 2006). The diagnosis of mechanical asphyxia as a cause of death is one 
of the most difficult tasks in forensic pathology, especially in cases lacking significant 
pathological evidence, even when ‘classic signs of asphyxia’ are apparent; for example, a 
very careful examination is needed to discriminate between smothering and sudden 
cardiac attack in cases without bruises or abrasions around the nose and mouth. The 
diagnosis of choking may also be obstructed when a foreign body has been removed in 
resuscitation measures. Furthermore, it is difficult to determine whether a food bolus in 
the air passages was the cause of death or a result of agonal or postmortem spillage; 
therefore, various procedures have been developed to detect and explain the 
pathophysiology of asphyxial death (Ishida et al., 2002; Zhu et al., 2000). In prolonged 
death cases, however, it is difficult to differentiate asphyxia from heart attack. With 
respect to this, immunohistochemistry of the brain detected no specific findings in acute 
asphyxial death, compared with sudden cardiac death; however, prolonged asphyxial 
death showed lower parietal glial GFAP positivity and neuronal loss with increased 
ssDNA positivity as a sign of apoptosis following advanced brain hypoxia, which was 
usually not detected in cardiac death (Table 3) (Wang et al., 2011a). 
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Traumatic insult Acute/subacute death Prolonged death
 
Asphyxia Poor glial and neuronal changes in
acute death 
Low parietal glial bFGF positivity 




   Burns High parietal neuronal ssDNA
Positivity 
Parietal neuronal loss and 
increased glial cells with 
increased cortical and white 
matter bFGF positivity, and higher 
cortical GFAP and lower white 
matter GFAP positivity; overall 
low neuronal ssDNA positivity 
 
   CO intoxication High parietal neuronal ssDNA
Positivity 
Parietal neuronal loss without 
glial activation; overall low glial 
bFGF and GFAP positivities; high 
neuronal ssDNA positivity 
 
CO intoxication High neuronal ssDNA positivity in
the pallidum 
 
Drug abuse High neuronal ssDNA positivity in
the cerebral cortex, pallidum and 





Increased glial bFGF positivity in
the cerebral cortex and white 
matter, and high S100β positivity 




Low glial GFAP and S100β 
positivities in the white matter, and 
high neuronal ssDNA positivity in 
the cerebral cortex and 
hippocampus, with high glial bFGF 
and S100β positivities in 
the cerebral cortex 
 
Cardiac attack Poor glial and neuronal changes in
acute death 
Increased parietal glial bFGF 
positivity and neuronal loss with 
low ssDNA positivity 
 
CO, carbon monoxide; ssDNA, single-stranded DNA, bFGF, basic fibroblast growth factor; GFAP, glial fibrillary 
acidic protein 
Table 3. Immunohistochemical findings of apoptosis-related biomarkers in non-injury traumas with 
regard to the survival time 
Immunohistochemistry of Neuronal Apoptosis in Fatal Traumas:  
The Contribution of Forensic Molecular Pathology in Medical Science 259 
5. Intoxication 
5.1. General considerations 
Numerous chemical substances are involved in accidental, suicidal and even homicidal 
intoxication; it is a very difficult task to screen and identify individual intoxication in 
forensic and clinical routine work, especially in cases where anamnesis or circumstantial 
evidence is obscure or absent, since intoxication often presents with non-specific signs and 
symptoms, or poor morphological findings. It is also important for forensic pathologists to 
discriminate other insults as the cause of death or contributory factor even when drugs or 
poisons are detected. Previous studies showed systemic deterioration in fatal intoxication, 
involving CNS, using biochemical markers (Maeda et al., 2011). Some drugs and poisons 
primarily affect the nervous system, and secondary brain damage is almost inevitable in any 
kind of intoxication; however, CO intoxication and drug abuse are most frequent in forensic 
routine work. 
5.2. Carbon monoxide 
The histo-/cytotoxicity of CO is due to its high affinity to iron-containing structures such as 
hemoglobin and myoglobin, as well as to specific sites of the brain, including the globus 
pallidus and the midbrain substantia nigra, which is different from cyanide, sulfide and azide 
(Knight & Saukko, 2004; Oehmichen et al., 2006). CO also depresses myocardial function, 
resulting in severe hypotension and subsequent global cerebral ischemia and hypoxia. 
Bilateral necrosis of the globus pallidus and the pars reticulata of the midbrain substatia nigra 
are known as non-specific alterations (Oehmichen et al., 2006); however, neuronal apoptosis in 
the pallidum has been suggested as an early change due to CO intoxication in an animal 
experiment (Piantadosi et al., 1997). With respect to this, immunohistochemistry of ssDNA 
demonstrated high positivity as a sign of apoptosis in the pallidum of the human brain in fatal 
CO intoxication (Table 3) (Michiue et al., 2008; Wang et al., 2011a). Similar findings were 
detected in acute and delayed fire fatalities having a fatal level of blood carboxyhemoglobin 
(COHb) saturation, different from those with lower COHb level, as described below. These 
findings indicate the specific neurotoxicity of CO to the pallidum. 
5.3. Drug abuse 
A variety of psychostimulants, narcotics and hallucinogens are involved in drug abuse, which 
results in brain damage and functional impairment. Among these drugs, animal experiments 
have shown that amphetamine and its derivatives, such as methamphetamine and ecstasy, 
induce apoptosis of cortical and striatal neurons, and cerebellar granular cells via various 
pathways (Cunha-Oliveira et al., 2008). Neuronal apoptosis has also been suggested with 
cocaine and opiates (Cunha-Oliveira et al., 2008). In forensic autopsy materials, 
immunohistochemistry also detected high neuronal ssDNA positivity as a sign of apoptosis in 
the cerebral cortex, pallidum and substantia nigra in fatal abuse of sedative hypnotics as well 
as methamphetamine, suggesting selective neuronal damage (Table 3) (Michiue et al., 2008). 
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Traumatic insult Acute/subacute death Prolonged death
 
Asphyxia Poor glial and neuronal changes in
acute death 
Low parietal glial bFGF positivity 




   Burns High parietal neuronal ssDNA
Positivity 
Parietal neuronal loss and 
increased glial cells with 
increased cortical and white 
matter bFGF positivity, and higher 
cortical GFAP and lower white 
matter GFAP positivity; overall 
low neuronal ssDNA positivity 
 
   CO intoxication High parietal neuronal ssDNA
Positivity 
Parietal neuronal loss without 
glial activation; overall low glial 
bFGF and GFAP positivities; high 
neuronal ssDNA positivity 
 
CO intoxication High neuronal ssDNA positivity in
the pallidum 
 
Drug abuse High neuronal ssDNA positivity in
the cerebral cortex, pallidum and 





Increased glial bFGF positivity in
the cerebral cortex and white 
matter, and high S100β positivity 




Low glial GFAP and S100β 
positivities in the white matter, and 
high neuronal ssDNA positivity in 
the cerebral cortex and 
hippocampus, with high glial bFGF 
and S100β positivities in 
the cerebral cortex 
 
Cardiac attack Poor glial and neuronal changes in
acute death 
Increased parietal glial bFGF 
positivity and neuronal loss with 
low ssDNA positivity 
 
CO, carbon monoxide; ssDNA, single-stranded DNA, bFGF, basic fibroblast growth factor; GFAP, glial fibrillary 
acidic protein 
Table 3. Immunohistochemical findings of apoptosis-related biomarkers in non-injury traumas with 
regard to the survival time 
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5. Intoxication 
5.1. General considerations 
Numerous chemical substances are involved in accidental, suicidal and even homicidal 
intoxication; it is a very difficult task to screen and identify individual intoxication in 
forensic and clinical routine work, especially in cases where anamnesis or circumstantial 
evidence is obscure or absent, since intoxication often presents with non-specific signs and 
symptoms, or poor morphological findings. It is also important for forensic pathologists to 
discriminate other insults as the cause of death or contributory factor even when drugs or 
poisons are detected. Previous studies showed systemic deterioration in fatal intoxication, 
involving CNS, using biochemical markers (Maeda et al., 2011). Some drugs and poisons 
primarily affect the nervous system, and secondary brain damage is almost inevitable in any 
kind of intoxication; however, CO intoxication and drug abuse are most frequent in forensic 
routine work. 
5.2. Carbon monoxide 
The histo-/cytotoxicity of CO is due to its high affinity to iron-containing structures such as 
hemoglobin and myoglobin, as well as to specific sites of the brain, including the globus 
pallidus and the midbrain substantia nigra, which is different from cyanide, sulfide and azide 
(Knight & Saukko, 2004; Oehmichen et al., 2006). CO also depresses myocardial function, 
resulting in severe hypotension and subsequent global cerebral ischemia and hypoxia. 
Bilateral necrosis of the globus pallidus and the pars reticulata of the midbrain substatia nigra 
are known as non-specific alterations (Oehmichen et al., 2006); however, neuronal apoptosis in 
the pallidum has been suggested as an early change due to CO intoxication in an animal 
experiment (Piantadosi et al., 1997). With respect to this, immunohistochemistry of ssDNA 
demonstrated high positivity as a sign of apoptosis in the pallidum of the human brain in fatal 
CO intoxication (Table 3) (Michiue et al., 2008; Wang et al., 2011a). Similar findings were 
detected in acute and delayed fire fatalities having a fatal level of blood carboxyhemoglobin 
(COHb) saturation, different from those with lower COHb level, as described below. These 
findings indicate the specific neurotoxicity of CO to the pallidum. 
5.3. Drug abuse 
A variety of psychostimulants, narcotics and hallucinogens are involved in drug abuse, which 
results in brain damage and functional impairment. Among these drugs, animal experiments 
have shown that amphetamine and its derivatives, such as methamphetamine and ecstasy, 
induce apoptosis of cortical and striatal neurons, and cerebellar granular cells via various 
pathways (Cunha-Oliveira et al., 2008). Neuronal apoptosis has also been suggested with 
cocaine and opiates (Cunha-Oliveira et al., 2008). In forensic autopsy materials, 
immunohistochemistry also detected high neuronal ssDNA positivity as a sign of apoptosis in 
the cerebral cortex, pallidum and substantia nigra in fatal abuse of sedative hypnotics as well 
as methamphetamine, suggesting selective neuronal damage (Table 3) (Michiue et al., 2008). 
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5.4. Others 
Very little knowledge is available with regard to the contribution of apoptosis to the 
neurotoxicity of other drugs and poisons at present; however, drug-related hyperthermia 
may induce neuronal apoptosis in a similar manner to that in heatstroke, described below. 
Various chemicals that trigger oxidative stress can induce neuronal apoptosis. Animal 
experiments showed that organophosphorus compounds caused acute necrosis of neurons 
in the brain at toxic doses, but induced apoptotic neuronal death at sublethal doses (Abou-
Donia, 2003). 
6. Fire fatality 
6.1. General considerations 
Fire fatality involves complex causes of death; major lethal factors involved in fire death are 
burns and inhalation of toxic gases, including CO and cyanide, which are produced by 
combustion, accompanied by smoke and ambient oxygen depletion (Stefanidou et al., 2008). 
Despite recent advances in clinical burn and CO intoxication care measures (Ipaktchi & 
Arbabi, 2006; Prockop & Chichkova, 2007), most fire victims are found dead, and in those 
found alive, severe burns or brain damage from CO intoxication can cause death despite 
intensive clinical care. In such cases, it is necessary to clarify the cause and process of death 
in a fire. In forensic casework, however, it may be difficult to determine the predominant 
cause of death due to fire or to exclude other causes of death, for which acute heart attack 
and asphyxiation are of particular interest, especially when clinical toxicological data are not 
available in cases of prolonged death without severe burns. In this respect, previous studies 
showed pulmonary pathology, and systemic hematological and biochemical disorders due 
to burns (Zhu et al., 2001a; Zhu et al., 2001b), while brain immunohistochemistry suggested 
specific findings of CO intoxication (Michiue et al., 2008). Thus, immunohistochemical 
markers in the brain that are involved in neuronal damage, apoptosis, degeneration and 
repair, including ssDNA, GFAP and bFGF, are useful to detect the specific neuropathology 
of CO intoxication for differentiation from fatal burns as well as other fatal insults. 
6.2. Burns 
Severe burns in a fire cause systemic disorders involving hypovolemic shock accompanied 
by hypoalbuminemia (burn shock), and hemolysis and skeletal muscle injury due to deep 
burns, followed by systemic inflammatory responses and hypoxia (Jeschke et al., 2008), 
which are usually detected by pathomorphology and biochemistry in postmortem 
investigation (Bohnert et al., 2010; Quan et al., 2009; Zhu et al., 2001b). Macro- and 
microscopic signs of vitality in fire death include soot deposits and thermal injury in the 
upper airways, but these findings may partly be sparse or even absent, especially in 
peracute deaths, making the diagnosis difficult (Bohnert et al., 2003). Recent 
immunohistochemical studies of the respiratory tract and lungs demonstrated intravital 
reactions in fatal burns (Boehm et al., 2010; Bohnert et al., 2010; Marschall et al., 2006); 
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however, the pathophysiological process leading to death is still unclear. In particular, the 
influences of toxic gases usually do not leave significant pathology that is detectable after 
death, except that bilateral pallidum necrosis is occasionally seen in CO intoxication. With 
respect to this, previous studies detected specific neuronal damage in the pallidum due to 
CO intoxication by immunohistochemistry (Michiue et al., 2008; Piantadosi et al., 1997); 
immunohistochemical markers in the brain may be used to differentiate pathological 
conditions of the neurons and glial cells due to ischemic, metabolic, toxic and traumatic 
brain injury (Chen et al., 1997; Piantadosi et al., 1997; Zhang et al., 2010). 
In acute fire fatality, immunohistochemistry demonstrated higher neuronal ssDNA 
immunopositivity in the parietal cortex than in acute cardiac and asphyxial deaths, 
suggesting the induction of neuronal apoptosis, irrespective of the blood COHb level; 
however, such findings were not seen in cases of postmortem burns (Wang et al., 2011a). 
These suggest that brain damage due to a fire is not simply caused by ischemia or hypoxia, 
but also involves cytotoxic factors, including massive thermal tissue injury and hemolysis, 
which can induce systemic oxidative stress involving the brain (Gatson et al., 2009). 
However, neuronal ssDNA immunopositivity in the pallidum was lower in cases of a low 
level of blood COHb saturation than in those with a fatal level of blood COHb saturation 
(>60%). Therefore, increased neuronal ssDNA immunopositivity in the parietal cortex and 
pallidum can be used as a vitality finding in acute fire deaths, with consideration of other 
pathological findings; these findings can be used to interpret death due to burns or CO 
intoxication in a fire. Furthermore, the topographical distribution of neuronal ssDNA 
immunopositivity in the brain may be helpful for determining the immediate cause of death 
in cases of other potentially fatal traumas or diseases, e.g. strangulation, drug abuse and 
acute cardiac attack. However, higher neuronal ssDNA immunopositivity was sporadically 
detected in other cases, suggesting the partial contribution of unspecific neuronal damage 
due to reperfusion, possibly involved with cardiopulmonary resuscitation measures (Li et 
al., 2010); this should be carefully considered when determining the cause of death, 
especially in cases where the vitality findings are sparse. 
In prolonged deaths, the macro- and microscopic signs of vitality in fire death, described 
above, may become obscure, making the pathological diagnosis quite difficult. In 
immunohistochemical study of the brain, however, there were significant differences 
between fatal burns and CO intoxication in prolonged fire deaths under critical clinical care 
(Fig. 2). Neuronal loss was seen in those with burns and CO intoxication as well as in 
patients with a fatal ischemic heart attack and prolonged asphyxial deaths, while glial cells 
were increased in burns and heart attack; the glial cell number was larger in fatality due to 
burns than in CO intoxication and asphyxiation, regardless of temporary cardiopulmonary 
arrest (CPA) after insult, suggesting glial activation. The increase in glial cells in cases of 
fatal burns was accompanied by higher glial bFGF immunopositivity in the parietal cortex 
and white matter, and higher and lower glial GFAP immunopositivity in the cortex and 
white matter, respectively, showing low neuronal ssDNA immunopositivity. The above-
mentioned findings differed from those in prolonged death due to heart attack or 
mechanical asphyxiation involving simple cerebral ischemia or hypoxia, regardless of 
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5.4. Others 
Very little knowledge is available with regard to the contribution of apoptosis to the 
neurotoxicity of other drugs and poisons at present; however, drug-related hyperthermia 
may induce neuronal apoptosis in a similar manner to that in heatstroke, described below. 
Various chemicals that trigger oxidative stress can induce neuronal apoptosis. Animal 
experiments showed that organophosphorus compounds caused acute necrosis of neurons 
in the brain at toxic doses, but induced apoptotic neuronal death at sublethal doses (Abou-
Donia, 2003). 
6. Fire fatality 
6.1. General considerations 
Fire fatality involves complex causes of death; major lethal factors involved in fire death are 
burns and inhalation of toxic gases, including CO and cyanide, which are produced by 
combustion, accompanied by smoke and ambient oxygen depletion (Stefanidou et al., 2008). 
Despite recent advances in clinical burn and CO intoxication care measures (Ipaktchi & 
Arbabi, 2006; Prockop & Chichkova, 2007), most fire victims are found dead, and in those 
found alive, severe burns or brain damage from CO intoxication can cause death despite 
intensive clinical care. In such cases, it is necessary to clarify the cause and process of death 
in a fire. In forensic casework, however, it may be difficult to determine the predominant 
cause of death due to fire or to exclude other causes of death, for which acute heart attack 
and asphyxiation are of particular interest, especially when clinical toxicological data are not 
available in cases of prolonged death without severe burns. In this respect, previous studies 
showed pulmonary pathology, and systemic hematological and biochemical disorders due 
to burns (Zhu et al., 2001a; Zhu et al., 2001b), while brain immunohistochemistry suggested 
specific findings of CO intoxication (Michiue et al., 2008). Thus, immunohistochemical 
markers in the brain that are involved in neuronal damage, apoptosis, degeneration and 
repair, including ssDNA, GFAP and bFGF, are useful to detect the specific neuropathology 
of CO intoxication for differentiation from fatal burns as well as other fatal insults. 
6.2. Burns 
Severe burns in a fire cause systemic disorders involving hypovolemic shock accompanied 
by hypoalbuminemia (burn shock), and hemolysis and skeletal muscle injury due to deep 
burns, followed by systemic inflammatory responses and hypoxia (Jeschke et al., 2008), 
which are usually detected by pathomorphology and biochemistry in postmortem 
investigation (Bohnert et al., 2010; Quan et al., 2009; Zhu et al., 2001b). Macro- and 
microscopic signs of vitality in fire death include soot deposits and thermal injury in the 
upper airways, but these findings may partly be sparse or even absent, especially in 
peracute deaths, making the diagnosis difficult (Bohnert et al., 2003). Recent 
immunohistochemical studies of the respiratory tract and lungs demonstrated intravital 
reactions in fatal burns (Boehm et al., 2010; Bohnert et al., 2010; Marschall et al., 2006); 
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however, the pathophysiological process leading to death is still unclear. In particular, the 
influences of toxic gases usually do not leave significant pathology that is detectable after 
death, except that bilateral pallidum necrosis is occasionally seen in CO intoxication. With 
respect to this, previous studies detected specific neuronal damage in the pallidum due to 
CO intoxication by immunohistochemistry (Michiue et al., 2008; Piantadosi et al., 1997); 
immunohistochemical markers in the brain may be used to differentiate pathological 
conditions of the neurons and glial cells due to ischemic, metabolic, toxic and traumatic 
brain injury (Chen et al., 1997; Piantadosi et al., 1997; Zhang et al., 2010). 
In acute fire fatality, immunohistochemistry demonstrated higher neuronal ssDNA 
immunopositivity in the parietal cortex than in acute cardiac and asphyxial deaths, 
suggesting the induction of neuronal apoptosis, irrespective of the blood COHb level; 
however, such findings were not seen in cases of postmortem burns (Wang et al., 2011a). 
These suggest that brain damage due to a fire is not simply caused by ischemia or hypoxia, 
but also involves cytotoxic factors, including massive thermal tissue injury and hemolysis, 
which can induce systemic oxidative stress involving the brain (Gatson et al., 2009). 
However, neuronal ssDNA immunopositivity in the pallidum was lower in cases of a low 
level of blood COHb saturation than in those with a fatal level of blood COHb saturation 
(>60%). Therefore, increased neuronal ssDNA immunopositivity in the parietal cortex and 
pallidum can be used as a vitality finding in acute fire deaths, with consideration of other 
pathological findings; these findings can be used to interpret death due to burns or CO 
intoxication in a fire. Furthermore, the topographical distribution of neuronal ssDNA 
immunopositivity in the brain may be helpful for determining the immediate cause of death 
in cases of other potentially fatal traumas or diseases, e.g. strangulation, drug abuse and 
acute cardiac attack. However, higher neuronal ssDNA immunopositivity was sporadically 
detected in other cases, suggesting the partial contribution of unspecific neuronal damage 
due to reperfusion, possibly involved with cardiopulmonary resuscitation measures (Li et 
al., 2010); this should be carefully considered when determining the cause of death, 
especially in cases where the vitality findings are sparse. 
In prolonged deaths, the macro- and microscopic signs of vitality in fire death, described 
above, may become obscure, making the pathological diagnosis quite difficult. In 
immunohistochemical study of the brain, however, there were significant differences 
between fatal burns and CO intoxication in prolonged fire deaths under critical clinical care 
(Fig. 2). Neuronal loss was seen in those with burns and CO intoxication as well as in 
patients with a fatal ischemic heart attack and prolonged asphyxial deaths, while glial cells 
were increased in burns and heart attack; the glial cell number was larger in fatality due to 
burns than in CO intoxication and asphyxiation, regardless of temporary cardiopulmonary 
arrest (CPA) after insult, suggesting glial activation. The increase in glial cells in cases of 
fatal burns was accompanied by higher glial bFGF immunopositivity in the parietal cortex 
and white matter, and higher and lower glial GFAP immunopositivity in the cortex and 
white matter, respectively, showing low neuronal ssDNA immunopositivity. The above-
mentioned findings differed from those in prolonged death due to heart attack or 
mechanical asphyxiation involving simple cerebral ischemia or hypoxia, regardless of 
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temporary CPA after insult. These observations suggest neuronal loss accompanied by 
active glial responses after severe burns regardless of CPA after insult. Lower glial GFAP 
immunopositivity in the white matter in prolonged deaths due to burns may be related to 
BBB damage, as discussed below. 
Both in vitro and in vivo, bFGF has been well established as a neuroprotective and 
neurotrophic factor (Dietrich et al., 1996; Louis et al., 1993). Severe trauma, including burn 
injury, can result in whole body tissue damage, for which an important early sign is 
systemic inflammatory response syndrome (SIRS), which may lead to multiple organ 
dysfunction syndrome (MODS). The early appearance of inflammatory cytokines in the 
systemic circulation has been demonstrated following thermal injury both in humans 
(Cannon et al., 1992) and animals (Kataranovski et al., 1999). Systemic inflammatory 
responses also develop in the brain (Reyes et al., 2006), which may induce, enhance or 
accompany astrogliosis (Balasingam et al., 1994). Thus, the up-regulation of bFGF and GFAP 
as well as increased numbers of glial cells in the parietal cerebral cortex in prolonged death 
due to burns may reflect self-protective responses of the brain. In acute death, such glial 
responses may not be apparent due to the shorter survival time. Furthermore, bFGF may be 
involved in anti-apoptotic pathways; the exogenous application of bFGF prevented 
apoptosis in both in vitro and in vivo studies (Ay et al., 2001; Tamatani et al., 1998). High 
cerebral cortex glial bFGF immunopositivity accompanied by low neuronal ssDNA 
expression suggests that endogenous bFGF is an anti-apoptosis factor in the brain. 
The BBB between systemic circulation and the cerebral parenchyma is composed of 
interendothelial tight junctions, basal lamina and perivascular astrocytes, and may also be 
damaged by severe burns; thus, BBB permeability can be increased, causing advanced brain 
edema (Reyes et al., 2009). Low glial GFAP immunopositivity in the white matter in 
prolonged deaths due to severe burns suggests astrocyte damage related to BBB 
dysfunction. In addition, systemic inflammatory responses followed by hyperthermia may 
also induce BBB dysfunction, which is characterized by vasogenic brain edema (Sharma, 
2006). Further investigation is needed to clarify the mechanism of BBB dysfunction in 
prolonged deaths due to severe burns. Meanwhile, high bFGF positivity in the white matter, 
which was detected in prolonged deaths due to severe burns, suggests that the self-
protective system involving bFGF is activated to maintain BBB function (Deguchi et al., 
2002); the damaged brain does not lose its self-protective capacity after severe burns. 
To summarize, typical pathologies in the brain after fatal burns are: 1) in acute deaths, 
increased neuronal ssDNA immunopositivity in the cerebral cortex, irrespective of the 
severity of the burns and CO intoxication; 2) neuronal loss in prolonged death; 3) increase in 
glial cells in prolonged death, accompanied by higher glial bFGF immunopositivity in the 
cerebral cortex and white matter, higher and lower glial GFAP immunopositivity in the 
cortex and white matter, respectively, with low neuronal ssDNA immunopositivity (Table 3) 
(Wang et al., 2011a). These findings suggest that: 1) increased neuronal ssDNA positivity, 
together with other pathological findings, can be used as a vitality finding in acute fire 
death; 2) the brain retained self-protective response capacity in fire victims who died due to 
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severe burns. However, progressive systemic deterioration after severe burns, accompanied 
by preexisting disorders or physical predispositions, can cause fatality due to respiratory 
failure, hypoxic brain damage, hypovolemic shock and secondary infection involving sepsis, 
even under critical life support care (Barber et al., 2007; Williams et al., 2009). These death 
processes should be assessed based on individual evidence. 
6.3. Toxic gases 
A spectrum of toxic or asphyxiating gases produced by combustion, including CO, cyanide 
and carbon dioxide, can contribute to death in a fire. CO has histo-/cytotoxicity due to its 
high affinity to specific sites of the brain, including the globus pallidus and the midbrain 
substantia nigra, but cyanide did not have such neurotoxicity (Oehmichen et al., 2006). In 
fire fatality with a fatal level of blood COHb saturation (>60%), immunohistochemistry 
detected higher neuronal ssDNA immunopositivity in the pallidum than in cases of a lower 
COHb level (<60%), as described above, suggesting CO-specific neuronal damage (Michiue 
et al., 2008; Tofighi et al., 2006; Wang et al., 2011a). Cyanide did not appear to contribute to 
neuronal ssDNA immunopositivity. 
In prolonged deaths, neuron and glial cell number was decreased in CO intoxication as well 
as asphyxiation, regardless of temporary CPA after insult, suggesting reduced glial 
reactivity due to CO intoxication and asphyxiation. Glial bFGF and GFAP immunopositivity 
was low at each site, but neuronal ssDNA immunopositivity was high in prolonged deaths 
due to CO intoxication (Fig. 2) (Wang et al., 2011a). These findings differed from those in 
prolonged death due to heart attack or mechanical asphyxiation involving simple cerebral 
ischemia or hypoxia regardless of temporary CPA after insult. These observations suggest 
neuronal loss and progressive apoptosis without glial responses after CO intoxication. 
When the crucial functions of glial bFGF and GFAP in the self-protective responses of the 
brain are considered, high neuronal ssDNA immunopositivity accompanied by low glial 
bFGF and GFAP expressions in prolonged deaths due to CO intoxication, as indicated 
above, suggests that the brain has failed to generate sufficient bFGF to prevent apoptosis, 
which may indicate serious damage to the brain due to CO intoxication; CO can exert direct 
damage on cells by inducing apoptosis (Tofighi et al., 2006). Low bFGF and GFAP positivity 
in the white matter in prolonged death due to CO intoxication suggests delayed effects of 
CO, characterized by bilateral, confluent lesions that reflect diffuse demyelination (Lo et al., 
2007). Such injury may also be caused by slowly progressive cytotoxic edema related to the 
direct toxic effect of CO. These findings suggest persistent and irreversible damage to the 
brain white matter due to CO intoxication. Similar findings suggesting damage to the BBB in 
the white matter were partly seen in prolonged asphyxial deaths, but were milder in 
ischemic heart attack. Such white matter damage may be responsible for delayed CNS 
deterioration due to CO intoxication and asphyxiation (Lo et al., 2007; Strackx et al., 2008). 
To summarize, typical pathologies in the brain of fire fatality with a fatal level of blood 
COHb saturation are: 1) in acute deaths, increased neuronal ssDNA immunopositivity in the 
cerebral cortex, irrespective of the severity of CO intoxication, and higher neuronal ssDNA 
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temporary CPA after insult. These observations suggest neuronal loss accompanied by 
active glial responses after severe burns regardless of CPA after insult. Lower glial GFAP 
immunopositivity in the white matter in prolonged deaths due to burns may be related to 
BBB damage, as discussed below. 
Both in vitro and in vivo, bFGF has been well established as a neuroprotective and 
neurotrophic factor (Dietrich et al., 1996; Louis et al., 1993). Severe trauma, including burn 
injury, can result in whole body tissue damage, for which an important early sign is 
systemic inflammatory response syndrome (SIRS), which may lead to multiple organ 
dysfunction syndrome (MODS). The early appearance of inflammatory cytokines in the 
systemic circulation has been demonstrated following thermal injury both in humans 
(Cannon et al., 1992) and animals (Kataranovski et al., 1999). Systemic inflammatory 
responses also develop in the brain (Reyes et al., 2006), which may induce, enhance or 
accompany astrogliosis (Balasingam et al., 1994). Thus, the up-regulation of bFGF and GFAP 
as well as increased numbers of glial cells in the parietal cerebral cortex in prolonged death 
due to burns may reflect self-protective responses of the brain. In acute death, such glial 
responses may not be apparent due to the shorter survival time. Furthermore, bFGF may be 
involved in anti-apoptotic pathways; the exogenous application of bFGF prevented 
apoptosis in both in vitro and in vivo studies (Ay et al., 2001; Tamatani et al., 1998). High 
cerebral cortex glial bFGF immunopositivity accompanied by low neuronal ssDNA 
expression suggests that endogenous bFGF is an anti-apoptosis factor in the brain. 
The BBB between systemic circulation and the cerebral parenchyma is composed of 
interendothelial tight junctions, basal lamina and perivascular astrocytes, and may also be 
damaged by severe burns; thus, BBB permeability can be increased, causing advanced brain 
edema (Reyes et al., 2009). Low glial GFAP immunopositivity in the white matter in 
prolonged deaths due to severe burns suggests astrocyte damage related to BBB 
dysfunction. In addition, systemic inflammatory responses followed by hyperthermia may 
also induce BBB dysfunction, which is characterized by vasogenic brain edema (Sharma, 
2006). Further investigation is needed to clarify the mechanism of BBB dysfunction in 
prolonged deaths due to severe burns. Meanwhile, high bFGF positivity in the white matter, 
which was detected in prolonged deaths due to severe burns, suggests that the self-
protective system involving bFGF is activated to maintain BBB function (Deguchi et al., 
2002); the damaged brain does not lose its self-protective capacity after severe burns. 
To summarize, typical pathologies in the brain after fatal burns are: 1) in acute deaths, 
increased neuronal ssDNA immunopositivity in the cerebral cortex, irrespective of the 
severity of the burns and CO intoxication; 2) neuronal loss in prolonged death; 3) increase in 
glial cells in prolonged death, accompanied by higher glial bFGF immunopositivity in the 
cerebral cortex and white matter, higher and lower glial GFAP immunopositivity in the 
cortex and white matter, respectively, with low neuronal ssDNA immunopositivity (Table 3) 
(Wang et al., 2011a). These findings suggest that: 1) increased neuronal ssDNA positivity, 
together with other pathological findings, can be used as a vitality finding in acute fire 
death; 2) the brain retained self-protective response capacity in fire victims who died due to 
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severe burns. However, progressive systemic deterioration after severe burns, accompanied 
by preexisting disorders or physical predispositions, can cause fatality due to respiratory 
failure, hypoxic brain damage, hypovolemic shock and secondary infection involving sepsis, 
even under critical life support care (Barber et al., 2007; Williams et al., 2009). These death 
processes should be assessed based on individual evidence. 
6.3. Toxic gases 
A spectrum of toxic or asphyxiating gases produced by combustion, including CO, cyanide 
and carbon dioxide, can contribute to death in a fire. CO has histo-/cytotoxicity due to its 
high affinity to specific sites of the brain, including the globus pallidus and the midbrain 
substantia nigra, but cyanide did not have such neurotoxicity (Oehmichen et al., 2006). In 
fire fatality with a fatal level of blood COHb saturation (>60%), immunohistochemistry 
detected higher neuronal ssDNA immunopositivity in the pallidum than in cases of a lower 
COHb level (<60%), as described above, suggesting CO-specific neuronal damage (Michiue 
et al., 2008; Tofighi et al., 2006; Wang et al., 2011a). Cyanide did not appear to contribute to 
neuronal ssDNA immunopositivity. 
In prolonged deaths, neuron and glial cell number was decreased in CO intoxication as well 
as asphyxiation, regardless of temporary CPA after insult, suggesting reduced glial 
reactivity due to CO intoxication and asphyxiation. Glial bFGF and GFAP immunopositivity 
was low at each site, but neuronal ssDNA immunopositivity was high in prolonged deaths 
due to CO intoxication (Fig. 2) (Wang et al., 2011a). These findings differed from those in 
prolonged death due to heart attack or mechanical asphyxiation involving simple cerebral 
ischemia or hypoxia regardless of temporary CPA after insult. These observations suggest 
neuronal loss and progressive apoptosis without glial responses after CO intoxication. 
When the crucial functions of glial bFGF and GFAP in the self-protective responses of the 
brain are considered, high neuronal ssDNA immunopositivity accompanied by low glial 
bFGF and GFAP expressions in prolonged deaths due to CO intoxication, as indicated 
above, suggests that the brain has failed to generate sufficient bFGF to prevent apoptosis, 
which may indicate serious damage to the brain due to CO intoxication; CO can exert direct 
damage on cells by inducing apoptosis (Tofighi et al., 2006). Low bFGF and GFAP positivity 
in the white matter in prolonged death due to CO intoxication suggests delayed effects of 
CO, characterized by bilateral, confluent lesions that reflect diffuse demyelination (Lo et al., 
2007). Such injury may also be caused by slowly progressive cytotoxic edema related to the 
direct toxic effect of CO. These findings suggest persistent and irreversible damage to the 
brain white matter due to CO intoxication. Similar findings suggesting damage to the BBB in 
the white matter were partly seen in prolonged asphyxial deaths, but were milder in 
ischemic heart attack. Such white matter damage may be responsible for delayed CNS 
deterioration due to CO intoxication and asphyxiation (Lo et al., 2007; Strackx et al., 2008). 
To summarize, typical pathologies in the brain of fire fatality with a fatal level of blood 
COHb saturation are: 1) in acute deaths, increased neuronal ssDNA immunopositivity in the 
cerebral cortex, irrespective of the severity of CO intoxication, and higher neuronal ssDNA 
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positivity in the pallidum due to CO intoxication; 2) neuronal loss in prolonged death; 3) 
overall low glial bFGF and GFAP immunopositivities with high neuronal ssDNA 
immunopositivity in prolonged death due to CO intoxication (Table 3) (Wang et al., 2011a). 
These findings suggest neuronal loss and progressive apoptosis without glial responses 
after CO intoxication; the brain sustained serious damage involving the loss of self-
protective capacity in CO intoxication, thus causing delayed death. 
 
Figure 2. Immunohistochemistry of single-stranded DNA (ssDNA), basic fibroblast growth factor 
(bFGF) and glial fibrillary acidic protein (GFAP) in the parietal cortex of prolonged fire death cases: 1) a 
case of fatal burns and low blood cardoxyhemoglobin (COHb) saturation (72 h survival), showing low 
ssDNA (a), and high bFGF (b) and GFAP (c) positivity; 2) a case of a fatal level of blood COHb 
saturation (48 h survival), showing high ssDNA (d), and low bFGF (e) and GFAP (f) positivity 
7. Extreme ambient temperature 
7.1. General considerations 
In forensic practice, the diagnosis of death due to extreme environmental temperatures 
involving hypothermia (cold exposure) and hyperthermia (heat stroke) is often difficult 
because of poor or nonspecific gross and microscopic findings, although hypothermia may 
present with typical pathologies, including frost erythema and hemorrhagic gastric erosions 
(Wischnewski spots) (Green et al., 2001; Nixdorf-Miller et al., 2006; Schuliar et al., 2001; 
Turk, 2010). Besides diagnosis by exclusion, histology, immunohistochemistry, biochemistry 
and molecular biology can be used for detailed investigation of functional deaths (Madea & 
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Saukko, 2010; Madea et al., 2010); previous studies have suggested that postmortem 
biochemistry, immunohistochemistry and molecular biology can detect systemic functional 
alterations in these fatalities (Fineschi et al., 2005; Ishikawa et al., 2008; Jakubeniene et al., 
2009; Maeda et al., 2011; Yoshida et al., 2011). Immunohistochemistry of the brain using 
ssDNA, bFGF, GFAP and S100 can also demonstrate functional alterations in fatalities due 
to extreme ambient temperature, involving glial responses and neuronal apoptosis (Wang et 
al., 2012a). 
7.2. Hypothermia (Cold exposure) 
When the human body cannot compensate for heat loss in an extremely cold environment, 
the body temperature decreases progressively, resulting in cerebral and cardiorespiratory 
dysfunction, and finally fatal arrhythmia and asystole. Metabolic deterioration involves 
dehydration, acidosis, azotemia and enhanced fat metabolism with ketonemia/ketouria, but 
myocardial and brain tissue damage are usually mild (Maeda et al., 2011). 
In immunohistochemcal investigation of the brain, hypothermia cases showed higher glial 
bFGF immunopositivity in the cerebral cortex and white matter, and higher S100β 
immunopositivity in the cerebral cortex with a lower CSF S100β concentration, without glial 
or neuronal loss (Fig. 3 and Table 3) (Wang et al., 2012a). The up-regulation of glial bFGF 
and S100β in the cerebral cortex suggests the self-protective responses of the brain and 
possible neurotrophic properties, respectively (Gomide & Chadi, 1999). Furthermore, since 
bFGF may be involved in the anti-apoptotic pathways (Ay et al., 2001; Tamatani et al., 1998), 
high glial bFGF immunopositivity accompanied by low neuronal ssDNA expression in 
hypothermia cases can indicate the activation of endogenous bFGF as an anti-apoptosis 
factor in the brain, which is similar to previous findings in prolonged fire fatality due to 
burns (Wang et al., 2011a). As above, the brain may retain self-protective response capacity 
without marked glial or neuronal damage in fatal hypothermia. The mechanism of death 
may mainly involve cardiac dysfunction, including ventricular fibrillation or asystole, 
resulting from myocardial ischemia, hypoxia, electrolyte abnormalities and elevated 
catecholamine levels (Turk, 2010), although there have been few postmortem investigations 
(Ishikawa et al., 2010; Wang et al., 2011b). To summarize, fatal hypothermia cases showed 
neuroprotective glial responses without marked neuronal or glial damage, which can serve 
as a condition for possible recovery and survival by means of adequate resuscitation and 
life-supporting measures. 
7.3. Hyperthermia (Heatstroke) 
A high ambient temperature in combination with predisposing factors and individual 
susceptibility ultimately impairs thermoregulation, and the body temperature rises 
precipitously; the main pathophysiology of heatstroke consists of hyperpyrexia involving 
impaired thermoregulation, accompanied by dehydration and profound systemic 
hypoxia, which is followed by further complications of pulmonary edema, renal tubular 
necrosis, adrenal hemorrhage, hepatic necrosis, myocardial necrosis, rhabdomyolysis, 
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positivity in the pallidum due to CO intoxication; 2) neuronal loss in prolonged death; 3) 
overall low glial bFGF and GFAP immunopositivities with high neuronal ssDNA 
immunopositivity in prolonged death due to CO intoxication (Table 3) (Wang et al., 2011a). 
These findings suggest neuronal loss and progressive apoptosis without glial responses 
after CO intoxication; the brain sustained serious damage involving the loss of self-
protective capacity in CO intoxication, thus causing delayed death. 
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ssDNA (a), and high bFGF (b) and GFAP (c) positivity; 2) a case of a fatal level of blood COHb 
saturation (48 h survival), showing high ssDNA (d), and low bFGF (e) and GFAP (f) positivity 
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systemic inflammatory response syndrome (SIRS), disseminated intravascular coagulation 
(DIC), and ultimately MODS. Clinical diagnosis of heatstroke and related syndromes is 
usually not difficult, considering hyperpyrexia and laboratory findings, and excluding 
other causes of hyperpyrexia; however, postmortem diagnosis is obstructed by a lack of 
specific findings. The diagnosis should be established by collecting pathological findings 
compatible with heatstroke, related to the predisposition, drug abuse, and physical abuse 
or neglect, and to differentiate other insults, in combination with toxicology and 
biochemistry (Maeda et al., 2011). Circumstantial evidence may also be considered when 
available. 
In immunohistochemcal investigation of the brain, characteristic findings in 
hyperthermia cases were lower glial GFAP and S100β immunopositivity in the white 
matter, and higher neuronal ssDNA immunopositivity in the cerebral cortex and 
hippocampus, accompanied by high glial bFGF and S100β immunopositivity in the 
cerebral cortex, without glial or neuronal loss (Fig. 3 and Table 3) (Wang et al., 2012a). 
Survival in hospital for days under a clinical diagnosis of heatstroke showed similar 
findings. Increased cortical glial bFGF and S100β may indicate self-protective responses 
of the brain, as described above for hypothermia; however, these findings were milder in 
hyperthermia than in hypothermia, involving neuronal and glial damage described 
below, and may also be related to the initiation of inflammatory processes involved in 
the systemic inflammatory response leading to MODS, in which encephalopathy 
predominates (Bouchama & Knochel, 2002). 
Hyperthermia can exert direct damage on tissue cells by inducing apoptosis (Basile et al., 
2008; Vogel et al., 1997); increased neuronal ssDNA expression can be used as evidence of 
brain dysfunction involving apoptosis as part of MODS from hyperthermia. These 
observations suggest diffuse neuronal apoptosis despite initiation of neuroprotective 
cortical astrocyte reactions in hyperthermia. Furthermore, the BBB, composed of endothelial 
tight junctions, basal lamina and perivascular astrocytes, may be damaged by hyperthermia, 
characterized by vasogenic brain edema (Sharma, 2006; Sharma & Hoopes, 2003). Low glial 
GFAP and S100β immunopositivity in the white matter in hyperthermia cases suggests that 
astrocyte damage may be involved in BBB dysfunction. In addition, low bFGF 
immunopositivity in the white matter in hyperthermia cases indicates that white matter 
loses the capacity for a compensatory response. 
These observations suggest characteristic brain responses in the death process due to an 
extreme environmental temperature; hyperthermia as well as hypothermia involved higher 
glial bFGF positivity in the cerebral cortex, indicating activation of neuroprotective 
processes. To summarize, fatal hyperthermia cases showed diffuse neuronal apoptosis 
despite the initiation of neuroprotective cortical astrocyte responses, accompanied by glial 
damage in the white matter; diffuse neuronal and glial deterioration in the brain may lead to 
a fatal outcome even under critical medical care. Further investigation is needed to clarify 
the underlying mechanisms. 
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Figure 3. Immunohistochemistry of single-stranded DNA (ssDNA), basic fibroblast growth factor 
(bFGF) and glial fibrillary acidic protein (GFAP) in the parietal cerebral cortex in fatalities due to 
extreme ambient temperatures: 1) hypothermia (cold exposure), showing low ssDNA (a) and high bFGF 
(b) positivity with unaffected GFAP positivity (c); 2) hyperthermia (heatstroke), showing high ssDNA 
(d) and bFGF (e) positivity with unaffected GFAP positivity (f) 
8. Limitations and outlook 
Different from animal experimentation, forensic and clinical materials are not homogenous 
owing to the complexity of insults and the consequent brain damage, varied susceptibility of 
subjects, and intensive clinical intervention. In addition, forensic autopsy materials partly 
include cases where the estimated survival time and/or postmortem interval depend on 
obscure circumstantial evidence. Therefore, it is difficult to elucidate the time course of 
cellular responses after individual specified insults in detail. It is important, however, to 
collect postmortem human data involving the whole brain pathology, which are not 
clinically or experimentally available. Further investigation is needed, including other 
markers involved in apoptotic pathways as well as in water homeostasis, BBB integrity and 
inflammatory responses, combined with the systematic analysis of related gene expressions. 
9. Conclusion 
A serial study of forensic autopsy cases suggested the involvement of neuronal apoptosis at 
specific sites of the brain, possibly contributing to CNS damage and dysfunction, which was 
characteristic of traumatic insults, including progressive or delayed brain damage due to 
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systemic inflammatory response syndrome (SIRS), disseminated intravascular coagulation 
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cerebral cortex, without glial or neuronal loss (Fig. 3 and Table 3) (Wang et al., 2012a). 
Survival in hospital for days under a clinical diagnosis of heatstroke showed similar 
findings. Increased cortical glial bFGF and S100β may indicate self-protective responses 
of the brain, as described above for hypothermia; however, these findings were milder in 
hyperthermia than in hypothermia, involving neuronal and glial damage described 
below, and may also be related to the initiation of inflammatory processes involved in 
the systemic inflammatory response leading to MODS, in which encephalopathy 
predominates (Bouchama & Knochel, 2002). 
Hyperthermia can exert direct damage on tissue cells by inducing apoptosis (Basile et al., 
2008; Vogel et al., 1997); increased neuronal ssDNA expression can be used as evidence of 
brain dysfunction involving apoptosis as part of MODS from hyperthermia. These 
observations suggest diffuse neuronal apoptosis despite initiation of neuroprotective 
cortical astrocyte reactions in hyperthermia. Furthermore, the BBB, composed of endothelial 
tight junctions, basal lamina and perivascular astrocytes, may be damaged by hyperthermia, 
characterized by vasogenic brain edema (Sharma, 2006; Sharma & Hoopes, 2003). Low glial 
GFAP and S100β immunopositivity in the white matter in hyperthermia cases suggests that 
astrocyte damage may be involved in BBB dysfunction. In addition, low bFGF 
immunopositivity in the white matter in hyperthermia cases indicates that white matter 
loses the capacity for a compensatory response. 
These observations suggest characteristic brain responses in the death process due to an 
extreme environmental temperature; hyperthermia as well as hypothermia involved higher 
glial bFGF positivity in the cerebral cortex, indicating activation of neuroprotective 
processes. To summarize, fatal hyperthermia cases showed diffuse neuronal apoptosis 
despite the initiation of neuroprotective cortical astrocyte responses, accompanied by glial 
damage in the white matter; diffuse neuronal and glial deterioration in the brain may lead to 
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the underlying mechanisms. 
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Different from animal experimentation, forensic and clinical materials are not homogenous 
owing to the complexity of insults and the consequent brain damage, varied susceptibility of 
subjects, and intensive clinical intervention. In addition, forensic autopsy materials partly 
include cases where the estimated survival time and/or postmortem interval depend on 
obscure circumstantial evidence. Therefore, it is difficult to elucidate the time course of 
cellular responses after individual specified insults in detail. It is important, however, to 
collect postmortem human data involving the whole brain pathology, which are not 
clinically or experimentally available. Further investigation is needed, including other 
markers involved in apoptotic pathways as well as in water homeostasis, BBB integrity and 
inflammatory responses, combined with the systematic analysis of related gene expressions. 
9. Conclusion 
A serial study of forensic autopsy cases suggested the involvement of neuronal apoptosis at 
specific sites of the brain, possibly contributing to CNS damage and dysfunction, which was 
characteristic of traumatic insults, including progressive or delayed brain damage due to 
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mechanical head injury, involving brain swelling and compression, as well as due to 
asphyxia, CO intoxication, fire fatality, and hyperthermia (heatstroke). Molecular 
pathological investigation of neuronal apoptosis and related biological responses in forensic 
materials can provide specific information in medical science for understanding the death 
process after traumatic insults. These studies will contribute not only in forensic casework 
but also to the clinical management of critically traumatized patients. 
Author details 
Qi Wang, Tomomi Michiue and Hitoshi Maeda 
Department of Legal Medicine, Osaka City University Medical School, Abeno, Osaka, Japan 
Acknowledgement 
Serial studies by the authors and coworkers were supported in part by Grants-in-Aid for 
Scientific Research from the Japan Society for the Promotion of Science and the Ministry of 
Education, Culture, Sports, Science and Technology, Japan (Grant Nos. 11670425, 12470109, 
08307006, 15390217, 15590585, 21790612 and 22590642). 
10. References 
Abou-Donia, M. B. (2003). Organophosphorus ester-induced chronic neurotoxicity. Archives 
of Environmental Health, 58(8), pp. 484-497. 
Alison, M. R. & Sarraf, C. E. (1992). Apoptosis: a gene-directed programme of cell death. 
Journal of the Royal College of Physicians of London, 26(1), pp. 25-35. 
Ay, I., Sugimori, H. & Finklestein, S. P. (2001). Intravenous basic fibroblast growth factor 
(bFGF) decreases DNA fragmentation and prevents downregulation of Bcl-2 expression 
in the ischemic brain following middle cerebral artery occlusion in rats. Brain Research. 
Molecular Brain Research, 87(1), pp. 71-80. 
Balasingam, V., Tejada-Berges, T., Wright, E., Bouckova, R. & Yong, V. W. (1994). Reactive 
astrogliosis in the neonatal mouse brain and its modulation by cytokines. Journal of 
Neuroscience, 14(2), pp. 846-856. 
Barbeito, L. H., Pehar, M., Cassina, P., Vargas, M. R., Peluffo, H., Viera, L., Estevez, A. G. & 
Beckman, J. S. (2004). A role for astrocytes in motor neuron loss in amyotrophic lateral 
sclerosis. Brain Research. Brain Research Reviews, 47(1-3), pp. 263-274. 
Barber, R. C., Aragaki, C. C., Chang, L. Y., Purdue, G. F., Hunt, J. L., Arnoldo, B. D. & 
Horton, J. W. (2007). CD14-159 C allele is associated with increased risk of mortality 
after burn injury. Shock, 27(3), pp. 232-237. 
Barzo, P., Marmarou, A., Fatouros, P., Hayasaki, K. & Corwin, F. (1997). Contribution of 
vasogenic and cellular edema to traumatic brain swelling measured by diffusion-
weighted imaging. Journal of Neurosurgery, 87(6), pp. 900-907. 
Basile, A., Biziato, D., Sherbet, G. V., Comi, P. & Cajone, F. (2008). Hyperthermia inhibits cell 
proliferation and induces apoptosis: relative signaling status of P53, S100A4, and Notch 
Immunohistochemistry of Neuronal Apoptosis in Fatal Traumas:  
The Contribution of Forensic Molecular Pathology in Medical Science 269 
in heat sensitive and resistant cell lines. Journal of Cellular Biochemistry, 103(1), pp. 212-
220. 
Becker, E. B. & Bonni, A. (2004). Cell cycle regulation of neuronal apoptosis in development 
and disease. Progress in Neurobiology, 72(1), pp. 1-25. 
Bikfalvi, A., Klein, S., Pintucci, G. & Rifkin, D. B. (1997). Biological roles of fibroblast growth 
factor-2. Endocrine Reviews, 18(1), pp. 26-45. 
Boehm, J., Fischer, K. & Bohnert, M. (2010). Putative role of TNF-alpha, interleukin-8 and 
ICAM-1 as indicators of an early inflammatory reaction after burn: a morphological and 
immunohistochemical study of lung tissue of fire victims. Journal of Clinical Pathology, 
63(11), pp. 967-971. 
Bohnert, M., Werner, C. R. & Pollak, S. (2003). Problems associated with the diagnosis of 
vitality in burned bodies. Forensic Science International, 135(3), pp. 197-205. 
Bohnert, M., Anderson, J., Rothschild, M. A. & Bohm, J. (2010). Immunohistochemical 
expression of fibronectin in the lungs of fire victims proves intravital reaction in fatal 
burns. International Journal of Legal Medicine, 124(6), pp. 583-588. 
Bouchama, A. & Knochel, J. P. (2002). Heat stroke. New England Journal of Medicine, 346(25), 
pp. 1978-1988. 
Bratzke, H. (2004). Research in forensic neurotraumatology. Forensic Science International, 
144(2-3), pp. 157-165. 
Byard, R. W., Bhatia, K. D., Reilly, P. L. & Vink, R. (2009). How rapidly does cerebral 
swelling follow trauma? Observations using an animal model and possible implications 
in infancy. Legal Medicine (Tokyo), 11 Suppl 1, pp. S128-131. 
Byard, R. W. (2011). Commentary on: Sauvageau A, Boghossian E. Classification of 
asphyxia: the need for standardization. Journal of Forensic Sciences, 56(1), pp. 264. 
Cadet, J. L. & Krasnova, I. N. (2009). Molecular bases of methamphetamine-induced 
neurodegeneration. International Review of Neurobiology, 88, pp. 101-119. 
Cannon, J. G., Friedberg, J. S., Gelfand, J. A., Tompkins, R. G., Burke, J. F. & Dinarello, C. A. 
(1992). Circulating interleukin-1 beta and tumor necrosis factor-alpha concentrations 
after burn injury in humans. Critical Care Medicine, 20(10), pp. 1414-1419. 
Castejon, O. J. & Arismendi, G. J. (2006). Nerve cell death types in the edematous human 
cerebral cortex. Journal of Submicroscopic Cytology and Pathology, 38(1), pp. 21-36. 
Chan, P. H. (2004). Mitochondria and neuronal death/survival signaling pathways in 
cerebral ischemia. Neurochemical Research, 29(11), pp. 1943-1949. 
Chen, J., Jin, K., Chen, M., Pei, W., Kawaguchi, K., Greenberg, D. A. & Simon, R. P. (1997). 
Early detection of DNA strand breaks in the brain after transient focal ischemia: 
implications for the role of DNA damage in apoptosis and neuronal cell death. Journal of 
Neurochemistry, 69(1), pp. 232-245. 
Clark, R. S. B., Chen, M., Kochanek, P. M., Watkins, S. C., Jin, K. L., Draviam, R., Nathaniel, 
P. D., Pinto, R., Marion, D. W. & Graham, S. H. (2001). Detection of single- and double-
strand DNA breaks after traumatic brain injury in rats: comparison of in situ labeling 
techniques using DNA polymerase I, the Klenow fragment of DNA polymerase I, and 
terminal deoxynucleotidyl transferase. Journal of Neurotrauma, 18(7), pp. 675-689. 
 
Apoptosis and Medicine 268 
mechanical head injury, involving brain swelling and compression, as well as due to 
asphyxia, CO intoxication, fire fatality, and hyperthermia (heatstroke). Molecular 
pathological investigation of neuronal apoptosis and related biological responses in forensic 
materials can provide specific information in medical science for understanding the death 
process after traumatic insults. These studies will contribute not only in forensic casework 
but also to the clinical management of critically traumatized patients. 
Author details 
Qi Wang, Tomomi Michiue and Hitoshi Maeda 
Department of Legal Medicine, Osaka City University Medical School, Abeno, Osaka, Japan 
Acknowledgement 
Serial studies by the authors and coworkers were supported in part by Grants-in-Aid for 
Scientific Research from the Japan Society for the Promotion of Science and the Ministry of 
Education, Culture, Sports, Science and Technology, Japan (Grant Nos. 11670425, 12470109, 
08307006, 15390217, 15590585, 21790612 and 22590642). 
10. References 
Abou-Donia, M. B. (2003). Organophosphorus ester-induced chronic neurotoxicity. Archives 
of Environmental Health, 58(8), pp. 484-497. 
Alison, M. R. & Sarraf, C. E. (1992). Apoptosis: a gene-directed programme of cell death. 
Journal of the Royal College of Physicians of London, 26(1), pp. 25-35. 
Ay, I., Sugimori, H. & Finklestein, S. P. (2001). Intravenous basic fibroblast growth factor 
(bFGF) decreases DNA fragmentation and prevents downregulation of Bcl-2 expression 
in the ischemic brain following middle cerebral artery occlusion in rats. Brain Research. 
Molecular Brain Research, 87(1), pp. 71-80. 
Balasingam, V., Tejada-Berges, T., Wright, E., Bouckova, R. & Yong, V. W. (1994). Reactive 
astrogliosis in the neonatal mouse brain and its modulation by cytokines. Journal of 
Neuroscience, 14(2), pp. 846-856. 
Barbeito, L. H., Pehar, M., Cassina, P., Vargas, M. R., Peluffo, H., Viera, L., Estevez, A. G. & 
Beckman, J. S. (2004). A role for astrocytes in motor neuron loss in amyotrophic lateral 
sclerosis. Brain Research. Brain Research Reviews, 47(1-3), pp. 263-274. 
Barber, R. C., Aragaki, C. C., Chang, L. Y., Purdue, G. F., Hunt, J. L., Arnoldo, B. D. & 
Horton, J. W. (2007). CD14-159 C allele is associated with increased risk of mortality 
after burn injury. Shock, 27(3), pp. 232-237. 
Barzo, P., Marmarou, A., Fatouros, P., Hayasaki, K. & Corwin, F. (1997). Contribution of 
vasogenic and cellular edema to traumatic brain swelling measured by diffusion-
weighted imaging. Journal of Neurosurgery, 87(6), pp. 900-907. 
Basile, A., Biziato, D., Sherbet, G. V., Comi, P. & Cajone, F. (2008). Hyperthermia inhibits cell 
proliferation and induces apoptosis: relative signaling status of P53, S100A4, and Notch 
Immunohistochemistry of Neuronal Apoptosis in Fatal Traumas:  
The Contribution of Forensic Molecular Pathology in Medical Science 269 
in heat sensitive and resistant cell lines. Journal of Cellular Biochemistry, 103(1), pp. 212-
220. 
Becker, E. B. & Bonni, A. (2004). Cell cycle regulation of neuronal apoptosis in development 
and disease. Progress in Neurobiology, 72(1), pp. 1-25. 
Bikfalvi, A., Klein, S., Pintucci, G. & Rifkin, D. B. (1997). Biological roles of fibroblast growth 
factor-2. Endocrine Reviews, 18(1), pp. 26-45. 
Boehm, J., Fischer, K. & Bohnert, M. (2010). Putative role of TNF-alpha, interleukin-8 and 
ICAM-1 as indicators of an early inflammatory reaction after burn: a morphological and 
immunohistochemical study of lung tissue of fire victims. Journal of Clinical Pathology, 
63(11), pp. 967-971. 
Bohnert, M., Werner, C. R. & Pollak, S. (2003). Problems associated with the diagnosis of 
vitality in burned bodies. Forensic Science International, 135(3), pp. 197-205. 
Bohnert, M., Anderson, J., Rothschild, M. A. & Bohm, J. (2010). Immunohistochemical 
expression of fibronectin in the lungs of fire victims proves intravital reaction in fatal 
burns. International Journal of Legal Medicine, 124(6), pp. 583-588. 
Bouchama, A. & Knochel, J. P. (2002). Heat stroke. New England Journal of Medicine, 346(25), 
pp. 1978-1988. 
Bratzke, H. (2004). Research in forensic neurotraumatology. Forensic Science International, 
144(2-3), pp. 157-165. 
Byard, R. W., Bhatia, K. D., Reilly, P. L. & Vink, R. (2009). How rapidly does cerebral 
swelling follow trauma? Observations using an animal model and possible implications 
in infancy. Legal Medicine (Tokyo), 11 Suppl 1, pp. S128-131. 
Byard, R. W. (2011). Commentary on: Sauvageau A, Boghossian E. Classification of 
asphyxia: the need for standardization. Journal of Forensic Sciences, 56(1), pp. 264. 
Cadet, J. L. & Krasnova, I. N. (2009). Molecular bases of methamphetamine-induced 
neurodegeneration. International Review of Neurobiology, 88, pp. 101-119. 
Cannon, J. G., Friedberg, J. S., Gelfand, J. A., Tompkins, R. G., Burke, J. F. & Dinarello, C. A. 
(1992). Circulating interleukin-1 beta and tumor necrosis factor-alpha concentrations 
after burn injury in humans. Critical Care Medicine, 20(10), pp. 1414-1419. 
Castejon, O. J. & Arismendi, G. J. (2006). Nerve cell death types in the edematous human 
cerebral cortex. Journal of Submicroscopic Cytology and Pathology, 38(1), pp. 21-36. 
Chan, P. H. (2004). Mitochondria and neuronal death/survival signaling pathways in 
cerebral ischemia. Neurochemical Research, 29(11), pp. 1943-1949. 
Chen, J., Jin, K., Chen, M., Pei, W., Kawaguchi, K., Greenberg, D. A. & Simon, R. P. (1997). 
Early detection of DNA strand breaks in the brain after transient focal ischemia: 
implications for the role of DNA damage in apoptosis and neuronal cell death. Journal of 
Neurochemistry, 69(1), pp. 232-245. 
Clark, R. S. B., Chen, M., Kochanek, P. M., Watkins, S. C., Jin, K. L., Draviam, R., Nathaniel, 
P. D., Pinto, R., Marion, D. W. & Graham, S. H. (2001). Detection of single- and double-
strand DNA breaks after traumatic brain injury in rats: comparison of in situ labeling 
techniques using DNA polymerase I, the Klenow fragment of DNA polymerase I, and 
terminal deoxynucleotidyl transferase. Journal of Neurotrauma, 18(7), pp. 675-689. 
 
Apoptosis and Medicine 270 
Cunha-Oliveira, T., Rego, A. C. & Oliveira, C. R. (2008). Cellular and molecular mechanisms 
involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Research 
Reviews, 58(1), pp. 192-208. 
Deguchi, Y., Okutsu, H., Okura, T., Yamada, S., Kimura, R., Yuge, T., Furukawa, A., 
Morimoto, K., Tachikawa, M., Ohtsuki, S., Hosoya, K. & Terasaki, T. (2002). 
Internalization of basic fibroblast growth factor at the mouse blood-brain barrier 
involves perlecan, a heparan sulfate proteoglycan. Journal of Neurochemistry, 83(2), pp. 
381-389. 
Dietrich, W. D., Alonso, O., Busto, R. & Finklestein, S. P. (1996). Posttreatment with 
intravenous basic fibroblast growth factor reduces histopathological damage following 
fluid-percussion brain injury in rats. Journal of Neurotrauma, 13(6), pp. 309-316. 
Dressler, J., Hanisch, U., Kuhlisch, E. & Geiger, K. D. (2007). Neuronal and glial apoptosis in 
human traumatic brain injury. International Journal of Legal Medicine, 121(5), pp. 365-375. 
Fawthrop, D. J., Boobis, A. R. & Davies, D. S. (1991). Mechanisms of cell death. Archives of 
Toxicology, 65(6), pp. 437-444. 
Fineschi, V., D'Errico, S., Neri, M., Panarese, F., Ricci, P. A. & Turillazzi, E. (2005). Heat 
stroke in an incubator: an immunohistochemical study in a fatal case. International 
Journal of Legal Medicine, 119(2), pp. 94-97. 
Frankfurt, O. S., Robb, J. A., Sugarbaker, E. V. & Villa, L. (1996). Monoclonal antibody to 
single-stranded DNA is a specific and sensitive cellular marker of apoptosis. 
Experimental Cell Research, 226(2), pp. 387-397. 
Gatson, J. W., Maass, D. L., Simpkins, J. W., Idris, A. H., Minei, J. P. & Wigginton, J. G. 
(2009). Estrogen treatment following severe burn injury reduces brain inflammation 
and apoptotic signaling. Journal of Neuroinflammation, 22(6), pp. 30. 
Gavrieli, Y., Sherman, Y. & Ben-Sasson, S. A. (1992). Identification of programmed cell death 
in situ via specific labeling of nuclear DNA fragmentation. Journal of Cell Biology, 119(3), 
pp. 493-501. 
Gomide, V. C. & Chadi, G. (1999). The trophic factors S-100beta and basic fibroblast growth 
factor are increased in the forebrain reactive astrocytes of adult callosotomized rat. 
Brain Research, 835(2), pp. 162-174. 
Gong, C., Boulis, N., Qian, J., Turner, D. E., Hoff, J. T. & Keep, R. F. (2001). Intracerebral 
hemorrhage-induced neuronal death. Neurosurgery, 48(4), pp. 875-883. 
Graham, D. I., Lawrence, A. E., Adams, J. H., Doyle, D. & McLellan, D. R. (1987). Brain 
damage in non-missile head injury secondary to high intracranial pressure. 
Neuropathology and Applied Neurobiology, 13(3), pp. 209-217. 
Graham, D. I., Lawrence, A. E., Adams, J. H., Doyle, D. & McLellan, D. R. (1988). Brain 
damage in fatal non-missile head injury without high intracranial pressure. Journal of 
Clinical Pathology, 41(1), pp. 34-37. 
Green, H., Gilbert, J., James, R. & Byard, R. W. (2001). An analysis of factors contributing to a 
series of deaths caused by exposure to high environmental temperatures. American 
Journal of Forensic Medicine and Pathology, 22(2), pp. 196-199. 
Greenfield, J. G. & Ellison, D. (2008). Greenfield's neuropathology. Hodder Arnold. 
Immunohistochemistry of Neuronal Apoptosis in Fatal Traumas:  
The Contribution of Forensic Molecular Pathology in Medical Science 271 
Hausmann, R., Kaiser, A., Lang, C., Bohnert, M. & Betz, P. (1999). A quantitative 
immunohistochemical study on the time-dependent course of acute inflammatory 
cellular response to human brain injury. International Journal of Legal Medicine, 112(4), 
pp. 227-232. 
Hausmann, R., Riess, R., Fieguth, A. & Betz, P. (2000). Immunohistochemical investigations 
on the course of astroglial GFAP expression following human brain injury. International 
Journal of Legal Medicine, 113(2), pp. 70-75. 
Hausmann, R. & Betz, P. (2001). Course of glial immunoreactivity for vimentin, tenascin and 
alpha1-antichymotrypsin after traumatic injury to human brain. International Journal of 
Legal Medicine, 114(6), pp. 338-342. 
Hausmann, R., Biermann, T., Wiest, I., Tubel, J. & Betz, P. (2004). Neuronal apoptosis 
following human brain injury. International Journal of Legal Medicine, 118(1), pp. 32-36. 
Hellal, F., Bonnefont-Rousselot, D., Croci, N., Palmier, B., Plotkine, M. & Marchand-
Verrecchia, C. (2004). Pattern of cerebral edema and hemorrhage in a mice model of 
diffuse brain injury. Neuroscience Letters, 357(1), pp. 21-24. 
Ipaktchi, K. & Arbabi, S. (2006). Advances in burn critical care. Critical Care Medicine, 34(9 
Suppl), pp. S239-244. 
Ishida, K., Zhu, B. L. & Maeda, H. (2002). A quantitative RT-PCR assay of surfactant-
associated protein A1 and A2 mRNA transcripts as a diagnostic tool for acute asphyxial 
death. Legal Medicine (Tokyo), 4(1), pp. 7-12. 
Ishikawa, T., Quan, L., Li, D. R., Zhao, D., Michiue, T., Hamel, M. & Maeda, H. (2008). 
Postmortem biochemistry and immunohistochemistry of adrenocorticotropic hormone 
with special regard to fatal hypothermia. Forensic Science International, 179(2-3), pp. 147-
151. 
Ishikawa, T., Yoshida, C., Michiue, T., Perdekamp, M. G., Pollak, S. & Maeda, H. (2010). 
Immunohistochemistry of catecholamines in the hypothalamic-pituitary-adrenal system 
with special regard to fatal hypothermia and hyperthermia. Legal Medicine (Tokyo), 
12(3), pp. 121-127. 
Jakubeniene, M., Irnius, A., Chaker, G. A., Paliulis, J. M. & Bechelis, A. (2009). Post-mortem 
investigation of calcium content in liver, heart, and skeletal muscle in accidental 
hypothermia cases. Forensic Science International, 190(1-3), pp. 87-90. 
Jeschke, M. G., Chinkes, D. L., Finnerty, C. C., Kulp, G., Suman, O. E., Norbury, W. B., 
Branski, L. K., Gauglitz, G. G., Mlcak, R. P. & Herndon, D. N. (2008). Pathophysiologic 
response to severe burn injury. Annals of Surgery, 248(3), pp. 387-401. 
Kataranovski, M., Magic, Z. & Pejnovic, N. (1999). Early inflammatory cytokine and acute 
phase protein response under the stress of thermal injury in rats. Physiological Research, 
48(6), pp. 473-482. 
Kimelberg, H. K. (1995). Current concepts of brain edema. Review of laboratory 
investigations. Journal of Neurosurgery, 83(6), pp. 1051-1059. 
Klatzo, I. (1994). Evolution of brain edema concepts. Acta Neurochirurgica. Supplementum, 60, 
pp. 3-6. 
Knight, B. & Saukko, P. J. (2004). Knight's Forensic pathology (3rd ed.). Arnold. 
 
Apoptosis and Medicine 270 
Cunha-Oliveira, T., Rego, A. C. & Oliveira, C. R. (2008). Cellular and molecular mechanisms 
involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Research 
Reviews, 58(1), pp. 192-208. 
Deguchi, Y., Okutsu, H., Okura, T., Yamada, S., Kimura, R., Yuge, T., Furukawa, A., 
Morimoto, K., Tachikawa, M., Ohtsuki, S., Hosoya, K. & Terasaki, T. (2002). 
Internalization of basic fibroblast growth factor at the mouse blood-brain barrier 
involves perlecan, a heparan sulfate proteoglycan. Journal of Neurochemistry, 83(2), pp. 
381-389. 
Dietrich, W. D., Alonso, O., Busto, R. & Finklestein, S. P. (1996). Posttreatment with 
intravenous basic fibroblast growth factor reduces histopathological damage following 
fluid-percussion brain injury in rats. Journal of Neurotrauma, 13(6), pp. 309-316. 
Dressler, J., Hanisch, U., Kuhlisch, E. & Geiger, K. D. (2007). Neuronal and glial apoptosis in 
human traumatic brain injury. International Journal of Legal Medicine, 121(5), pp. 365-375. 
Fawthrop, D. J., Boobis, A. R. & Davies, D. S. (1991). Mechanisms of cell death. Archives of 
Toxicology, 65(6), pp. 437-444. 
Fineschi, V., D'Errico, S., Neri, M., Panarese, F., Ricci, P. A. & Turillazzi, E. (2005). Heat 
stroke in an incubator: an immunohistochemical study in a fatal case. International 
Journal of Legal Medicine, 119(2), pp. 94-97. 
Frankfurt, O. S., Robb, J. A., Sugarbaker, E. V. & Villa, L. (1996). Monoclonal antibody to 
single-stranded DNA is a specific and sensitive cellular marker of apoptosis. 
Experimental Cell Research, 226(2), pp. 387-397. 
Gatson, J. W., Maass, D. L., Simpkins, J. W., Idris, A. H., Minei, J. P. & Wigginton, J. G. 
(2009). Estrogen treatment following severe burn injury reduces brain inflammation 
and apoptotic signaling. Journal of Neuroinflammation, 22(6), pp. 30. 
Gavrieli, Y., Sherman, Y. & Ben-Sasson, S. A. (1992). Identification of programmed cell death 
in situ via specific labeling of nuclear DNA fragmentation. Journal of Cell Biology, 119(3), 
pp. 493-501. 
Gomide, V. C. & Chadi, G. (1999). The trophic factors S-100beta and basic fibroblast growth 
factor are increased in the forebrain reactive astrocytes of adult callosotomized rat. 
Brain Research, 835(2), pp. 162-174. 
Gong, C., Boulis, N., Qian, J., Turner, D. E., Hoff, J. T. & Keep, R. F. (2001). Intracerebral 
hemorrhage-induced neuronal death. Neurosurgery, 48(4), pp. 875-883. 
Graham, D. I., Lawrence, A. E., Adams, J. H., Doyle, D. & McLellan, D. R. (1987). Brain 
damage in non-missile head injury secondary to high intracranial pressure. 
Neuropathology and Applied Neurobiology, 13(3), pp. 209-217. 
Graham, D. I., Lawrence, A. E., Adams, J. H., Doyle, D. & McLellan, D. R. (1988). Brain 
damage in fatal non-missile head injury without high intracranial pressure. Journal of 
Clinical Pathology, 41(1), pp. 34-37. 
Green, H., Gilbert, J., James, R. & Byard, R. W. (2001). An analysis of factors contributing to a 
series of deaths caused by exposure to high environmental temperatures. American 
Journal of Forensic Medicine and Pathology, 22(2), pp. 196-199. 
Greenfield, J. G. & Ellison, D. (2008). Greenfield's neuropathology. Hodder Arnold. 
Immunohistochemistry of Neuronal Apoptosis in Fatal Traumas:  
The Contribution of Forensic Molecular Pathology in Medical Science 271 
Hausmann, R., Kaiser, A., Lang, C., Bohnert, M. & Betz, P. (1999). A quantitative 
immunohistochemical study on the time-dependent course of acute inflammatory 
cellular response to human brain injury. International Journal of Legal Medicine, 112(4), 
pp. 227-232. 
Hausmann, R., Riess, R., Fieguth, A. & Betz, P. (2000). Immunohistochemical investigations 
on the course of astroglial GFAP expression following human brain injury. International 
Journal of Legal Medicine, 113(2), pp. 70-75. 
Hausmann, R. & Betz, P. (2001). Course of glial immunoreactivity for vimentin, tenascin and 
alpha1-antichymotrypsin after traumatic injury to human brain. International Journal of 
Legal Medicine, 114(6), pp. 338-342. 
Hausmann, R., Biermann, T., Wiest, I., Tubel, J. & Betz, P. (2004). Neuronal apoptosis 
following human brain injury. International Journal of Legal Medicine, 118(1), pp. 32-36. 
Hellal, F., Bonnefont-Rousselot, D., Croci, N., Palmier, B., Plotkine, M. & Marchand-
Verrecchia, C. (2004). Pattern of cerebral edema and hemorrhage in a mice model of 
diffuse brain injury. Neuroscience Letters, 357(1), pp. 21-24. 
Ipaktchi, K. & Arbabi, S. (2006). Advances in burn critical care. Critical Care Medicine, 34(9 
Suppl), pp. S239-244. 
Ishida, K., Zhu, B. L. & Maeda, H. (2002). A quantitative RT-PCR assay of surfactant-
associated protein A1 and A2 mRNA transcripts as a diagnostic tool for acute asphyxial 
death. Legal Medicine (Tokyo), 4(1), pp. 7-12. 
Ishikawa, T., Quan, L., Li, D. R., Zhao, D., Michiue, T., Hamel, M. & Maeda, H. (2008). 
Postmortem biochemistry and immunohistochemistry of adrenocorticotropic hormone 
with special regard to fatal hypothermia. Forensic Science International, 179(2-3), pp. 147-
151. 
Ishikawa, T., Yoshida, C., Michiue, T., Perdekamp, M. G., Pollak, S. & Maeda, H. (2010). 
Immunohistochemistry of catecholamines in the hypothalamic-pituitary-adrenal system 
with special regard to fatal hypothermia and hyperthermia. Legal Medicine (Tokyo), 
12(3), pp. 121-127. 
Jakubeniene, M., Irnius, A., Chaker, G. A., Paliulis, J. M. & Bechelis, A. (2009). Post-mortem 
investigation of calcium content in liver, heart, and skeletal muscle in accidental 
hypothermia cases. Forensic Science International, 190(1-3), pp. 87-90. 
Jeschke, M. G., Chinkes, D. L., Finnerty, C. C., Kulp, G., Suman, O. E., Norbury, W. B., 
Branski, L. K., Gauglitz, G. G., Mlcak, R. P. & Herndon, D. N. (2008). Pathophysiologic 
response to severe burn injury. Annals of Surgery, 248(3), pp. 387-401. 
Kataranovski, M., Magic, Z. & Pejnovic, N. (1999). Early inflammatory cytokine and acute 
phase protein response under the stress of thermal injury in rats. Physiological Research, 
48(6), pp. 473-482. 
Kimelberg, H. K. (1995). Current concepts of brain edema. Review of laboratory 
investigations. Journal of Neurosurgery, 83(6), pp. 1051-1059. 
Klatzo, I. (1994). Evolution of brain edema concepts. Acta Neurochirurgica. Supplementum, 60, 
pp. 3-6. 
Knight, B. & Saukko, P. J. (2004). Knight's Forensic pathology (3rd ed.). Arnold. 
 
Apoptosis and Medicine 272 
Korfias, S., Stranjalis, G., Papadimitriou, A., Psachoulia, C., Daskalakis, G., Antsaklis, A. & 
Sakas, D. E. (2006). Serum S-100B protein as a biochemical marker of brain injury: a 
review of current concepts. Current Medicinal Chemistry, 13(30), pp. 3719-3731. 
Li, D. R., Zhu, B. L., Ishikawa, T., Zhao, D., Michiue, T. & Maeda, H. (2006a). Postmortem 
serum protein S100B levels with regard to the cause of death involving brain damage in 
medicolegal autopsy cases. Legal Medicine (Tokyo), 8(2), pp. 71-77. 
Li, D. R., Zhu, B. L., Ishikawa, T., Zhao, D., Michiue, T. & Maeda, H. (2006b). 
Immunohistochemical distribution of S-100 protein in the cerebral cortex with regard to 
the cause of death in forensic autopsy. Legal Medicine (Tokyo), 8(2), pp. 78-85. 
Li, D. R., Michiue, T., Zhu, B. L., Ishikawa, T., Quan, L., Zhao, D., Yoshida, C., Chen, J. H., 
Wang, Q., Komatsu, A., Azuma, Y. & Maeda, H. (2009a). Evaluation of postmortem 
S100B levels in the cerebrospinal fluid with regard to the cause of death in medicolegal 
autopsy. Legal Medicine (Tokyo), 11 Suppl 1, pp. S273-275. 
Li, D. R., Ishikawa, T., Zhao, D., Michiue, T., Quan, L., Zhu, B. L. & Maeda, H. (2009b). 
Histopathological changes of the hippocampus neurons in brain injury. Histology and 
Histopathology, 24(9), pp. 1113-1120. 
Li, J., Han, B., Ma, X. & Qi, S. (2010). The effects of propofol on hippocampal caspase-3 and 
Bcl-2 expression following forebrain ischemia-reperfusion in rats. Brain Research, 1356, 
pp. 11-23. 
Liedtke, W., Edelmann, W., Bieri, P. L., Chiu, F. C., Cowan, N. J., Kucherlapati, R. & Raine, 
C. S. (1996). GFAP is necessary for the integrity of CNS white matter architecture and 
long-term maintenance of myelination. Neuron, 17(4), pp. 607-615. 
Lo, C. P., Chen, S. Y., Lee, K. W., Chen, W. L., Chen, C. Y., Hsueh, C. J. & Huang, G. S. 
(2007). Brain injury after acute carbon monoxide poisoning: early and late 
complications. American Journal of Roentgenology, 189(4), pp. W205-211. 
Louis, J. C., Magal, E., Gerdes, W. & Seifert, W. (1993). Survival-promoting and protein 
kinase C-regulating roles of basic FGF for hippocampal neurons exposed to phorbol 
ester, glutamate and ischaemia-like conditions. European Journal of Neuroscience, 5(12), 
pp. 1610-1621. 
Love, S. (1999). Oxidative stress in brain ischemia. Brain Pathology, 9(1), pp. 119-131. 
Macmillan, C. S., Grant, I. S. & Andrews, P. J. (2002). Pulmonary and cardiac sequelae of 
subarachnoid haemorrhage: time for active management? Intensive Care Medicine, 28(8), 
pp. 1012-1023. 
Madea, B. & Saukko, P. (2010). Molecular pathology in forensic medicine. Preface. Forensic 
Science International, 203(1-3), pp. 1-2. 
Madea, B., Saukko, P., Oliva, A. & Musshoff, F. (2010). Molecular pathology in forensic 
medicine--Introduction. Forensic Science International, 203(1-3), pp. 3-14. 
Maeda, H., Zhu, B. L., Ishikawa, T. & Michiue, T. (2010). Forensic molecular pathology of 
violent deaths. Forensic Science International, 203(1-3), pp. 83-92. 
Maeda, H., Ishikawa, T. & Michiue, T. (2011). Forensic biochemistry for functional 
investigation of death: concept and practical application. Legal Medicine (Tokyo), 13(2), 
pp. 55-67. 
Immunohistochemistry of Neuronal Apoptosis in Fatal Traumas:  
The Contribution of Forensic Molecular Pathology in Medical Science 273 
Marmarou, A., Fatouros, P. P., Barzo, P., Portella, G., Yoshihara, M., Tsuji, O., Yamamoto, T., 
Laine, F., Signoretti, S., Ward, J. D., Bullock, M. R. & Young, H. F. (2000). Contribution 
of edema and cerebral blood volume to traumatic brain swelling in head-injured 
patients. Journal of Neurosurgery, 93(2), pp. 183-193. 
Marschall, S., Rothschild, M. A. & Bohnert, M. (2006). Expression of heat-shock protein 70 
(Hsp70) in the respiratory tract and lungs of fire victims. International Journal of Legal 
Medicine, 120(6), pp. 355-359. 
Martin, L. J., Al-Abdulla, N. A., Brambrink, A. M., Kirsch, J. R., Sieber, F. E. & Portera-
Cailliau, C. (1998). Neurodegeneration in excitotoxicity, global cerebral ischemia, and 
target deprivation: A perspective on the contributions of apoptosis and necrosis. Brain 
Research Bulletin, 46(4), pp. 281-309. 
Matute, C., Domercq, M. & Sanchez-Gomez, M. V. (2006). Glutamate-mediated glial injury: 
mechanisms and clinical importance. Glia, 53(2), pp. 212-224. 
Michiue, T., Ishikawa, T., Quan, L., Li, D. R., Zhao, D., Komatsu, A., Zhu, B. L. & Maeda, H. 
(2008). Single-stranded DNA as an immunohistochemical marker of neuronal damage 
in human brain: an analysis of autopsy material with regard to the cause of death. 
Forensic Science International, 178(2-3), pp. 185-191. 
Nag, S. (2011). Morphology and properties of astrocytes. Methods in Molecular Biology, 686, 
pp. 69-100. 
Nakamura, T., Keep, R. F., Hua, Y., Hoff, J. T. & Xi, G. (2005). Oxidative DNA injury after 
experimental intracerebral hemorrhage. Brain Research, 1039(1-2), pp. 30-36. 
Nixdorf-Miller, A., Hunsaker, D. M. & Hunsaker, J. C., 3rd. (2006). Hypothermia and 
hyperthermia medicolegal investigation of morbidity and mortality from exposure to 
environmental temperature extremes. Archives of Pathology and Laboratory Medicine, 
130(9), pp. 1297-1304. 
Oehmichen, M., Walter, T., Meissner, C. & Friedrich, H. J. (2003). Time course of cortical 
hemorrhages after closed traumatic brain injury: statistical analysis of posttraumatic 
histomorphological alterations. Journal of Neurotrauma, 20(1), pp. 87-103. 
Oehmichen, M., Auer, R. N. & König, H. G. (2006). Forensic neuropathology and associated 
neurology. Springer Verlag. 
Parizel, P. M., Makkat, S., Jorens, P. G., Ozsarlak, O., Cras, P., Van Goethem, J. W., van den 
Hauwe, L., Verlooy, J. & De Schepper, A. M. (2002). Brainstem hemorrhage in 
descending transtentorial herniation (Duret hemorrhage). Intensive Care Medicine, 28(1), 
pp. 85-88. 
Piantadosi, C. A., Zhang, J., Levin, E. D., Folz, R. J. & Schmechel, D. E. (1997). Apoptosis and 
delayed neuronal damage after carbon monoxide poisoning in the rat. Experimental 
Neurology, 147(1), pp. 103-114. 
Polazzi, E., Gianni, T. & Contestabile, A. (2001). Microglial cells protect cerebellar granule 
neurons from apoptosis: evidence for reciprocal signaling. Glia, 36(3), pp. 271-280. 
Prockop, L. D. & Chichkova, R. I. (2007). Carbon monoxide intoxication: an updated review. 
Journal of the Neurological Sciences, 262(1-2), pp. 122-130. 
Quan, L., Ishikawa, T., Michiue, T., Li, D. R., Zhao, D., Yoshida, C., Chen, J. H., Komatsu, A., 
Azuma, Y., Sakoda, S., Zhu, B. L. & Maeda, H. (2009). Analyses of cardiac blood cells 
 
Apoptosis and Medicine 272 
Korfias, S., Stranjalis, G., Papadimitriou, A., Psachoulia, C., Daskalakis, G., Antsaklis, A. & 
Sakas, D. E. (2006). Serum S-100B protein as a biochemical marker of brain injury: a 
review of current concepts. Current Medicinal Chemistry, 13(30), pp. 3719-3731. 
Li, D. R., Zhu, B. L., Ishikawa, T., Zhao, D., Michiue, T. & Maeda, H. (2006a). Postmortem 
serum protein S100B levels with regard to the cause of death involving brain damage in 
medicolegal autopsy cases. Legal Medicine (Tokyo), 8(2), pp. 71-77. 
Li, D. R., Zhu, B. L., Ishikawa, T., Zhao, D., Michiue, T. & Maeda, H. (2006b). 
Immunohistochemical distribution of S-100 protein in the cerebral cortex with regard to 
the cause of death in forensic autopsy. Legal Medicine (Tokyo), 8(2), pp. 78-85. 
Li, D. R., Michiue, T., Zhu, B. L., Ishikawa, T., Quan, L., Zhao, D., Yoshida, C., Chen, J. H., 
Wang, Q., Komatsu, A., Azuma, Y. & Maeda, H. (2009a). Evaluation of postmortem 
S100B levels in the cerebrospinal fluid with regard to the cause of death in medicolegal 
autopsy. Legal Medicine (Tokyo), 11 Suppl 1, pp. S273-275. 
Li, D. R., Ishikawa, T., Zhao, D., Michiue, T., Quan, L., Zhu, B. L. & Maeda, H. (2009b). 
Histopathological changes of the hippocampus neurons in brain injury. Histology and 
Histopathology, 24(9), pp. 1113-1120. 
Li, J., Han, B., Ma, X. & Qi, S. (2010). The effects of propofol on hippocampal caspase-3 and 
Bcl-2 expression following forebrain ischemia-reperfusion in rats. Brain Research, 1356, 
pp. 11-23. 
Liedtke, W., Edelmann, W., Bieri, P. L., Chiu, F. C., Cowan, N. J., Kucherlapati, R. & Raine, 
C. S. (1996). GFAP is necessary for the integrity of CNS white matter architecture and 
long-term maintenance of myelination. Neuron, 17(4), pp. 607-615. 
Lo, C. P., Chen, S. Y., Lee, K. W., Chen, W. L., Chen, C. Y., Hsueh, C. J. & Huang, G. S. 
(2007). Brain injury after acute carbon monoxide poisoning: early and late 
complications. American Journal of Roentgenology, 189(4), pp. W205-211. 
Louis, J. C., Magal, E., Gerdes, W. & Seifert, W. (1993). Survival-promoting and protein 
kinase C-regulating roles of basic FGF for hippocampal neurons exposed to phorbol 
ester, glutamate and ischaemia-like conditions. European Journal of Neuroscience, 5(12), 
pp. 1610-1621. 
Love, S. (1999). Oxidative stress in brain ischemia. Brain Pathology, 9(1), pp. 119-131. 
Macmillan, C. S., Grant, I. S. & Andrews, P. J. (2002). Pulmonary and cardiac sequelae of 
subarachnoid haemorrhage: time for active management? Intensive Care Medicine, 28(8), 
pp. 1012-1023. 
Madea, B. & Saukko, P. (2010). Molecular pathology in forensic medicine. Preface. Forensic 
Science International, 203(1-3), pp. 1-2. 
Madea, B., Saukko, P., Oliva, A. & Musshoff, F. (2010). Molecular pathology in forensic 
medicine--Introduction. Forensic Science International, 203(1-3), pp. 3-14. 
Maeda, H., Zhu, B. L., Ishikawa, T. & Michiue, T. (2010). Forensic molecular pathology of 
violent deaths. Forensic Science International, 203(1-3), pp. 83-92. 
Maeda, H., Ishikawa, T. & Michiue, T. (2011). Forensic biochemistry for functional 
investigation of death: concept and practical application. Legal Medicine (Tokyo), 13(2), 
pp. 55-67. 
Immunohistochemistry of Neuronal Apoptosis in Fatal Traumas:  
The Contribution of Forensic Molecular Pathology in Medical Science 273 
Marmarou, A., Fatouros, P. P., Barzo, P., Portella, G., Yoshihara, M., Tsuji, O., Yamamoto, T., 
Laine, F., Signoretti, S., Ward, J. D., Bullock, M. R. & Young, H. F. (2000). Contribution 
of edema and cerebral blood volume to traumatic brain swelling in head-injured 
patients. Journal of Neurosurgery, 93(2), pp. 183-193. 
Marschall, S., Rothschild, M. A. & Bohnert, M. (2006). Expression of heat-shock protein 70 
(Hsp70) in the respiratory tract and lungs of fire victims. International Journal of Legal 
Medicine, 120(6), pp. 355-359. 
Martin, L. J., Al-Abdulla, N. A., Brambrink, A. M., Kirsch, J. R., Sieber, F. E. & Portera-
Cailliau, C. (1998). Neurodegeneration in excitotoxicity, global cerebral ischemia, and 
target deprivation: A perspective on the contributions of apoptosis and necrosis. Brain 
Research Bulletin, 46(4), pp. 281-309. 
Matute, C., Domercq, M. & Sanchez-Gomez, M. V. (2006). Glutamate-mediated glial injury: 
mechanisms and clinical importance. Glia, 53(2), pp. 212-224. 
Michiue, T., Ishikawa, T., Quan, L., Li, D. R., Zhao, D., Komatsu, A., Zhu, B. L. & Maeda, H. 
(2008). Single-stranded DNA as an immunohistochemical marker of neuronal damage 
in human brain: an analysis of autopsy material with regard to the cause of death. 
Forensic Science International, 178(2-3), pp. 185-191. 
Nag, S. (2011). Morphology and properties of astrocytes. Methods in Molecular Biology, 686, 
pp. 69-100. 
Nakamura, T., Keep, R. F., Hua, Y., Hoff, J. T. & Xi, G. (2005). Oxidative DNA injury after 
experimental intracerebral hemorrhage. Brain Research, 1039(1-2), pp. 30-36. 
Nixdorf-Miller, A., Hunsaker, D. M. & Hunsaker, J. C., 3rd. (2006). Hypothermia and 
hyperthermia medicolegal investigation of morbidity and mortality from exposure to 
environmental temperature extremes. Archives of Pathology and Laboratory Medicine, 
130(9), pp. 1297-1304. 
Oehmichen, M., Walter, T., Meissner, C. & Friedrich, H. J. (2003). Time course of cortical 
hemorrhages after closed traumatic brain injury: statistical analysis of posttraumatic 
histomorphological alterations. Journal of Neurotrauma, 20(1), pp. 87-103. 
Oehmichen, M., Auer, R. N. & König, H. G. (2006). Forensic neuropathology and associated 
neurology. Springer Verlag. 
Parizel, P. M., Makkat, S., Jorens, P. G., Ozsarlak, O., Cras, P., Van Goethem, J. W., van den 
Hauwe, L., Verlooy, J. & De Schepper, A. M. (2002). Brainstem hemorrhage in 
descending transtentorial herniation (Duret hemorrhage). Intensive Care Medicine, 28(1), 
pp. 85-88. 
Piantadosi, C. A., Zhang, J., Levin, E. D., Folz, R. J. & Schmechel, D. E. (1997). Apoptosis and 
delayed neuronal damage after carbon monoxide poisoning in the rat. Experimental 
Neurology, 147(1), pp. 103-114. 
Polazzi, E., Gianni, T. & Contestabile, A. (2001). Microglial cells protect cerebellar granule 
neurons from apoptosis: evidence for reciprocal signaling. Glia, 36(3), pp. 271-280. 
Prockop, L. D. & Chichkova, R. I. (2007). Carbon monoxide intoxication: an updated review. 
Journal of the Neurological Sciences, 262(1-2), pp. 122-130. 
Quan, L., Ishikawa, T., Michiue, T., Li, D. R., Zhao, D., Yoshida, C., Chen, J. H., Komatsu, A., 
Azuma, Y., Sakoda, S., Zhu, B. L. & Maeda, H. (2009). Analyses of cardiac blood cells 
 
Apoptosis and Medicine 274 
and serum proteins with regard to cause of death in forensic autopsy cases. Legal 
Medicine (Tokyo), 11 Suppl 1, pp. S297-300. 
Reyes, R., Guo, M., Swann, K., Shetgeri, S. U., Sprague, S. M., Jimenez, D. F., Barone, C. M. & 
Ding, Y. (2009). Role of tumor necrosis factor-alpha and matrix metalloproteinase-9 in 
blood-brain barrier disruption after peripheral thermal injury in rats. Journal of 
Neurosurgery, 110(6), pp. 1218-1226. 
Reyes, R., Jr., Wu, Y., Lai, Q., Mrizek, M., Berger, J., Jimenez, D. F., Barone, C. M. & Ding, Y. 
(2006). Early inflammatory response in rat brain after peripheral thermal injury. 
Neuroscience Letters, 407(1), pp. 11-15. 
Rink, A., Fung, K. M., Trojanowski, J. Q., Lee, V. M., Neugebauer, E. & McIntosh, T. K. 
(1995). Evidence of apoptotic cell death after experimental traumatic brain injury in the 
rat. American Journal of Pathology, 147(6), pp. 1575-1583. 
Rosenblum, W. I. (1997). Histopathologic clues to the pathways of neuronal death following 
ischemia/hypoxia. Journal of Neurotrauma, 14(5), pp. 313-326. 
Sauvageau, A. & Boghossian, E. (2010). Classification of asphyxia: the need for 
standardization. Journal of Forensic Sciences, 55(5), pp. 1259-1267. 
Schuliar, Y., Savourey, G., Besnard, Y. & Launey, J. C. (2001). Diagnosis of heat stroke in 
forensic medicine. Contribution of thermophysiology. Forensic Science International, 
124(2-3), pp. 205-208. 
Sharma, H. S. & Hoopes, P. J. (2003). Hyperthermia induced pathophysiology of the central 
nervous system. International Journal of Hyperthermia, 19(3), pp. 325-354. 
Sharma, H. S. (2006). Hyperthermia induced brain oedema: current status and future 
perspectives. Indian Journal of Medical Research, 123(5), pp. 629-652. 
Stefanidou, M., Athanaselis, S. & Spiliopoulou, C. (2008). Health impacts of fire smoke 
inhalation. Inhalation Toxicology, 20(8), pp. 761-766. 
Stoica, B. A. & Faden, A. I. (2010). Cell death mechanisms and modulation in traumatic brain 
injury. Neurotherapeutics, 7(1), pp. 3-12. 
Strackx, E., Van den Hove, D. L., Steinbusch, H. P., Steinbusch, H. W., Vles, J. S., Blanco, C. 
E. & Gavilanes, A. W. (2008). A combined behavioral and morphological study on the 
effects of fetal asphyxia on the nigrostriatal dopaminergic system in adult rats. 
Experimental Neurology, 211(2), pp. 413-422. 
Stroick, M., Fatar, M., Ragoschke-Schumm, A., Fassbender, K., Bertsch, T. & Hennerici, M. 
G. (2006). Protein S-100B--a prognostic marker for cerebral damage. Current Medicinal 
Chemistry, 13(25), pp. 3053-3060. 
Takamiya, M., Fujita, S., Saigusa, K. & Aoki, Y. (2007). Simultaneous detections of 27 
cytokines during cerebral wound healing by multiplexed bead-based immunoassay for 
wound age estimation. Journal of Neurotrauma, 24(12), pp. 1833-1844. 
Tamatani, M., Ogawa, S., Nunez, G. & Tohyama, M. (1998). Growth factors prevent changes 
in Bcl-2 and Bax expression and neuronal apoptosis induced by nitric oxide. Cell Death 
and Differentiation, 5(10), pp. 911-919. 
Tao, L., Chen, X., Qin, Z. & Bian, S. (2006). Could NF-kappaB and caspase-3 be markers for 
estimation of post-interval of human traumatic brain injury? Forensic Science 
International, 162(1-3), pp. 174-177. 
Immunohistochemistry of Neuronal Apoptosis in Fatal Traumas:  
The Contribution of Forensic Molecular Pathology in Medical Science 275 
Tofighi, R., Tillmark, N., Dare, E., Aberg, A. M., Larsson, J. E. & Ceccatelli, S. (2006). 
Hypoxia-independent apoptosis in neural cells exposed to carbon monoxide in vitro. 
Brain Research, 1098(1), pp. 1-8. 
Turk, E. E. (2010). Hypothermia. Forensic Sci Med Pathol, 6(2), pp. 106-115. 
Unterberg, A. W., Stover, J., Kress, B. & Kiening, K. L. (2004). Edema and brain trauma. 
Neuroscience, 129(4), pp. 1021-1029. 
Vaux, D. L. & Strasser, A. (1996). The molecular biology of apoptosis. Proceedings of the 
National Academy of Sciences of the United States of America, 93(6), pp. 2239-2244. 
Vogel, P., Dux, E. & Wiessner, C. (1997). Evidence of apoptosis in primary neuronal cultures 
after heat shock. Brain Research, 764(1-2), pp. 205-213. 
Wang, Q., Ishikawa, T., Michiue, T., Zhu, B. L. & Maeda, H. (2011a). Evaluation of human 
brain damage in fire fatality by quantification of basic fibroblast growth factor (bFGF), 
glial fibrillary acidic protein (GFAP) and single-stranded DNA (ssDNA) 
immunoreactivities. Forensic Science International, 211(1-3), pp. 19-26. 
Wang, Q., Michiue, T., Ishikawa, T., Zhu, B. L. & Maeda, H. (2011b). Combined analyses of 
creatine kinase MB, cardiac troponin I and myoglobin in pericardial and cerebrospinal 
fluids to investigate myocardial and skeletal muscle injury in medicolegal autopsy 
cases. Legal Medicine (Tokyo), 13(5), pp. 226-232. 
Wang, Q., Ishikawa, T., Michiue, T., Zhu, B. L., Guan, D. W. & Maeda, H. (2012a). 
Evaluation of human brain damage in fatalities due to extreme environmental 
temperature by quantification of basic fibroblast growth factor (bFGF), glial fibrillary 
acidic protein (GFAP), S100beta and single-stranded DNA (ssDNA) 
immunoreactivities. Forensic Science International, doi:10.1016/j.forsciint.2012.01.015 
Wang, Q., Ishikawa, T., Michiue, T., Zhu, B. L., Guan, D. W. & Maeda, H. (2012b). 
Quantitative immunohistochemical analysis of human brain basic fibroblast growth 
factor, glial fibrillary acidic protein and single-stranded DNA expressions following 
traumatic brain injury. Forensic Science International, doi:10.1016/j.forsciint.2012.04.025. 
Williams, F. N., Herndon, D. N., Hawkins, H. K., Lee, J. O., Cox, R. A., Kulp, G. A., Finnerty, 
C. C., Chinkes, D. L. & Jeschke, M. G. (2009). The leading causes of death after burn 
injury in a single pediatric burn center. Critical Care, 13(6), pp. R183. 
Williams, S., Raghupathi, R., MacKinnon, M. A., McIntosh, T. K., Saatman, K. E. & Graham, 
D. I. (2001). In situ DNA fragmentation occurs in white matter up to 12 months after 
head injury in man. Acta Neuropathological, 102(6), pp. 581-590. 
Yakovlev, A. G. & Faden, A. I. (2001). Caspase-dependent apoptotic pathways in CNS 
injury. Molecular Neurobiology, 24(1-3), pp. 131-144. 
Yoshida, C., Ishikawa, T., Michiue, T., Quan, L. & Maeda, H. (2011). Postmortem 
biochemistry and immunohistochemistry of chromogranin A as a stress marker with 
special regard to fatal hypothermia and hyperthermia. International Journal of Legal 
Medicine, 125(1), pp. 11-20. 
Zhang, D., Hu, X., Qian, L., O'Callaghan, J. P. & Hong, J. S. (2010). Astrogliosis in CNS 
pathologies: is there a role for microglia? Molecular Neurobiology, 41(2-3), pp. 232-241. 
 
Apoptosis and Medicine 274 
and serum proteins with regard to cause of death in forensic autopsy cases. Legal 
Medicine (Tokyo), 11 Suppl 1, pp. S297-300. 
Reyes, R., Guo, M., Swann, K., Shetgeri, S. U., Sprague, S. M., Jimenez, D. F., Barone, C. M. & 
Ding, Y. (2009). Role of tumor necrosis factor-alpha and matrix metalloproteinase-9 in 
blood-brain barrier disruption after peripheral thermal injury in rats. Journal of 
Neurosurgery, 110(6), pp. 1218-1226. 
Reyes, R., Jr., Wu, Y., Lai, Q., Mrizek, M., Berger, J., Jimenez, D. F., Barone, C. M. & Ding, Y. 
(2006). Early inflammatory response in rat brain after peripheral thermal injury. 
Neuroscience Letters, 407(1), pp. 11-15. 
Rink, A., Fung, K. M., Trojanowski, J. Q., Lee, V. M., Neugebauer, E. & McIntosh, T. K. 
(1995). Evidence of apoptotic cell death after experimental traumatic brain injury in the 
rat. American Journal of Pathology, 147(6), pp. 1575-1583. 
Rosenblum, W. I. (1997). Histopathologic clues to the pathways of neuronal death following 
ischemia/hypoxia. Journal of Neurotrauma, 14(5), pp. 313-326. 
Sauvageau, A. & Boghossian, E. (2010). Classification of asphyxia: the need for 
standardization. Journal of Forensic Sciences, 55(5), pp. 1259-1267. 
Schuliar, Y., Savourey, G., Besnard, Y. & Launey, J. C. (2001). Diagnosis of heat stroke in 
forensic medicine. Contribution of thermophysiology. Forensic Science International, 
124(2-3), pp. 205-208. 
Sharma, H. S. & Hoopes, P. J. (2003). Hyperthermia induced pathophysiology of the central 
nervous system. International Journal of Hyperthermia, 19(3), pp. 325-354. 
Sharma, H. S. (2006). Hyperthermia induced brain oedema: current status and future 
perspectives. Indian Journal of Medical Research, 123(5), pp. 629-652. 
Stefanidou, M., Athanaselis, S. & Spiliopoulou, C. (2008). Health impacts of fire smoke 
inhalation. Inhalation Toxicology, 20(8), pp. 761-766. 
Stoica, B. A. & Faden, A. I. (2010). Cell death mechanisms and modulation in traumatic brain 
injury. Neurotherapeutics, 7(1), pp. 3-12. 
Strackx, E., Van den Hove, D. L., Steinbusch, H. P., Steinbusch, H. W., Vles, J. S., Blanco, C. 
E. & Gavilanes, A. W. (2008). A combined behavioral and morphological study on the 
effects of fetal asphyxia on the nigrostriatal dopaminergic system in adult rats. 
Experimental Neurology, 211(2), pp. 413-422. 
Stroick, M., Fatar, M., Ragoschke-Schumm, A., Fassbender, K., Bertsch, T. & Hennerici, M. 
G. (2006). Protein S-100B--a prognostic marker for cerebral damage. Current Medicinal 
Chemistry, 13(25), pp. 3053-3060. 
Takamiya, M., Fujita, S., Saigusa, K. & Aoki, Y. (2007). Simultaneous detections of 27 
cytokines during cerebral wound healing by multiplexed bead-based immunoassay for 
wound age estimation. Journal of Neurotrauma, 24(12), pp. 1833-1844. 
Tamatani, M., Ogawa, S., Nunez, G. & Tohyama, M. (1998). Growth factors prevent changes 
in Bcl-2 and Bax expression and neuronal apoptosis induced by nitric oxide. Cell Death 
and Differentiation, 5(10), pp. 911-919. 
Tao, L., Chen, X., Qin, Z. & Bian, S. (2006). Could NF-kappaB and caspase-3 be markers for 
estimation of post-interval of human traumatic brain injury? Forensic Science 
International, 162(1-3), pp. 174-177. 
Immunohistochemistry of Neuronal Apoptosis in Fatal Traumas:  
The Contribution of Forensic Molecular Pathology in Medical Science 275 
Tofighi, R., Tillmark, N., Dare, E., Aberg, A. M., Larsson, J. E. & Ceccatelli, S. (2006). 
Hypoxia-independent apoptosis in neural cells exposed to carbon monoxide in vitro. 
Brain Research, 1098(1), pp. 1-8. 
Turk, E. E. (2010). Hypothermia. Forensic Sci Med Pathol, 6(2), pp. 106-115. 
Unterberg, A. W., Stover, J., Kress, B. & Kiening, K. L. (2004). Edema and brain trauma. 
Neuroscience, 129(4), pp. 1021-1029. 
Vaux, D. L. & Strasser, A. (1996). The molecular biology of apoptosis. Proceedings of the 
National Academy of Sciences of the United States of America, 93(6), pp. 2239-2244. 
Vogel, P., Dux, E. & Wiessner, C. (1997). Evidence of apoptosis in primary neuronal cultures 
after heat shock. Brain Research, 764(1-2), pp. 205-213. 
Wang, Q., Ishikawa, T., Michiue, T., Zhu, B. L. & Maeda, H. (2011a). Evaluation of human 
brain damage in fire fatality by quantification of basic fibroblast growth factor (bFGF), 
glial fibrillary acidic protein (GFAP) and single-stranded DNA (ssDNA) 
immunoreactivities. Forensic Science International, 211(1-3), pp. 19-26. 
Wang, Q., Michiue, T., Ishikawa, T., Zhu, B. L. & Maeda, H. (2011b). Combined analyses of 
creatine kinase MB, cardiac troponin I and myoglobin in pericardial and cerebrospinal 
fluids to investigate myocardial and skeletal muscle injury in medicolegal autopsy 
cases. Legal Medicine (Tokyo), 13(5), pp. 226-232. 
Wang, Q., Ishikawa, T., Michiue, T., Zhu, B. L., Guan, D. W. & Maeda, H. (2012a). 
Evaluation of human brain damage in fatalities due to extreme environmental 
temperature by quantification of basic fibroblast growth factor (bFGF), glial fibrillary 
acidic protein (GFAP), S100beta and single-stranded DNA (ssDNA) 
immunoreactivities. Forensic Science International, doi:10.1016/j.forsciint.2012.01.015 
Wang, Q., Ishikawa, T., Michiue, T., Zhu, B. L., Guan, D. W. & Maeda, H. (2012b). 
Quantitative immunohistochemical analysis of human brain basic fibroblast growth 
factor, glial fibrillary acidic protein and single-stranded DNA expressions following 
traumatic brain injury. Forensic Science International, doi:10.1016/j.forsciint.2012.04.025. 
Williams, F. N., Herndon, D. N., Hawkins, H. K., Lee, J. O., Cox, R. A., Kulp, G. A., Finnerty, 
C. C., Chinkes, D. L. & Jeschke, M. G. (2009). The leading causes of death after burn 
injury in a single pediatric burn center. Critical Care, 13(6), pp. R183. 
Williams, S., Raghupathi, R., MacKinnon, M. A., McIntosh, T. K., Saatman, K. E. & Graham, 
D. I. (2001). In situ DNA fragmentation occurs in white matter up to 12 months after 
head injury in man. Acta Neuropathological, 102(6), pp. 581-590. 
Yakovlev, A. G. & Faden, A. I. (2001). Caspase-dependent apoptotic pathways in CNS 
injury. Molecular Neurobiology, 24(1-3), pp. 131-144. 
Yoshida, C., Ishikawa, T., Michiue, T., Quan, L. & Maeda, H. (2011). Postmortem 
biochemistry and immunohistochemistry of chromogranin A as a stress marker with 
special regard to fatal hypothermia and hyperthermia. International Journal of Legal 
Medicine, 125(1), pp. 11-20. 
Zhang, D., Hu, X., Qian, L., O'Callaghan, J. P. & Hong, J. S. (2010). Astrogliosis in CNS 
pathologies: is there a role for microglia? Molecular Neurobiology, 41(2-3), pp. 232-241. 
 
Apoptosis and Medicine 276 
Zhu, B. L., Ishida, K., Fujita, M. Q. & Maeda, H. (2000). Immunohistochemical investigation 
of a pulmonary surfactant in fatal mechanical asphyxia. International Journal of Legal 
Medicine, 113(5), pp. 268-271. 
Zhu, B. L., Ishida, K., Oritani, S., Quan, L., Taniguchi, M., Li, D. R., Fujita, M. Q. & Maeda, 
H. (2001a). Immunohistochemical investigation of pulmonary surfactant-associated 
protein A in fire victims. Legal Medicine (Tokyo), 3(1), pp. 23-28. 
Zhu, B. L., Ishida, K., Quan, L., Taniguchi, M., Oritani, S., Kamikodai, Y., Fujita, M. Q. & 
Maeda, H. (2001b). Post-mortem urinary myoglobin levels with reference to the causes 
of death. Forensic Science International, 115(3), pp. 183-188. 
 
Apoptosis and Medicine 276 
Zhu, B. L., Ishida, K., Fujita, M. Q. & Maeda, H. (2000). Immunohistochemical investigation 
of a pulmonary surfactant in fatal mechanical asphyxia. International Journal of Legal 
Medicine, 113(5), pp. 268-271. 
Zhu, B. L., Ishida, K., Oritani, S., Quan, L., Taniguchi, M., Li, D. R., Fujita, M. Q. & Maeda, 
H. (2001a). Immunohistochemical investigation of pulmonary surfactant-associated 
protein A in fire victims. Legal Medicine (Tokyo), 3(1), pp. 23-28. 
Zhu, B. L., Ishida, K., Quan, L., Taniguchi, M., Oritani, S., Kamikodai, Y., Fujita, M. Q. & 
Maeda, H. (2001b). Post-mortem urinary myoglobin levels with reference to the causes 
of death. Forensic Science International, 115(3), pp. 183-188. 
Apoptosis and Medicine
Edited by Tobias M. Ntuli
Edited by Tobias M. Ntuli
This book looks at the latest research studies on apoptosis in medicine. It is divided into 
three sections for convenient and easy reading. The first section which comprises two 
chapters is an introduction of the subject of apoptosis to the uninitiated. The second 
section which comprises a single solitary chapter looks at apoptosis in normal physiology 
during bone resorption under mechanical stress. The third and the final section reviews 
apoptosis in a number of pathological conditions with an emphasis on cancer.
Photo by Sinhyu / iStock
ISBN 978-953-51-0701-9
A
poptosis and M
edicine
531 5
